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ABSTRACT 
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of 
non-melanoma skin cancer and accounts for the majority of deaths from this 
disease.  Its incidence is increasing rapidly, contributing significant morbidity to 
patients and a burden on healthcare resources.  The molecular events underlying 
cSCC development remain largely uncharacterised, despite the well established 
role of ultraviolet radiation as a principal carcinogen.  Genomewide analyses of 
the genetic changes underlying cSCC development have shown they are subject 
to large chromosomal aberrations, which often involve whole chromosome arms.  
Many of these events occur in a high proportion of tumours, yet the genes they 
target are unknown.  In this study, genomewide expression microarray data has 
been obtained from a series of cSCC and integrated with single nucleotide 
polymorphism (SNP) microarray data, to provide a comprehensive analysis of 
the events associated with tumour development.  In total, 222 genes were 
identified as differentially expressed in cSCC, of which, 21% were concordant 
with copy number changes. 
 
Previous genomewide SNP data of cSCC had identified microdeletions within 
the PTPRD gene in a subset of tumours (Purdie et al., 2009).  This was 
investigated in further detail and revealed microdeletions in this gene were 
significantly associated with metastatic cSCC.  Sequencing analysis showed 37% 
of cSCC had a mutation at this locus, which suggests PTPRD is aberrant in a 
significant proportion of tumours.  Decreased expression levels of PTPRD were 
correspondingly found in moderately and poorly differentiated tumours.  The 
role of PTPRD in skin biology is not known and further functional work is 
required to elucidate its role in skin cancer.  
 
Taken together, these data provide a valuable insight into the genetic background 
against which cSCC develop.  Furthermore, the association of PTPRD disruption 
with aggressive tumours may potentially be of future benefit as a prognostic 
biomarker and therapeutic target. 
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The term „cancer‟ encompasses over 100 different diseases and includes striking 
diversity in epidemiology, risk factors, response to treatment and survival.  
Cancer is caused by the progressive accumulation of genetic alterations within a 
cell that disrupts the balance between proliferation, differentiation and survival, 
allowing the cell to expand autonomously and develop invasive properties.  The 
treatment of cancer has continued to advance and has been transformed, in part, 
by the study of molecular changes in cancer cells.  This has led to a greater 
understanding of the biology underlying cancer development and improved 
targeted therapy for the treatment of different cancer types.  Cutaneous squamous 
cell carcinoma (cSCC) is the second most common skin cancer worldwide and its 
incidence is increasing rapidly (Harris and Alberts, 2004).  Despite the frequency 
of this cancer and easy accessibility of lesions for research, the genetic events 
underlying cSCC pathogenesis are poorly understood.  For high-risk patients 
such as those on immunosuppression or with the blistering skin disease recessive 
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dystrophic epidermolysis bullosa (RDEB), cSCC represents a major cause of 
morbidity.  Improved understanding of the biology of this cancer and 
identification of biomarkers for disease progression is essential to develop more 
effective clinical strategies for treatment of this cancer. 
 
1.1 CANCER BIOLOGY 
Tumour cells develop inherently different properties from normal cells that are 
characteristic of their manifestation.  Hanahan and Weinberg (2000) proposed 
that there are 6 essential physiological characteristics that are altered in a cancer 
cell.  These include self-sufficiency in growth signals, insensitivity to growth 
inhibitory signals, evasion of programmed cell death (most commonly 
apoptosis), limitless replicative potential, sustained angiogenesis and tissue 
invasion and metastasis (Figure 1.1).  A tumour cell is only considered to be 
malignant if it develops invasive properties enabling it to locally invade the 
tissue of origin and metastasise to other tissues.  Changes to these features occur 
by the disruption of genes and proteins that play key roles in the above processes.  
Arguably the most well known example is disruption of the tumour protein 53 
(TP53) gene which has been documented in a wide variety of cancer types, 
including skin, colon, breast, lung and brain cancers (Vogelstein et al., 2000).  In 
normal cells, the p53 protein inhibits progress through the cell cycle in the 
presence of DNA damage, targeting that cell for either repair or apoptosis.  When 
p53 is disrupted, cells develop uncontrolled growth and evasion of apoptosis, 
which contributes directly to a tumourigenic phenotype. 
 
1.1.1  Tumour suppressors and oncogenes 
Genes that are abrogated in tumour development typically fall into two 
categories: recessive, loss of function genes (tumour suppressors, TS) or 
dominant, gain of function genes (oncogenes).  Tumours suppressors have a 
repressive effect on tumour attributes and are abrogated in tumour cells to silence 
their function.  They were first discovered in retinoblastomas by the 
identification of the Retinoblastoma 1 (RB1) gene and are commonly subject to 
„two-hits,‟ meaning both alleles are disrupted before their constraining effect on 
the tumour cell is removed (Knudson, 1971).  There are of course exceptions to 
this rule, as some TS genes show haploinsufficiency, whereby loss of one allele 
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is sufficient to cause a phenotypic effect in a dose dependant manner (Kwabi-
Addo et al., 2001, Staff et al., 2003).  Conversely, oncogenes contribute 
positively to the attributes of a tumour cell and are usually activated by a single 
„hit‟ of mutation, amplification or loss of methylation.  The first somatic 
mutation to be documented in a cancer sample was the G12V missense mutation 
in the Harvey ras (HRAS) protooncogene, which activates the protein to promote 
tumourigenesis (Reddy et al., 1982, Tabin et al., 1982).  It is estimated at least 5-
7 key genes must be abrogated in a tumour cell to develop a malignant phenotype 
and this must include a combination of oncogenic activation and TS inactivation 
(Stratton et al., 2009).   
 
 
 
 
 
 
 
Figure 1.1   The 6 physiological processes that are altered in cancer cells.  Figure taken 
from Hanahan and Weinberg, 2000. 
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Classical protein-coding genes are not the only class of genes that can act as 
either TS or oncogenes in tumour development.  MicroRNAs (miRNA) are non-
coding single stranded RNA molecules of ~22 nucleotides in length that regulate 
the expression of protein-coding genes by binding to the 3‟ untranslated region 
(UTR) of messenger RNA (mRNA) and repressing translation.  Each miRNA 
can have multiple targets and they are estimated to potentially control the 
expression of a third of all human protein-coding genes (Esquela-Kerscher and 
Slack, 2006).  Due to their influence over so many protein-coding genes, 
miRNAs have a great diversity in function, which is reflected by their disruption 
in cancer.  Some miRNAs have an effect similar to a TS gene and are associated 
with deletion or downregulation in cancer, whilst others have oncogenic effects 
and are commonly upregulated in tumour development.  Examples of TS 
miRNAs include the miR-15a and miR-16-1 genes, which are frequently deleted 
in B-cell chronic lymphocytic leukaemia, resulting in overexpression of the anti-
apoptotic protein B-cell lymphoma 2 (Bcl-2) (Calin et al., 2002, Cimmino et al., 
2005).  Conversely, miR-21 itself has an anti-apoptotic function and is 
upregulated in glioblastomas and breast cancer (Chan et al., 2005, Iorio et al., 
2005).  In skin, overexpression of miR-203 is associated with the programme of 
terminal differentiation, through downregulation of tumour protein p63 (TP63) 
which promotes stem-cell like properties (Yi et al., 2008, Lena et al., 2008).  It 
has been suggested this miRNA may contribute to skin carcinogenesis (Lena et 
al., 2008), although no study to date has reported a decreased expression of miR-
203 in cutaneous malignancies. 
 
1.1.2 Types of somatic change in cancer cells 
Oncogenes and TS are subject to two main types of heritable DNA change in the 
process of tumourigenesis: genetic and epigenetic.  Genetic changes alter the 
nucleotide sequence of DNA by mutation or chromosomal aberration, whereas 
epigenetic changes regulate gene expression through the alteration of promoter 
methylation and chromatin remodelling.  Genetic changes include a wide range 
of chromosomal aberrations and mutations, from large scale translocations, 
insertions and deletions (indels), to point mutations.  These can disrupt a gene by 
deletion or amplification, alteration of the protein sequence or by the creation of 
fusion genes, which join two protein coding genes together to create a mutant 
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protein with altered properties.  Genomic rearrangements can also disrupt a gene 
by placing it under the control of a different promoter.  For example, the avian 
myelocytomatosis viral oncogene homolog (c-Myc) oncogene can be activated in 
Burkitt‟s Lymphoma by translocation to a region on chromosome 14 near the 
immunoglobulin promoter, which drives strong gene expression and promotes 
tumourigenesis (Taub et al., 1982).   
 
Epigenetic changes are equally as prominent in tumour development and control 
the expression of both TS and oncogenes (Esteller, 2008).  Promoter methylation 
is an important regulatory mechanism in normal cells and represses the 
expression of a gene by attaching a methyl group to cytosines at CpG 
dinucleotides in the promoter region.  Along with histone modifications such as 
lysine methylation and acetylation, these epigenetic changes keep the chromatin 
structure of a gene condensed and physically prevent the binding of transcription 
complexes, thereby preventing transcription of the gene.  In normal cells this is 
an important mechanism for controlling tissue specific gene expression and 
imprinting, where either the paternal or maternal allele is silenced.  In cancer 
cells, TS genes such as the Cyclin-dependent kinase inhibitor 2A (CDKN2A) and 
Breast cancer 1 (BRCA1) are commonly hypermethylated, which reduces their 
expression and promotes tumourigenesis (Brown et al., 2004, Esteller et al., 
2000).  In contrast, oncogenes such as the S100 calcium binding protein P 
(S100P) can become hypomethylated in comparison to normal cells, resulting in 
upregulated expression (Sato et al., 2004).   
 
Many genes are not disrupted by one mechanism alone, but are subject to a 
multitude of genetic, epigenetic and regulatory changes.  The TP53 gene for 
example is altered by a wide variety of mechanisms across different cancer types, 
including the disruption of other proteins that interact with p53 and alter its 
activity (Table 1.1, Vogelstein et al., 2000).  This combinatorial mechanism of 
gene disruption means the importance of a gene in tumour development can be 
underestimated, as no single laboratory technique can identify the many different 
types  of  aberration  reported  in  cancer  cells.  The  significance  of  this  can be 
fundamental to our understanding and treatment of cancer.  For example, 
inherited mutations were identified in the BRCA1 and BRCA2 genes in familial, 
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early onset breast cancer, but no similar mutations were found in sporadic breast 
cancers, suggesting these genes were only important in familial cases (Futreal et 
al., 1994, Miki et al., 1994, Wooster et al., 1995).  However, subsequent studies 
found hypermethylation of these two key genes in 10-15% of sporadic breast 
cancer, indicating they are also important in the development of some sporadic 
breast cancer cases (Esteller et al., 2000).  This has direct clinical implications, as 
the use of poly(adenosine-diphosphate-ribose) polymerase (PARP) inhibitors are 
currently in clinical trials and demonstrate effective anti-tumour activity against 
the subset of tumours displaying BRCA1/BRCA2 inactivation (Fong et al., 2009). 
 
 
 
 
Mechanism of p53 
inactivation 
Typical tumours Effect of inactivation 
Amino-acid changing 
mutation in the DNA-
binding domain. 
Colon, breast, lung, bladder, 
brain, pancreas, stomach, 
oesophagus and many others. 
Prevents p53 from binding to 
specific DNA sequences and 
activating the adjacent genes. 
Deletion of the carboxy-
terminal domain. 
Occasional tumours at many 
different sites. 
Prevents the formation of 
tetramers of p53. 
Amplification of the MDM2 
gene. 
Sarcomas, brain. Extra MDM2 stimulates the 
degradation of p53. 
Viral infection. Cervix, liver, lymphomas.  Products of viral oncogenes 
bind to and inactivate p53. 
Deletion of the p14
ARF
 gene. Breast, brain, lung and others. Failure to inhibit MDM2, 
leading to increased 
degradation of p53. 
Mislocalisation of p53 to the 
cytoplasm. 
Breast, neuroblastoma. Lack of p53 function (p53 
only functions in the nucleus). 
 
Table 1.1 Mechanisms of p53 inactivation.  The interactions shown in this Table 
between p53, its repressor double minute 2 protein (MDM2) and the MDM2 inhibitor p14
ARF
 also 
highlights the importance of studying molecular pathways in cancer cells, rather than focusing 
purely on individual genes.  Table taken from Vogelstein, 2000. 
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1.1.3 Metastasis 
Despite extensive research and improvements in cancer therapy, cancer is still 
responsible for approximately every 1 in 8 deaths worldwide and particular 
cancers, such as pancreatic cancer and multiple myeloma, still have an extremely 
poor prognosis (Garcia et al., 2007).  Metastasis is the major cause of cancer 
related deaths and accounts for greater than 90% of cancer mortality (Mehlen and 
Puisieux, 2006).  For successful metastasis, a tumour cell must overcome a 
variety of barriers, including evasion of anoikis (a form of programmed cell 
death induced when cells detach from their surroundings), survival in the absence 
of oxygen or nutrients and colonisation of a new niche with a different 
microenvironment to the tissue of origin (Figure 1.2, Chiang and Massague, 
2008).  It is estimated that fewer than 0.01% of cancer cells entering the 
circulation develop into metastatic tumours, with the remaining cells either 
unsuccessfully colonising the new niche or unable to promote and support the 
growth of a macroscopic tumour (Fidler, 1970, Luzzi et al., 1998).  Many genes 
and pathways that are disrupted in cancer cells have been associated with the 
above processes, including activation of the Hypoxia-inducible factor 1 (HIF-1) 
pathway which promotes angiogenesis, proliferation and resistance to anoikis 
and the activation of developmental regulators such as Twist, which enhances 
invasion (Harris, 2002, Vernon and LaBonne, 2004). 
 
1.1.4 Cancer therapy – a targeted approach 
The aim of therapeutic agents for the treatment of cancer is to selectively destroy 
tumour cells, whilst leaving healthy, normal cells intact.  Traditional therapeutic 
agents include radiotherapy and cytotoxic drugs, which are typically targeted 
against tumour-specific properties such as enhanced proliferation.  Although both 
have clinically beneficial results in some patients, they can also have unwanted 
side effects on healthy cells and are effective in a subset of patients only.  
Identifying the somatic changes underlying tumour formation is pivotal to our 
understanding of how cancer develops and the subsequent progression towards 
targeted therapy for improved outcome for cancer patients.  For example, the 
identification of the BCR-ABL fusion protein in chronic myeloid leukaemia 
(CML) made an attractive clinical target, as the fusion protein is found in 95% of 
CML patients and is only expressed by cancer cells (Druker et al., 1996).  This 
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Figure 1.2 Stages during the process of metastasis.  Tumour cells are coloured blue.  
There are multiple stages of metastasis, including proliferation of the primary tumour (a and b), 
detachment and migration through the circulatory system (c and d), followed by extravasation 
and colonisation of a distant site to the original tumour (e and f).  During all stages of the above 
metastatic process, the tumour cells are subject to numerous stresses which they must overcome 
to successfully form a metastatic tumour.  Figure taken from Fidler, 2003. 
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led to the development of Imatinib, a drug that specifically inhibits the tyrosine 
kinase activity of the BCR-ABL protein and is now used as the treatment of 
choice in CML and other cancers (Druker et al., 2001). 
 
Recent advances in targeted therapy have been used for the treatment of a patient 
with advanced medulloblastoma and 33 patients with advanced basal cell 
carcinoma, which both show frequent disruption of the Hedgehog (HH) pathway 
(Rudin et al., 2009, Von Hoff et al., 2009).  A novel clinical agent (GDC-0449) 
targeted against the HH pathway showed initial promising results in phase I 
clinical trials in both cancer types, although the patient with metastatic 
medulloblastoma did eventually relapse and die from the disease (Rudin et al., 
2009, Yauch et al., 2009).  This was due to the expansion of a clone of tumour 
cells that had developed resistance to the drug, through mutation of a different 
component of the HH pathway, rendering the drug ineffective (Yauch et al., 
2009).  Resistance to targeted therapies is a potential pitfall of their extremely 
specific, targeted nature and may represent the most significant problem for the 
next generation of chemotherapeutic agents.  
 
1.1.5 The role of technology in the fight against cancer 
Technologies for the detection of somatic changes in cancer cells are continually 
evolving, increasing in resolution, power and the number of mutation types that 
can be detected.  Recent advances in the detection of somatic changes in cancer 
have focused predominantly on whole genome studies.  The use of microarray 
technology for both genotyping and gene expression studies has been widely 
applied to many cancer types and has enhanced the molecular classification of 
different subtypes of cancer within established clinical categories (Alizadeh et 
al., 2001).  Furthermore, within the last two years, large-scale sequencing 
projects and next generation sequencing have been used to document sequence 
and structural variants at a basepair level.  Although these studies have been 
carried out in a small number of samples, they have already yielded vast 
quantities of information on the type and frequency of changes in cancer cells 
and are discussed in further detail below.   
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In the first set of large-scale sequencing projects, the coding exons of over 
20,000 protein-coding genes were sequenced in 11 colorectal cancers, 11 breast 
cancers, 22 glioblastoma multiforme (GBM) tumours and 24 pancreatic cancers 
(Wood et al., 2007, Jones et al., 2008, Parsons et al., 2008, Sjoblom et al., 2006).  
In addition, the GBM and pancreatic cancers were also investigated by SNP 
genotyping and expression analyses, allowing an integrated approach for the 
detection of cancer associated genes.  Using pathway analysis of the genes found 
to be altered in these studies, potential clinical targets have been identified that 
may improve treatment strategies in these cancers.  This included the possible 
use of HH pathway inhibitors in the treatment of pancreatic cancer, which 
showed aberrant regulation of this pathway in all 24 tumours analysed (Jones et 
al., 2008).  For an overview of the HH pathway see Figure 1.11 (page 56).  
 
These studies have also provided crucial information on the type and frequency 
of mutations in cancer cells.  The number of mutations was lowest in GBM, with 
only 685 mutations across 22 tumours and highest in breast cancer, which despite 
only including 11 tumours for analysis, displayed 1026 mutations in total.  This 
suggests different types of cancer have a high degree of diversity in the 
frequency of mutations and this may reflect a „mutator phenotype,‟ whereby 
disruption of DNA repair pathways in some cancers causes accelerated 
accumulation of additional genetic defects.  The frequency of the type of 
mutation was similar across all four cancer types: missense mutations were by far 
the most common and occurred at a frequency of 81.7-85.0%.  Nonsense 
mutations were the next most frequent change at 5.2-5.8%, indels occurred at a 
frequency of 0.3-7.0%, with deletions more common than insertions, whilst 
duplications showed the lowest rate of incidence at 0.3-2.7%. 
 
The second approach recently adopted to characterise cancer genomes has used 
next generation sequencing to analyse the genome or transcriptome of a given 
sample at high resolution.  Campbell and colleagues (2008) have used the 
technique to generate a catalogue of genomic structural variants and mutations 
from two lung cancer cell lines.  They used short sequence reads from both ends 
of a selected size of randomly sheared DNA fragments, which were then 
subsequently aligned back to a reference sequence.  From the spacing of 
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fragments aligned to the reference sequence they were able to identify 
translocations, insertions, deletions and even point mutations (Figure 1.3).  In 
total, they mapped 103 somatic rearrangements to the basepair level, including 
two previously unknown fusion genes (Campbell et al., 2008).  This technique 
has also been applied to 15 breast cancers and 9 breast cancer cell lines, which 
identified great diversity in the pattern of somatic rearrangement in these 
tumours (Stephens et al., 2009).  Overall, breast cancer cell lines displayed more 
rearrangements than primary tissue, which could be an artefact of additional 
changes acquired in vitro or a result of contaminating normal cells in primary 
tissue that may mask some genetic changes.  Furthermore, a correlation between 
the frequency of rearrangement and subtype of tumour was identified, with 
oestrogen-receptor positive tumours exhibiting fewer rearrangements than 
oestrogen- and progesterone-receptor negative tumours.   
 
Next generation sequencing technology has also been applied to the 
transcriptome, for the identification of tumour specific changes at the mRNA 
level.  Levin and colleagues (2009) applied the technology to targeted 
sequencing of the transcriptome of 467 cancer-related genes in a CML cell line, 
K-562.  This included the majority of protein kinase genes, nuclear hormone 
receptor genes and genes catalogued by the Cancer Gene Census (Futreal et al., 
2004).  They were able to identify translocations, mutations, transcript-fusions 
and splicing variants, as well as the overall expression levels of the genes 
studied, suggesting this is a powerful approach for the study of cancer cells.  
Berger and colleagues (2010) applied a similar approach to analysing the 
transcriptome of 10 melanoma cell lines and identified 11 novel gene fusions, 
which could represent potential therapeutic targets for the treatment of 
melanoma.  They also discovered a higher than expected frequency of point 
mutations, which was consistent with previous mutation studies in melanoma and 
postulated to arise from UVB-induced DNA damage (Greenman et al., 2007). 
 
The aim of ambitious projects such as those described is not only to advance our 
understanding of how a cancer develops, but also to identify molecular 
prognostic biomarkers that can be used to predict a patient‟s response to 
treatment and likelihood of disease relapse.  Cancer drugs are increasingly
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Figure 1.3 The landscape of somatic mutations discovered by next generation 
sequencing of the NCI-H2171 small-cell lung cancer cell line.  Chromosome numbers are 
indicated on the outside of the circle.  Concentric tracks depict the presence of point mutations, 
copy number changes and rearrangements relative to their position in the genome.  Figure taken 
from Stratton et al., 2009. 
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tailored to specific molecular targets and deducing which patients are likely to 
respond to which drugs prior to the onset of treatment has clear clinical benefits.  
Not only would it increase the chances of survival for patients by receiving a 
drug regime that is most likely to be effective for their tumour, but it would also 
spare patients who will not respond to treatment from the unwanted side effects 
of cytotoxic agents.  Furthermore, such tailored medicine could have a huge 
impact on healthcare resources, by ensuring the allocation of drugs in the most 
efficient manner, thereby reducing costs.  Of course, such technology comes at a 
price and the current limiting factor for this technology is the cost per sample and 
subsequent analysis of such vast quantities of data. 
 
1.1.5.1 Passenger versus driver somatic changes 
Whilst mutations, chromosomal aberrations and epigenetic disruption of some 
genes confer a direct effect on tumourigenesis, it is apparent that many mutations 
occur in a cancer cell simply as a result of genomic instability and do not actively 
contribute to the malignant phenotype (Frohling et al., 2007, Stratton et al., 
2009).  Such mutations are called „passenger‟ mutations and recent efforts have 
focused on distinguishing passenger mutations from „driver,‟ cancer causing, 
mutations using model algorithms and functional assessment of somatic changes 
(Carter et al., 2009).  This has become increasingly important with the advent of 
high resolution technologies, as a single screen now identifies hundreds of 
potential candidates, of which, only a small percentage (<10%) would be 
predicted to lead directly to tumourigenesis (Carter et al., 2009).  Discerning 
between driver and passenger mutations is therefore critical to streamline follow-
up and generate effective targets for drug development. 
 
1.2 SKIN BIOLOGY 
Skin is a dynamic organ that constantly faces environmental challenges such as 
microbial pathogens, physical damage and ultraviolet (UV) radiation.  Its role is 
to protect the body from such challenges, to prevent excessive fluid loss and to 
regulate temperature.  The uppermost layer of the skin is called the epidermis and 
provides the barrier function against pathogens and physical damage (Figure 
1.4).  The basal layer of the epidermis rests on the basement membrane, which is 
composed of extracellular matrix (ECM) proteins and growth factors and 
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provides a stable structure for the layers of keratinocyte cells that form the 
epidermis.  As keratinocytes from the basal layer of the epidermis move upwards 
towards the outermost part of the skin, they become terminally differentiated, 
which is an irreversible change accompanied by an alteration of gene expression 
(Fuchs, 2007).  This includes a switch from the keratin (K) 14 and K5 proteins 
which are used as markers for the basal cells, to the K1 and K10 proteins which 
are markers of suprabasal cells.  The keratin proteins form intracellular 
intermediate filaments which impart tensile strength to the tissue.  By the time 
the cells reach the most outer layer of the epidermis to form the stratum corneum, 
they are flat, dead cells with extensively crosslinked proteins deposited under the 
plasma membrane to provide an impervious barrier.  Eventually, these dead cells 
are sloughed from the skin‟s surface, to be replaced by the cells below.   
 
 
 
 
 
 
Figure 1.4 Cross-section showing the structure of skin and epidermal layers.  Figure 
taken from Fuchs and Raghavan (2002). 
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To maintain a fully functioning barrier, keratinocytes must continuously self-
renew, to replace old cells and repair damaged tissue at the site of wounds.  This 
continuous self-renewal is achieved by keratinocyte stem cells, which reside in 
the basal layer of the epidermis and the bulge region of the hair follicle and are 
responsible for skin homeostasis (Fuchs, 2007).  The stem cells cycle slowly to 
preserve their proliferative potential and minimise DNA replication errors.  The 
traditional view of epidermal renewal is that the keratinocyte stem cell divides 
asymmetrically, to give rise to a daughter stem cell and a second cell called a 
transit amplifying (TA) cell (Alonso and Fuchs, 2003).  Transit amplifying cells 
have a limited replicative potential and differentiate after several cell divisions, 
but allow appropriate repopulation of the epidermis prior to their differentiation.  
This view has been challenged recently, with the discovery that stem cells in 
mouse tail epidermis are directly capable of renewing the epidermis without the 
need for a progeny of TA cells (Clayton et al., 2007).  Currently there is no 
evidence to support this theory in human epidermal repopulation. 
 
1.3  SKIN CANCER 
The most common form of cancer in fair-skinned individuals is nonmelanoma 
skin cancer (NMSC), which has a predicted prevalence equal to that of all other 
cancers combined (Madan et al., 2006).  There are over 81,500 new cases of 
NMSC each year in the UK alone and their incidence is rising rapidly, placing a 
burden on both patients and healthcare organisations (Harris and Alberts, 2004, 
Eedy, 2000).  The two main forms of NMSC are basal cell carcinoma (BCC) and 
cutaneous squamous cell carcinoma (cSCC) which occur at a frequency of 4:1 
respectively.  Both arise from keratinocytes in the epidermal layer of the skin, 
but show markedly different patterns of growth, prevalence and morphology 
(Figure 1.5, Figure 1.6).  The second most common skin cancer is malignant 
melanoma, which arise from the melanocytic cells in the epidermal layer.  
Melanoma are aggressive skin cancers and are responsible for the majority of 
deaths from skin cancer.  Once they have metastasised, they are relatively 
resistant to current chemotherapeutic agents and are therefore associated with a 
poor prognosis. 
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Figure 1.5 Clinical presentation of BCC and cSCC.  Clinical photos kindly provided by 
Dr Catherine Harwood and Dr Charlotte Proby. 
Large BCC on side of nose, showing cosmetic 
difficulty of removing large, ulcerated lesions. 
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Figure 1.6 Histology of normal epithelium, BCC and cSCC.  A) Normal epithelium 
showing an organised structure of cells, B) nodular BCC, displaying multiple tumour islands in 
the dermis and C) cSCC of different histological grades, showing a decreasing degree of 
keratinisation and increasing cytologic atypia from WD to PD. 
A) Normal skin 
B) Nodular BCC 
 cSCC: Well differentiated    Moderately differentiated     Poorly differentiated 
Tumour islands 
C) 
Dermis 
Stroma 
Overlying epidermis 
Basal layer 
Suprabasal layer 
Epidermis 
Cornified layer 
 42 
Risk factors common to all types of skin cancer include fair skin, propensity to 
sunburn and exposure to sunlight.  Recently, genome wide association studies 
(GWAS) have been undertaken in BCC, cSCC and melanoma to identify variants 
that confer a higher risk of developing these cancers.  These studies have yielded 
novel information of potential clinical relevance, by isolating variants that may 
be useful for identifying patients at an increased risk of skin cancer.  In a study of 
BCC, the two strongest variants associated with a 2.68 times increased risk were 
at 1p36 and 1q42.  These two loci included five potential candidate genes, none 
of which had been previously associated with BCC pathogenesis (Stacey et al., 
2008).  Four further SNPs located in the keratin 5 (K5) gene, at 9p21 (near the 
CDKN2A gene), in the TERT-CLPTM1L gene and on 7q32 also conferred an 
increased risk to BCC (Stacey et al., 2009).  Of all these loci, only the K5 locus 
was also associated with susceptibility to cSCC, with none of the identified loci 
conferring susceptibility to melanoma.  A separate GWAS of melanoma did 
identify several loci with variants that conferred an increased risk of developing 
melanoma, two of which, in the MC1R and TYR genes, are associated with 
pigmentation and freckling, which are well-recognised melanoma risk factors 
(Bishop et al., 2009).  These studies suggest the molecular pathogenesis of 
NMSC is distinct from melanoma, which is consistent with pathological and 
clinical observations.  As this project is based on NMSC only, melanoma will not 
be discussed in further detail. 
 
1.3.1 Clinical features of BCC 
BCC is a slow-growing tumour that is believed to develop de novo as a result of 
intermittent sun exposure throughout a person‟s lifetime (Backvall et al., 2005).  
Approximately 80% of BCCs occur on the head and neck and they can present as 
small pink or red papules, ulcerated lesions, flat pink or red lesions with scale or 
indurated white lesions (Lang and Maize, 2005).  They typically exhibit non- 
aggressive behaviour, with a metastatic rate of 0.0028% to 0.55% (Wong et al., 
2003).  If left untreated however, they can locally invade causing soft tissue 
destruction and cosmetic disfigurement (Figure 1.5).  There are various subtypes 
of BCC that are classified by morphological differences and are largely 
responsible for the wide variety in clinical presentation.  This includes nodular 
BCC (also commonly known as rodent BCC), morpheic/infiltrative BCC and 
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superficial BCC.  Of these, morpheic BCCs exhibit the most invasive phenotype, 
often with ill-defined borders that makes complete excision more difficult (Wong 
et al., 2003).   
 
Due to the low metastatic rate of BCC, the main clinical problem associated with 
these tumours is the high number that are diagnosed each year and the 
corresponding healthcare burden.  The usual treatment for BCC is surgical 
excision, accompanied by histological confirmation of complete removal of the 
tumour.  In the case of large tumours or tumours in cosmetically sensitive areas, 
Moh‟s micrographic surgery is the gold standard, allowing margin control for 
complete excision with minimal tissue loss (Rowe et al., 1989).  Moh‟s surgery 
involves cryosectioning, staining and histological examination of excised tissue 
whilst the patient is still in surgery.  If tumour cells are present in the margins, 
more tissue is excised from that region.  Excisions are smaller than conventional 
surgery and typically utilise a 2 mm margin, as opposed to a 4-6 mm margin.  
Alternative treatments include cryotherapy, photodynamic therapy, radiotherapy 
and the use of topical agents such as 5-fluorouracil (5-FU), Imiquimod and 
Diclofenac. 
 
1.3.2 Clinical features of cSCC 
Cutaneous SCC usually occur on chronically sun exposed areas of the skin, with 
70% of cases found on the head and neck (Nguyen and Yoon, 2005).  They are 
associated with cumulative exposure to UV and if treated early have a cure rate 
of >95% (Nguyen and Yoon, 2005).  They can present as papules/nodules, 
ulcerated lesions or hyperkeratotic growths and are categorised morphologically 
according to the degree of keratinocyte differentiation the tumour cells display 
(Figure 1.6).  Well differentiated (WD) tumours are characterised by the 
presence of high levels of keratinisation, whereas moderately and poorly 
differentiated (MD and PD) tumours show intermediate and near absent 
keratinisation respectively.  Treatment is the same as for BCC, with surgery the 
most frequently used curative option. 
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1.3.2.1 Metastatic cSCC 
A subset of cSCC exhibit particularly aggressive behaviour, with local 
recurrences and metastasis (Figure 1.7).  Metastatic cSCC represents a major 
clinical problem associated with these tumours and is the most common cause of 
NMSC related deaths, despite cSCC only accounting for 20% of total cases.  
Metastasis occurs in 0.1%-9.9% of patients with cSCC (Lund, 1965, Rowe et al., 
1992, Tavin and Persky, 1996, Brantsch et al., 2008).  The wide variety in 
metastatic rates is due to study design and sample sizes, with the lowest rates of 
metastasis reported in studies that have excluded cSCC from high-risk 
anatomical sites and have less than 5 years follow-up since diagnosis of the 
primary tumour.  The most comprehensive prospective study to date found 4% 
(26/615) of patients with cSCC developed metastases, however even this Figure 
is likely to underestimate the metastatic rate, as median follow-up was only 43 
months (Brantsch et al., 2008).  
 
 
 
 
A)                                                                          B) 
   
 
Figure 1.7 Clinical presentation of a primary cSCC of the right temple (A) that 
metastasised to the right parotid gland (B).  This metastatic cSCC arose in an 
immunocompetent patient, but was prognostically at risk of metastasis due to its large size, depth 
of invasion and recurrent behaviour.  The metastatic lesion is indicated by an arrow.  Clinical 
photos kindly provided by Dr Catherine Harwood.     
 
 
 45 
Risk factors for metastasis include immunosuppression, recurrence, site of the 
primary tumour (lip and ear show higher metastatic rates), perineural invasion 
and differentiation status, with PD tumours showing an increased propensity for 
metastasis (Rowe et al., 1992, Petter and Haustein, 2000, Cherpelis et al., 2002, 
Brantsch et al., 2008).  Tumour size and depth are also important risk factors, 
with tumours ≤2 mm in depth rarely metastasising, whilst those >6 mm 
exhibiting a metastatic rate of 16% (Breuninger et al., 1990, Brantsch et al., 
2008).  The study by Brantsch and colleagues (2008) found PD tumours were 
significantly associated with metastasis in a univariate statistical analysis of risk 
factors, but were not deemed an independently significant prognostic factor when 
combined with other risk factors, indicating that tumour grade alone should not 
be used to predict metastatic potential (Brantsch et al., 2008).  Sentinel lymph 
node biopsies that are used as a diagnostic aide for metastasis in other cancers, 
including head and neck SCC, are not routinely used in the UK for the 
management of cSCC.  Recent studies support the introduction of sentinel lymph 
node biopsies in high-risk cases such as those on immunosuppression with 
particularly large, deep (>5 cm) or recurrent tumours (Ross and Schmults, 2006, 
Renzi et al., 2007).  
 
1.3.2.2 Multistep model of cSCC pathogenesis 
Unlike BCCs which have no clinically apparent precursor lesions, cSCC is 
characterised by a multistep model of carcinogenicity, from benign precursor 
lesions through to metastatic disease (Figure 1.8).  It has been suggested that 
very early changes in the epidermis characterised by the intense nuclear 
accumulation of p53 are the primary stage from which cSCC develop (Kanjilal et 
al., 1995).  Approximately 70% of cells in these clones contain p53 mutations, 
which is a common and early event in cSCC development (Boukamp, 2005a).  
Expansion of mutant p53 clones occurs under the influence of continued UVB 
exposure and does not require additional mutations (Jonason et al., 1996).  It is 
hypothesised that these p53 mutant clones display relative resistance to 
apoptosis, which allows the accumulation of additional genetic changes and 
malignant transformation (Kramata et al., 2005). 
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Figure 1.8 Proposed multistep model of cSCC pathogenesis.  Key genes or aberrations involved at each step of the process are marked underneath by arrows.  
Changes documented from 
1 
van der Schroeff et al. (1990), 
2 
Campbell et al. (1993), 
3 
Pierceall et al. (1991), 
4 
Kanjilal et al. (1995), 
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Ashton et al. (2003), 
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Brown et al. 
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Maubec et al., (2005), 
8  
Purdie et al. (2009).  
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The second premalignant stage of cSCC development is the formation of actinic 
keratoses (AK), which represent keratinocyte intraepithelial neoplasia (KIN) and 
progress to cSCC in 0.1-4% of cases (Marks et al., 1986, Criscione et al., 2009).  
The progression of AK to cSCC may or may not involve an intermediate stage 
called carcinoma-in-situ (CIS), or Bowen‟s disease, which is a preinvasive form 
of cSCC.  Actinic keratoses are benign precursor lesions characterised by small, 
erythematous lesions with surface scale and are indicative of UV damage to skin.  
They tend to present as multiple lesions, creating a „field‟ of abnormality which 
is representative of KIN.  Actinic keratoses share a similar genetic profile to 
cSCC, but display a reduced degree of karyotypic complexity (6.3 chromosomal 
imbalances compared to 8.1 chromosomal imbalances in cSCC), that is 
suggestive of an earlier stage of tumour development (Ashton et al., 2003).  
Similarities in the regions of imbalance found between AK and cSCC support a 
common origin of cSCC from AK.   
 
Another skin lesion linked to cSCC is keratoacanthoma (KA), which is a 
spontaneously involuting keratinocyte neoplasm that usually regresses after 3-6 
months, but shows initial growth rates and morphology similar to a WD cSCC 
(Boukamp, 2005a).  Three theories exist regarding a link between KA and cSCC: 
1) KAs are a cSCC that are aborted by a host response (Bonnetblanc et al., 1981, 
Schwartz, 1994), 2) they are genetically incomplete versions of cSCC (Boukamp, 
2005a) and 3) they are an entity unrelated to cSCC formation.  Cytogenetic 
studies show recurrent chromosomal aberration patterns differ between the two 
lesions, suggesting KAs are not precursors for cSCC (Clausen et al., 2006).  
Clinically they can look very similar to WD cSCC and are usually removed by 
surgery upon diagnosis as a precautionary measure. 
  
1.3.3 Causes of NMSC 
Early epidemiological studies of NMSC noted an association of tumour 
occurrence with fair skin, sun exposed skin and in populations from decreasing 
latitude, which are all indicative of UV radiation as a causative agent (Hussein, 
2005).  Whilst UV is now accepted as the principle aetiological agent of NMSC, 
other causative factors have also been linked with the disease.  These include 
human papillomaviruses (HPV), chemicals such as arsenic and tar, high meat and 
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fat diets, ionising radiation used in medical treatments and immunosuppression 
(Alam and Ratner, 2001, Ibiebele et al., 2007).  Furthermore, certain conditions 
are known to predispose to NMSC, including scarring from a previous trauma 
(particularly burns and frostbite) and inherited skin diseases (genodermatoses).  
Examples of genodermatoses that predispose to cSCC include xeroderma 
pigmentosum which is caused by inherited mutations in the nucleotide excision 
repair (NER) pathway and Muir Torre syndrome caused by inherited mutations 
in DNA mismatch repair genes.  In both cases, the ability of cells to respond to 
UV-induced DNA damage is reduced, resulting in an increased risk of 
developing cSCC.  Patients suffering from the blistering skin condition RDEB 
are also at an increased risk of developing particularly aggressive cSCC, as a 
result of inherited mutations in the type VII collagen gene (COL7A1) (Hovnanian 
et al., 1997, Martins et al., 2009).  For the purposes of this study, UV radiation, 
HPV and immunosuppression will be discussed in further detail. 
 
1.3.3.1 Ultraviolet radiation 
Since epidemiological studies linked NMSC to UV radiation, studies have shown 
that both UVA and UVB are complete carcinogens, meaning they are capable of 
initiating and promoting tumour formation in the absence of other carcinogens 
(Bachelor and Bowden, 2004).  UVA includes radiation with a wavelength of 
400-315 nm, whilst UVB has a wavelength of 315-280 nm.  They both have 
distinct carcinogenic mechanisms, which are detailed below.  UVB is directly 
absorbed by DNA, causing excitation of the bonds within DNA molecules.  This 
results in strand breaks, DNA cross-linking and the formation of photoproducts 
such as cyclopyrimidine dimers (CPDs) and pyrimidine (6-4) pyrimidone 
artefacts.  CPDs are formed when two adjacent pyrimidine bases dimerise by 
forming a double bond, whilst 6-4 photoproducts form a single bond between 
carbon 6 and carbon 4 of two adjacent pyrimidines.  Both DNA lesions interfere 
with normal DNA replication and if they are not removed by DNA repair 
mechanisms such as the nucleotide excision repair (NER) pathway and/or the 
cell is not targeted for apoptosis, the lesions can be incorrectly paired with 
adenine, resulting in transition mutations (Pfeifer et al., 2005).  Conversely, UVA 
causes oxidative damage to cells in the skin, resulting in the production of 
reactive oxygen species (ROS) that indirectly cause DNA damage.  The most 
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common ROS produced by UVA is singlet oxygen, which reacts with guanine to 
form 8-hydroxy-deoxyguanosine (Bachelor and Bowden, 2004).  If this DNA 
lesion is not removed, adenine is incorporated opposite the lesion during DNA 
replication, again resulting in transition mutations.   
 
The incorporation of mutations as a result of UV induced DNA damage can 
accumulate to directly cause tumour formation in skin.  Both UV wavelengths 
have a characteristic mutation signature: UVA associated DNA damage typically 
causes G to T transitions, whereas UVB causes CC to TT or C to T transitions 
(Pfeifer et al., 2005).  UVA and UVB signature mutations have been reported in 
key genes that are known to be involved in the pathogenesis of NMSC, for 
example the TP53 gene in cSCC and the patched (PTCH) gene in BCC, both of 
which are discussed in further detail in sections 1.4 and 1.5 (Brash et al., 1991, 
Heitzer et al., 2007).  A study by Halliday and colleagues used laser capture 
microdissection to sample different areas from the same tumour and identified a 
similar frequency of UVA and UVB signature mutations in TP53, indicating both 
wavelengths are important to cSCC development (Halliday et al., 2004).  UVA 
mutations were reported in deeper or basal regions of the tumour, whereas UVB 
mutations predominated in superficial parts of the tumour, which is consistent 
with the absorption profile of UV in skin (Bachelor and Bowden, 2004). 
 
Besides their mutagenic effect, UVA and UVB can also promote tumour growth 
and formation through the altered expression of genes and cellular pathways 
involved in tumourigenesis.  Bachelor and Bowden (2004) found UVA activated 
the mitogen activated protein kinase (MAPK) pathway, which has been 
associated with many different cancer types.  Upregulation of this pathway 
activates the AP-1 transcription factor complex, which in turn controls the 
expression of genes required for angiogenesis, apoptosis, invasion and 
keratinocyte differentiation (Angel et al., 2001, Florin et al., 2004).  Furthermore, 
UV causes immunosuppression (IS) through the production of 
immunosuppressive cytokines such as interleukin 10 (IL-10) and the abrogation 
of dendritic cell function, which are responsible for the presentation of antigens 
to T-cells (Elmets et al., 1983, Vink et al., 1997, Ullrich, 2005).  It has been 
suggested that skin tumours are actually highly antigenic and their presence 
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predominantly on sun exposed skin is permitted only because of local immune 
suppression by UV radiation (Bachelor and Bowden, 2004, Ullrich, 2005).  This 
is supported by the observation that skin tumours transplanted into 
immunocompetent animals are rejected, whereas tumours transplanted into 
immunodeficient or UV-irradiated mice are able to survive and support tumour 
growth (Fisher and Kripke, 1977). 
 
1.3.3.2 Human papillomavirus 
Whilst there is a clear epidemiological link between UV and NMSC, the 
involvement of the human papillomavirus (HPV) in NMSC is considerably less 
clear.  An association was first proposed in patients with the rare inherited skin 
disease epidermodysplasia verruciformis (EV), who have a predisposition to 
infection with beta-papillomaviruses (beta-PVs), some as a result of mutations in 
the EVER1 and EVER2 genes (Orth, 2005).  Up to 60% of these patients develop 
skin cancers, 90% of which contain oncogenic beta-PVs (predominantly HPV5 
and 8) (Orth, 1987).  Initial PCR based typing studies in cSCC from non-EV 
patients supported the epidemiological link between HPV and skin cancer, with 
HPV DNA detected in approximately 30-50% of cSCC from immunocompetent 
(IC) individuals and 65->80% of cSCC from immunosuppressed (IS) patients 
(Harwood and Proby, 2002).  Recent studies using a more sensitive reverse 
hybridisation assay for typing has found HPV DNA is equally as prevalent in 
cSCC from both IS and IC patients, at 70-78% positivity (Purdie et al., 2009).  
The high prevalence of HPV DNA in cSCC and the detection of HPV gene 
expression in a proportion of cSCC containing either beta-PVs and/or other HPV 
types, supports the suggestion that HPV contributes to tumour initiation in 
synergy with UV in skin (Storey, 2002, Pfister, 2003, Purdie et al., 2005).  
 
Human papillomaviruses are small double-stranded epitheliotrophic viruses, of 
which >100 different types have been characterised on the basis of their L1 gene 
(Figure 1.9, de Villiers et al., 2004).  The HPV genome contains a maximum of 8 
open reading frames (ORFs) consisting of 3 genes involved in transformation 
(E5, E6, E7), 2 encoding regulatory proteins (E1 and E2) and 3 genes for capsid 
protein and virion assembly (E4, L1 and L2) (Figure 1.10).  The E5 ORF is 
absent in gamma- and beta-papillomavirus genera.  The virus must recruit host 
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Figure 1.9 Phylogenetic classification of papillomaviruses (PVs).  PV types are 
classified phylogenetically according to the sequence of their L1 gene.  There are 5 human 
papillomavirus genera (alpha, beta, gamma, mu and nu) which are in turn grouped into species 
and subdivided into types.  The two high-risk types HPV 16 and 18 that are associated with 
cervical cancer development are highlighted by red circles.  Figure taken from de Villiers et al., 
2004. 
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Figure 1.10  Schematic representation of the HPV16 genome, which is representative of a 
high-risk mucosal alpha-PV type.  Note the presence of the E5 ORF which is absent in HPV 
types from other genera, including the beta-papillomaviruses.  Figure taken from Microbiology 
bytes (http://www.microbiologybytes.com/virology/Papillomaviruses.html). 
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cell functions in order to replicate its genome and thus HPV must maintain its 
host cell (differentiating epithelial cells of the skin or mucosae) in a cycling state 
if it is to survive and propagate (Burns and Maitland, 2005).  They cause benign 
common warts (papillomas) and genital warts as a result of infection of the basal 
layer of the epidermis or mucosae respectively.  A subset of alpha-PVs (types 16, 
18, 5, 6, 7, 9 and 11) have been confirmed as the causative agent of cervical 
cancer, with up to 100% of lesions showing the presence of HPV DNA, over 
70% of which are attributable to the high-risk types HPV 16 and 18 (Bosch et al., 
2002, Munoz et al., 2006).  This has led to the recent introduction of two 
vaccines from GlaxoSmithKline and Merck, which protect against HPV types 16 
and 18 and are expected to dramatically reduce the incidence of cervical cancer 
in decades to come.  
 
The critical viral proteins involved in tumour formation in cervical cancer are E6 
and E7, which interact with various cellular pathways to prevent apoptosis and 
increase host cell replication.  The E7 protein interacts with the RB1 protein to 
activate the E2F transcription factor and promote cell replication, whilst E6 
targets p53 for degradation thus abrogating its apoptotic function in response to 
uncontrolled cell replication and DNA damage (Munoz et al., 2006).  Viral DNA 
is often found integrated in cervical tumour cells, resulting in the stabilisation of 
viral mRNA and constant production of E6 and E7 proteins.  In contrast to high-
risk alpha-PV, the E6 proteins of beta-PV types are unable to abrogate apoptosis 
via the degradation of p53 (Elbel et al., 1997).  Furthermore, the E7 proteins of 
several putative oncogenic beta-PV have low affinity for the Rb protein,  
suggesting  the  mechanism  of  cutaneous  carcinogenesis  by  HPV could be 
markedly different to that in cervical cancer (Schmitt et al., 1994, Giarre et al., 
2001).  One possible mechanism which allows initiated skin tumour cells to 
avoid apoptosis could be via beta-PV E6-mediated proteolytic degradation of 
Bak, which is produced in response to UVB damage and initiates a pro-apoptotic 
response (Jackson et al., 2000, Leverrier et al., 2007).  This function is not 
associated with cervical cancer types.  
 
The precise role of HPV in NMSC however is confounded by the detection of 
HPV in normal skin and hairs in approximately 32-67% of healthy individuals 
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and the detection of seroconversion to HPV types in 84-94% of IS and IC 
patients without skin cancer (Harwood and Proby, 2002, Casabonne et al., 2009a, 
Casabonne et al., 2009b, Waterboer et al., 2009, de Koning et al., 2009).  In 
direct contrast to the oncogenic genital types of HPV that cause cervical cancers, 
most beta-PVs show low transforming ability in vitro, have a very low copy 
number in skin tumours (typically one HPV DNA copy per 20-5000 cells) and 
remain episomal rather than integrated (Pfister, 2003).  The assignment of high- 
risk cutaneous HPV types has also been difficult due to the large number of 
different types detected in skin tumours and the occurrence of infection with 
multiple HPV types.  These differences could potentially be explained by the 
difference in function of the beta-PV E6 and E7 genes and the role of these 
viruses as a cofactor in UV-induced tumours, rather than a direct carcinogenic 
agent. 
 
1.3.3.3 Immunosuppression 
The high ratio of BCC to cSCC (4:1) seen in the general population is typically 
reversed in IS patients, with the prevalence of cSCC between 65-250 times more 
frequent than in the general population (Boukamp, 2005a).  Organ transplant 
recipients are one group of IS patients that are considered at high-risk for 
developing cSCC.  A study by Harwood and colleagues (2006) has shown renal 
transplant recipients (RTR) present with cSCC 15 years younger than their 
counterparts in the general population and commonly have multiple tumours.  A 
more aggressive behaviour of cSCC in IS patients has also been noted in multiple 
studies, with the severity of disease linked to the number of tumours (Harwood et 
al., 2006, Moloney et al., 2005, Euvrard et al., 2003).  In comparison, BCCs are 
only reported as increased 10-fold in association with IS and do not tend to 
exhibit more aggressive behaviour (Harwood et al., 2006, Boukamp, 2005b).  An 
extended duration of treatment with an immunosuppressive agent is linked to an 
increased risk of developing cSCC, with tumours arising anytime from two years 
post-transplantation onwards (Caforio et al., 2000, Fortina et al., 2004, Moloney 
et al., 2005).  Immunosuppressive agents commonly used for the treatment of 
organ transplantation are corticosteroids, mammalian target of rapamycin 
(mTOR) inhibitors, azathioprine and mycofenolate mofetil.  There is evidence 
that these agents contribute directly to tumourigenesis.  Azathioprine in 
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particular interacts with UVA to cause oxidative DNA damage and potential 
azathioprine signature mutations have been reported in the PTCH gene in BCC 
from non-sun exposed skin of patients treated with this drug (O'Donovan et al., 
2005, Harwood et al., 2008). 
 
1.4 MOLECULAR PATHOGENESIS OF BCC  
The genetic changes underlying BCC pathogenesis were initially characterised in 
patients with a rare autosomal dominant disease called naevoid BCC syndrome 
(NBCCS) (or Gorlins), which is characterised by the development of multiple 
BCC at an early age, as well as developmental abnormalities (Tilli et al., 2005).  
Linkage analysis of DNA from families with NBCCS mapped an association of 
the disease to chromosome 9q22.3 and identified the PTCH gene as the causative 
gene for this disease (Hahn et al., 1996, Johnson et al., 1996).  Since then, 
biallelic mutations in PTCH have been found in approximately 42-69% of 
sporadic BCC, suggesting this is a major TS gene in BCC development 
(Reifenberger et al., 2005, Teh et al., 2005).  Patched encodes a transmembrane 
protein that forms a receptor complex along with Smoothened (Smo) for the 
sonic hedgehog (SHH) signalling molecule.  Binding of SHH to the receptor 
releases repression of Smo activity by Ptch, causing an intracellular signal 
transduction that contributes to pathways involved in neoplastic transformation 
(Figure 1.11).  Since the discovery of PTCH mutations in sporadic BCC, 
mutations have also been detected at a lower frequency in other key genes of the 
SHH pathway such as SMO and this pathway is now recognised as the major 
genetic factor underlying BCC development (Reifenberger et al., 2005).   
 
As well as abrogation of the SHH signalling pathway, other key genes are also 
mutated in BCC, including TP53 which is mutated in approximately 50% of 
BCC and commonly displays a UV-signature mutation profile (Reifenberger et 
al., 2005, Boukamp, 2005b).  The contribution of oncogenes in the development 
of BCC is less clear.  Mutations in the Ras family of oncogenes are reported at a 
high frequency in many cancers, including 90% of pancreatic cancers and 50% 
of colon cancers (Bos, 1989).  In BCC, the most commonly mutated Ras family 
member is H-ras, yet this gene is mutated in a much smaller percentage of 
tumours compared with other cancers types, with the highest reported frequency 
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at 31% of cases (van der Schroeff et al., 1990, Lieu et al., 1991, Pierceall et al., 
1991, Campbell et al., 1993).  Pierceall and colleagues (1991) who reported the 
highest frequency of Ras mutation, noted that the majority of mutations occurred 
opposite pyrimidine dimers, suggesting a potential causative link to UV 
exposure.  A further oncogene linked to BCC is BCL-2, which encodes an anti-
apoptotic protein and promotes cell survival when upregulated, often as a result 
of active Gli1 signalling (Verhaegh et al., 1995).   
 
 
 
 
 
 
 
Figure 1.11  Role of Patched in HH signalling.  There are 3 extracellular ligands of the 
hedgehog pathway: sonic hedgehog (SHH), Indian hedgehog (IHH) and desert hedgehog (DHH).  
A) In the presence of HH ligand binding to the patched (PTCH1) receptor, inhibition of 
smoothened (SMO) is relieved, allowing internalisation of the protein and activation of the 
transcription factor complexes Gli1 and Gli2.  Active Gli1 translocates to the nucleus where it 
induces the activation of key genes involved in tumourigenesis, such as Bcl-2.  In the absence of 
HH ligand, Ptch inhibits Smo, thereby preventing the activation of downstream signalling and 
Gli1.  B) In BCCs where PTCH1 is mutated or depleted, the pathway is constitutively active, 
resulting in upregulation of Gli target genes.  Figure taken from Epstein (2008). 
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1.5 MOLECULAR PATHOGENESIS OF cSCC  
1.5.1 Mouse models of skin carcinogenesis 
Unlike the identification of the PTCH gene as a critical TS in BCC development, 
no single gene or pathway has emerged as key to the development of cSCC.  
Much of our knowledge regarding the pathogenesis underlying cSCC formation 
has originated from murine skin carcinogenesis models, which allow direct 
evaluation of the contribution of a disrupted gene or protein to tumour 
development in vivo.  The most frequently used model uses one topical 
application of 7,12-dimethylbenz[a]anthracene (DMBA) to initiate cells and 
subsequent promotion of initiated cells using twice weekly topical application of 
the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA).  This model 
results in Ras-dependent formation of benign papillomas, of which, a certain 
proportion will progress to cSCC through the accumulation of further somatic 
changes (Balmain et al., 1984).  As a model of cSCC pathogenesis, it has been 
used to investigate key apoptotic proteins such as Bcl-2 and Bax in normal 
epidermal function and cSCC formation, as well as aberrant signal transduction 
through the activation of transcription factors such as signal transducer and 
activator of transcription 3 (Stat3) (Cho et al., 2001, Chan et al., 2004, Pedranzini 
et al., 2004).  However, the direct relevance of this model to human skin 
carcinogenesis is questionable, as chemical carcinogenesis is distinctly different 
to that of UV-induced carcinogenesis, the latter being the key determinant of 
human cSCC development.  Furthermore, H-ras is not implicated as a key 
oncogene in UV-induced human cSCC, suggesting the investigation of genes and 
proteins on a background of activated H-ras may not extrapolate directly to the 
development of human cSCC. 
 
A second murine model that overcomes several of the limitations of the chemical 
carcinogenesis model is UVB-induced skin carcinogenesis in the hairless SKH-1 
mouse (de Gruijl and van der Leun, 1991).  Skin tumours that develop in this 
model have a high frequency of p53 mutation and low incidence of Ras 
mutations, which is consistent with human cSCC (van Kranen et al., 1995).  
Furthermore, the majority of p53 mutations identified in tumours derived from 
these mice are indicative of UVB-induced mutagenesis, which again mimics the 
findings from human cSCC (van Kranen et al., 1995, van Kranen and de Gruijl, 
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1999).  As well as being used to investigate genes that are implicated in cSCC 
development, this model has been used to provide information on the dose and 
frequency of UVB required to initiate tumour formation and the use of novel 
agents such as epigallocatechin-3-gallate (the active ingredient of green tea) in 
skin cancer prevention (de Gruijl and van der Leun, 1991, Kramata et al., 2005).   
 
Murine models have become increasingly sophisticated and the introduction of 
transgene and knockout mice are now used extensively to investigate many 
aspects of tumour development, from the importance of individual genes, to the 
role of the immune system and the contribution of beta-PV oncogenes (Vassar et 
al., 1992, Schaper et al., 2005, Swann et al., 2008).  One of the earliest examples 
of a transgene model used to investigate cSCC pathogenesis was the 
development of mice with the transforming growth factor alpha (TGF-α) gene 
under the control of the K-14 promoter, which targets overexpression of TGF-α 
to the basal layer of the epidermis (Vassar et al., 1992).  These mice develop 
papillomas upon wounding or treatment with TPA, circumventing the need for 
DMBA as an initiating treatment and overcoming the reliance upon H-ras driven 
carcinogenesis.  The diversity of these murine models means they remain an 
important tool for investigating the pathogenesis of cSCC.   
 
1.5.2 Human tissue models of skin carcinogenesis 
Whilst murine models are an important tool for investigating cSCC pathogenesis, 
they have numerous limitations.  Notably, mouse skin is different in composition 
(including melanin content, which protects against UV-induced damage) and 
thickness to human skin and is more susceptible to the induction of neoplasia 
than primary human skin cells (Berking et al., 2002).  The development of 
human skin grafts onto immunocompromised mice and 3D in vitro models of 
human skin has partially addressed these issues, by allowing the manipulation of 
human skin cells for carcinogenesis studies (Bell et al., 1981, Blanton et al., 
1991).  These models have been used to demonstrate that blockade of the nuclear 
factor kappa-B (NFκB) pathway controls keratinocyte terminal differentiation 
and cooperates with oncogenic Ras to cause cSCC formation, suggesting this 
may be a key pathway in cSCC tumour development (Seitz et al., 1998, Seitz et 
al., 2000, Dajee et al., 2003).  As with mouse models however, extrapolation to 
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human skin development and carcinogenesis should always be corroborated by in 
vivo studies on human tissue biopsies. 
 
1.5.3 Genetic development of human cSCC 
As alluded to in the previous section, mutations of the TP53 gene are an early 
and common event in human cSCC development, with approximately 50% of 
tumours showing mutation of both alleles (Boukamp, 2005a).  Furthermore, the 
majority of mutations are consistent with UVB-induced DNA damage and occur 
at hot spot locations within the gene such as codons 151/152, 286 and 278 which 
are all dipyrimidine sites (Tornaletti et al., 1994).  It has been suggested that 
clonal expansion of these mutant cells is enhanced by the induction of apoptosis 
in normal surrounding cells through the action of further exposure to UV (Ziegler 
et al., 1994).  Another common genetic aberration is mutation or epigenetic 
silencing of the CDKN2A locus.  This locus encodes two TS proteins via 
alternate reading frames: p16
INK4a
 and p14
ARF
.  The most common mechanism of 
inactivation is promoter methylation, which accounts for loss of 20-36% and 15-
42% of p16 and p14 respectively (Brown et al., 2004, Murao et al., 2006).  The 
p16 protein inhibits progression through the G1 phase of the cell cycle by 
blocking phosphorylation of the retinoblastoma protein, whereas p14 promotes 
p53 cell cycle control by binding to the p53/MDM2 complex to prevent p53 
degradation.  Disruption of these 3 key genes in cSCC leads to loss of cell cycle 
control, enhanced proliferation and evasion of apoptosis. 
 
Like BCC, the role of specific oncogenes in cSCC tumourigenesis has not been 
established.  Mutations in the Ras family have been reported in 0% to 46% of 
cSCC, with such wide variation a likely result of the experimental technique used 
to detect mutations and the site of the tumours analysed (non-sun exposed vs. 
sun-exposed) (van der Schroeff et al., 1990, Campbell et al., 1993, Pierceall et 
al., 1991).  The low frequency of Ras mutations reported in some studies 
certainly emphasises that in vivo studies using two-stage chemical carcinogenesis 
mouse models must be validated by investigation of the gene or protein of 
interest in human cSCC tissue samples as appropriate.  Amplification of the 
cMyc oncogene has been reported in up to 50% of cSCC from 
immunosuppressed patients, often as a result of amplification of the chromosome 
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arm 8q, where cMyc resides (Pelisson et al., 1996, Purdie et al., 2009).  cMyc is a 
transcription factor that is implicated in many key cellular processes, including 
cell growth, cell proliferation and apoptosis, all of which are abrogated in tumour 
development. 
 
1.5.4 Karyotypic aberrations in cSCC 
Karyotypic aberrations in cSCC are common, but it is difficult to determine 
carcinogenic „driver‟ mutations from those that are simply a consequence of 
genomic instability.  Furthermore, the recurrent gains and losses reported from 
studies using microsatellite instability (MSI) mapping or comparative genomic 
hybridisation (CGH) are often across large regions involving whole chromosome 
arms, making it difficult to relate loss or gain to a specific gene(s) involved in 
tumourigenesis.  From three studies using CGH, only gains of 3q, 8q and 20q 
and loss of 3p, 4p, 9p, 13q, 17p and 17q were commonly found, with each study 
also identifying further specific changes in their subset of cSCCs (Ashton et al., 
2003, Clausen et al., 2006, Popp et al., 2000).  This was consistent with an early 
karyotypic study using polymorphic microsatellite markers to identify LOH, 
suggesting there is good reproducibility for these recurrent changes (Quinn et al., 
1994).   
 
More recent studies in our group have used higher resolution single nucleotide 
polymorphism (SNP) microarrays to map the genomic instability in cSCC 
(Purdie et al., 2007, Purdie et al., 2009).  Sixty cSCC were analysed by 10K, 50K 
or 250K SNP microarrays, which revealed the most frequent aberrations were 
loss of heterozygosity (LOH) at 3p and 9p in 65% (39/60) and 75% (45/60) of 
tumours respectively.  This study also identified uniparental disomy (UPD) as a 
mechanism of copy number neutral LOH in cSCC.  UPD occurs through mitotic 
non-dysjunction or mitotic recombination and results in loss of one allele and 
subsequent duplication of the remaining allele.  The most frequent chromosomal 
gain events were of 3q in 43% (26/60) of tumours, 8q in 38% (23/60) and 9q in 
35% (21/60) (Figure 1.12).  These results are largely consistent with the previous 
studies using microsatellite markers and CGH.  As well as identifying large-scale 
chromosomal gains and losses, the higher resolution SNP microarrays also 
identified focal deletions and gains, pinpointing genes that may be important in 
 6
1
 
 
Figure 1.12 Ideogram of karyotypic aberrations identified in cSCC using Affymetrix SNP microarray profiling of 60 tumours.  LOH events are indicated to the 
left of chromosomes with deletion shown in green and uniparental disomy in blue, whilst gains are indicated to the right in red.  Well differentiated cSCC are indicated by 
light coloured lines, whilst MD and PD are shown by dark coloured lines.  Figure taken from Purdie et al., 2009. 
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cSCC development.  For example, 3 tumours had homozygous deletion at the 
CDKN2A locus at 9p21.2-9p21.3, whilst another 3 tumours had homozygous 
deletions within the fragile histidine triad (FHIT) gene at 3p14.2, both of which 
have been previously associated with cSCC development (Brown et al., 2004, 
Gray et al., 2008). 
 
These studies also identified homozygous and heterozygous focal deletions in the 
protein tyrosine phosphatase receptor type D (PTPRD) gene in 15% (9/60) of 
cSCC, including the only two primary tumours with proven metastatic potential 
in the series.  This gene has not previously been associated with cSCC 
development, but has emerged in recent years as a potential TS in many different 
cancer types, including lung cancer, neuroblastoma, melanoma and colon cancer 
(Sato et al., 2005, Zhao et al., 2005, Stallings et al., 2006, Stark and Hayward, 
2007, Chan et al., 2008).  It has often been speculated that chromosome 9p 
contains an additional TS gene to the CDKN2A locus and the identification of 
focal deletions in a novel gene at chromosome 9p supports the use of this 
technology for isolating genes that are potentially abrogated by these large-scale 
chromosomal losses and gains.  They are clearly not exhaustive however and 
many more genes that may play a role in tumour development remain to be 
identified in recurrent regions of chromosomal instability. 
 
The latter study by Purdie and colleagues (2009) also found a significant 
association between the number of chromosomal aberrations and the 
differentiation status of the tumour, with WD tumours displaying significantly 
fewer aberrations than MD and PD tumours.  This suggests WD cSCC are a 
distinct genetic subgroup to MD and PD tumours.  This finding is in contrast to a 
previous study that noted an association between the number of chromosomal 
aberrations and the immune status of the patient, with cSCC from IS patients 
exhibiting less than half the number of aberrations as IC patients (Rehman et al., 
1997).  However, 60% of IS cSCC analysed in the study by Rehman and 
colleagues were WD, compared to only 35% of IC cSCC, which is likely to have 
confounded the analysis.  This observation has interesting clinical implications, 
as although WD cSCC do metastasise, MD and PD cSCC are associated with a 
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higher metastatic rate and this could be a reflection of the increased genomic 
instability in these tumours. 
 
1.5.5 Whole genome expression studies in cSCC 
Recently, several global gene expression studies have investigated the expression 
pattern of cSCC.  Haider and colleagues (2006) used Affymetrix U95A arrays to 
measure the expression of >12,000 genes in cSCC, site-matched control skin and 
psoriasis biopsies.  Psoriasis is a hyperproliferative disorder of the skin and was 
included to isolate changes that are directly related to tumourigenesis rather than 
hyperproliferation of the epidermis.  A total of 2,520 genes were differentially 
expressed between cSCC and psoriasis, including genes involved in cell cycle 
control, immune response and key cellular signalling pathways.  Two further 
studies by Nindl and colleagues (2006) and Serewko and colleagues (2002) also 
used microarray technology to investigate cSCCs.  The study by Nindl et al. 
(2006) compared cSCC and AK with normal skin, whereas Serewko et al. (2002) 
compared cSCC cells grown on organotypic rafts with normal human epidermal 
keratinocyte cells.   
 
Each study identified a large subset of genes that were dysregulated, but there 
was little consensus between the key genes implicated in tumourigenesis.  Such 
differences are likely to be a result of experimental design.  For example, Haider 
et al. (2006) compared the genetic profiles of two totally different clinical 
conditions (psoriasis and cSCC), assuming genes upregulated in both diseases 
would only be associated with benign disease, whereas Serewko et al. (2002) 
used cultured cells which may have significantly altered gene expression through 
culture conditions.  Furthermore, Nindl et al. (2006) pooled samples from 
different patients where insufficient RNA had been isolated, thus limiting the 
opportunity to correlate results with clinical variables.  The only consistent 
finding in all three studies was an upregulation of matrix metallopeptidases 
(MMPs) which are involved in matrix degradation – a key process in tumour 
invasion. 
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1.6 AIMS 
Despite many years of research, easy accessibility of lesions and the well 
established role of UV radiation as an aetiological agent, the molecular 
progression underlying the development of cSCC is largely uncharacterised in 
comparison to other solid tumours such as breast and colorectal cancer.  Unlike 
the role of the HH pathway in BCC, there is no key pathway implicated in the 
pathogenesis of cSCC, which is limiting for understanding the biology of these 
tumours and the development of novel drug targets.  Coupled with the enhanced 
propensity for metastasis, cSCC represent a significant burden to both patients 
and healthcare organisations.  As discussed earlier, genomewide SNP microarray 
profiling of cSCC has recently been carried out within our group, which has 
identified novel candidate genes in cSCC carcinogenesis and defined WD cSCC 
as a genetically distinct subgroup of tumours compared to MD and PD tumours.  
The aim of this PhD project is to expand these findings by identifying key 
pathways and candidate genes that may be involved in cSCC pathogenesis using 
whole genome expression microarrays and integration with pre-existing SNP 
data.  A second aim of this project is to confirm and characterise the nature of the 
association between PTPRD aberration and cSCC pathogenesis. 
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CHAPTER TWO: MATERIALS AND METHODS 
 
2.1 SAMPLE COLLECTION 
2.2 PREPARATION OF NUCLEIC ACIDS 
2.3  TECHNIQUES BASED ON DNA MANIPULATION 
2.4 TECHNIQUES BASED ON RNA MANIPULATION 
2.5 PROTEIN BASED TECHNIQUES 
2.6 TISSUE CULTURE 
2.7 STANDARD BUFFERS AND REAGENTS 
 
 
2.1 SAMPLE COLLECTION 
Tissue biopsies were collected in accordance with ethical approval from the East 
London and City Health Authority local ethics committee and immediately snap-
frozen in liquid nitrogen upon excision.  If multiple biopsies from the same piece 
of tissue were available, tissue was also collected into transport media for the 
culture of keratinocytes and/or RNAlater (Qiagen, UK) for 12 hours at 4
o
C prior 
to storage at -80 
o
C.  Paraffin embedded tissue samples were obtained from Barts 
and the London NHS Trust, Department of Pathology.  Venous blood samples 
were taken from patients into ethylenediaminetetraacetic acid (EDTA) tubes, 
aliquoted into cyrovials and stored at -80 
o
C. 
 
2.2 PREPARATION OF NUCLEIC ACIDS 
2.2.1 Laser capture microdissection of frozen tissue for DNA extraction 
Snap-frozen tumour biopsies were embedded on dry ice in optimal cutting 
temperature compound (O.C.T. VWR, UK) and cross-sectioned using the 
OTF5000 cryostat (Bright Instrument Company Ltd., UK).  Eight micron 
sections were cut onto pre-cooled 1.0 mm polyethylene napthalate (PEN) coated 
membrane slides (Carl Zeiss Ltd., UK) that had been treated with 1500 mJ of UV 
for 40 minutes to enhance adhesion of the section to the slide.  Sections that had 
been cut onto membrane slides were kept at -80 
o
C until use.  Prior to laser 
capture microdissection (LCM), sections were fixed with 70% ethanol for two 
minutes and stained with haematoxylin and eosin (H&E) to aid visualisation of 
the tissue on the microscope.  An increasing alcohol series was used to dehydrate 
the slides, followed by thorough drying with a low heat airdryer.  Post-staining, 
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the slides were used immediately for LCM.  Target cells were identified by a 
reference H&E slide and isolated from the tissue section using the PALM 
Microbeam laser capture microscope (Carl Zeiss Ltd).  Once excised by the UV 
laser, the target cells were collected into 40 µl ATL lysis buffer (Qiagen, UK) 
using a sterile needle and the DNA extracted by the standard protocol for LCM 
samples from Qiagen‟s DNA Micro Kit.  DNA was eluted from the column in 
200 μl of water and concentrated using the Microcon YM30 spin columns 
(Millipore, USA). 
 
2.2.2 Crude microdissection of formalin fixed paraffin embedded tissue for 
DNA extraction 
Five to thirty 10 µm sections of formalin fixed paraffin embedded (FFPE) tissue 
were cut onto SuperFrost slides (VWR, UK) and dried overnight at ambient 
temperature.  A reference H&E slide was used to identify regions of ≥85% purity 
of target cells and the corresponding cells were scraped from the tissue sections 
into a 1.5 ml centrifuge tube using a sterile scalpel.  Xylene treatment was used 
to deparaffinise the tissue, followed by two 96-100% ethanol washes before 
thoroughly air-drying the pellet and resuspending in 180 µl ATL lysis buffer 
(Qiagen).  An extended proteinase K digestion of 48–96 hours was performed 
until the tissue was completely lysed, with the addition of 20 μl proteinase K 
every 24 hours.  DNA was extracted using the Qiagen DNA Mini Kit and eluted 
in 200 μl of water.  Following extraction, the DNA was spun through Microcon 
YM-30 centrifuge columns (Millipore, USA) to concentrate the DNA and 
remove highly degraded DNA molecules of less than 50 basepairs (bp).  DNA 
integrity was assessed by polymerase chain reaction (PCR) using the following 
primer sets for the Beta-globin gene: B1 (5
‟
-GTGTGCTGGCCCATCACTTT-3
‟
) 
and B19 (5
‟
-CAAGAAAGCGAGCTTAGTGA-3
‟
) to give a 120 bp amplicon 
(Hiyama et al., 1990) and PC04 (5
‟
-CAACTTCATCCACGTTCACC-3
‟
) and 
GH20 (5
‟
-GAAGAGCCAAGGACAGGTAC-3
‟
) to give a 268 bp amplicon 
(Bauer et al., 1991).  Of the 74 FFPE tumours analysed, 11 failed to show a 
product with the 269 bp Beta-globin PCR, but only 2 of these also failed to show 
a product with the 120 bp PCR, indicating the vast majority of FFPE DNAs were 
of reasonable quality. 
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2.2.3 DNA extraction from whole blood 
DNA was extracted from 1.5 mls of EDTA blood using the Nucleon BACC1 kit 
(Tepnel Life Sciences, UK), according to their standard protocol.  This kit uses a 
resin-based method to separate DNA from other cellular components, including 
proteins and cell debris.  DNA was eluted into 50 μl water. 
 
2.2.4 DNA extraction from cultured cells 
Cell lines were grown to 70% confluency in 90 mm dishes, washed twice in 
phosphate buffered saline (PBS), detached from the tissue culture dishes by 
incubation with a solution of 0.05% trypsin and 0.02% EDTA in PBS, pelleted 
by centrifugation and resuspended in 200 μl sterile PBS (see section 2.6 for full 
details of tissue culture techniques).  DNA was extracted from the cells using the 
Blood and Body Fluid Spin protocol from the Qiagen DNA Mini Kit.  DNA was 
eluted from the column with 200 μl of water. 
 
2.2.5 H&E staining 
Slides were equilibrated to ambient temperature and rehydrated in decreasing 
strengths of ethanol (100, 90 and 70%) for two minutes each, before being 
washed in water and submerged in haematoxylin for 2-5 minutes to stain the 
nuclei of cells.  Slides were rinsed in water for 5 minutes to oxidise the dye to its 
blueish colour and dipped briefly in acid for differentiation.  A counterstain of 
eosin was used for 1 minute to stain the cytoplasm and connective tissue, 
followed by washing with water, a series of alcohols of increasing concentration 
and fixation in xylene.  Immediately after staining, coverslips were used to 
protect the region of slide with stained tissue using DPX (Sigma Aldrich, UK) as 
a mounting medium, which contains a mixture of distyrene, plasticizer and 
xylene. 
 
2.2.6 Laser capture microdissection of frozen tissue for RNA extraction 
Prior to cryosectioning fresh frozen (FF) tissue for RNA, the cryostat, membrane 
slides and blades were cleaned with RNase Zap (Ambion, USA) to remove any 
contaminating RNases.  Between 10-20 eight micron sections were cut onto UV 
treated membrane slides (see section 2.2.1) and fixed immediately in ice-cold 
70% ethanol for 2 minutes.  Ice-cold cresyl violet was used to stain the nuclei of 
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cells for two minutes, followed by brief rinses in an increasing series of ice-cold 
ethanols.  Slides were dried completely using a low heat airdryer and either used 
immediately for LCM or stored for one week at -80 
o
C in a sealed air-tight 
container.  Fresh staining solutions were used for each sample.  Laser capture 
was performed as previously described for DNA, using a reference H&E slide to 
identify target areas for microdissection (section 2.2.1).  Target cells were 
collected into 350 µl RLT lysis buffer (Qiagen) containing β-mercaptoethanol 
and guanidine salts to reduce the activity of RNases.  RNA was extracted using 
the Qiagen RNA Micro Kit, with on-column DNase I treatment (Qiagen) to 
minimise the carryover of genomic DNA (gDNA) contamination.  RNA was 
eluted from the column in 14 μl of RNase-free water and stored at -80 oC until 
use. 
 
2.2.7 RNA extraction from frozen tissue 
 
Approximately 5 mg of FF tissue was ground under liquid nitrogen using a 
pestle and mortar and scraped into a tube containing 350 µl RLT lysis buffer 
(Qiagen).  Homogenisation of the sample was achieved by vortexing the sample 
for 1 minute at full force.  The sample was spun for 3 minutes at full speed to 
pellet cell debris, before removing the supernatant and extracting RNA according 
to the protocol for total RNA isolation from human tissues (RNeasy Micro Kit, 
Qiagen, UK).  On-column DNase I treatment was performed and the RNA eluted 
with 14 μl RNase-free water. 
 
2.2.8 RNA extraction from cultured cells 
Keratinocyte cell lines were grown to 70% confluency in 90 mm dishes, washed 
twice with ice-cold PBS and pelleted following typsinisation (see chapter 2.6 for 
tissue culture techniques).  RLT lysis buffer (Qiagen) was used to resuspend the 
pellet and the sample was homogenised by vortexing at full force for 1 minute.  
RNA was extracted using the Qiagen RNeasy Mini Kit, with on-column DNase I 
treatment and elution in 50 μl RNase-free water. 
 
2.2.9  Spectrophotometry 
DNA and RNA were quantified using the Nanodrop 1000 (LabTech 
International, UK), with water as a blank measurement to adjust for background.  
 69 
RNA samples that had been laser captured and registered under 5 ng/μl on the 
Nanodrop were quantified using the Agilent Bioanalyser 2100 Pico chips. 
 
2.2.10 Agilent Bioanalyser  
The Lab-on-a-chip technology from Agilent (UK) is an electrophoretic system 
that allows the quantification of DNA, RNA and protein.  Glass chips are used to 
separate and visualise up to 12 DNA or RNA samples at a time.  Each chip has 
16 wells that are connected by channels containing a gel matrix with intercalating 
dye.  The 12 sample wells and 1 ladder well contain electrodes in which a 
voltage is applied individually, moving the sample or ladder along a common 
channel.  Once the product is flowing past a central separation channel which is 
at right angles to the main channel, the voltage is changed allowing the exact 
quantity of sample at the intersection of the channels to enter the separation 
channel.  From here, the product is separated through the gel matrix according to 
size, where it is visualised and quantified by a laser beam at the far end of the 
channel.  Into each of the sample wells and ladder well, 5 μl of marker and 1 μl 
of sample or ladder were loaded.  The three remaining wells contain matrix 
reservoirs.  RNA samples were analysed using the RNA pico chips, which can 
quantify up to 11 RNA samples on one chip in the range of 200 pg to 5 ng.   
 
2.3 TECHNIQUES BASED ON DNA MANIPULATION 
2.3.1   Primer design 
Primers were designed for PCR using the web-based software Primer3 (Rozen 
and Skaletsky, 2000) and checked for their internal stability and compatibility 
using NetPrimer (PREMIER Biosoft International, USA), which highlights 
hairpin and primer-dimer formation.  A nucleotide-nucleotide BLAST on the 
NCBI web-based interface was used to determine the specificity of the primer to 
the desired sequence (www.ncbi.nlm.nih.gov).  All primers were ordered as dried 
pellets from Sigma-Aldrich (UK) and were made up to 100 μM using water. 
 
2.3.2 Repli-G whole genome amplification 
Repli-G (Qiagen) utilises multiple displacement amplification (MDA) 
technology, which allows multiple polymerase enzymes to bind to the same 
strand of DNA, enabling uniform amplification of the sample.  The polymerase 
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has a 3‟-5‟ exonuclease proofreading activity to maintain high fidelity.  One 
microlitre of template DNA (>10 ng/μl) was mixed with 1 μl denaturation buffer 
(Qiagen) and incubated at ambient temperature for 5 minutes to denature the 
DNA.  Two microlitres of neutralisation buffer was added, before the addition of 
15 μl of REPLI-g UltraFast Reaction Buffer mixed with 1 μl of REPLI-g 
UltraFast DNA Polymerase.  This was incubated at 30 
o
C for 1.5 hours and 
yielded between 7-10 μg of DNA, irrespective of the starting quantity of DNA.  
Following amplification the polymerase was inactivated by heating at 65 
o
C for 3 
minutes.  A negative control reaction was performed using water as a substitute 
for template DNA.  Although the negative control reaction has a positive reading 
on the Nanodrop due to the presence of unused reaction primers, it should not 
amplify in downstream PCR reactions and was used to check for contamination 
of reagents. 
 
2.3.3 Polymerase chain reaction 
Standard PCR reactions were carried out in a 25 or 50 μl reaction volume using 
1.1x Reddymix PCR Master Mix (Table 2.1, ABgene, UK).  The standard 
reagents for a 50 μl reaction were 45 μl of Reddymix PCR master mix, 0.5 μl of 
each forward and reverse primer (100 pmol/μl) and a variable quantity of 
template DNA (between 50 and 100 ng) and water.  Standard cycling parameters 
are shown in Table 2.2 and were performed on the MJ Research DNA Engine 
Dyad thermal cycler (Genetic Research Instrumentation, UK). 
 
 
Reagent Final concentration 
Thermoprime Plus DNA polymerase 1.25 U 
MgCl2 1.5 mM 
Each dNTP 0.2 mM 
Tris-HCl 75 mM 
(NH4)2SO4 20 mM 
Tween 20 0.01% 
Precipitant & electrophoresis dye / 
 
Table 2.1  Components of Abgene’s Reddymix PCR Master mix. 
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Step Duration (minutes) No of cycles 
Taq activation, 85 
o
C 2  1 
Denaturation, 95 
o
C 1  35-40 
Annealing, 50-62 
o
C* 1  
Extension, 72 
o
C 1
† 
Final extension, 72 
o
C 5-10  1 
 
Table 2.2   Cycling parameters for a standard PCR reaction using the Reddymix PCR 
master mix from Abgene.  *Annealing temperatures were determined empirically for each 
primer set.  
†
Extension times were increased by 30 seconds per 500 bp for amplification products 
larger than 500 bp. 
 
 
2.3.4 Multiplex PCR 
Multiplex PCR (mPCR) reactions were carried out in a 30 μl volume, using 15 μl 
of Multiplex PCR Master Mix (Qiagen), to give a final MgCl2 concentration of 
3mM.  Three microlitres of a 10x stock primer mix (containing each primer at 2 
μM) and 150 ng of DNA was added.  The reaction was made up to 30 μl with 
water.  All reactions were performed at an annealing temperature of 60 
o
C in 
accordance with the manufacturer‟s recommendations.  If non-specific products 
were produced, Q-solution (Qiagen) was added to improve the PCR specificity.  
Multiplex PCRs were visualised and analysed semi-quantitatively using the 
Agilent Bioanalyser 2100 and DNA 1000 kit (Agilent, UK).  The following 
criteria – in order of importance – were used to group 3-4 PTPRD primer sets for 
mPCR: a) amplicon size, with ≥20 bp difference in size between amplicons; b) 
similar intensity of products from individual PCR reactions; c) primer sets 
amplifying adjacent exons were not included in the same reaction, in order to 
avoid the generation of large non-specific PCR products.  Figure 2.1 shows the 
final mPCR products as visualised on a 2% agarose gel. 
 
2.3.5 Agarose gel electrophoresis 
PCR products were visualised using agarose gel electrophoresis.  Briefly, 5–10 μl 
of PCR product were loaded into wells of an agarose gel consisting of 100 mls 
tris-borate-EDTA acid (TBE) buffer and agarose that had been heated and 
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allowed to set.  The percentage of agarose was dependant on the size of the 
product: from 0.8% for 5-10 kb fragments to 2% for 0.1-1kb fragments.  PCR 
products that did not contain a precipitant dye in the PCR master mix were mixed 
with 5x Orange G loading dye (see section 2.7) to weight the sample in the well.  
Six microlitres of ethidium bromide was added to the gel to visualize products.  
Gels were run at 120 volts (V) for a minimum of 30 minutes and visualized using 
UV light. 
 
 
 
 
 
 
 
Figure 2.1  2% agarose gel showing mPCRs designed for the PTPRD gene.  Six mPCRs 
amplifying exons B1-B9 and X1-X6 were optimised on placental DNA.  The largest amplicon in 
each mPCR is a 269 bp fragment of the Nol10 gene.  mPCR groups are indicated above the gel 
picture.  Primer details of exons included in each mPCR group are listed in Appendix F.  NTC is 
no template control and is used to indicate control PCR reactions that were carried out with water 
substituted for DNA. 
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2.3.6 PCR Product purification by gel extraction 
PCR products that required purification by gel extraction were loaded into a 
wide-comb well of a low melting point agarose gel (percentage dependant on 
product size).  Gels were run at 100 V for a minimum of 45 minutes, until the 
band of interest was completely separated from non-specific products.  The 
appropriate band was visualised using a UV light box and excised from the gel 
using a sterile scalpel.  Products were purified using the QIAquick Gel 
Extraction Kit (Qiagen) and eluted in 30 μl water. 
 
2.3.7 Direct Sequencing 
PCR products were purified for sequencing using Exonuclease I and Shrimp 
Alkaline Phosphatase (ExoSap, GE Healthcare, UK).  Four microlitres of 
ExoSap was added to 10 μl of the PCR reaction, incubated at 37 oC for 15 
minutes and inactivated by heating at 80 
o
C for a further 15 minutes.  
Exonuclease I degrades excess single stranded primers and unfinished PCR 
products, whilst Sap removes excess dNTPs.  Direct sequencing was carried out 
by the DNA Analysis Facility at Dundee University, using the fluorescent end 
terminator chemistry of BigDye v3.1 (Applied Biosystems, UK), with 
visualization on the 96 capillary Prism 3700 (Applied Biosystems).  Briefly, 1 μl 
of BigDye v3.1 is combined with 1 μl Better buffer (Microzone Ltd, UK), 1 μl 
primer (at 5 pmol/μl) and 7 μl of template and H2O, to give a final template 
concentration of 3-10 ng.  The sequencing reaction is shown in Table 2.3. 
 
 
Step Duration No of cycles 
Denaturation, 96 
o
C 30 s 25 
Denaturation, 96
 o
C 10 s 
Annealing, 50 
o
C 15 s 
Extension, 60 
o
C 4 mins 
4 
o
C Hold 1 
 
Table 2.3   Sequencing reaction cycling conditions. 
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Samples were purified after the sequencing reaction using ethanol and sodium 
acetate.  Briefly, 2 μl of 125 mM EDTA and 2 μl 3 M sodium acetate was added 
to each reaction along with 25 μl of 100% ethanol.  The samples were incubated 
at ambient temperature for 15 minutes and then spun at full speed for 30 minutes.  
The supernatant was removed immediately, 30 μl of 70% ethanol added and the 
samples spun at 1650 x g for 15 minutes.  The supernatant was again discarded, 
the pellet air-dried and resuspended in 10 μl of water and 8 μl of HiDi 
formamide.  The samples were immediately analysed by the Prism 3700 
sequencer and sequencing files reviewed using the web-based BioEdit Sequence 
Alignment Editor software (Hall, 1999).  Potential mutations were confirmed to 
be novel variants using the Ensembl database which lists known polymorphic 
variants (www.ensembl.org).  Mutations were confirmed by sequencing two 
independent PCR products in both the forward and reverse direction. 
 
2.3.8 Bisulphite modification for methylation analysis 
For methylation analysis, 200 ng of gDNA from FF samples or cell lines were 
treated with bisulphite using the Zymo EZ DNA Methylation Kit (Zymo, USA).    
Bisulphite treatment converts all unmethylated cytosines to uracil by 
deamination, whereas methylated CpG sites are protected from the treatment and 
remain as cytosine.  Post bisulphite conversion, the DNA was cleaned up using a 
column based desulphonation and wash system (Zymo) and eluted in 100 μl of 
water.  Five microlitres of modified DNA was used directly as a template in 
PCR. 
 
2.3.9 Methylation specific PCR 
Methylation specific PCR (MSP) relies on the discrimination of two primer sets 
designed to the same region of DNA: one set to specifically amplify methylated 
DNA, the other, unmethylated DNA.  CpG islands associated with the PTPRD 
promoter regions were identified using the University of California, Santa Cruz 
(UCSC) genome browser (www. genome.ucsc.edu) and primers were designed 
using the MethPrimer software (Table 2.4, Li and Dahiya, 2002). For MSP, 
primers were designed to contain multiple CpG sites in their sequence, 
particularly towards the 3‟ end of the primer to enhance their discrimination 
between methylated and unmethylated DNA.  Primer sequences are often long, 
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as bisulphite modified DNA contains an excess of thymine which has a lower Tm 
than cytosine. 
 
MSP reactions were performed using 2x Thermo-Start PCR Master Mix 
(Abgene, UK).  Five microlitres of DNA was mixed with 10 μl PCR master mix 
and 1 μl of each primer (F and R) at a concentration of 10 pmol/μl each.  The 
reaction volume was made up to 20 μl with water.  Final concentrations of 
components in the 2x master mix are shown Table 2.5, whilst the cycling 
conditions are detailed in Table 2.6.  The initial 8 cycles activate the Taq 
gradually, resulting in more stringent PCR amplification.  PCRs were optimised 
using CpGenome Universal Methylated DNA (Millipore, UK) and unmethylated 
DNA from blood, to ensure discriminate amplification of the methylated and 
unmethylated primer sets.   
 
Primer set 
name 
Primer sequence (3’ – 5’) Position Amplicon 
size (bp) 
MSP CpG59 M  GGGGTTCGTTTAGGTCGC 
TACGAACGCGCCAAATAAAA 
-769 
-686 
83 
MSP CpG59 U GGTGGGGTTTGTTTAGGTTG 
AACAACAACACTACAAACACACCAAATAAAACA 
-772 
-675 
98 
Bisulphite seq 
CpG59 
GGTTATAGTGATGGGGAATAGTTTGT(btn) 
ACCCACCCACCCAAAACTACC 
Seq (R): ACCCACCCAAAACTAC 
-872 
-727 
146 
MSP CpG87 M TTTCGTGGGATTTTTAGTACGTTAC 
AAAACCGAAAAATAAAATAACCGAT 
8848599-
8848397 
203 
MSP CpG87 U TGTGGGATTTTTAGTATGTTATGA 
AAAACCAAAAAATAAAATAACCAAT 
8848596-
8848397 
200 
Bisulphite seq 
CpG87 
GGAGGGGGAGGAGATAAATA 
CCACCCCTACCCCCTTTT(btn) 
Seq (F): GGGGGAGGAGATAAATA 
8848098-
8847923 
176 
 
Table 2.4   Primer sequences for MSP and bisulphite sequencing analysis of PTPRD 
CpG islands.  Btn indicates biotin labelled primers.  F and R = forward and reverse and are used 
to indicate the direction of sequencing primer in the bisulphite sequencing assays.  Seq = 
sequencing primer.  Position of the CpG59 primers are shown relative to the transcription start 
site, designated +1.  CpG87 primer positions are shown as genomic locations, in the absence of 
an annotated transcription start site. 
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Reagent Final concentration 
Thermo-Start Taq DNA polymerase 0.625 U 
Thermo-Start reaction buffer 1x 
dNTP 0.2 mM each 
MgCl2 1.5 mM 
 
Table 2.5   PCR master mix components for MSP analysis. 
 
 
Step Duration No of cycles 
Taq activation/denaturation 95 
o
C 2 mins 8 
Annealing 55-65 
o
C 30 secs 
Extension 72 
o
C 30 secs 
Activation/denaturation 95 
o
C 30 secs 32 
Annealing 55-65 
o
C 30 secs 
Extension 72 
o
C 30 secs 
Final extension 72 
o
C 5 mins 1 
 
Table 2.6   PCR cycling conditions for MSP analysis. 
 
 
2.3.10 Bisulphite sequencing 
Bisulphite sequencing utilises one primer set to amplify both methylated and 
unmethylated bisulphite modified DNA for subsequent quantitative analysis 
using pyrosequencing.  In brief, pyrosequencing involves the hybridisation of a 
sequencing primer to a single-stranded PCR amplicon, in the presence of DNA 
polymerase, adenosine triphosphate (ATP) sulfurylase, luciferase, apyrase, 
adenosine 5‟ phosphosulfate (APS) and luciferin.  Deoxynucleotide triphosphates 
(dNTPs) are added sequentially to the reaction and are incorporated into the 
DNA strand by the DNA polymerase if complementary to the template.  This 
results in the release of pyrophosphate (PPi) that is directly proportional to the 
amount of dNTP incorporated.  ATP sulfurylase converts PPi to adenosine 
triphosphate (ATP) in the presence of APS, which subsequently drives the 
conversion of luciferin to oxyluciferin, generating a proportional quantity of 
 77 
visible light in the process.  The light is detected by the pyrosequencer and seen 
as a peak in the pyrogram (data output).  Apyrase continuously degrades ATP 
and dNTPs that have not incorporated and when degradation is complete, the 
next nucleotide is added.  Deoxyadenosine alfa-thio triphosphate (dATP·S) is 
used as a replacement for dATP, as it is successfully incorporated into the 
template without driving non-specific luciferase activity. 
 
Primers for bisulphite sequencing were designed using Pyrosequencing Assay 
Design Software (Table 2.4, Biotage, Sweden).  According to the design 
parameters of the software, either the F or R primer was biotinylated at the 5‟ end 
and purified by high performance liquid chromatography (HPLC).  PCR 
conditions were optimised using the same reagents and conditions as MSP.  
Primer sets were shown to specifically amplify only bisulphite modified DNA, 
by testing gDNA that had not been bisulphite modified.  If primer sets did also 
amplify non-modified gDNA, the primer set was either optimised until it 
specifically amplified modified DNA only, or discarded and re-designed. 
 
Post-PCR, samples were cleaned up using the PSQ96 vacuum prep tool 
(Qiagen).  Twenty microlitres of PCR product were incubated with 3 μl 
streptavadin beads and 37 μl  binding buffer (Qiagen) on a shaking platform for 
at least 10 minutes.  The samples were immediately aspirated using the vacuum 
prep tool.  The streptavadin beads with immobilised PCR products were washed 
in 70% ethanol for 5 seconds, 0.5 M sodium hydroxide for 5 seconds (to create a 
single stranded PCR product for sequencing) and 1x wash buffer for 10 seconds.  
The products were released into 40 μl annealing buffer containing 5 μl of 
sequencing primer at a concentration of 3 μM and incubated at 80 oC for 2 mins.  
Following clean-up, the plate containing the PCR products and sequencing 
primers were loaded onto the pyrosequencing machine.  A cartridge was 
prepared with appropriate quantities of substrate, enzyme mix and dNTPs (as 
determined by the PyroMark ID Software (Qiagen)).   
 
Sequence details of the PCR amplicon were uploaded into the PyroMark ID 
software, which generates a dispensation order according to the amplicon 
sequence and will release the appropriate dNTP in order.  CpG dinucleotides are 
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represented in the dispensation order by dCTP and dTTP, followed by a negative 
dispensation of dATP·S.  To check bisulphite modification was complete, a non-
CpG associated cytosine was also given the dCTP/dTTP/dATP·S dispensation 
order and checked for 100% incorporation of dTTP.  Data from the sequencing 
run was viewed as pyrograms using the PyroMark ID software. 
 
2.3.11 Affymetrix 250K SNP microarray 
Affymetrix 250K SNP microarrays were performed according to the 
manufacturer‟s instructions.  Genomic DNA (250 ng) was digested for 2 hours 
with the Nsp restriction enzyme, followed by ligation of Nsp-specific adaptors to 
the digested DNA.  PCR using adaptor-specific primers was performed to 
amplify the digested DNA and the corresponding products were purified using 
Amicon ultrafree-MC centrifugal filter units (Millipore).  Purified PCR products 
were fragmented using DNase I, labelled and hybridised to the GeneChip Human 
Mapping 250K microarray, which contains probes for 262,000 SNPs.  
Hybridised arrays were processed with the Affymetrix Fluidics Station 450 and 
fluorescence signals were detected using the Affymetrix GeneChip Scanner 
3000.  Signal intensity data was analysed by the GeneChip DNA analysis 
software, which uses a model algorithm to generate SNP calls.   
 
Signal intensity and SNP call data were analysed using in-house Genome 
Orientated Laboratory File (GOLF) software (Horsley et al., 2008).  Genotype 
calls and the signal intensity (on a log2 scale) were plotted visually to identify 
regions of altered copy number.  A decrease in the signal intensity with loss of 
heterozygote SNPs indicates homozygous deletion or loss of heterozygosity 
(LOH), whilst loss of heterozygous SNPs without a decrease in the signal 
intensity is indicative of uniparental disomy (UPD).  An increase in signal 
intensity indicates amplification (Figure 2.2). 
 
2.3.12 Illumina PTPRD custom SNP microarray 
To analyse FFPE tumours for deletion at the PTPRD locus, a 384 SNP oligo pool 
all (OPA) was designed using the Illumina Assay Design Tool (ADT).  The 
coordinates of chromosome 9p 8304000-10605000 which encompasses the entire 
locus were uploaded to the ADT and a SNP score file containing 10848 SNPs  
 7
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Figure 2.2  Signal Intensity data of a tumour sample as displayed by the GOLF software programme.  The panel shows the signal intensity for tumour DNA extracted 
from a cell line plotted on a log2 scale.  The data are arranged by chromosome as indicated at the top.  The central axis indicates a normal copy number of 2, whilst the upper 
line indicates log2 (2) and represents gain of copy number and the lower line indicates log2 (0.5) and represents loss of copy number.  This tumour sample displays LOH on 
chromosomes 3, 8, 9, 11 and 19 and gain of copy number on chromosomes 1, 5, 7, 8, 9, and 11. 
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from dbSNP v127 was returned.  Of these SNPs, 1296 were GoldenGate 
validated, which meant they had successfully been used in other GoldenGate 
assays, whilst a further 6309 were two-hit validated SNPs with a design score 
>0.60, meaning both alleles of the SNP had been identified from two 
independent sources and were highly likely to perform well in the assay.  All 
SNPs that were chosen for the custom array were either GoldenGate validated or 
two-hit validated SNPs with a design score above 0.60.  Each SNP was chosen to 
give approximately 6 kb spacing.  SNPs with a minor allele frequency (MAF) of 
≥10% in the Caucasian population were preferentially used, as the majority of 
tumour samples were from Caucasian patients. 
 
Once the OPA had been designed and manufactured, 250 ng of each DNA 
sample was prepared with the OPA according to the methodology of the 
GoldenGate assay and hybridised to the 96-sample Universal Array Matrix by 
the Genome Centre, at Barts and the London.  Initially, the DNA is activated by 
binding a paramagnetic complex to the DNA before being mixed with the OPA.  
For each SNP there are 3 primers: one for each of the two alleles designated 
AS01 and AS02 and a third locus specific oligo (LSO) that binds several bases 
downstream of the targeted SNP.  After hybridisation of the oligos to the target 
SNP, extension and ligation between the allele specific oligo (ASO) that has 
bound to the DNA and LSO results in a template for PCR.  All three primers for 
each SNP contain a universal PCR primer sequence to enable amplification of all 
384 target SNPs in the same reaction.  The universal primers to AS01 and AS02 
are labelled with Cy3 and Cy5 respectively, to enable discrimination between the 
alleles once the array process is complete.  The LSO also contains a unique 
address sequence that targets a particular bead type.  After PCR, the products 
were hybridised to the BeadChip array, with each LSO targeting its 
complementary bead.  The array was scanned using the Illumina BeadScanner, 
which measures the level of fluorescence for each SNP.  Gene calls are 
automatically extracted from the fluorescent signal and the data subsequently 
analysed using the BeadStudio Genotyping Module. 
 
Due to the inherent noise from FFPE tissue, genotype clusters were based on the 
blood DNA samples included on the array.  The clusters for each SNP were 
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manually reviewed and altered as appropriate to ensure three distinct genotype 
clusters (AA, AB and BB) were detected.  FFPE DNA samples were analysed 
using the Genome Viewer function, which plots SNP results by chromosome.  In 
all cases, the signal intensity was reviewed as a log scale along with the B allele 
frequency (BAF).  Deletions were only considered genuine events if there was a 
decrease in the signal intensity accompanied by either loss of the heterozygote 
SNPs or, in the case of homozygous deletions, a „waterfall‟ effect of randomly 
called SNPs based on background noise in the deleted region. 
 
2.4 TECHNIQUES BASED ON RNA MANIPULATION 
2.4.1 cDNA synthesis for reverse transcriptase PCR  
For standard reverse transcriptase (RT) PCR from cell lines or whole tissue 
biopsies, 1 μg of RNA was used as a template for the generation of 
complementary DNA (cDNA) using SuperScript II RT First Strand synthesis 
system (Invitrogen, UK).  Briefly, the RNA was incubated at 65 
o
C for 5 minutes 
with 50 μM Oligo(dT) primers and 10 mM of each dNTP.  After chilling on ice, 
5x First Strand Buffer, 0.1 M DTT and SuperScript II RT were added in a 20 μl 
total reaction volume and incubated at 50 
o
C for 1 hour.  The reaction was 
terminated by incubation at 85 
o
C for 15 minutes.  All reactions were carried out 
in duplicate using one tube as a reaction control without the addition of RT.  If 
the amplicon size for downstream PCR reactions was greater than 1 Kb, 
carryover RNA was removed by incubation at 37 
oC for 20 minutes with 1 μl 
Escherichia coli RNase H (Invitrogen) to prevent its inhibition of the 
downstream PCR.  To confirm the quality of cDNA, RT-PCR of the Beta-actin 
gene was performed on all samples before use in individual experiments.  The 
primer sequences for Beta-actin were: forward primer 5‟-
GATCTTCGGCACCCAGCACAATGAAGATC-3‟ and reverse primer 5‟-
AAGTCATAGTCCGCCTAGAAGCAT-3‟.  PCRs were performed using the 
standard PCR master mix with 3 mM MgCl2, an annealing temperature of 55 
o
C 
and 35 cycles.  The expected product size for cDNA is 183 bp, contamination 
with gDNA would be revealed as a larger band at 295 bp. 
 
For LCM samples, a lower starting quantity of 50 ng RNA was used as a 
template for cDNA synthesis due to the lower yield from LCM samples.  cDNA 
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was generated using the SuperScript III system with 100 ng of random primers 
(both from Invitrogen).  The protocol was the same as for the SuperScript II 
system, with the exception of a 5 minute incubation at 25 
o
C prior to cDNA 
synthesis at 50 
o
C.  One microlitre of RNaseOUT (an RNase inhibitor) was also 
added to the reaction to prevent degradation of the RNA during the synthesis.   
 
2.4.2 RT-PCR 
For standard RT-PCR reactions using cDNA from cell lines or whole tissue 
biopsies, cDNA was diluted 1:10 before use in PCR.  cDNA from LCM samples 
was diluted 1:2 prior to use.  PCR reactions were performed as described 
previously in section 2.3.3. 
 
2.4.3 Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) for PTPRD, HPRT and 18S RNA was 
performed using the TaqMan primer and probe sets Hs00295441_s1, 
Hs99999909_m1 and Hs99999901_s1 respectively (Applied Biosystems (ABI), 
UK).  All TaqMan probes had a minor groove binder (MGB) at the 3‟ end of the 
probe to increase the melting temperature (Tm), as well as a FAM reporter dye at 
the 5‟ end and a non-fluorescent quencher at the 3‟ end.  Two microlitres of 
cDNA that had been diluted 1:2 with water was added to 10 μl of Universal Gene 
Expression PCR Master Mix (ABI) and 1 μl of primer and probe mix (to give 
final concentrations of 0.9 μM for each primer and 0.25 μM for the probe) on ice.  
The reaction volume was made up to 20 μl with water.  Reactions were carried 
out in triplicate for each sample and probe set.  PCR programmes were set up 
according to the conditions in Table 2.7 on the ABI 7500 Real Time PCR 
machine and data analysed using the 7500 System Software (ABI).  Standard 
curves were generated using a serial dilution of a cDNA sample to check the 
efficiency of all new primer and probe sets was 100%. 
 
Quantitative RT-PCR analysis of GUS was performed using Brilliant II Sybr 
Green qPCR Master Mix (Stratagene, UK) with the primer set 5‟-
AAACGATTGCAGGGTTTCAC-3‟ and 5‟-TCTCGTCGGTGACTGTTCA-3‟.  
In brief, 12.5 μl of SYBRGreen master mix was mixed with 10 pmol of each 
primer, 0.375 μl Rox (diluted 1:500 with RNase-free water) and 2 μl diluted
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cDNA.  The reaction volume was made up to 25 μl and the PCR reaction run on 
the ABI 7500 Real Time PCR machine according to the conditions in Table 2.8.  
Data were collected during the extension step of each cycle.  A dissociation 
curve was generated to check for specificity of the PCR products produced. 
 
 
Step Duration  Number of cycles 
AmpliTaq Gold activation, 95 
o
C 10 mins 1 
Denaturation, 95 
o
C 15 secs 40  
Anneal/Extend, 60 
o
C 1 min 
 
Table 2.7   PCR conditions for TaqMan qRT-PCR. 
 
Step Duration  Number of cycles 
DNA polymerase 
activation, 95 
o
C 
10 mins 1 
Denaturation, 95 
o
C 15 secs 40 
Annealing, 60 
o
C 30 secs 
Extension, 72 
o
C 1 min 
 
Table 2.8   PCR cycling conditions for SYBR green qRT-PCR of GUS. 
 
 
2.4.4 Affymetrix HGU133 Plus 2.0 gene expression microarrays 
For expression microarray analysis, RNA was extracted from FF AKs and cSCC 
by LCM (see section 2.2.6).  Non-sun exposed (NSE) normal skin and sun 
exposed (SE) normal skin biopsies that had been collected into RNAlater were 
pulverised under liquid nitrogen for subsequent RNA extraction (see section 
2.2.7).  RNA was assessed for quality by the Agilent Bioanalyser RNA Pico 
Chips (see section 2.2.10).  Whole transcriptome amplification, pre-microarray 
processing and hybridization to the arrays were performed by the Paterson 
Institute for Cancer Research (University of Manchester, UK).  Briefly, 10 ng of 
RNA was used a template for whole transcriptome amplification and cDNA 
synthesis using the NuGen WT-ovation Pico RNA Amplification System 
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(NuGen, USA).  This technology generates first-strand cDNA from total RNA 
(500 pg – 50 ng input requirement) using both poly-A tail primers and random 
primers to ensure uniform amplification of all transcripts in the sample (Dafforn 
et al., 2004).  DNA polymerase is then used for linear amplification of cDNA, 
resulting in 6-10 µg of cDNA in 5 hours.  Five micrograms of amplified cDNA 
was labeled with the FL-ovation Biotin kit (NuGen) for hybridization to the 
array.  The HGU133 Plus 2.0 arrays have probes for transcripts from 
approximately 38,572 genes.  Each transcript is represented on the array by 
multiple probes, as well as mismatch probes, which differ by 1 bp and can be 
used as a measure of background noise. 
 
2.4.4.1 Microarray quality control 
Following hybridisation of the samples to the microarrays, standard quality 
control (QC) checks were performed on the cel files to assess the quality of 
hybridisation.  Each cel file contains a raw image of the microarray and can be 
assessed for the level of background (determined by percentage of mismatch 
probes hybridised by labelled products), percentage of present transcript calls 
(measured by hybridisation of labelled products to perfect-match probes), scale 
factor (a measure of how much scaling is required for each array to conform to a 
mean intensity) and 3‟:mid ratios of the GAPDH and Beta-actin genes.  All 
arrays included for analysis had similar levels of background and present calls, 
with scale factors within 3-fold of each other.  These are all within standard 
recommendations for microarray QC and indicate RNA input, labelling 
procedures and hybridisation were consistent across all samples (Wilson and 
Miller, 2005).  Four samples had GAPDH 3‟:mid ratios higher than 1.25 and 
Beta-actin 3‟:mid ratios higher than 3 which indicates either truncated transcripts 
are present in the samples or inefficient amplification has occurred using the 
NuGen whole transcript amplification kit.  Advanced QC checks using 
Bioconductor did not identify these samples as outlier arrays (see below) so they 
were included for downstream analysis. 
 
Established Affymetrix microarray QC checks were performed by Dr Gavin 
Kelly using Bioconductor, which utilises the R statistical package to identify 
poor quality arrays that may affect data interpretation (Gentleman et al., 2004).  
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An MA plot was generated for each array, whereby the intensity of an individual 
array was compared to the median intensity values of all the arrays.  The 
distribution of this plot should be concentrated along the M=0 axis, indicating the 
individual array is consistent with the average intensity of all arrays (Figure 2.3).  
Further QC checks included a boxplot and histogram of the log2(Intensity) of all 
arrays to compare the level of perfect-match probe bound by labelled products 
across each array (Figure 2.3).  All three of these plots showed good 
homogeneity across all arrays indicating no poor quality arrays were present in 
the group.   
 
Having passed the QC checks, all microarray data were analysed using Partek 
(Partek, US).  Robust multichip averaging (RMA) was used to normalise the data 
prior to statistical comparisons, which includes an adjustment for background, 
quantile normalisation, a median centering step and logarithmic conversion of 
perfect-match probe intensities (Irizarry et al., 2003).  Quantile normalisation 
scales the smallest value on each array to each other, the second smallest value 
on each array to each other etc.  This reduces bias between arrays that show 
different hybridisation efficiencies due to technical variation during the 
microarray process.  Median centering brings the median centre of each 
microarray into alignment with each other, upon the assumption that the majority 
of genes are unchanged between samples.  Whilst normalisation will mask some 
genuine expression changes, it is essential to minimise the potential effect of 
technical variables on subsequent data analysis including performance artefacts 
such as printing, hybridisation and scanning differences between microarrays. 
 
2.5 PROTEIN TECHNIQUES 
2.5.1 PTPRD antibody generation 
For the generation of antisera against the PTPRD protein, two epitopes were 
chosen for antibody production in collaboration with Dr John Foerster (Dundee 
University).  Both epitopes mapped to the ECD and showed low sequence 
similarity to other proteins – including PTPR family members – as determined by 
ClustalW alignment (www.ebi.ac.uk/Tools/clustalw/) and BLASTp 
(www.blast.ncbi.nlm.nih.gov/) analysis.  Epitopes with ≥30% predicted surface 
exposure were preferentially targeted and identified using a 3D model of PTPRD 
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Figure 2.3 Expression microarray quality control checks generated by Bioconductor.  
A) shows MA plots for 8 individual arrays, where M = the log2 intensity of an individual array – 
the log2 intensity of a median average intensity of all arrays and A = ½ the log2 intensity of an 
individual array + the log2 intensity of a median average intensity of all arrays.  In all cases the 
majority of expression values fall along the M=0 axis, indicating good consensus between the 
individual sample and an average measurement of the group as a whole.  B) shows a histogram of 
the intensity of each array and reveals good consistency between all arrays, as demonstrated by 
an equal pattern of distribution for all arrays. 
 
A) 
B) 
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generated by the Swiss-Model programme on the ExPASy interface 
(www.swissmodel.expasy.org/).  The two epitopes used for antisera generation 
were NSEELYKEIDGVA (designated peptide A) and TQHVNNWM 
(designated peptide B).  Peptides were manufactured by the Protein and Peptide 
Chemistry Laboratory of Cancer Research UK.  The peptides were generated 
with a free cysteine at the carboxyl-terminus, for conjugation to the carrier 
protein keyhole limpet haemocyanin (KLH).  Each conjugated peptide was 
initially inoculated into two rabbits with Freund‟s complete adjuvant (FCA) to 
stimulate the cell-mediated immune response.  All subsequent inoculations were 
performed with Freund‟s incomplete adjuvant (FIA).  Immunisation was carried 
out by Harlan Laboratories UK according to the schedule in Table 2.9. 
 
 
 
Day No Action 
0 Pre-bleed 10 ml + immunisation FCA 1 ml 
14 Boost 1 FIA 1 ml 
28 Boost 2 FIA 1 ml 
35 Test-bleed 1-10 ml 
42 Boost 3 FIA 1 ml 
49 Test-bleed 2 2-10 ml 
56 Boost 4 FIA 1 ml 
63 Test-bleed 3 3-10 ml 
70 Boost 5 FIA 1 ml 
77 Production bleed 1 
98 Boost 6 FIA 1 ml 
105 Production bleed 2 
126 Boost 7 FIA 1 ml 
133 Terminal bleed 
   
Table 2.9 Schedule of immunisation for generation of PTPRD anti-sera.  Two rabbits 
were inoculated with each peptide (A or B).  FCA indicates Freund‟s complete adjuvant and FIA 
indicates Freund‟s incomplete adjuvant.  Immunisations were performed by subcutaneous 
injection. 
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2.5.2 Protein extraction from cells 
Cells were grown in a 90 mm dish to approximately 70% confluency (see section 
2.6).  The media was aspirated and 2 washes with ice-cold PBS were performed 
on ice.  After fully removing the PBS, 200 μl of ice-cold Radio-
Immunoprecipitation Assay (RIPA) buffer (see section 2.7) with complete mini 
protease inhibitors (Roche, UK) was added and the cells removed using a cell 
scraper.  The RIPA buffer containing the cells was transferred to an Eppendorf, 
briefly vortexed and lysed by rapidly freeze-thawing the cell pellet three times 
between temperatures of -70 and 37 
o
C, before being left on ice for 15 minutes to 
complete the lysis.  After 15 minutes, the solution was centrifuged at 4 
o
C for a 
further 15 minutes at full speed and the supernatant transferred to a clean, chilled 
Eppendorf.  Protein supernatants were stored at -20 
o
C.  The concentration of 
protein was measured using the Bradford assay.  Briefly, 200 μl of 1x Bradford 
reagent (BioRad, UK) was added to a 96 well plate, along with 1 μl of sample.  
The plate was mixed briefly before being immediately analysed using the 
Synergy HT Multi-Mode Microplate Reader (BioTek, USA) at a wavelength of 
595 nm.  The Bradford reagent reacts with protein in the sample to produce a 
directly proportional quantity of coloured compound that absorbs wavelengths of 
595 nm.  A bovine serum albumin (BSA) standard of known concentration 
between 0-10 μg was used to extrapolate protein concentrations from the 
absorbance readings, to determine the concentration of each sample. 
 
2.5.3 Western blotting 
Western blotting was performed using the BioRad Minigel Western Blotting 
equipment (BioRad).  For protein analysis of PTPRD which has a molecular 
weight of 215 kDa for the full length protein and 170 kDa for the cleaved 
extracellular portion of the protein, an 8% acrylamide resolving gel was poured 
into a Biogel cassette, placed into a mould and allowed to polymerise, with a 
layer of isopropanol on top of the gel to ensure even distribution of gel in the 
cassette.  Once the isopropanol was removed, an 8% stacking gel was poured on 
top with a comb in place.  Once this had polymerised, the comb was removed 
and the gel cassette transferred from the mould to an electrophoresis tank 
containing 1x running buffer (see section 2.7).  The appropriate quantity of each 
protein sample (20-60 μg) was mixed with NuPAGE LDS 4x sample buffer 
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(Invitrogen) and heated to 95 
o
C for 5 minutes to denature the proteins.  
Following denaturation, the samples were centrifuged briefly and loaded into the 
gel.  The tank was sealed and electrophoresis performed at 12 mAmps (mA) per 
gel until the Full Range Rainbow Marker (GEHealthcare, UK) showed the 
corresponding size of interest had resolved.  The gel was removed from the 
cassette and placed in a sandwich with pre-soaked materials in the following 
order: sponge, two times blotting paper, gel, membrane (Hybond-P 
polyvinylidene fluoride (PVDF), GE Healthcare), two times blotting paper and 
sponge.  Air bubbles were removed by gentle rolling over the top of the 
assembly.  The sandwich was placed in the transfer tank with 1x transfer buffer 
(see section 2.7), making sure the current was flowing through the gel to the 
membrane to transfer the proteins onto the membrane.  Transfer was performed 
overnight at 100 mA.   
 
Following transfer, the membrane was removed and stained for 5 minutes with 
Ponceau stain to check equal transfer of the proteins.  The Ponceau stain was 
removed with a brief rinse in distilled water and the membrane placed in 5% 
dried non-fat milk in tris buffered saline (TBS) with 0.01% tween (TBS-T) for 1 
hour at ambient temperature to block non-specific protein binding sites on the 
membrane.  The primary antibody was diluted to the appropriate dilution factor 
in 5% milk TBS-T and either incubated overnight at 4 
o
C or for 2 hours at 
ambient temperature on a shaker.  After incubation with the primary antibody, 
the membrane was washed 3 times for ten minutes each in TBS-T, before being 
incubated with the secondary antibody at a 1 in 2000 dilution in 5% milk TBS-T 
for 1 hour at ambient temperature.  All secondary antibodies were raised against 
immunoglobulins of the species from which the primary antibody was generated 
and were conjugated to horseradish peroxidase (HRP) (Dako, UK).  The 
membrane was washed 3 times in TBS-T, before excess buffer was allowed to 
drip off the membrane and the blot incubated for 5 minutes with ECL Plus 
blotting detection reagent (GE Healthcare), which uses a chemiluminescent 
detection system based on peroxide oxidation of the lumigen substrate to produce 
light.  Excess detection reagent was removed, the blot placed within transparent 
layers in a dark cassette and exposed for autoradiography, using  Hyperfilm 
autoradiography film (GE Healthcare). 
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2.5.4 Immunofluroescence 
Five micron FF sections were collected on polylysine slides and fixed in either 
4% paraformaldehyde (PFA) or ice cold acetone for ten minutes at ambient 
temperature, before drying for a further 30 minutes at ambient temperature.  
Slides were rinsed twice in PBS with 0.1% Triton X-100 (PBS-T) and incubated 
for 1 hour with 0.2% fish skin gelatin in PBS-T to block non-specific binding 
sites.  Excess blocking solution was drained from the slides and the primary 
antibody added at the appropriate dilution in PBS-T with 0.5% BSA.  After 
incubation with the primary antibody for 2 hours at ambient temperature or 
overnight at 4 
o
C, slides were washed 3 times with PBS-T for ten minutes each.  
An AlexaFluor secondary antibody (Invitrogen, UK) – raised against the IgG of 
the species in which the primary antibody was generated – was diluted 1/1000 in 
PBS-T and incubated on the slide for 1 hour at ambient temperature in the dark.  
In all subsequent steps, the slides were protected from light.  Slides were washed 
3 times in PBS-T for ten minutes each, before being mounted with 
Immunomount (Thermo Scientific, UK), containing 4',6-diamidino-2-
phenylindole (DAPI).  Immunofluorescent (IF) images were obtained using the 
Leica Epifluorescence microscope (Leica Microsystems Ltd, UK). 
 
2.5.5 Immunocytochemistry 
Cells were seeded onto sterile coverslips in a 12 well dish at a density of 1 x 10
5
 
and grown to 70% confluency.  Upon reaching the desired confluency, the cells 
were washed twice with PBS and fixed for 10 minutes at room temperature using 
4% PFA.  After fixation, the cells were washed twice with PBS to remove all 
traces of PFA and stored in PBS at 4 
o
C for up to one week prior to commencing 
staining.  Cells were permeabilised using 0.1% triton in PBS (PBS-T) for 15 
minutes at room temperature, followed by three washes with PBS of 5 minutes 
each.  Cells were blocked using 0.2% fish skin gelatin in PBS for 1 hour at room 
temperature.  Following blocking, the cells were washed three times with PBS-T 
prior to incubation with the primary antibody, that was diluted 1/50 in 0.5% 
BSA/PBS-T overnight.  The following day, cells were washed three times for 10 
minutes each with PBS-T to remove unbound primary antibody.  They were 
subsequently incubated in the dark for one hour at room temperature with an 
AlexaFluor 488 secondary antibody (Invitrogen, UK) raised against rabbit IgG.  
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The secondary antibody was diluted 1/1000 using PBS-T.  Following incubation, 
the cells were washed three times with PBS-T to remove unbound secondary 
antibody and mounted with Immunomount (Thermo Scientific, UK), containing 
4',6-diamidino-2-phenylindole (DAPI).  Immunofluorescent (IF) images were 
obtained using the Leica Epifluorescence microscope (Leica Microsystems Ltd, 
UK). 
 
2.5.6 Immunohistochemistry 
Five micron sections of FFPE tissue blocks were cut onto glass slides by the 
Royal London Hospital Experimental Pathology Service.  IHC using a pStat3 
antibody (Cell Signalling Technology Incorporated, USA) and a MTSS1 
antibody (Abcam, UK) was performed using the automated Ventana system.  A 
brief protocol is detailed below. 
 
1) Deparaffinization using xylene   75 
o
C for 8 mins 
       37
o
C for 2 mins 
2) Conditioner #1      100 
o
C for 4 mins 
3) Mild CC1 (cell conditioner 1) buffer wash 10 x 4 mins 
4) Standard CC1 buffer    37 
o
C for 2 mins 
5) Primary antibody      60 mins 
- 1/50 dilution for pStat3; 1/300 dilution for MTSS1 
6) Universal secondary antibody,  
- 3,3-diaminobenzidine (DAB (One Drop))  16 mins 
7) Counterstain with haematoxylin (one drop) 4 mins 
8) Bluing reagent (one drop)    4 mins 
9) Rinse x3 
 
2.5.7 Enzyme-linked immunosorbent assay (ELISA) 
An ELISA was used to assess the antibody titre from each rabbit that had been 
immunised with a PTPRD peptide.  Each well of the ELISA plate was coated for 
3 hours at ambient temperature with 2 g of peptide in 200 l of 0.2 M sodium 
carbonate buffer, pH 9.6 (see section 2.7).  Sodium carbonate buffer alone was 
used for a negative control to measure background signal during the assay.  
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Unbound antigen was removed by washing the plate 3 times for 10 minutes each 
with TBS-T (0.05% Tween-20).  The remaining adsorption sites of the wells 
were blocked by adding 300 l 3% BSA/TBS-T for 2 hours at ambient 
temperature.  Following blocking, the plate was washed twice with TBS-T for 
ten minutes each.  A 1:50 dilution of anti-serum was made in 1x blocking 
solution, from which serial dilutions of 1:100, 1:200, 1:400, 1:800 etc to 
1:102,400 were made.  200 l of each anti-serum dilution was added to duplicate 
antigen-coated wells.  As a negative control, anti-serum was added to the wells 
containing no antigen.  After 3 hours of incubation with the anti-serum at 
ambient temperature, the plate was washed with TBS-T 3 times for 15 minutes 
each.  Anti-rabbit IgG-AP conjugate (Roche, UK) was prepared in 1x blocking 
solution and 200 units (U) added to each well before being incubated at 37 
o
C for 
3 hours.  Unbound conjugate was removed by washing three times with TBS-T.  
200 l of 10 mg/ml 4-nitrophenylphosphate (p-NPP) solution (Roche) in 0.05 M 
sodium carbonate buffer was added to each well for 30 minutes, or until the 
development of a yellow substrate was visible.  To stop the reaction, 50 l of 2 
M NaOH was added.  The absorbance at 405 nm was measured. 
 
2.5.8 Antibody purification 
Affinity chromatography was used to purify the PTPRD JF1 antibody, using the 
peptide against which the antibody had been raised.  Four milligrams of the 
peptide was mixed with 12 mg dithiothreitol (DTT) in 400 μl of buffer (0.1 M 
Tris/HCl, 0.3 M NaCl, 1 mM EDTA pH 8.0) for 1 hour at ambient temperature 
to reduce disulphide bonds that may have formed between peptide molecules.  
The peptide was separated from the DTT using a 20 ml disposable 
chromatography column (BioRad, UK) filled with 6 g of Biogel P2 (BioRad) that 
had been previously hydrated for 1 hour with distilled water (dH2O).  The 
peptide/DTT solution was added to the top of the column and allowed to pass 
through the gel matrix.  The peptide moves through the column faster than the 
DTT and was collected in 0.5 ml fractions.  The A230 was measured for each 
fraction using the nanodrop to confirm which fractions contained peptide.  The 
purified peptide fractions were then pooled and added to 300 mg 
thiopropylactivated sepharose beads that had been previously hydrated for 1 hour 
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with dH2O.  The peptide has a free cysteine group at the 3‟ end which forms a 
disulphide bond with the thiopropylactivated beads.  The peptide and beads were 
mixed by gentle rolling in the dark for 2 hours at ambient temperature.  The 
beads were washed with 10 volumes of buffer and then incubated with 10 
volumes of 0.1 M citrate pH 4.5 containing 1 mM β-mercaptoethanol for 45 
minutes at ambient temperature in the dark to inactivate any active groups on the 
beads that had not been bound by peptide. 
 
After blocking, the beads were washed with 30 mls of 0.1 M citrate pH 4.5, 
before being equilibrated with PBS.  Ten millilitres of anti-serum was added to 
the beads and mixed by gentle rolling overnight at 4 
o
C to bind the antibody to 
the immobilised peptide.  The following day, the beads were washed with 2 
times 50 mls PBS, to remove any unbound proteins.  The beads with 
immobilised peptide/antibody complexes were poured into a BioRad 20 ml 
chromatography column and rinsed with PBS.  To elute the antibody from the 
column, 0.2 M glycine/HCl pH 2-3 was added slowly to the top of the column.  
The low pH solution disrupts peptide/antibody bonds, allowing the purified 
antibody to flow through the column for elution.  The purified antibody was 
collected in 0.5 ml fractions into tubes containing 70 μl 1 M Tris, pH 8.5 to 
neutralise the pH to 7.  The A230 of each fraction was measured using the 
nanodrop to determine which fractions contained antibody.  These fractions were 
pooled and injected into a dialysis cassette (Pearce, UK).  The cassette was 
placed in 1 L of PBS with 0.05% sodium azide (NaN3) for 4 hours at 4 
o
C, before 
being dialysed overnight at 4 
o
C against 1 L fresh PBS-0.05% NaN3.  The 
following day, the PBS-0.05% NaN3 was changed for a third time and the 
purified antibody was dialysed for a further 6 hours.  Following dialysis, the 
purified antibody was removed from the cassette, aliquoted and stored at -80 
o
C. 
 
2.6  TISSUE CULTURE 
2.6.1 Culture of primary keratinocytes and cell lines 
Human primary keratinocytes and cSCC short-term passaged cells were grown in 
DMEM/Ham‟s F12 medium in a 3:1 ratio, supplemented with 10% fetal calf 
serum (FCS) and RM+ (see standard reagents, section 2.7).  Half a million 
proliferation inhibited 3T3 mouse fibroblast cells were added to each T25 flask 
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of cells every 2-3 days.  Prior to treatment to inhibit proliferation, 3T3 mouse 
fibroblasts were grown in DMEM medium supplemented with 10% newborn calf 
serum (see standard reagents, Section 2.7).  Proliferation of 3T3 cells was 
inhibited by the treatment of a T175 flask with 70 µg of mitomycin C for 3 
hours.  Treated 3T3 cells were detached from the culture flask by incubation in a 
solution of 0.05% trypsin and 0.02% EDTA in PBS and added to the 
keratinocyte flasks.  Upon reaching near confluency, flasks of keratinocytes were 
cleared of contaminating fibroblasts by treatment with versene (0.02% EDTA in 
PBS) and subsequently trypsinised.  The trypsin was neutralised with media and 
split accordingly into the number of divisions required.  Following centrifugation 
for 5 minutes at 1,500 rpm, the supernatant was removed and the pellets either 
snap frozen for DNA extraction, resuspended in media for re-seeding or 
resuspended in 1.5 mls of freezing media (70% DMEM/F12 medium, 20% FCS 
and 10% DMSO).  Cells to be frozen were placed in cyrovials in a Nalgene Cryo 
freezing container (Fisher Scientific, UK) that freezes cells at a rate of 1 
o
C per 
minute and placed in -80 
o
C storage.  For long term storage, cells were 
transferred to liquid nitrogen.  
 
Cutaneous SCC cell lines and the oral SCC cell line H357 were grown in the 
standard DMEM/F12 media without feeders.  HeLa cells, Hek 293T cells and 
SW620 cells were grown in DMEM supplemented with 10% FCS.  The 
metastatic melanoma lines WM1158 and WM239a were grown in RPMI with 
10% FCS and 1% L-glutamine.  All cell lines were grown at 37 
o
C and 10% CO2, 
with the exception of H357 and SW620 which were both grown at 5% CO2. 
 
2.7  STANDARD BUFFERS AND REAGENTS 
10x TBE buffer 
Trizma-base   108.0 g 
Boric acid   55.0 g 
0.5 M EDTA pH8.0  200 mls 
Make up to 1L with dH2O. 
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Orange G loading dye 
Sucrose   3 g 
Orange G   3.5 mg 
Make up to 10 mls with dH2O. 
 
1x Sodium carbonate buffer for ELISA 
Sodium carbonate (0.2 M) 21.2 g 
Adjust pH to 9.64 and make up to 1 L.  Final concentration is shown in brackets. 
 
10x Running buffer for western blotting 
Tris (250 mM)  30.29 g 
Glycine (1.9 M)  144.0 g 
SDS (1%)   10 g 
Make up to 1L with dH2O.  Final concentrations are shown in brackets. 
    
10x Transfer buffer for western blotting  
Tris (250 mM)  30.29 g 
Glycine (1.9 M)  144.0 g 
Make up to 1L with dH2O.  Final concentrations are shown in brackets.  Add 
20% methanol when preparing a 1 x solution. 
 
8% resolving gel for WB (20 mls) 
dH2O    9.3 ml 
30% acrylamide mix  5.3 ml 
1.5 M Tris (pH 8.8)  5.0 ml 
10% SDS   0.2 ml 
10% ammonium persulphate 0.2 ml 
TEMED   12.0 μl 
 
 
 
 
 
 
 96 
8% stacking gel for WB (5 mls) 
dH2O    3.4 mls 
30% acrylamide mix  0.83 ml 
1.5 M Tris (pH 6.8)  0.63 ml 
10% SDS   50.0 μl 
10% ammonium persulphate 50. 0 μl 
TEMED   5.0 0 μl 
 
10x TBS 
Tris (500 mM)  60.57 g 
NaCl (1.5 M)   87.66 g 
HCl to adjust pH to 7.6 and make up to 1 L with dH2O.  Final concentrations are 
shown in brackets. 
 
10x PBS 
NaCl (1.37 M)  80.06 g 
KCl (27 mM)   20.13 g 
Na2HPO4 (43 mM)  6.10 g 
KH2PO4 (147 mM)  2.00 g  
Adjust to a final pH of 7.4 and make up to 1 L with dH2O.  Final concentrations 
are shown in brackets. 
 
RIPA lysis buffer 
NaCl (150 mM)  877 mg 
Tris-HCl pH 8.0 (50 mM) 788 mg 
0.5 % Sodium deoxycholate 5 mls of 10% solution 
1.0% Triton X-100  1 ml 
0.1 % SDS   1 ml of 10% solution 
Adjust to 100 mls with dH2O.  Final concentrations are shown in brackets.  
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4% PFA 
PFA    2 g 
2 M sodium hydroxide 20 µl 
Heat in 45 ml distilled water, rotate until dissolved.  Make up to 50 mls with 10x 
PBS. 
 
10x tri-sodium citrate buffer  
Tri-sodium citrate (0.1M) 14.7 g 
Make up to 500 mls with H2O, adjust pH to 6.0 using HCl. 
 
DMEM medium 
DMEM   400 ml 
Fetal calf serum  40 ml 
L-Glutamine (200 μM) 4.4 ml 
 
DMEM/F12 keratinocyte medium 
For 440 ml: 
DMEM   300 ml 
Ham‟s F12 Medium  100 ml 
Fetal calf serum  40 ml 
L-Glutamine (200 μM) 4.4 ml 
 
RM+ medium 
4 ml RM+ concentrate added to 440 ml of keratinocyte base to give final 
concentrations of: 
Hydrocortisone   0.4 μg/ml 
Cholera toxin    10
-10
 M 
Transferrin    5 μg/ml 
Liothyronine     2 x 10
-11
 M 
Adenine    1.8 x 10
-4
 M 
Insulin     5 μg/ml 
Epidermal growth factor (EGF) 10 ng/ml 
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CHAPTER THREE: RESULTS ONE 
EXPRESSION MICROARRAY ANALYSIS OF cSCC 
 
3.1 BACKGROUND 
3.2 RESULTS 
3.2.1 Optimisation of RNA extraction from skin biopsies 
3.2.2 cSCC samples for expression microarray analysis 
3.2.3 Protocol for expression microarray analysis 
3.2.4 Unsupervised hierarchical clustering reveals no bias from known technical 
variables 
3.2.5 Principal component analysis reveals AK and cSCC expression profiles 
overlap  
3.2.6 222 genes are differentially expressed between AK and cSCC  
3.2.7 Pathway analysis identifies MAPK as a central pathway in cSCC 
development 
3.2.8 Integration of SNP and expression microarray data 
3.2.9 ANOVA 4: one-way: metastatic cSCC vs. AK  
3.3 DISCUSSION AND SUGGESTIONS FOR FUTURE WORK 
 
 
3.1 BACKGROUND 
Microarray technology has advanced rapidly over the last few years both in 
resolution and affordability, allowing in-depth studies of whole genome events in 
tumour cells.  This has not only improved our knowledge of the basic biology 
underlying tumour development, but also identified molecular signatures for 
tumour cells that can be used as biomarkers of disease and as targets for therapy.  
Several genomewide expression microarray studies of cSCC have been 
performed to date, but they have shown little consensus on the differentially 
expressed genes (DEGs) identified (Van Haren et al., 2009).  This is unsurprising 
given the use of different technologies and study designs, which, combined with 
small sample numbers, is likely to influence the outcome of an expression 
microarray study.  Two of the largest expression microarray studies of cSCC 
tissue biopsies to date have only examined 5 or 8 samples respectively (Nindl et 
al., 2006, Haider et al., 2006).  Furthermore, Nindl and colleagues compared 
their tumour data to the expression profile of RNA pooled from multiple normal 
skin biopsies, whereas the study by Haider and colleagues used normal skin and 
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psoriatic skin (as an example of a benign hyperproliferative disease) for 
comparison.  Only two genes – matrix metallopeptidase 1 (MMP1, located at 
11q22.3) and cadherin 3, type 1 (CDH3, located at 16q22.1) – were identified as 
consistently upregulated across both studies.  These two genes are associated 
with copy number amplification in a small percentage of cSCC – 7% (4/60) and 
5% (3/60) respectively (Purdie et al., 2009) – indicating their consistent 
upregulation is unlikely to be a direct result of common copy number 
amplification. 
 
In a similar analysis, Kathpalia and colleagues (2006) analysed 5 cSCC tissue 
biopsies using site-matched normal skin for comparison.  All the tumours were 
confirmed histologically to be WD and no microdissection was performed, 
limiting the relevance of their analysis.  Marionnet and colleagues (2003) also 
used 5 cSCC tissue biopsies in comparison to site-matched normal skin and 
BCC.  They identified an upregulation of genes associated with the immune 
system, which most likely reflects the contamination of immune infiltrate in the 
tumour biopsies.  Of the remaining gene expression studies, RNA was extracted 
either from cultured cells or from mouse models of skin carcinogenesis, neither 
of which can be directly extrapolated to human cSCC development.   Darwiche 
and colleagues (2007) used the two-step chemical carcinogenesis mouse model 
to compare low-risk (early) and high-risk papillomas with normal murine skin 
and cSCC.  Whilst they were able to successfully categorise murine papillomas 
using the gene signature generated, no correlation to human skin carcinogenesis 
was made.  In contrast, Serewko and colleagues (2002) used an organotypic raft 
model of skin carcinogenesis, but extrapolated their findings to human tissue 
samples using IHC of a subset of genes identified from their analysis.  They 
identified dysregulation of the AP-1/MAPK pathway, implicating this pathway in 
cSCC development. 
 
The genetic aberrations underlying cSCC pathogenesis have been more 
consistently profiled.  A study of 60 cSCC in our group using high resolution 
SNP microarrays identified the most frequent chromosomal aberrations as LOH 
on 3p and 9p in 65% (39/60) and 75% (45/60) of tumours respectively, which is 
consistent with previous CGH and MSI analyses (Quinn et al., 1994, Popp et al., 
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2000, Ashton et al., 2003).  This study also identified recurrent microdeletions in 
genes such as P16, FHIT and PTPRD suggesting their involvement in cSCC 
development.  However, most of the changes were gross chromosomal 
aberrations, often involving a whole chromosome arm.  This could include 
hundreds or thousands of potential target genes, which makes it difficult to 
identify those genes that are consistently targeted for disruption by recurrent 
aberrations.  A combined genotyping and gene expression approach has been 
used in other cancer types to overcome this problem and to identify genes that 
may potentially be targeted by common genetic aberrations (Walker et al., 2006). 
 
The aim of the work presented in this chapter was to perform gene expression 
microarray profiling on 35 cSCC, using matched normal skin and actinic 
keratoses (AK) (where available) for the identification of DEGs in cSCC.  
Furthermore, the integration of SNP and expression microarray data will be 
undertaken for the first time in cSCC, to investigate the parallels between regions 
of deletion or amplification and the down- or upregulation of genes respectively.   
 
3.2 RESULTS 
3.2.1 Optimisation of RNA extraction from skin biopsies 
Expression studies measure an absolute value for each probe set in a sample and 
it is therefore imperative the sample consists of a pure population of target cells.  
Due to the heterogeneous nature of a cSCC biopsy which comprises tumour 
cells, surrounding benign keratinocytes and invading immune cells, RNA was 
extracted from fresh frozen (FF) cSCC biopsies by laser capture microdissection 
(LCM).  Whilst LCM is a powerful tool for the isolation of target cells, extensive 
optimisation was required to ensure handling during the procedure did not 
adversely affect the quality of RNA from samples.  Protocols for LCM and RNA 
extraction were optimised on a subset of FF biopsies.  This included optimising 
the thickness of sections used for LCM, the staining protocol prior to LCM and 
the method of RNA extraction from collected cells, all of which are discussed in 
turn below.  All RNA extractions were assessed for quality and yield using the 
Agilent Bioanalyser, which assigns a RNA integrity number (RIN) to each 
sample as a measure of overall RNA quality (Figure 3.1).  All optimisation 
procedures were contributed to equally by the author of this thesis and Dr Abha 
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Gulati, with both persons undertaking an equal share of all experimental work 
(including cryosectioning, staining, LCM, RNA extraction and analysis). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Schematic representation of the RIN scale from Agilent’s Bioanalyser.  The 
RIN is a numerical value from 1-10, where 1 indicates completely degraded RNA, 4-7 indicates 
moderately degraded RNA and 10 indicates RNA of high quality.  The RIN is assigned on 
various parameters including the degree of RNA degradation, 18S and 28S ribosomal peak ratio 
and the presence of contaminants such as DNA.  Below the scale are two profiles from a sample 
with low RNA quality (RIN 2.2) and a sample with high RNA quality (RIN 9.60).  The sample 
with a RIN of 2.2 has multiple low molecular weight products that elute earlier through the 
system and loss of the 18S and 28S ribosomal peaks, both of which indicate highly degraded 
RNA.  Conversely, the sample with a RIN of 9.60 has two clear peaks for the 18S and 28S 
ribosomal fractions and no degraded products or contamination.  The Y axis of each plot 
indicates the fluorescence units (FU) whilst the x axis indicates time in seconds. 
RIN 2.2 RIN 9.60 
18S   28S 
1 10 7 4 
RNA Integrity Number (RIN) scale: 
Low molecular 
weight products 
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3.2.1.1 Thickness of sections for LCM 
Skin is a structurally complex tissue that is protected in part against mechanical 
damage by the inherent presence of proteins such as keratins.  This unfortunately 
makes it a more difficult tissue to dissect using LCM, as the proteins absorb the 
energy of the laser resulting in insufficient energy to cut through the entire tissue 
section.  Whilst the energy of the laser can be adjusted, high energy can result in 
laser burn, whereby the cells immediately adjacent to the laser are burnt and 
destroyed.  For accuracy of dissecting tumour borders with normal tissue, this is 
highly undesirable.  Three sections of 6, 8, 10, 12 and 15 μm were cut from the 
same sample and tested by LCM.  Eight microns was found to be the maximum 
thickness that was consistently cut with the UV laser.  Sections that were thicker 
– even by 2 μm – led to patchy and inaccurate cutting and had to be discarded.   
 
3.2.1.2 Staining protocols prior to LCM 
A key aspect of LCM is the identification of target cells, which is achieved by 
staining the sections prior to LCM.  Good morphological resolution is essential 
for discerning the boundaries between target cells and unwanted tissue, however 
increased handling of the samples during staining, particularly in aqueous 
solutions where RNases are active, can result in RNA degradation.  Staining 
protocols were therefore compared for their resolution of cellular features against 
preservation of RNA integrity.  Stains that were tested included unstained 
dehydrated sections, H&E, cresyl violet and toludine blue (Figure 3.2).  In all 
cases, a reference H&E slide was used to identify tumour cells prior to LCM.  
Unstained slides and those stained with toludine blue gave the poorest resolution 
and were subsequently excluded.  Cresyl violet gave the best cellular resolution 
in the shortest staining time (which is beneficial for preserving the integrity of 
RNA in the cells) and was subsequently used for all samples (see chapter 2.2.6 
for the staining protocol).   
 
3.2.1.3 RNA extraction kits 
Extracting RNA from small quantities of starting material requires specialist 
procedures that minimise the loss of RNA during the extraction process and elute 
the extracted RNA in a small, concentrated volume.  The two most common 
commercially available kits used in conjunction with LCM are the RNeasy micro
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Figure 3.2 Examples of staining images viewed using the laser capture microscope.  
Cresyl violet and H&E staining showed the clearest resolution of morphological features, 
whereas toludine blue showed very poor resolution. 
 
Actinic keratosis 
(AK) 
(stained with H&E) 
Dysplastic 
epithelium 
WD cSCC 
(stained with 
cresyl violet) 
Tumour islands 
Invading 
lymphocytes 
MD cSCC 
(stained with 
toludine blue) 
Tumour islands 
Invading 
lymphocytes 
Dermis 
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Kit (Qiagen, UK) and PicoPure kit (Arcturus, UK) (Espina et al., 2006, Wang et 
al., 2006, Kube et al., 2007).  Both of these kits have the advantage of on-column 
DNase treatment to remove any contaminating DNA that may have carried over 
during the extraction, as well as allowing elution of the RNA in a small volume 
(14 μl and 11 μl respectively).  A comparison of the two kits using RNA 
extracted from two samples revealed little difference between the integrity and 
yield of RNA obtained from either kit.  The RNeasy kit had greater ease of use 
with a reduced number of steps and was used for all subsequent extractions. 
 
3.2.1.4 RNA extractions from normal skin 
Once the protocols for LCM and RNA extraction were optimised, RNA was 
extracted from a series of FF biopsies from 8 patients.  RNA from AK and cSCC 
samples was of consistently high integrity (Table 3.1).  In comparison, RNA 
extracted from normal non-sun exposed (NSE) skin or normal sun-exposed (SE) 
skin was of very poor quality and showed such high levels of degradation they 
were unsuitable for analysis by microarrays (Table 3.1).  All samples were 
collected, handled and processed in the same way, so the difference between 
RNA from the normal skin and AK/cSCC could not be explained by technical 
variables during collection, initial handling or storage.   
 
To determine the stage at which RNA degradation was occurring, four FF normal 
skin biopsies were cut in two under liquid nitrogen.  One half was used 
immediately for RNA extraction, whilst the other half was embedded in OCT 
and cryosectioned.  Three sections from the embedded half were collected 
straight into lysis buffer for RNA extraction and three sections were stained and 
subject to LCM for RNA extraction.  This showed that the four biopsies had a 
range of RIN between 4.4 and 6.6 before any handling, which is typically lower 
than the average RIN for RNA extracted from the AK and cSCC after LCM 
(Table 3.2).  Subsequent embedding or LCM did not affect the integrity of the 
RNA in 2/4 samples, however in the remaining two samples, the processing 
caused a reduction in RNA integrity (Table 3.2).    
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Patient no RNA integrity number (RIN) 
NSE SE AK cSCC 
1 2.0 3.3 5.0 7.9 
2 2.3 1.7 3.2 6.4 
3 3.7 3.1 6.6 6.9 
4 2.7 3.6 4.4 7.2 
5 3.6 2.8 7.6 8.6 
6 2.7 7.7 7.5 6.7 
7 2.6 3.2 6.8 7.8 
8 4.2 1.4 6.7 4.5 
 3.0 3.4 6.0 7.0 
 
Table 3.1 RIN values for 8 series of NSE, SE, AK and cSCC RNA extractions from 
fresh frozen tissue.  Average RINs are shown in bold for each stage of skin carcinogenesis, at 
the bottom of the Table.  Both NSE and SE RNA extractions yielded RNA of poor quality, whilst 
the AK and cSCC samples have RINs that are more consistent with high quality RNA.  Samples 
that were excluded from future analysis are shown in red. 
 
 
 
 
Sample RNA integrity number (RIN) 
Pre-embedding in 
OCT 
Post-embedding 
in OCT 
Post staining and 
LCM 
N1 6.6 4.7 5.3 
N2 4.4 3.7 4.5 
N3 5.9 5.9 5.8 
N4 4.9 3.3 1.1 
 
Table 3.2 Effect of processing normal skin biopsies for RNA extraction.  Prior to 
embedding the samples in OCT, they had been stored at -80 
o
C since extraction from the patient.  
Sample handling had a detrimental effect on the RIN of N1 and N4, whereas N2 and N3 were 
unaffected.   
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Due to the compromised integrity of FF normal skin biopsies, normal skin that 
had been collected into RNAlater (Qiagen, UK) was investigated for its quality 
of RNA.  RNAlater quickly permeabilises tissue and stabilises RNA, so it is not 
subject to degradation.  As a consequence of treatment however, the tissue 
becomes rubbery and is often unable to be cryosectioned, making LCM an 
unavailable option.  RNA was extracted from these biopsies by crude removal of 
excess dermal layers with a scalpel and pulverisation of the remaining epidermal 
layer under liquid nitrogen.  This method consistently produced RNA of high 
quality that was comparable in integrity to the FF AK and cSCC biopsies (Table 
3.3).   
 
 
 
 
Patient no_sample 
type 
RNA integrity number (RIN) 
FF (post LCM) RNAlater 
1_NSE 2.0 8.1 
1_SE 3.3 9.3 
2_NSE 2.3 8.5 
2_SE 1.7 8.3 
3_NSE 3.7 7.3 
3_SE 3.1 8.7 
4_NSE 2.7 8.7 
4_SE 3.6 7.0 
 
Table 3.3 Comparison of sample treatment on the integrity of RNA from normal 
skin biopsies.  Each biopsy was bisected upon excision, half was snap frozen and the other half 
processed in RNAlater.  
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3.2.1.5 Skin biopsies treated with RNAlater show a different expression profile to 
snap frozen biopsies 
As it was intended that the RNAlater treated normal skin samples were to be 
compared with FF LCM AK and cSCC samples, the expression profiles from 
samples treated by RNAlater and snap-freezing were compared.  RNA from two 
cSCC that had been bisected upon excision for collection into RNAlater and 
immediate snap-freezing were analysed by the Affymetrix HGU133 Plus 2.0 
microarrays.  Both samples were pulverised under liquid nitrogen for RNA 
extraction and subject to the standard protocol for expression microarray analysis 
(see section 3.2.3 and chapter 2.4.4 for methodology).  Following successful 
microarray quality control (QC) checks, the data were analysed by Dr Gavin 
Kelly, who performed an analysis of variance (ANOVA) statistical test using the 
R statistical package (www.r-project.org).  Although this comprised a small 
number of samples, there were substantial differences between the two 
treatments, which was later confirmed with a larger sample size.  In total, 6815 
probe sets were differentially regulated between the two treatments (the 300 most 
significantly dysregulated probe sets are listed in Appendix A).  The samples 
collected into RNAlater showed significant upregulation of genes associated with 
metabolism and protein transport and downregulation of genes associated with 
signal transduction, apoptosis and transcription.  This suggests placing a biopsy 
in RNAlater causes transcriptome changes that may affect the outcome of 
expression microarray studies if sample processing differs between the samples 
that are analysed. 
 
3.2.2 cSCC samples for expression microarray analysis 
For analysis of the series of skin samples, cSCC had to be microdissected by 
LCM to obtain a pure population of tumour cells.  This required FF biopsies in 
view of the effects of RNAlater on tissue consistency (section 3.2.1.4).  
Conversely, normal skin had to be collected into RNAlater, to extract RNA of 
high enough quality to use with the microarrays.  To overcome the intrinsic 
problem of comparing samples processed by the different treatments, NSE and 
SE normal skin biopsies collected into RNA later were ground for RNA 
extraction, whilst AK biopsies that had been bisected into two pieces upon 
excision for snap-freezing and collection into RNAlater were subject to LCM or 
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grinding under liquid nitrogen respectively.  This strategy for processing the 
different sample types allowed direct comparison across the sequential series of 
skin carcinogenesis, ensured all RNA was of good integrity and that a pure 
population of tumour cells was obtained from the cSCC biopsies.  The extraction 
of RNA and analysis of RNAlater treated NSE, SE and AK samples was carried 
out by Dr A. Gulati and will be described only in the context of cSCC results.  
The extraction of RNA and subsequent microarray analysis of FF AK and cSCC 
was performed by the author of this thesis and is discussed below. 
 
RNA was extracted from 35 FF cSCC of different histological grades and 2 
cSCC lymph node metastases (Figure 3.3).  Five of the cSCC had RINs lower 
than 5, indicating a high degree of degradation and were subsequently excluded 
from further analysis.  Of the remaining 30 cSCC and 2 lymph node metastases 
(Table 3.4), 11 had a matched FF AK biopsy that was also available for analysis.  
Two of the AK RNA extractions had RIN values lower than 5 and were excluded 
from downstream analysis, leaving 9 matched pairs (Table 3.4).  One cSCC arose 
from a background of extensive bowenoid papulosis (BP), which is a form of 
preinvasive epidermal dysplasia, equivalent to AK.  A matched FF biopsy of BP 
was also analysed from this patient (Table 3.4, Figure 3.3).  Unlike the other 
cSCC which had developed by UV-induced carcinogenesis, these samples were 
driven by infection with HPV6 and therefore treated as a distinct pair of samples 
to the rest of the dataset. 
 
3.2.3 Protocol for expression microarray analysis 
The quantity of AK and cSCC sections used for LCM was variable and depended 
on the size of the biopsy and total area of dysplastic epidermis or tumour 
available for collection.  Typically, around 20-30 sections were used for the AK 
biopsies, whilst 10-20 sections were used for the cSCC.  This produced total 
yields of RNA ranging from 10-320 ng (Table 3.4).  An initial pilot study was 
performed in AK and cSCC samples from 3 patients using 10 ng of RNA as a 
template for whole transcriptome amplification prior to analysis by the 
Affymetrix HGU133 Plus 2.0 microarrays (see chapter 2.4.4 for methodology).  
Whole transcriptome amplification was performed using the NuGen WT-Ovation 
Pico RNA amplification kit. 
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Figure 3.3 cSCC sections before and after laser capture microdissection and clinical 
presentation of the samples with HPV-driven carcinogenesis.  Photographs taken with the 
Zeiss LCM microscope A) before LCM, with the laser path highlighted in green, B) after LCM.  
Tissue sections were stained with cresyl violet.  C) clinical presentation of a HPV-driven cSCC 
arising on a background of bowenoid papulosis, included in the sample set for expression 
microarray analysis.   
 
A) B) 
C) 
Extensive bowenoid papulosis 
covering the abdomen and lower 
groin region. 
 
 
 
 
cSCC 
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Sample 
ID 
Subject 
ID 
Tissue 
type 
Differentiation 
status 
Immune 
status 
RNA 
Concentration 
(ng/ul) 
RIN Batch 
Date 
1 1 AK N/A RTR 8.3 7.6 4_8_8 
2 1 SCC WD RTR 7.3 8.6 4_8_8 
3 2 AK N/A RTR 8.3 7.5 4_8_8 
4 2 SCC WD RTR 7.5 6.7 4_8_8 
5 3 AK N/A RTR 37.4 6.8 4_8_8 
6 3 SCC MD RTR 1.4 7.8 4_8_8 
7 4 AK N/A RTR 6.8 6.6 18_3_8 
8 4 SCC WD RTR 6.6 6.9 18_3_8 
9 5 AK N/A IC 11.5 6.6 23_12_8 
10 5 SCC  MD IC 26 7 23_12_8 
11 6 AK N/A CTR 2.6 5.0 18_3_8 
12 6 SCC WD CTR 4.8 7.9 18_3_8 
13 7 AK N/A CTR 34 5.5 23_12_8 
14 7 SCC WD CTR 24.2 6.8 23_12_8 
15 8 AK N/A RTR 6 5.6 23_12_8 
16 8 SCC WD RTR 8.4 7.5 23_12_8 
17 9 AK N/A IC 12.8 6.1 23_12_8 
18 9 SCC WD IC 83 7.2 23_12_8 
19 10 AK N/A IC 1.1 5.9 29_9_8 
20 11 SCC WD RTR 7.8 5.6 2_3_9 
21 12 SCC WD IC 11.8 7.2 18_3_8 
22 13 SCC PD IC 16 9.6 18_2_9 
23 14 SCC PD RTR 2.4 7.8 18_2_9 
24 15 SCC WD IC 53.1 9.5 18_2_9 
25 16 SCC WD IC 49 8.7 18_2_9 
26 17 SCC WD RTR 59 7.2 18_2_9 
27 18 SCC  MD IC 45 8.1 18_2_9 
28 18 LN LN IC 28.7 8.8 18_2_9 
29 19 SCC PD RTR 29.8 9.4 18_2_9 
30 20 SCC PD RTR 72 8.4 18_2_9 
31 21 SCC PD RTR 30 7.2 18_2_9 
32 22 SCC WD RTR 13.4 7.1 2_3_9 
33 23 SCC MD CLL 46.5 8.4 2_3_9 
34 24 SCC WD RTR 33.5 7.8 2_3_9 
35 25 SCC MD RTR 106 6.2 2_3_9 
36 26 SCC MD RTR 26.8 5.8 2_3_9 
37 27 SCC MD RTR 45.2 7.5 2_3_9 
38 28 SCC MD IC 7.2 6.4 2_3_9 
39 29 SCC PD RTR 2.4 7.3 2_3_9 
40 29 LN LN RTR 24 7.8 2_3_9 
41 30 SCC WD RTR 15.4 8.6 2_3_9 
42 31 BP N/A IC 111 8.9 2_3_9 
43 31 SCC WD IC 105 8.2 2_3_9 
 
Table 3.4 Properties of samples for expression microarray analysis.  LN = lymph 
node metastasis, N/A = not applicable.  RTR = renal transplant recipient, CTR = cardiac 
transplant recipient, CLL = chronic lymphocytic leukaemia, all of which indicate patients who 
are IS; IC = immunocompetent and indicates those with no known immune suppression. 
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Using this approach, all six samples were successfully hybridised to the 
microarrays and passed the standard QC checks for Affymetrix expression 
microarrays (see chapter 2.4.4.1).  The remaining samples were subsequently 
subject to the same protocol and the entire dataset combined for final data 
analysis. 
 
3.2.4 Unsupervised hierarchical clustering reveals no bias from known 
technical variables 
Unsupervised hierarchical clustering was performed using Partek software 
(Partek, USA), which uses the normalised expression values of all perfect-match 
probes on each array to group samples according to their level of similarity.  
Samples with a high level of similarity are grouped closely together, whilst 
dissimilar samples are on branches further apart.  Unsupervised clustering of the 
AK and cSCC microarray data revealed the samples clustered into two main 
groups: group one contained four samples including two PD cSCC, one WD 
cSCC and one AK (sample IDs 17, 22, 30 and 41), whilst group two contained 
the remaining 39 samples (Figure 3.4).  The four samples in group one could not 
be identified by a common variable (including RNA quality, tissue type, subject 
ID, batch date or immune status of the patient), suggesting they could either be 
potential outlier samples or subject to an unknown variable.  Outlier microarray 
data can skew downstream analysis and therefore subsequent analysis was 
performed both with and without these four samples where appropriate, to reduce 
the possibility of data distortion from „rogue‟ arrays. 
 
The samples that clustered into group two could be further categorised into 6 
subgroups (Figure 3.4).  No clear pattern of clustering was identified by the 
different tissue types represented in the sample cohort, although the majority of 
WD cSCC clustered together into subgroups 1, 2 and 3, whilst subgroups 4, 5 
and 6 contained most MD and PD cSCC.  The AK samples were spread across 
subgroups 1, 3 and 5 and showed no separation from the cSCC samples.  Of the 
matched AK and cSCC pairs, 4/9 AK samples clustered in the same subgroup as 
the corresponding cSCC from the same patient.  Taken together, this indicates 
that there is considerable variability between patients in the baseline 
premalignant expression profile.  Both metastatic samples clustered closely to 
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Figure 3.4 Hierarchical clustering of microarray samples by disease state, batch date 
and immune status of the patients.  A) dendrogram of the microarray samples by disease state.  
The arms of this dendrogram are colour coordinated by subject ID, whilst the blocks are coloured 
according to disease state.  Dendrogram arms of the same colour indicate samples that are from 
the same patient, whilst black lines indicate subjects with only one sample included in the 
analysis.  Dendrogram by B) batch date and C) immune status of the patient.  Group and 
subgroup classifications are shown beneath the top dendrogram.  Colour coordinated keys for 
each dendrogram are shown in D). 
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each other in group 4, along with the primary cSCC from the same patients.  The 
HPV-driven BP and cSCC samples did not cluster separately from the rest of the 
cSCC, although given only two samples were included in this group, this 
observation has limited value.  The clustering was not visibly affected by 
immune status or batch date, indicating these variables were not responsible for 
the observed clustering pattern.  
 
3.2.5 Principal component analysis reveals AK and cSCC expression 
profiles overlap  
Principal component analysis (PCA) is an exploratory, multivariate statistical 
technique that is widely used with microarray data to assess the contribution of 
different variables on the distribution of data.  In this case, PCA was used to 
facilitate the identification of outlier samples and to investigate in further detail 
the effect of known variables on the overall similarity between samples.  Three 
PCA plots are shown in Figure 3.5 and display the similarity of expression 
profiles for all samples in the context of tissue type (AK or cSCC), 
differentiation state of the tumours (WD, MD, PD or metastatic), immune status 
of the patient and batch date of the microarray.  PCA analysis of the dataset by 
tissue type and differentiation status revealed the cSCC had a broad spread of 
expression profiles, which overlapped with the AK samples at one end of the 
scale.  This suggests the expression profiles between AK and cSCC of different 
histological grades have variation amongst the same histological category and 
show substantial overlap with each other (Figure 3.5a and 3.5b).  The exception 
to this was the two metastatic samples which clustered closely to each other and 
were distinctly separate from the AK samples (Figure 3.5b).  The BP and cSCC 
samples from the patient with HPV-driven carcinogenesis did not show a distinct 
distribution, which, as with the hierarchical clustering, suggests their profile is 
similar to the other AK and cSCC samples analysed.   
  
The AK samples themselves separated into two groups, one of which was 
slightly separate to the cSCC samples and the other of which overlapped with the 
cSCC (Figure 3.5a).  The two groups were indistinguishable by histological and 
pathological features and were represented by multiple batch dates, suggesting 
they could either represent two subgroups of AK or natural variation in AK 
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Figure 3.5 PCA plots of the AK and cSCC expression microarray data.  PCA plot by 
A) tissue type and immune status of the patient, B) disease state and C) batch date of the 
microarray processing.  PCA measures the overall similarity between the expression values of all 
perfect-match probe sets and plots samples within a 3D dimension.  Samples that show a similar 
expression profile are plotted closely together in the matrix, whereas those that show a greater 
degree of variation are plotted further apart.  Samples towards the back of the 3D matrix are 
shaded in a lighter colour.  In plot A, the four potential outlier samples are indicated by red 
circles. 
 
 
C) 
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expression profiles that had not been fully represented by the small sample size.  
The latter suggestion is supported by data from a larger population of 20 AK 
samples, which showed no separation into distinct groups when expression 
profiled (personal communication, Dr A. Gulati).   
 
There was no concordance between the distribution of samples and the immune 
status of the patient (Figure 3.5a).  Batch date had a minor effect on the 
clustering pattern, suggesting samples analysed in different batches showed some 
variation to each other (Figure 3.5c).  This is consistent with published data that 
has shown small changes in laboratory procedures, including atmospheric 
laboratory ozone levels, can influence batch-to-batch consistency (Johnson et al., 
2007, Fare et al., 2003, Lander, 1999).  To minimise the effect of batch variation, 
the protocols for RNA extraction and microarray processing were kept constant 
once optimised.  Furthermore, the overall number of batches was kept to a 
minimum and all matched cSCC were processed in the same batch as their 
corresponding AK.  
 
PCA analysis identified four outlier samples that showed a greater deviation in 
expression values from the main group (sample IDs 23, 26, 36 and 41).  All these 
samples were cSCC of different histological grades (2 WD, 1 MD and 1 PD), one 
of which had also been identified as „miscellaneous‟ from the hierarchical 
clustering (SCC 41).  As with the hierarchical clustering, it is difficult to 
determine whether these samples represent „rogue‟ microarray data or genuine 
variation in expression values, particularly as the number of samples in some 
categories – such as PD cSCC - was low.  All samples had passed stringent QC 
checks, but to exclude the possibility of outlier data skewing downstream results, 
analyses were performed both with and without the 7 outlier samples identified 
by hierarchical clustering and/or PCA where appropriate. 
 
3.2.6 222 genes are differentially expressed between AK and cSCC  
3.2.6.1 ANOVA 1 – two-way: tissue type and subject ID 
To identify genes that contribute to cSCC pathogenesis, a two-way ANOVA was 
performed in Partek using the response variables of tissue type and subject ID.  
The AK data was used as a pooled baseline measurement, as not all cSCC had a 
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matched sample available for analysis.  This was initially performed using all 
samples except for the HPV-driven BP and associated cSCC from patient 31.  
The degree of variation accounted for by each of the response variables was 
plotted using a bar chart, which revealed that subject ID accounted for the most 
variation amongst the dataset, followed by tissue type (Figure 3.6).  The strong 
effect of subject ID supports the hierarchical cluster analysis, which showed 
nearly half of the AK samples clustered in the same subgroup as their matched 
cSCC, rather than clustering in a group distinct from the cSCC.  A proportion of 
the variation from ANOVA 1 was due to neither variable (shown in the plot as 
„error‟), suggesting other factor(s) not included in the ANOVA also influenced 
variability in expression profiles within the dataset.   
 
 
 
 
 
 
 
Figure 3.6 ANOVA 1 variation attributable to the response variables of tissue type 
and subject ID.  The F ratio, shown on the y axis, is an average mean square of all probe 
measurements, which is ANOVA‟s measure of variance.  Any bar with a higher F ratio than the 
error bar indicates a variable that has significantly influenced variation in the dataset.  
 118 
To identify genes that are differentially expressed between AK and cSCC, the 
variation attributable to tissue type was investigated in further detail.  Each 
microarray measures the expression level of greater than 54,000 probe sets and 
therefore an adjustment of the statistical analysis for multiple sampling must be 
used to avoid the generation of false positive results.  After adjusting the p-values 
to a false discovery rate (FDR) of 0.05 (which assumes 5% of identified probe 
sets are false positives), 16 probe sets were identified as differentially expressed 
between the AK and cSCC.  This corresponded to a total of 14 genes, with the 
remaining two probe sets representing hypothetical transcripts.  Of these 14 
genes, 9 were upregulated in the cSCC samples and 5 were downregulated 
(Table 3.5 and Table 3.6).  All except for 3 of the genes showed greater than two 
fold difference in expression between the AK and cSCC, with the highest fold 
change reported for the adhesion molecule with Ig-like domain 2 (Amigo2) gene, 
which showed 5.6 fold increased expression levels in the cSCC. 
 
A more lenient FDR cut-off of 0.1 was used to identify more differentially 
expressed probe sets between the two samples groups.  This identified 318 probe 
sets that were differentially expressed between the AK and cSCC samples 
(Appendix B). Of these, 222 belonged to known genes, with the remaining probe 
sets corresponding either to hypothetical transcripts or duplicate probe sets for 
the same gene.  In total there were 59 duplicate probe sets representing 24 genes, 
all of which showed consistent up- or downregulation for the same gene.  This is 
a useful indicator of reliability across the microarrays.  The most significant 20 
genes that were up- and downregulated are shown in Tables 3.5 and 3.6.  
Overexpression events were more common in the tumour samples, with 71% 
(158/222) of the DEGs showing upregulation in the cSCC, compared to 29% 
(64/222) showing downregulation.  The gene with the largest fold change was 
keratin 9 (Krt9), which showed a -39.2 fold downregulation in the cSCC 
compared to AK.  In comparison, the next largest negative fold change was -6.3 
for the aldehyde dehydrogenase 1 family, member A1 (ALDH1A1) gene.  The 
gene with the highest positive fold change was matrix metallopeptidase 1 
(MMP1), which was expressed at levels 22.9 fold higher in the cSCC, closely 
followed by MMP10, which was expressed at levels 19.3 fold higher. 
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Gene Title Gene 
Symbol 
Cytoband p-value Fold-
Change 
coiled-coil domain containing 109B CCDC109B 4q25 2.23E-06 1.69093 
met proto-oncogene (hepatocyte growth 
factor receptor) 
MET 7q31.2 2.96E-06 2.80179 
S100 calcium binding protein A10 S100A10 1q21.3 3.55E-06 2.05505 
SH2 domain containing 5 SH2D5 1p36.12 4.54E-06 4.85248 
cytochrome P450, family 27, subfamily B, 
polypeptide 1 
CYP27B1 12q14.1 5.41E-06 4.58211 
mitogen-activated protein kinase 1 MAPK1 22q11.21 - 
22q11.22 
7.44E-06 1.5263 
adhesion molecule with Ig-like domain 2 AMIGO2 12q13.11 7.62E-06 5.57191 
ERO1-like  ERO1L 14q22.1 8.32E-06 3.43587 
cyclin K CCNK 14q32.2 9.27E-06 1.4076 
CAP, adenylate cyclase-associated protein 1  CAP1 1p34.2 1.75E-05 1.50643 
isoamyl acetate-hydrolyzing esterase 1 
homolog  
IAH1 2p25.1 1.80E-05 1.42922 
matrix metallopeptidase 10 (stromelysin 2) MMP10 11q22.2 1.97E-05 19.3414 
neuropilin 2 NRP2 2q33.3 2.00E-05 1.90916 
methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1-like 
MTHFD1L 6q25.1 2.43E-05 2.76837 
Annexin A1 ANXA1 9q21.13 2.47E-05 5.95756 
parathyroid hormone-like hormone PTHLH 12p11.22 2.50E-05 6.32889 
interleukin 4 receptor IL4R 16p12.1 2.84E-05 2.37028 
protein tyrosine phosphatase, non-receptor 
type 12 
PTPN12 7q11.23 2.92E-05 1.89658 
single-stranded DNA binding protein 1 SSBP1 7q34 3.28E-05 1.23288 
SLIT-ROBO Rho GTPase activating protein 
1 
SRGAP1 12q14.2 3.75E-05 2.17369 
 
 
Table 3.5 Top 20 upregulated genes in cSCC compared to AK.  The genes listed 
represent the 20 most significant upregulated genes, as identified by the ANOVA.  Genes shown 
in bold also passed the more stringent FDR cut-off 0.05. 
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Gene Title Gene 
Symbol 
Cytoband p-value Fold-
Change 
PDZ domain containing 2 PDZD2 5p13.3 3.09E-06 -3.14394 
activin A receptor, type IIA ACVR2A 2q22.3 - 
2q23.1 
3.63E-06 -2.05176 
RAR-related orphan receptor A RORA 15q22.2 6.86E-06 -3.71951 
CD36 molecule (thrombospondin 
receptor) 
CD36 7q21.11 9.34E-06 -4.58633 
flavin containing monooxygenase 5 FMO5 1q21.1 1.01E-05 -3.62491 
transmembrane protein 170B TMEM170B 6p24.1 3.09E-05 -3.15968 
eukaryotic translation initiation factor 2C, 
4 
EIF2C4 1p34.3 3.22E-05 -1.83623 
ankyrin repeat and MYND domain 
containing 1 
ANKMY1 2q37.3 6.11E-05 -1.42345 
HBS1-like  HBS1L 6q23.3 7.42E-05 -1.57954 
glycerophosphodiester phosphodiesterase 
1 
GDE1 16p12.3 7.59E-05 -1.78374 
LON peptidase N-terminal domain and 
ring finger 1 
LONRF1 8p23.1 8.19E-05 -3.07316 
solute carrier family 6 (neurotransmitter 
transporter, serotonin), member 4 
SLC6A4 17q11.2 8.51E-05 -1.41113 
gliomedin GLDN 15q21.2 8.95E-05 -3.49393 
FAST kinase domains 2 FASTKD2 2q33.3 9.42E-05 -1.28937 
keratin 9 KRT9 17q21.2 9.48E-05 -39.196 
mbt domain containing 1 MBTD1 17q21.33 0.000116 -1.56071 
phosphoglycerate dehydrogenase PHGDH 1p12 0.000127 -2.05541 
transmembrane protein 144 TMEM144 4q32.1 0.000132 -1.80169 
prolactin receptor PRLR 5p13.2 0.000133 -3.86993 
sperm flagellar 2 SPEF2 5p13.2 0.000144 -1.8938 
 
 
Table 3.6 Top 20 downregulated genes in cSCC compared to AK.  The genes listed 
represent the 20 most significant downregulated genes, as identified by the ANOVA.  Genes 
shown in bold also passed the more stringent FDR cut-off 0.05. 
 
 
 121 
Clustering all the samples based on the 318 probe sets identified by ANOVA 1 
(0.1 FDR) separated them into two main groups.  The first group contained all of 
the AK samples, the BP sample and 6 cSCC, whilst the second group contained 
24 cSCC and the two metastatic samples (Figure 3.7).  Unlike the hierarchical 
clustering, the clustering using this set of probes showed a clear trend towards 
distinguishing the precancerous lesions from the tumour samples, suggesting the 
variation identified by the ANOVA is a good representation of the differences 
between AK and cSCC in this dataset.  The anomaly to this was the 6 cSCC that 
clustered in the same group as the precancerous lesions.  None of these tumours 
were matched to an AK sample, indicating patient effect was not responsible for 
their position within this group.  Differentiation status was also not a factor, as 
they included 3 WD, 1 MD and 2 PD cSCC.  Three of the samples had been 
previously identified by PCA as potential outlier samples (sample IDs 23, 26 and 
36).  Furthermore, all 6 of these samples had been hybridised to the microarrays 
across two particular batch dates – 03.05.09 and 03.12.09 – which could indicate 
a potential technical error when processing these samples.  Importantly, the two 
metastatic tumours which were not included in the analysis were grouped with 
the bulk of the cSCC samples in group two and the BP and associated cSCC 
from patient 31 (which had also not been included in the ANOVA) were 
categorised with the AK or group two cSCC respectively.  This indicates that the 
probe set list was able to independently categorise 3 tumour samples and 1 
precancerous sample based on their expression profile. 
 
Stratifying the data by differentiation status and immune status 
The ANOVA was repeated using disease state (WD, MD or PD vs. AK) and 
subject ID.  This identified one DEG between the WD cSCC and the AK samples 
and zero DEGs between MD or PD cSCC and AK samples (either as separate 
categories, or grouped together as one category).  The DEG identified between 
the WD cSCC and AK samples was the polymerase (RNA) I polypeptide A, 
194kDa (POLR1A) gene, which was expressed at levels 1.3 fold higher in the 
WD cSCC (p = 1.16x10
-6
).  This gene was also identified as upregulated by a 
similar fold change in the previous ANOVA (all cSCC vs. AK).  The very small 
number of DEGs from this analysis is unsurprising in the context of the PCA 
plot, as this showed that the samples did not cluster significantly by 
 1
2
2
 
                        
                                               
Figure 3.7 Clustering of all samples based on the 318 differentially expressed probe sets from ANOVA 1.  The dendrogram on the left hand side of the diagram displays 
similarity between samples and is colour categorised according to tissue type (key is shown immediately to the right of the dendrogram).  Two main clusters are shown, the top cluster 
contains all precancerous lesions with 6 cSCC samples mixed in, whilst the second contains tumour samples only.  * Indicates cSCC in the first cluster that were identified as potential 
outliers by PCA.  ** Indicates samples that were not included in the ANOVA but were correctly classified as precancer or cancer samples as appropriate.  On the right of the diagram 
is a heatmap showing the expression of each of the 318 differentially expressed probe sets.  Blue is used to denote downregulated genes and red shows upregulated genes.   
* 
* 
* 
** 
** 
** 
** 
BP 
 
AK 
 
MET 
 
SCC 
 123 
differentiation status and that the MD and PD tumours in particular showed quite 
high levels of variation within the same histological category.  The lower sample 
numbers of MD and PD tumours may have affected the outcome of this analysis.  
Comparing cSCC from IS patients to those from IC patients also revealed no 
statistically significant genes, which is consistent with the PCA plot.   
 
3.2.6.2 ANOVA 2 – two-way: tissue type and subject ID.  Outlier samples from 
hierarchical clustering and PCA removed 
To investigate if the samples identified as potential outliers by hierarchical 
clustering or PCA had a significant effect on the ANOVA, the analysis was 
repeated with these 7 samples removed.  This comprised a total of 6 cSCC and 1 
AK.  This analysis – designated ANOVA 2 – showed a significantly reduced 
number of DEGs between the AK and cSCC samples.  This is unsurprising, as 
the samples that were removed showed greater variation to the rest of the dataset.  
In total, 65 probe sets were differentially expressed using a FDR of 0.1, which 
represented 44 different genes (Table 3.7).  Of these, 37 were in common with 
the previous ANOVA, suggesting a high level of concordance for this list of 
genes (Table 3.7).  The 7 DEGs that were identified by ANOVA 2 but not by 
ANOVA 1 were: ACTN1, SERPINA12, FAM114A2, COQ7, KRT10, SERPINB12 
and NUP43.  None of these genes have been previously associated with cSCC 
development or found to be differentially expressed by previous microarray 
studies of cSCC, although KRT10 is a marker for hyperproliferative cells of the 
basal layer (Haider et al., 2006 and Nindl et al., 2006). 
 
Like the previous ANOVA, more genes showed upregulation in the cSCC, with 
68% (30/44) of genes upregulated and 32% (14/44) downregulated.  The gene 
showing the highest fold change was KRT9, expressed at levels -55.7 fold lower 
in the cSCC, which is similar to the first ANOVA analysis.  The gene showing 
the largest upregulation was MMP10, which was increased 20.6 fold in the 
cSCC.  MMP1, which showed the highest upregulation in ANOVA 1, was not 
identified as differentially expressed by ANOVA 2.  Using the reduced list of 65 
probe sets to cluster the samples did not significantly alter the clustering pattern 
from the DEG identified by ANOVA 1 (Figure3.8).  The AK samples clustered 
together alongside the BP precancerous lesion and 7 cSCC samples (6 of which 
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Table 3.7 Differentially expressed genes between AK and cSCC identified by 
ANOVA 2.   
 
Gene Title 
Gene 
Symbol 
Cytoband p-value 
Fold-
Change 
Ezrin EZR 6q25.3 6.27E-07 1.34629 
adhesion molecule with Ig-like domain 2 AMIGO2 12q13.11 1.92E-06 6.39992 
protein tyrosine phosphatase, non-
receptor type 12 
PTPN12 7q11.23 2.80E-06 1.75974 
cadherin 3, type 1, P-cadherin (placental) CDH3 16q22.1 4.01E-06 2.86574 
discoidin, CUB and LCCL domain 
containing 1 
DCBLD1 6q22.2 8.37E-06 3.00776 
RAR-related orphan receptor A RORA 15q22.2 8.47E-06 -4.0085 
serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 
SERPINA12 14q32.13 9.85E-06 -11.9712 
CD36 molecule (thrombospondin receptor) CD36 7q21.11 1.04E-05 -5.02831 
FERM domain containing 6 FRMD6 14q22.1 1.14E-05 1.44867 
S100 calcium binding protein A10 S100A10 1q21.3 1.30E-05 1.98714 
coiled-coil domain containing 109B CCDC109B 4q25 1.39E-05 1.67991 
PDZ domain containing 2 PDZD2 5p13.3 1.49E-05 -3.02079 
met proto-oncogene (hepatocyte growth 
factor receptor) 
MET 7q31.2 1.65E-05 2.81372 
cytochrome P450, family 27, subfamily B, 
polypeptide 1 
CYP27B1 12q14.1 1.72E-05 4.80704 
SLIT-ROBO Rho GTPase activating protein 
1 
SRGAP1 12q14.2 1.93E-05 2.32008 
activin A receptor, type IIA ACVR2A 2q22.3 - 
2q23.1 
2.03E-05 -2.0541 
ERO1-like  ERO1L 14q22.1 2.05E-05 3.1815 
myosin IB MYO1B 2q32.3 2.07E-05 1.86841 
SH2 domain containing 5 SH2D5 1p36.12 2.15E-05 4.58458 
mitogen-activated protein kinase 1 MAPK1 22q11.21 
- 
22q11.22 
2.84E-05 1.49609 
RNA binding motif protein 9 RBM9 22q12.3 2.86E-05 1.359 
Annexin A1 ANXA1 9q21.13 3.06E-05 5.10077 
cyclin K CCNK 14q32.2 3.37E-05 1.41944 
keratin 9 KRT9 17q21.2 4.04E-05 -55.7226 
transmembrane protein 170B TMEM170B 6p24.1 4.25E-05 -3.38612 
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Gene Title 
Gene 
Symbol 
Cytoband p-value 
Fold-
Change 
CAP, adenylate cyclase-associated protein 1  CAP1 1p34.2 4.48E-05 1.45661 
actinin, alpha 1 ACTN1 14q24.1 4.56E-05 2.86159 
LON peptidase N-terminal domain and ring 
finger 1 
LONRF1 8p23.1 4.66E-05 -3.39359 
flavin containing monooxygenase 5 FMO5 1q21.1 5.18E-05 -3.60745 
family with sequence similarity 114, 
member A2 
FAM114A2 5q33.2 6.21E-05 1.4989 
parathyroid hormone-like hormone PTHLH 12p11.22 6.22E-05 5.56517 
coenzyme Q7 homolog, ubiquinone  COQ7 16p12.3 6.46E-05 1.42917 
THAP domain containing, apoptosis 
associated protein 2 
THAP2 12q21.1 6.60E-05 1.82214 
matrix metallopeptidase 10 (stromelysin 2) MMP10 11q22.2 7.05E-05 20.6393 
isoamyl acetate-hydrolyzing esterase 1 
homolog  
IAH1 2p25.1 7.73E-05 1.43403 
B-cell CLL/lymphoma 8 BCL8 15q11.2 7.99E-05 -1.17726 
BAT2 domain containing 1 BAT2D1 1q24.3 8.18E-05 1.37244 
keratin 10 KRT10 17q21.2 8.36E-05 -3.39377 
neuropilin 2 NRP2 2q33.3 8.44E-05 1.85721 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 12 
SERPINB12 18q21.33 0.0001009 -25.0039 
beta-site APP-cleaving enzyme 1 BACE1 11q23.3 0.0001133 -1.9091 
nucleoporin 43kDa NUP43 6q25.1 0.0001133 1.51155 
methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1-like 
MTHFD1L 6q25.1 0.0001166 2.71057 
solute carrier family 6 (neurotransmitter 
transporter, serotonin), member 4 
SLC6A4 17q11.2 0.0001183 -1.44221 
 
Genes highlighted in bold also passed the 0.05 FDR cut-off.  * Indicates genes that were not in 
common with ANOVA 1.  Grey shading indicates downregulated genes.  All other genes were 
upregulated. 
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  Figure 3.8 Clustering using the 65 probe sets identified as differentially expressed between AK and cSCC by ANOVA 2. 
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had clustered in this group using the probe sets from ANOVA 1), whilst the 
remaining cSCC and metastatic samples grouped together in a separate cluster 
(Figure 3.8).  Although one additional cSCC was misclassified using this probe 
list, the separation of 22/29 tumour samples from the precancerous samples 
supports these 65 probe sets as a key list of differentially expressed transcripts 
between AK and cSCC. 
 
3.2.6.3 ANOVA 3 – two-way: tissue and subject ID.  Matched AK:cSCC pairs 
only 
As a large percentage of variation in the microarray data from ANOVA 1 was 
attributable to subject ID, a separate analysis – designated ANOVA 3 – was 
performed using only the 9 matched AK:cSCC pairs.  This reduced the 
significance of subject ID as a confounding factor in the ANOVA (although it 
was still an important response variable) and subsequently tissue type accounted 
for the most variation between the two samples groups (Figure 3.9).  The 
analysis identified 47 differentially expressed probe sets using a FDR cut-off of 
0.1.  This corresponded to 36 genes, which included all 14 genes identified using 
an FDR of 0.05 in ANOVA 1 (Table 3.8).  In total, 44 of the probe sets 
(corresponding to 33 genes) were in common with ANOVA 1 (FDR 0.1).  The 
three additional genes that were identified by this analysis but not ANOVA 1 
were ribonuclease H1 (RNASEH1), polo-like kinase 1 (Drosophila) (PLK1) and 
solute carrier family 19 (folate transporter), member 1 (SLC19A1).  PLK1 has a 
role in mitosis and is upregulated in many different tumour types, including 
BCCs and SCCs, implying these three genes may also be important for tumour 
development in this sample cohort (Schmit et al., 2009, Chopra et al., 2010).  All 
three of these genes showed less than a two-fold difference between the AK and 
cSCC, suggesting the analysis incorporating unmatched cSCC may have 
obscured the identification of some genes that show small fold changes between 
the two groups. 
 
Upregulation was again more common in the paired analysis, with 78% (28/36) 
of genes upregulated and only 22% (8/36) of genes downregulated in the cSCC.  
Clustering using the 47 probe sets showed a very similar pattern to the clustering 
seen using the 65 differentially expressed probe sets from ANOVA 2 (cSCC vs. 
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AK with outlier samples removed).  The samples separated into two groups, one 
of which contained all the AK, the BP sample and 7 cSCC, the other of which 
contained the remaining cSCC and two metastatic samples (Figure 3.10).  Of the 
7 cSCC, 6 were the same samples that clustered with the AKs using the 
differentially expressed probe sets from ANOVA 1.  The additional cSCC that 
clustered with the AK was not matched to an AK sample, indicating patient 
effect was not a factor in the clustering 
 
 
 
 
 
 
   
 
Figure 3.9 Sources of variation for ANOVA 3 - matched AK:cSCC analysis.  In this 
analysis, tissue type accounted for the largest source of variation within the dataset, but subject 
ID remained an important factor. 
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Table 3.8 Differentially expressed genes identified from matched AK vs. cSCC 
analysis (ANOVA 3).   
 
Gene Title 
Gene 
Symbol Cytoband p-value 
Fold-
Change 
neuropilin 2 NRP2 2q33.3 1.90E-06 1.90916 
eukaryotic translation initiation factor 2C, 4 EIF2C4 1p34.3 4.37E-06 -1.83623 
coiled-coil domain containing 109B CCDC109B 4q25 5.53E-06 1.69093 
activin A receptor, type IIA ACVR2A 2q22.3 - 
2q23.1 
6.25E-06 -2.05176 
PDZ domain containing 2 PDZD2 5p13.3 7.65E-06 -3.14394 
SH2 domain containing 5 SH2D5 1p36.12 8.34E-06 4.85248 
met proto-oncogene (hepatocyte growth 
factor receptor) 
MET 7q31.2 1.00E-05 2.80179 
prolactin receptor PRLR 5p13.2 1.12E-05 -3.86993 
S100 calcium binding protein A10 S100A10 1q21.3 1.30E-05 2.05505 
cytochrome P450, family 27, subfamily B, 
polypeptide 1 
CYP27B1 12q14.1 1.80E-05 4.58211 
adhesion molecule with Ig-like domain 2 AMIGO2 12q13.11 1.85E-05 5.57191 
isoamyl acetate-hydrolyzing esterase 1 
homolog  
IAH1 2p25.1 1.87E-05 1.42922 
mitogen-activated protein kinase 1 MAPK1 22q11.21 - 
22q11.22 
2.12E-05 1.5263 
RAR-related orphan receptor A RORA 15q22.2 2.29E-05 -3.71951 
CD36 molecule (thrombospondin receptor) CD36 7q21.11 2.44E-05 -4.58633 
ERO1-like  ERO1L 14q22.1 2.60E-05 3.43587 
flavin containing monooxygenase 5 FMO5 1q21.1 2.92E-05 -3.62491 
cyclin K CCNK 14q32.2 3.05E-05 1.4076 
cyclic nucleotide gated channel beta 1 CNGB1 16q13 3.96E-05 5.57959 
ribonuclease H1 RNASEH1 17p11.2 4.78E-05 1.40926 
Annexin A1 ANXA1 9q21.13 4.91E-05 5.95756 
polo-like kinase 1  PLK1 16p12.1 5.03E-05 1.27092 
CAP, adenylate cyclase-associated protein 1  CAP1 1p34.2 5.18E-05 1.50643 
matrix metallopeptidase 10 (stromelysin 2) MMP10 11q22.2 5.35E-05 19.3414 
interferon regulatory factor 6 IRF6 1q32.2 5.45E-05 2.32054 
single-stranded DNA binding protein 1 SSBP1 7q34 5.91E-05 1.23288 
interleukin 4 receptor IL4R 16p12.1 6.37E-05 2.37028 
guanine nucleotide binding protein (G 
protein), q polypeptide 
GNAQ 2q21.1 6.82E-05 1.75944 
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Gene Title 
Gene 
Symbol Cytoband p-value 
Fold-
Change 
methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1-like 
MTHFD1L 6q25.1 6.84E-05 2.76837 
RNA guanylyltransferase and 5'-
phosphatase 
RNGTT 6q15 7.10E-05 1.65204 
solute carrier family 19 (folate transporter), 
member 1 
SLC19A1 21q22.3 7.20E-05 1.2456 
transmembrane protein 170B TMEM170B 6p24.1 7.30E-05 -3.15968 
parathyroid hormone-like hormone PTHLH 12p11.22 7.39E-05 6.32889 
protein tyrosine phosphatase, non-receptor 
type 12 
PTPN12 7q11.23 8.34E-05 1.89658 
PCTAIRE protein kinase 1 PCTK1 Xp11.3 8.34E-05 1.37206 
ubiquitin-conjugating enzyme E2Q family 
member 2 
UBE2Q2 15q24.2 8.58E-05 2.1095 
 
No DEGs were identified using a FDR cut-off of 0.05. Grey shading indicates downregulated 
genes.  All other genes were upregulated. 
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 Figure 3.10   Clustering of all samples using the 47 probe sets differentially expressed between the matched AK and cSCC. 
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3.2.6.4 Probe sets identified by all three ANOVA analyses 
In total, 31 probe sets were commonly identified by ANOVA 1, 2 and 3, 
suggesting these probes are likely to represent a robust set of differentially 
expressed transcripts between AK and cSCC (Figure 3.11).  This corresponded to 
a total of 23 annotated genes, which were investigated in further detail by 
literature mining for their role in cancer and in particular, cSCC pathogenesis 
(Table 3.9).  15/23 genes had been previously associated with cancer, 3 of which 
had also been identified as overexpressed in cSCC (CYP27B1, PTHLH and 
CD36).  This suggests this analysis has identified many novel candidate genes 
that may be involved in cSCC pathogenesis. 
 
 
 
 
 
Figure 3.11 Venn diagram showing the overlap of genes identified by 3 ANOVA 
analyses on the cSCC vs. AK dataset.  The number of genes in each category are indicated in 
the centre of each category.  The name of the different ANOVA analyses are shown around the 
outside of each circle, with the number of differentially expressed probe sets indicated in 
brackets. 
DEG ANOVA 2 (65) 
DEG ANOVA 1 (318) DEG ANOVA 3 (47) 
31 
13 
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Table 3.9  Function and role in cancer of 23 genes in common to all three ANOVA analyses.   
 
Gene Symbol Fold-
Change 
Function Expression in cancer Reference 
ACVR2A -2.05176 Signaling, growth and 
differentiation 
Overexpressed in multiple myeloma Grcevic et al., 2009 
AMIGO2 5.57191 Cell adhesion? Not established  
ANXA1 5.95756 Mediator of inflammation Overexpressed in hepatocellular cancer; 
downregulated in breast, oesophageal, prostate 
and gastric cancers 
Garcia Pedrero et al., 2004, Shen et al., 2006, Hsieh 
et al., 2009  
CAP1 1.50643 Motility via cyclic AMP pathway Overexpressed in pancreatic cancer Yamazaki et al., 2009 
CCDC109B 1.69093 Unknown Not established  
CCNK 1.4076 Transcriptional regulation Not established  
CD36 -4.58633 Receptor, cell adhesion Overexpression associated with favourable 
prognosis in colorectal cancer, varied 
expression in cSCC - overexpressed in 
tumours of higher differentiation 
Allen et al., 1991, Tsuchida et al., 1999 
CYP27B1 4.58211 Vitamin D synthesis, calcium 
homeostasis, differentiation 
Overexpressed in glioblastoma, osteosarcoma 
and cSCC 
Diesel et al., 2003, Reichrath et al., 2004, Atiye et 
al., 2005 
ERO1L 3.43587 Oxidoreductase, ROS generation High expression in NSCLC associated with 
good prognosis 
Endoh et al., 2004 
FMO5 -3.62491 Metabolism Downregulated in colorectal cancer Birkenkamp-Demtroder et al., 2002 
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Gene Symbol Fold-
Change 
Function Expression in cancer Reference 
IAH1 1.42922 Unknown Not established  
MAPK1 1.5263 Regulation of meiosis, mitosis 
and postmitotic functions 
Activated in many different cancer types, 
including breast, colorectal, prostate and 
cSCC 
Loda et al., 1996, Zhang et al., 2007c 
MET 2.80179 Hepatocyte growth factor 
receptor, invasion 
Overexpressed in many cancers, including 
brain, colorectal, gastric, lung and HNSCC 
Liu et al., 2009 
MMP10 19.3414 Degrades proteoglycans and 
fibronectin, extracellular matrix 
(ECM) breakdown and 
metastasis 
Overexpressed in many cancers including 
colorectal adenomas, prostate cancer, cervical 
cancer, merkel cell carcinoma, oral SCC 
Martinez et al., 2005, Riddick et al., 2005, Vazquez-
Ortiz et al., 2005, Fernandez-Figueras et al., 2007, 
Yen et al., 2009 
MTHFD1L 2.76837 Folate synthesis Not established  
NRP2 1.90916 Angiogenesis Overexpressed in epithelium cancers Bielenberg et al., 2006 
PDZD2 -3.14394 Transcriptional activation of p53 Overexpressed in prostate cancer Chaib et al., 2001, Tam et al., 2008 
PTHLH 6.32889 Growth factor and developmental 
regulator, metastasis 
Overexpressed in oral SCC, lung cancer, 
breast cancer; overexpressed in cSCC co-
cultures with fibroblasts 
Suva et al., 1987, Bundred et al., 1991, Lowik et al., 
1992, Kornberg et al., 2005 
PTPN12 1.89658 Signaling, cytoskeletal structure 
and cell adhesion 
Overexpressed in anaplastic large cell 
lymphoma, dephosphorylates TS targets in 
pancreatic cancer 
Lamant et al., 2007, Taieb et al., 2008 
Table 3.9 continued 
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Gene Symbol Fold-
Change 
Function Expression in cancer Reference 
RORA -3.71951 Transcription factor, hypoxic 
response, fragile site 
Not established  
S100A10 2.05505 Regulation of plasminogen 
activity, extracellular matrix 
degradation and invasion 
Overexpressed in renal cell carcinoma, gastric 
cancer, lymphoma, thyroid neoplasms; 
downregulated in esophageal SCC and 
melanoma 
Teratani et al., 2002, El-Rifai et al., 2002, Ji et al., 
2004, Rust et al., 2005, Ito et al., 2007, Petersson et 
al., 2009 
SH2D5 4.85248 Unknown Not established  
TMEM170B -3.15968 Unknown Not established  
 
Genes highlighted in bold were also identified as differentially expressed between cSCC and normal skin in the study by Haider and colleagues (2006), underlined genes 
indicate those also identified as differentially expressed by Nindl and colleagues (2006).  Those in red showed a different direction of differential expression between this 
study and the corresponding published dataset. 
 
Table 3.9 continued 
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3.2.6.5 Validation of gene lists using additional datasets 
To validate the list of differentially expressed transcripts identified by this study, 
the probe set lists were used to cluster two independent sets of data.  The first set 
of data included the normal NSE, SE and AK samples from 20 patients that had 
been analysed by Dr Abha Gulati.  These samples were combined with the AK 
and cSCC expression samples used to generate the gene lists presented in this 
chapter.  Using the 318 differentially expressed probe sets from ANOVA 1 and 
the 47 probe sets from ANOVA 3, 23/29 cSCC were correctly grouped together 
in a cluster that was distinct from the normal and precancerous skin samples 
(Figure 3.12 and Appendix C).  The 6 cSCC that were misclassified in the 
normal skin cluster were the same 6 samples that were not correctly classified in 
the previous clustering analyses.  The 65 probe sets identified from ANOVA 2 
and the list of probe sets common to all three ANOVAs also showed a similar 
pattern for separation of the precancer and cSCC samples, but misclassified 7 or 
8 cSCC respectively (Appendix C).     
 
The second dataset used for validation was a published set of microarray data 
deposited in the Gene Expression Omnibus (GEO) database (reference GSE7553, 
www.ncbi.nlm.nih.gov/geo).  This dataset was generated by Riker and colleagues 
(2008) to identify the expression profiles associated with the progression of 
primary and metastatic melanoma.  For a baseline comparison, they also 
analysed 11 cSCC, 15 BCC and 4 normal skin samples using the Affymetrix 
HGU133 Plus 2.0 microarrays.  None of these samples were microdissected.  
The raw data for the SCC, BCC and normal skin samples were downloaded from 
the GEO website in the form of cel files and uploaded into Partek for analysis.  
The 318 probe sets identified from ANOVA 1 clearly separated the normal skin 
samples from the NMSC and also showed a trend towards separating the BCC 
and cSCC samples, with 11/15 BCC grouping in a separate cluster to the cSCC.  
No clinical data was included for the NMSC samples and therefore it was not 
possible to identify if the 4 BCC samples that grouped with the cSCC 
represented a distinct subtype of BCC, for example, basosquamous BCC, that 
show histological overlap with cSCC.  This suggests the probe sets identified 
from ANOVA 1 are capable of distinguishing cSCC from normal skin and the 
majority of BCC (Figure 3.13).   
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Figure 3.12  Clustering of all normal, precancerous and cSCC skin samples using the 318 differentially expressed probe sets from ANOVA 1.  A) Heatmap of the 47 genes in cSCC and 
normal skin samples, coloured on a sliding scale, whereby blue denotes downregulated genes and red indicates upregulated genes.  B) Dendrogram of all samples (enlarged from left-hand side 
of the heatmap), colour categorised according to tissue type (key is shown on the right of the picture).  AK_2 indicates regions of widespread dysplasia (equivalent to AK) that had been treated 
with one of 3 topical agents for 3 months prior to sample collection.   
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Figure 3.13  Microarray dataset generated by Riker and colleagues (2008), clustered using the 318 differentially expressed probe sets identified by ANOVA 1. 
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Clustering using the probe lists from ANOVA 2 and 3 also revealed good 
separation of the 4 normal skin samples from the cSCC (Appendix D), as well as 
a trend towards separation of the BCC and cSCC.  The list of 31 probe sets that 
were common to all 3 ANOVAs did not show such a defined separation of the 
cSCC from the normal skin samples however, with the normal skin clustering on 
a dendrogram arm that was not as distantly removed from the cSCC as with the 
other probe set lists (Figure 3.14).  This indicates that although the list of 31 
differentially expressed probe sets are an important set of differentially expressed 
transcripts between precancer and cSCC samples, there are transcripts within the 
larger probe set lists that are also important for defining a cSCC expression 
signature.  
 
3.2.7 Pathway analysis identifies MAPK as a central pathway in cSCC 
development 
Canonical pathways and gene ontology (GO) groups that were enriched by the 
identified gene lists were investigated using Ingenuity Pathway Analysis (IPA) 
database (Ingenuity, USA).  For pathway analysis, IPA uses published scientific 
literature to establish a database of biological and chemical relationships between 
proteins, whilst gene ontology is based on literature annotation and conserved 
protein domains.  Briefly, the DEGs were uploaded to the website along with 
corresponding p-values and fold changes.  The software then mapped each gene 
to a gene ontology category, disease-association category and relevant 
pathway(s), to identify elements that were enriched by the list of genes.   
 
Of the 222 annotated genes identified by ANOVA 1, 86 had been previously 
associated with cancer, suggesting an enrichment of cancer-associated genes in 
the dataset.  Furthermore, the top 5 GO groups represented by the gene list were 
cellular movement, growth and proliferation, cellular development, cell-to-cell 
signalling and cell death, all of which are important in tumour development.  
Similar gene ontology groupings were observed using the DEGs identified by 
ANOVA 2 and 3.  The DEGs were interactively mapped by the software into a 
network of associated pathways.  For all three ANOVAs, the network showing 
the most significant enrichment included the mitogen activated protein kinase 
(MAPK) pathway (Figure 3.15), implicating this pathway in cSCC development.
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Figure 3.14 Clustering of Riker dataset using 31 probe sets common to all 3 ANOVA analyses. 
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Figure 3.15 Ingenuity pathway analysis of genes identified by ANOVA 1.  The network 
shown is the most significantly enriched network from the DEGs identified by ANOVA 1.  This 
network reveals the MAPK complex is central to many of the DEGs, implicating MAPK 
signalling in cSCC pathogenesis.  Red indicates genes that are upregulated in the dataset and 
green indicates downregulated genes.  The higher the fold change, the more intense the colour.  
Genes in white boxes were not identified as differentially expressed in this analysis.  Box shapes 
are used to indicate different functional classes of proteins: triangles for phosphatases, inverted 
triangles for kinases, concentric circles for groups or complexes, diamonds for enzymes, ovals for 
transcriptional regulators and circles for other.  Filled lines indicate direct interactions between 
two protein products and dotted lines indicate indirect interactions.  Protein associations assigned 
by Ingenuity are based on literature mining and do not necessarily imply validation. 
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3.2.8 Integration of SNP and expression microarray data 
To investigate the correlation between copy number changes and corresponding 
gene expression change in cSCC, copy number data that had been analysed by 
Purdie et al. (2009) was integrated with the 318 differentially expressed probe 
sets from ANOVA 1.  For consistency, only 34/60 cSCC that had been profiled 
using the 250K SNP microarrays were included.  The remaining samples had 
been analysed using 10K or 50K SNP microarrays and may not have identified 
the same resolution of copy number events due to their lower genomewide 
coverage of SNPs.  The two datasets were integrated with Partek, using copy 
number events that occurred in at least two cSCC to generate an overall 
consensus between copy number and gene expression.  This revealed that 27% 
(58/214) of the upregulated probe sets from ANOVA 1 corresponded to regions 
that were commonly amplified in cSCC and 10% (10/104) of the downregulated 
probe sets corresponded to commonly deleted regions.     
 
Mapping the corresponding genetic/expression events by chromosome identified 
the most correlation on chromosomes 1q, 3q, 7 and 22q (Figure 3.16).  
Chromosomes 3p, 4q, 5, 8, 9, 11q, 17p, and 19p also showed regions of 
corresponding copy number change and up- or downregulation of gene 
expression.  This suggests the genes identified within these regions may be 
targeted by the large scale genetic chromosomal aberrations.  In particular, LOH 
on chromosomes 3p and 9p and gain of chromosomes 3q and 9q are the most 
frequent events reported in cSCC.  On 3p, the TREX1 gene was 1.4 fold 
downregulated, whilst PHLDB2, PDIA5, FNDC3B, LRRFIP1, B3GNT5, 
PSMD2, POLR2H and PAK2 on 3q were all upregulated.  Similarly, on 9q, 
TJP2,  ANXA1 and PRPF4 were also upregulated.  These genes could represent 
key targets of the recurrent aberrations seen on these chromosomes.  
Furthermore, 6/23 dysregulated genes that were in common to all 3 ANOVAs 
mapped to regions of copy number change in the SCC.  They were FMO5 (1q), 
S100A10 (1q), PTPN12 (7q), MET (7q), ANXA1 (9q) and MAPK1 (22q). 
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Figure 3.16 Correlation between copy number and gene expression on chromosomes a) 
3 and b) 7.  The upper panel in each plot (with narrow line spacing) indicates gene expression 
changes, whilst the lower panel (with wider line spacing) indicates copy number change.  In the 
gene expression panel, lines above the central bar indicate transcripts that are upregulated, whilst 
lines below indicate those that are downregulated.  The length of each line indicates the fold 
change, with larger fold changes represented by longer lines.  In the copy number panel, lines 
above the central bar indicate amplification events, whilst lines below indicate deletion events.  
The height of the line represents the number of samples in which copy number change occurs.  
Each line represents an individual transcript. 
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3.2.9 ANOVA 4: one-way: metastatic cSCC vs. AK 
The two metastatic tumours were compared with the baseline AK samples.  This 
identified more DEGs than the cSCC vs. AK analysis, with 133 probe sets 
differentially expressed at a 0.05 FDR cut-off and 396 probe sets at 0.1 FDR cut-
off (the top 20 most significant genes are shown in Table 3.10).  Of the 396 
probe sets that were differentially expressed, only 34 were in common with the 
318 probe sets identified from ANOVA 1 (cSCC vs. AK), corresponding to a 
total of 26 annotated genes.  This suggests the analysis has identified many genes 
unique to the metastatic tumours, although sample numbers are too small to be 
definitive.  The probe sets that were differentially expressed between the 
metastatic and AK samples corresponded to a total of 255 genes, of which 76% 
(194/225) were upregulated and 24% (61/225) were downregulated.  Some genes 
showed extremely large fold changes between the metastatic and AK samples, 
for example the secreted phosphoprotein 1 (SPP1) gene was expressed at levels 
116 fold higher in the metastatic samples, alpha-2-glycoprotein 1, zinc-binding 
(AZGP1) was 111 fold downregulated and CD36 molecule (thrombospondin 
receptor) (CD36) showed 88 fold lower expression levels.   
 
Within the list of differentially expressed genes were three matrix 
metallopeptidases (MMP 10, 11 and 13) which all showed upregulation in the 
metastatic samples.  MMP10 and MMP13 in particular showed high 
upregulation, with 77 fold and 45.7 fold respective increases in expression in the 
metastatic tumours.  Furthermore, three members of the mucin family (Muc3a, 
3b and 15) were also dysregulated in the metastatic samples.  Muc3a and Muc3b 
are both transcribed from the same locus and were both upregulated in the 
metastatic samples (8.4 and 4.2 fold higher respectively).  Conversely, Muc15 
was downregulated at levels 52.9 fold lower than in the AK samples.  Both of 
these families of proteins have been implicated in the metastatic process. 
 
The gene list generated from the comparison between the two metastatic samples 
and the AK samples was also analysed using Ingenuity pathway analysis 
software.  This revealed 74/255 DEGs had been previously associated with 
cancer.  The top GO categories were cell-to-cell signalling, cellular development, 
growth and proliferation, cellular movement and cell death, all of which are 
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consistent with tumour development.  Network analysis identified the Myc 
oncogene as central to the most significantly enriched network, implicating this 
oncogene in metastatic progression of cSCC (Figure 3.17).   
 
 
 
 
Gene name Gene Symbol Fold-Change p-value 
Mucin 3A, cell surface associated MUC3A 8.39213 1.66E-08 
Host cell factor C1 regulator 1 (XPO1 dependent) HCFC1R1 4.28399 6.76E-08 
Coiled-coil domain containing 148 CCDC148 2.08829 7.73E-08 
Matrix metallopeptidase 11 (stromelysin 3) MMP11 8.27272 7.83E-08 
Mucin 3B, cell surface associated MUC3B 4.22645 1.59E-07 
Jun oncogene JUN 5.91626 6.95E-07 
Glutamate decarboxylase 1 (brain, 67kda) GAD1 2.55818 8.81E-07 
Olfactory receptor, family 2, subfamily L, member 13 OR2L13 2.99635 9.89E-07 
Regulator of G-protein signaling 16 RGS16 3.30966 2.81E-06 
Fms-related tyrosine kinase 4 FLT4 1.96422 4.26E-06 
SH3 and multiple ankyrin repeat domains 2 SHANK2 4.33835 4.29E-06 
Sushi-repeat-containing protein, X-linked SRPX 20.0842 5.16E-06 
Cytidine monophosphate-N-acetylneuraminic acid 
hydroxylase (CMP-N-acetylneuramin 
CMAH 1.88746 5.63E-06 
4-aminobutyrate aminotransferase ABAT 4.86341 5.79E-06 
Nuclear receptor 2C2-associated protein NR2C2AP 2.2087 6.08E-06 
Patatin-like phospholipase domain containing 3 PNPLA3 -37.6766 6.72E-06 
Erythrocyte membrane protein band 4.1 like 4A EPB41L4A -4.04601 6.87E-06 
Sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short cyt 
SEMA4F 2.03837 7.39E-06 
Ring finger and CCCH-type zinc finger domains 1 RC3H1 -1.97677 7.41E-06 
Neuregulin 1 NRG1 18.7803 7.74E-06 
 
Table 3.10 Top 20 most significant DEGs between the metastatic and AK samples.  
Genes are arranged by p-value, with the most significant at the top of the Table.  All genes in this 
list passed the 0.05 FDR cut-off. 
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Figure 3.17 Network 1 identified using DEG from ANOVA 4: metastatic cSCC vs. AK 
samples.  The Myc protein was central to interactions with some of the DEGs identified from this 
analysis.  Red indicates genes that are upregulated in the dataset and green indicates 
downregulated genes.  The higher the fold change, the more intense the colour.  Genes in white 
boxes were not identified as differentially expressed in this analysis.  Box shapes are used to 
indicate different functional classes of proteins: triangles for phosphatases, inverted triangles for 
kinases, concentric circles for groups or complexes, diamonds for enzymes, ovals for 
transcriptional regulators and circles for other.  Filled lines indicate direct interactions between 
two protein products and dotted lines indicate indirect interactions.  Protein associations assigned 
by Ingenuity are based on literature mining and do not necessarily imply validation. 
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3.3 DISCUSSION AND SUGGESTIONS FOR FUTURE WORK 
Prior to this study, expression microarray analysis of cSCC had been carried out 
on limited sample numbers using either cultured SCC cells (Curto et al., 2002, 
Serewko et al., 2002) or whole tissue biopsies with no microdissection (Nindl et 
al., 2006, Haider et al., 2006, Kathpalia et al., 2006).  Combined with different 
baseline measurements and statistical approaches, little consensus was identified, 
making it difficult to interpret which events are genuine expression changes that 
are involved in cSCC pathogenesis.  The aim of this project was to use whole 
genome expression profiling of 35 laser capture microdissected cSCC to 
investigate the expression changes that accompany the transition from 
precancerous AK lesions into fully invasive cSCC.  RNA was successfully 
extracted from 30 cSCC using a LCM protocol adapted specifically for this 
study, along with 9 matched AK samples and 2 lymph node metastases.  This 
represents the largest expression microarray study of AK and cSCC carried out to 
date and revealed 222 annotated genes were differentially regulated between AK 
and cSCC lesions.  Notably, the Jun and MET oncogenes were both upregulated 
in the cSCC, as well as the Myc oncogene in the two metastatic samples, 
implicating these oncogenes in cSCC development and progression. 
 
Optimisation of RNA extraction and expression microarray protocols 
cSCC are often surrounded by normal keratinocytes and can be subject to heavy 
infiltration by invading immune cells.  Purifying normal cell populations 
alongside tumour cells will influence the expression profile generated and may 
lead to erroneous results.  Furthermore, it is very difficult to account for normal 
contamination, as the nature and extent of contamination will differ between any 
two samples.  Indeed, Wenzel and colleagues (2008) used serial analysis of gene 
expression (SAGE) to analyse ~12,000 genes in whole cSCC and BCC biopsies 
and identified an interferon gene signature that corresponded to the extent of 
immune cell infiltrate.   The use of cultured cells eliminates this problem if 
cultures are thoroughly cleared of contaminating fibroblasts prior to analysis.  
However, cultured cells are often subject to extensive changes in vitro and 
therefore any genes isolated from such studies cannot be directly extrapolated to 
in vivo pathogenesis without subsequent validation (Lai and Pittelkow, 2004, 
Mazzatti et al., 2007).   
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LCM of cSCC tissue is a useful technique to overcome the problems cited above.  
It allows the isolation of pure tumour cell populations, circumventing the need 
for in vitro enrichment of tumour cells.  The protocol optimised in this study 
required careful evaluation of each stage of the experimental process, to ensure 
RNA of good quality was extracted for analysis by the microarrays.  Despite this, 
it was not possible to obtain RNA of good quality from normal skin biopsies 
using LCM.  A possible explanation for this is that the thin epidermal layer of 
normal skin is more sensitive to the action of RNases that are inherently present 
on the surface of skin.  The epidermis from AK lesions – from which intact RNA 
was isolated – is thickened and therefore contains epidermal cell layers that are 
not in such close proximity to surface contaminants such as RNases.  Several 
studies have used LCM of the epidermis for RNA extraction, but they have either 
used samples that are not 100% normal, uninvolved skin, or they have not 
specified a specific cut-off value for the assessment of RNA quality.  Asplund 
and colleagues (2007) isolated keratinocytes by LCM from the basal layer of 
epidermis that was within 3 mm of BCC tumour nests.  The epidermis overlying 
BCCs is often atypical (Kikuchi et al., 1993, Rittie et al., 2007) and this may 
have enhanced the extraction of RNA from these samples.  In a separate study, 
Pederson and colleagues (2003) used LCM to isolate keratinocytes from wound 
edges in mice.  Wound sites are subject to hyperproliferation and also display a 
thickened epidermis in comparison to normal skin (Kurman and Argyris, 1975). 
 
To overcome the problem of poor RNA quality from the normal skin samples, 
biopsies that had been treated with RNAlater were used as an alternative.  This 
consistently produced RNA of good quality, supporting the use of this treatment 
for clinical samples.  RNAlater has the additional benefit of allowing sample 
collection and transport at room temperature, which negates the need for liquid 
nitrogen in operating theatres at the time of resection.  However, in this study, 
the comparison of microarray data from biopsies that had been snap frozen in 
liquid nitrogen or collected into RNAlater revealed widespread variation between 
the two treatments.  Many studies that have validated the use of RNAlater as an 
alternative to snap-freezing have only examined its effects on RNA yield, quality 
and histology, which, as this study has also shown, is comparable – and in some 
cases superior – to FF biopsies (Florell et al., 2001, Chowdary et al., 2006).  
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Several studies have used microarray analysis to compare samples collected by 
the two different treatments, but the study designs have often been flawed and 
subsequently no significant differences between the treatments have been 
identified.  Ellis and colleagues (2002) used 5 unmatched samples in each 
treatment group and assessed the corresponding expression profiles by PCA and 
hierarchical clustering alone, whilst Grotzer and colleagues (2000) only analysed 
1 sample in each treatment group and ignored any genes with less than a 2 fold 
difference.  Similarly, Mutter and colleagues (2004) only used 3 samples and did 
not apply statistical testing to the data. 
  
The most comprehensive study to date investigated 30 breast cancer specimens 
and 21 colorectal carcinomas that were bisected upon excision and either snap 
frozen or treated with RNAlater (Chowdary et al., 2006).  This study revealed 
only 2 genes were differentially expressed after correction for multiple testing.  
This is in contrast to the findings from our study and a study published by Micke 
and colleagues (2006), which found significant differences between the two 
treatments.  A possible explanation for this is that the tissue used by Chowdary 
and colleagues was sliced into thin pieces prior to immersion in RNAlater, 
whereas in this study and the study by Micke et al., punch biopsies or cubes of 
tissue respectively were placed directly into RNAlater.  Pathway analysis of the 
DEGs identified from the study presented in this thesis showed an upregulation 
of genes involved in metabolism and protein transport in RNAlater treated 
samples.  This is consistent with hypoxic or stress induced responses in cells that 
are still metabolically active after resection (Huang et al., 2001) and may be a 
result of a time lag between resection of the tissue and RNAlater diffusing into 
the centre of a piece of tissue.  Subsequently, a limitation of this study was that 
direct comparison from normal skin to cSCC was not possible.  However, the 
analysis of AK samples that had been processed by both treatments meant that 
transcriptome changes across the series of skin carcinogenesis could still be 
investigated by ad hoc comparison. 
 
A further limitation of LCM is that the overall yield of RNA is typically low, due 
to the extraction of RNA from small quantities of target material.  In this study, 
10 ng of RNA was used for amplification and subsequent microarray processing.  
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Although this is a relatively low starting input for microarray analysis, the Nugen 
WT-Ovation Pico RNA amplification kit (which was used to amplify the RNA 
prior to microarray processing) has been validated for use with such small 
quantities of starting material (Clement-Ziza et al., 2009).  It has been 
demonstrated to generate reproducible microarray data from picogram quantities 
of starting RNA, making it ideal for samples of low yield such as those obtained 
by LCM (Dafforn et al., 2004, Slebos et al., 2006, Vermeulen et al., 2009).   
 
Statistical and bioinformatic analysis 
As with any microarray dataset, expression values are generated from thousands 
of genes and subsequent analysis requires careful evaluation and thorough QC 
checks.  The QC checks performed in this study are recommended for the 
analysis of Affymetrix expression microarray data and are well established for 
isolating samples of poor quality or arrays that have performed badly (Gentleman 
et al., 2004, Smyth, 2005).  All AK and cSCC samples used in this study passed 
the QC checks, indicating good consistency between sample quality and 
processing.  For statistical analysis of the data, the ANOVA statistical test was 
performed using Partek software.  This is a common method used for microarray 
data analysis and has been used extensively with similar datasets (Downey, 2006, 
Andrews et al., 2010).  Despite its merits however, Partek does not provide as 
much flexibility for data analysis as the industry gold standard of the R Statistical 
package, which incorporates a user-generated script to analyse microarray data.  
The R statistical package requires computer programming knowledge to ensure 
the dataset is interrogated correctly.  Unfortunately bioinformatic help was 
unavailable at the time of analysis for this study, so the R statistical package was 
not pursued for data analysis. 
 
Expression changes from AK to cSCC 
This study identified 318 differentially expressed probe sets between AK and 
cSCC, corresponding to a total of 222 genes.  Analysis using the Ingenuity IPA 
software revealed 86 of these genes had been previously associated with cancer, 
which is a good indication that the dataset has generated plausible biological 
targets for the progression of AK to cSCC.  Furthermore, the top molecular and 
cellular functions represented by the gene list were all consistent with processes 
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that are involved in cancer, such as cellular movement, proliferation and cell-cell 
signalling.  Throughout all statistical analyses that were performed, 
overexpression of genes was more common than downregulation, which is 
consistent with a previous report of cSCC differential gene expression 
(Marionnet et al., 2003).  Of particular note, two common oncogenes – Jun and 
Met – were overexpressed in the cSCC.  The role of key oncogenes in cSCC 
pathogenesis has remained elusive, with studies of commonly activated 
oncogenes, such as RAS, producing conflicting data on their role in cSCC 
pathogenesis (van der Schroeff et al., 1990, Pierceall et al., 1991, Campbell et al., 
1993).  Both Jun and Met are discussed in further detail below. 
 
c-Jun 
The c-Jun protein forms part of the activator protein 1 (AP-1) transcription factor 
complex, which consists of homo- or heterodimers of c-Jun, Fos, activating 
transcription factor or Fra family members.  c-Jun is activated in response to 
tumour necrosis factor alpha (TNFα) and transforming growth factor beta 
(TGFβ) via the MAPK pathway and the c-Jun NH2-terminal kinases (JNK) 
(Johansson et al., 2000).  It is upregulated in response to UVB in hairless mice 
and its phosphorylation correlates with the overexpression of multiple MMPs, 
including MMP1 and MMP10 which were also found to be upregulated in this 
study (Sato et al., 1997, Westermarck et al., 2000, Orbe et al., 2009).  In mouse 
models of skin carcinogenesis, inhibition of the AP-1 transcription complex by 
expression of a dominant negative c-Jun mutant resulted in a reduced capacity to 
form cSCC after injection of tumour cells into nude mice (Bowden et al., 1994).  
Furthermore, Zhang and colleagues (2007a) proposed JNK pathway activation 
cooperates with Ras to induce epidermal tumours in mice, via phosphorylation of 
c-Jun and activation of the AP1 complex.  Both total c-Jun protein and the active, 
phosphorylated form have been reported to be overexpressed at the protein level 
in cSCC in comparison to normal skin and psoriatic lesions, which is supportive 
evidence for the data from this microarray study (Lohman et al., 1997, Zhang et 
al., 2006, Zhang et al., 2007a, Marcekova et al., 2009). 
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Met 
The Met protein is the receptor for hepatocyte growth factor and controls cell 
survival, migration and endothelial proliferation.  It has been associated with 
many different cancer types, including oral SCC, thyroid carcinoma and 
colorectal cancer (Di Renzo et al., 1992, Di Renzo et al., 1995, Morello et al., 
2001).  In a BALB/c mouse model of progressive cSCC, expression of the Met 
oncogene was shown to increase with tumour progression (ie: from primary 
keratinocytes to a metastatic cSCC cell line) (Dong et al., 2004).  However, no 
data has been provided for human cSCC tissue samples, suggesting Met is a 
novel target warranting investigation in human cSCC.  A common mechanism 
for Met overexpression is gene amplification (Muleris et al., 1994, Di Renzo et 
al., 1995).  Integration of the expression data from this study with cSCC SNP 
data revealed amplification at 7q31.2 (where the Met gene resides), indicating 
this may be an important mechanism for c-Met overexpression in cSCC.  
 
MAPK pathway in cSCC 
Using Ingenuity pathway analysis, the MAPK pathway was identified as central 
to cSCC development in all 3 cSCC ANOVA analyses.  In particular, the 
MAPK1 gene – otherwise known as ERK2 or p42MAPK – was upregulated 1.5 
fold in the cSCC, with a highly significant p-value (p = 7.44E-06).  This is 
consistent with a previous microarray study undertaken using organotypic rafts 
of two cSCC cell lines, which also identified alterations in the MAPK pathway 
(Serewko et al., 2002).  The various pathways that constitute MAPK signalling 
are responsible for linking virtually all extracellular stimuli to their appropriate 
cellular responses (Figure 3.17, Dhanasekaran and Johnson, 2007).  Collectively, 
the MAPK pathways control a diverse range of downstream cellular functions, 
including proliferation, migration, apoptotic response and cell survival, all of 
which are central to tumour development.  The ERK pathway in particular has 
been extensively studied and is dysregulated in approximately one-third of all 
human cancers (Dhillon et al., 2007).  ERK1 and ERK2 (MAPK1) are activated 
upon phosphorylation by MEK (a MAPK kinase, or MAPKK), which is itself 
activated by the Raf kinases (a MAPKK kinase, or MAPKKK).  Upstream of 
Raf, the binding of extracellular ligands such as mitogens or growth factors to 
receptor tyrosine kinases activates Ras GTPase, which recruits Raf kinases to the  
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Figure 3.18 Overview of the MAPK pathway.  The signalling cascade that controls 
ERK1/2 activation is indicated on the left hand side of the diagram.  Figure taken from 
Dhanasekaran and Johnson (2007). 
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membrane and stimulates the signalling cascade.  Downstream targets of the 
ERK pathway include members of the AP-1 transcription factor complex (fos 
and c-jun), the Myc oncogene and cell cycle regulators such as cyclin D1 
(Bernstein et al., 1994, Chuang and Ng, 1994, Lavoie et al., 1996). 
 
Dysregulation of ERK1/2 signalling has been reported in a diverse range of 
cancers, including prostate, melanoma, breast and colorectal cancer (Loda et al., 
1996, Davies et al., 2002, Satyamoorthy et al., 2003, Burger et al., 2006, Zhang 
et al., 2007c).  In melanoma, the most common mechanism of activation of the 
pathway is via somatic mutations in the BRAF gene, which occurs in 66% of 
tumours (Davies et al., 2002).  In a limited analysis of 5 normal skin samples, 
immunostaining for phosphoERK (pERK) revealed no positive nuclear staining 
(Zhang et al., 2007c).  Conversely, nuclear staining of pERK was reported in 20 
cSCC, with an increase in expression between WD and PD tumours (Zhang et 
al., 2007c).  This is consistent with previous reports in oral SCC and cervical 
cancer, that also correlated increasing levels of pERK with higher tumour grades 
(Mishima et al., 1998, Kapetanios et al., 2008).  The increased expression of 
MAPK1 identified by the expression analysis presented in this thesis is 
supportive evidence for its differential expression between low-grade dysplasia 
and cSCC.  Taken together, these data indicate that activation of the MAPK 
pathway is a tumour specific event in cSCC development and may be a useful 
indicator for assessing tumour grade.  Furthermore, the association between 
MAPK1 and AP-1 activation suggest this could be a key pathway in cSCC 
development.   
 
Stratification by differentiation of the tumour and immune status of the patient 
Analysis of the dataset by differentiation status of the tumour and immune status 
of the patient only revealed one DEG for the comparison between WD cSCC 
versus AK samples and no DEGs for the other analyses.  This is surprising 
because WD cSCC were identified as a genetically distinct subgroup of cSCC by 
SNP microarray analysis and both histologically and clinically, WD cSCC show 
divergent characteristics to MD and PD tumours (Nguyen and Yoon, 2005, 
Purdie et al., 2009).  Furthermore, the tumour microenvironment has a key role 
in neoplasia and systemic immunosuppressive drugs would be predicted to 
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impact on tumour growth through the microenvironment, potentially resulting in 
expression differences between tumours from IS and IC patients.  Different 
immunosuppressive drug regimes have been associated with distinct gene 
expression signatures in peripheral blood lymphocytes in vitro, as well as 
differential cytokine expression in vivo (Niemczyk et al., 2009, Rumberger et al., 
2009).  The analysis in this study is limited, however, by low sample numbers in 
some categories, which is likely to influence the outcome.  In particular, only 6 
PD and 8 MD cSCC were available for analysis, compared to 16 WD cSCC.  
Furthermore, the ratio of IS:IC tumours for each category was 11:5 WD, 5:3 MD 
and 4:1 PD tumours.  For future work, it would be useful to increase the number 
of MD and PD cSCC analysed, particularly from IC patients, to see if subsequent 
analyses still support the finding of no DEGs between the different variables.   
 
It is also possible other factors not included in the analysis may have confounded 
the analysis.  In HNSCC for example, tumours that were positive for alpha-PV 
types such as HPV16 and 18, showed a significant upregulation of cell cycle 
genes in comparison to HPV negative tumours (Pyeon et al., 2007).  There is 
epidemiological evidence the beta-PV types – rather than alpha-PV types – play 
a role in skin carcinogenesis and mechanistic evidence that the E6 and E7 
proteins influence apoptotic responses in keratinocytes exposed to UVB 
(reviewed in chapter 1.3.3.2).  For future work, it would be interesting to 
undertake HPV typing analysis of the tumours and stratify the expression data 
accordingly. 
 
Integration of SNP and expression microarray data 
Integration of SNP and expression data is a powerful tool to identify genes that 
may be dysregulated by large-scale chromosomal aberrations.  It has been 
applied to other cancer types to identify novel candidate genes for 
tumourigenesis (Walker et al., 2006, Chitale et al., 2009, Rhodes and 
Chinnaiyan, 2005).  This is particularly important in cSCC, as the most common 
genetic aberrations occur in up to 75% of tumours, yet the genes in these regions 
that may directly contribute to pathogenesis often remain elusive.  The 
integration of genotype and expression microarray data presented in this study 
represents the first analysis of its kind in cSCC.  In total, only 21% (68/318) of 
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gene expression changes occurred in a region of corresponding copy number 
change, indicating the majority of gene expression changes occur by alternative 
mechanisms such as epigenetic regulation or alteration of signalling processes.  
From the integration analysis, 12 candidate genes were identified on 
chromosomes 3p, 3q and 9q, which are the most frequently disrupted 
chromosomes in cSCC.  This suggests these genes may be key targets of the 
recurrent genetic changes.  The 12 genes were TREX1, PHLDB2, PDIA5, 
FNDC3B, LRRFIP1, B3GNT5, PSMD2, POLR2H, PAK2, TJP2, ANXA1 and 
PRPF4.   
 
Of the 12 genes cited above, 4 – TREX1, PDIA5, B3GNT5 and POLR2H – have 
not been previously reported to be associated with cancer development, 
indicating they may either be novel targets for tumourigenesis or simply 
„passenger‟ events that occur as a result of tumourigenesis, rather than a cause of 
tumourigenesis.  Of the remaining genes, only one (ANXA1) has previously 
associated with cSCC development, suggesting the rest may be novel candidate 
genes in the pathogenesis of cSCC.  PHLDB2, PSMD2 and PAK2 which were all 
upregulated in cSCC, have also been reported as overexpressed in HNSCC, 
breast or ovarian cancer respectively (Carles et al., 2006, Deng et al., 2007, Siu et 
al., 2009).  PRPF4, which was overexpressed in cSCC, is associated with drug 
resistance in ovarian cancer cell lines (Duan et al., 2008), whilst ANXA1, which 
was also overexpressed in cSCC, is similarly overexpressed in hepatocellular 
carcinomas (Hsieh et al., 2009).  The TJP2 gene (commonly known as zona 
occludens 2) was upregulated in cSCC, but has been reported as a target for 
methylation in pancreatic cancer and prostate cancer cell lines (Sato et al., 2003, 
Wang et al., 2005).  TJP2 is involved in the organisation of intercellular tight 
junctions and its function in tumour development is not yet clear.  Mutations in 
this gene have been linked with hypercholanaemia, which is characterised by 
elevated serum bile acid (Carlton et al., 2003).  Of particular interest, the 
remaining two genes, FNDC3B and LRRFIP1, are direct targets of miR-143 and  
miR-12 respectively (Li et al., 2009, Zhang et al., 2009), suggesting their 
overexpression in cSCC could be a result of regulation by miRNAs.  Both of 
these miRNAs have been previously associated with cancer development (Li et 
al., 2009, Zhang et al., 2009). 
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Validation of the microarray findings 
To validate the genes identified by this study, two separate ANOVA analyses 
were also performed.  The first excluded potential outlier samples identified by 
hierarchical clustering or PCA, whilst the second used only matched AK:cSCC 
pairs.  The first validation analysis was used to find transcripts that were 
consistently up- or downregulated in the cSCC, irrespective of potential outlier 
samples.  As all arrays had passed the stringent QC checks, it is very difficult to 
determine whether outlier data represent genuine biological variation or „rogue‟ 
samples/arrays.  Performing the analysis both with and without these samples is a 
useful way to exclude possible outlier effects (through the identification of 
transcripts that are consistently up- or downregulated in both analyses), whilst 
retaining information from the analysis of all samples to ensure full biological 
variation is represented.  The analysis with outlying data removed showed good 
correlation to the initial ANOVA, with 84% (37/44) of genes matching DEGs 
identified by the original analysis.  The reduced number of DEGs from this 
analysis was expected, as the samples showing the greatest variation had been 
removed. 
 
A third analysis was performed using the 9 matched AK:cSCC pairs.  Both the 
PCA and initial ANOVA analysis suggested differences between patients were 
an important source of variability in the expression profile of samples, which 
strongly supports the use of matched samples for expression microarray analysis.  
Unfortunately, matched AK samples were not available for all cSCC, which is a 
limitation of the original analysis that was performed.  The matched analysis 
revealed a substantially smaller list of differentially expressed transcripts, which 
is likely to reflect, in part, the exclusion of between-patient variability.  However, 
there was also a skewed distribution of tumours by differentiation status (7/9 
were WD cSCC) and this may have influenced the analysis.  As discussed 
earlier, this study identified very few DEGs when AK samples were compared to 
each differentiation status category, but this may be a result of lower sample 
numbers in the MD and PD categories.  SNP data has shown that WD cSCC are 
a genetically distinct subgroup of cSCC that display fewer chromosomal 
aberrations than MD and PD tumours (Purdie et al., 2009).  Similarly, there is 
evidence that AK samples also display fewer chromosomal aberrations than 
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cSCC (Quinn et al., 1994, Ashton et al., 2003).  Therefore, the matched analysis 
using a majority of WD cSCC may reflect a smaller degree of biological 
variation between AK and WD cSCC and might not be representative of cSCC 
per se.  Nevertheless, 44/47 probe sets identified by this analysis were in 
common with the first ANOVA, suggesting good consistency between the 
analyses.  Furthermore, the matched analysis identified 3 additional genes with 
low fold changes between AK and cSCC, one of which, the PLK1 gene, is 
known to be upregulated in cSCC and is already in design as a therapeutic target 
in cancer (Schmit et al., 2009, Chopra et al., 2010). 
 
Combining all three ANOVA analyses isolated a set of 31 differentially 
expressed probe sets between AK and cSCC (corresponding to 23 genes), of 
which, 65% (15/23) had been previously associated with tumour development.  
Of these, only two – ANXA1 and CAP1 – had been previously identified in the 
studies by Nindl et al (2006) and Haider et al (2006) respectively.  As neither of 
the previously published microarray studies used LCM, their data is likely to be 
skewed by stromal contamination and small sample number sizes, suggesting 
less reliability than the results presented here. 
 
Clustering of data sets using the differentially expressed probe sets from this 
study 
To further validate the probe list identified by this study, it was used to cluster 
the normal skin samples analysed by Dr A. Gulati and an existing microarray 
data set consisting of normal skin, BCC and cSCC (Riker et al., 2008).  The 318 
differentially expressed probe sets from ANOVA 1 correctly classified the 
majority of cSCC from normal skin and precancerous lesions.  Clustering of the 
data set generated by Riker and colleagues also showed the gene list was capable 
of separating the cSCC from both normal skin and BCC, despite there having 
been no prior microdissection of the tumour samples.  Furthermore, the smaller 
lists of probe sets from ANOVA 2 and 3 and those that were in common to all 3 
ANOVAs showed a clear trend towards separating the cSCC from normal skin 
and BCC.  This indicates that the probe sets in common to all three ANOVAs 
represent a robust set of differentially expressed probe sets in cSCC, but that 
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there are also likely to be additional probe sets in the larger gene list that are 
important for defining a cSCC expression signature.  
 
Normal skin to cSCC expression changes 
A series of NSE-SE-AK samples from 20 patients that had been collected into 
RNAlater was analysed by Dr A. Gulati, allowing ad hoc comparison between 
the two datasets.  Only one gene was identified as differentially regulated 
between NSE and SE skin (FDR 0.05), whereas 428 probe sets were 
differentially regulated between SE and AK skin (FDR 0.05) (Dr A. Gulati, 
personal communication).  Using the same FDR cut-off, 16 probe sets were 
differentially expressed between AK and cSCC, indicating the largest change in 
gene expression in the sequential series of skin carcinogenesis occurs between 
SE normal skin and AK lesions.  This supports the use of AK biopsies as a 
baseline measurement for determining changes in gene expression that are 
involved in the progression of cSCC from premalignant lesions, as the use of 
normal skin would also have identified potentially benign changes in normal skin 
that occur as a result of UV exposure.   
 
Of the 16 differentially expressed probe sets in the cSCC analysis, 2 were also 
identified as differentially regulated in the transition from SE normal skin to AK.  
ACVR2A was downregulated in both AK and cSCC, suggesting it is a continued 
target for downregulation throughout skin carcinogenesis.  ACVR2A is part of a 
signalling complex belonging to the TGF-beta superfamily that recruits SMAD 
proteins in response to the growth factor activin.  Overexpression of activin 
inhibits cell growth in breast cancer cell lines (Cocolakis et al., 2001), suggesting 
the downregulation of ACVR2A in cSCC may disrupt this effect of growth 
inhibition.  Conversely, CD36 was upregulated 5.4 fold in the AK samples, but 
downregulated 4.6 fold in the cSCC.  It was also 88 fold lower in the analysis of 
the metastatic samples, suggesting it might have distinct roles in low grade 
hyperplasia compared to neoplasia.  CD36 is the receptor for thrombospondin 
and is involved in cell adhesion.  Its expression has been investigated previously 
in cSCC and shown to correlate with tumours that display higher levels of 
differentiation (Allen et al., 1991).  This is in keeping with the findings presented 
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here, whereby the AK expressed high levels of CD36, but levels were 
dramatically reduced in the metastatic cSCC. 
 
cSCC metastases 
Analysis of the two metastatic samples was performed in comparison to the AK 
baseline.  This identified 255 DEGs, of which, only 26 were in common with the 
cSCC analysis.  Of particular note, members of the mucin and MMP gene 
families were dysregulated, both of which have been linked to the metastatic 
process.  During metastasis, malignant cells must detach from the primary 
tumour, migrate and invade through structural barriers such as the extracellular 
matrix (ECM).  Collectively, MMP proteins degrade virtually all components of 
the ECM, thereby facilitating the metastatic process (Johansson et al., 2000).  
This study suggests that MMP10, 11 and 13 are important for cSCC metastasis, 
all of which have been implicated with enhanced invasive capacity or metastasis 
in other cancer types (Shi et al., 2009, Muller et al., 1993, Ellsworth et al., 2009).  
Similarly, three mucin genes were also dysregulated in the two lymph node 
metastases.  MUC3A and MUC3B were both upregulated in the metastatic 
tumours, whilst MUC15 was downregulated.  Mucins are a family of heavily 
glycosylated proteins that play a protective role in epithelial tissues through 
lubrication or the formation of physical barriers.  Overexpression of the Muc3 
proteins have been implicated in poor prognosis of renal cell and breast cancers, 
whilst Muc15 downregulation has been reported in metastatic melanoma (Leroy 
et al., 2003, Rakha et al., 2005, Riker et al., 2008).  The precise function of these 
mucins in tumourigenesis is not known, however a role in disrupting cell-cell 
adhesion – which is a key feature of metastasis – has been demonstrated for 
several mucin family members (Chauhan et al., 2009, Regimbald et al., 1996). 
 
Pathway analysis placed the Myc oncogene as central to the most significantly 
enriched network identified by the differentially expressed genes.  Myc itself was 
upregulated 2.5 fold in the two metastatic samples and was not identified from 
the cSCC vs. AK analyses, indicating its upregulation may be associated with 
metastatic progression.  A common mechanism of upregulation of the Myc 
oncogene is via gene amplification.  This has been previously reported to 
positively correlate with tumour grade in cSCC, supporting the association found 
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in this study between Myc upregulation and metastasis (Toll et al., 2009).  Myc is 
activated in many different human cancers and is associated with functional 
effects on proliferation, apoptosis and cell cycle regulation (Gustafson and 
Weiss, 2010).  It is already being investigated as a therapeutic target in other 
cancer types (Gustafson and Weiss, 2010) and, based on the findings from the 
study presented in this thesis, could potentially be a useful target for the 
treatment of metastatic cSCC. 
 
Future work 
Despite the validation of this expression microarray analysis using existing 
datasets and alternative statistical analyses, a major limitation is that due to time 
constraints, it was not possible to confirm the findings of dysregulated genes by 
qRT-PCR or other methods such as IHC.  This is essential for corroborating the 
microarray findings and to confirm the experimental and statistical approach has 
not yielded false-positive results.  For future work, qRT-PCR should be 
performed on a separate set of normal skin, AK and cSCC to those analysed in 
this series.  For validation, it would be interesting to confirm the upregulation of 
the JUN and Met oncogenes, as well as the 12 candidate targets on chromosomes 
3 and 9 that were identified by the integration of SNP and expression data.  
Furthermore, four other genes (FMO5, S100A10, PTPN12 and MAPK1) that 
were in common to all 3 ANOVA analyses mapped to regions of recurrent 
genomic aberration and it would also be interesting to investigate these in further 
detail. 
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CHAPTER FOUR: RESULTS TWO 
PTPRD AS A CANDIDATE GENE IN cSCC 
 
4.1 BACKGROUND 
4.2 RESULTS 
4.2.1 PTPRD is expressed in skin 
4.2.2 Optimisation of methods for screening FFPE tissue for deletions of PTPRD 
4.2.3 Deletions of PTPRD are significantly associated with metastatic tumours 
4.2.4 Metastatic cSCC display clonal deletions in PTPRD 
4.2.5 PTPRD deletions frequently target the 5’ UTR 
4.2.6 PTPRD is frequently mutated in cSCC 
4.2.7 Promoter methylation is not a common mechanism of inactivation of 
PTPRD in cSCC 
4.2.8 PTPRD is expressed at a lower level in MD and PD cSCC 
4.3 DISCUSSION AND SUGGESTIONS FOR FUTURE WORK 
 
 
4.1 BACKGROUND 
Many of the genes that are important in the development of cSCC have been 
previously identified by targeted gene-specific analyses based on their role in 
other types of cancer.  For example, the TP53 gene and the CDKN2A locus 
which are disrupted early in cSCC pathogenesis, were both previously shown to 
be altered in other types of cancer prior to being studied in cSCC (Brash et al., 
1991, Soufir et al., 1999).  An initial 10K SNP genotyping analysis of 16 cSCC 
by Purdie et al. (2007), identified microdeletions in a novel candidate gene, the 
protein tyrosine phosphatase receptor type D (PTPRD) gene.  At this time, 
PTPRD had emerged as a potential tumour suppressor in both lung cancer and 
neuroblastoma, with homozygous and heterozygous deletions similar to those 
seen in cSCC identified in 4-10% and 13% of tumours respectively (Sato et al., 
2005, Zhao et al., 2005, Stallings et al., 2006).  Subsequent publications have 
identified deletions within PTPRD in 9% of melanoma cell lines and 14% of 
glioblastoma multiforme (GBM) and also shown alternative mechanisms of 
disruption such as mutation and methylation affect the gene (Stark and Hayward, 
2007, Solomon et al., 2008, Chan et al., 2008, Veeriah et al., 2009).  
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An extension of the cSCC SNP genotyping to 60 tumours with higher resolution 
50K and 250K SNP microarrays identified PTPRD microdeletions in a total of 
15% (9/60) of tumours (Purdie et al., 2009).  Only 7% (2/31) of well 
differentiated (WD) cSCC had a microdeletion at the locus, compared to 16% 
(3/19) of moderately differentiated (MD) tumours and 40% (4/10) of poorly 
differentiated (PD) cSCC, suggesting an association with the more aggressive 
tumours.  Furthermore, both of the two primary-metastatic pairs in the series 
showed a deletion within PTPRD in the primary cSCC and corresponding 
metastasis, whilst a third patient with a particularly aggressive primary cSCC and 
unconfirmed lung metastases also had a microdeletion in the primary tumour.  
The majority of microdeletions reported in cSCC were located in the 5‟ 
untranslated region (UTR) and ranged in size from 100-900 Kb. 
 
PTPRD belongs to a family of transmembrane proteins that are associated with 
neural development and cell adhesion.  The exact physiological function of 
PTPRD has not yet been fully characterised, although a recent publication has 
shown PTPRD dephosphorylates the signal transducer and activator of 
transcription 3 (STAT3) protein in vitro (Veeriah et al., 2009).  PTPRD is 
classified as a type IIa PTPR, with two catalytic intracellular phosphatase 
domains and an extracellular domain (ECD) consisting of 8 fibronectin (FN) 
subunits and 3 immunoglobulin (IG) subunits (see Figure 5.1, page 213).  The 
gene itself is large, containing 35 coding exons that are alternatively spliced to 
produce 6 protein variants.  These are differentially expressed in a tissue specific 
pattern (Pulido et al., 1995a).  Furthermore, two 5‟ UTRs have been identified, 
one with a longer 711 bp sequence consisting of exons B1-B9 (L isoform) and a 
shorter sequence comprising 103 bp (S isoform), designated exon 1 onwards 
(Sato et al., 2005).  Both 5‟ UTR variants share a common coding sequence and 
protein, with the translation start site located in exon 2. 
 
The aim of the work presented in this chapter was to investigate in further detail 
the association of PTPRD microdeletions with more aggressive tumours and to 
fully characterise this gene in cSCC by screening for other mechanisms of 
inactivation such as mutations (eg: missense or nonsense) and methylation.  To 
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consolidate these genetic analyses, corresponding gene expression data from 
cSCC of different histological grades was also investigated. 
 
4.2 RESULTS 
4.2.1 PTPRD is expressed in skin 
Before embarking on extensive genetic analyses, the expression of PTPRD in 
skin was investigated to determine if it may play a role in skin biology.  No 
previous publication had reported on the expression of PTPRD in skin.  RNA 
was extracted from 8 normal skin samples and a microdissected primary and 
metastatic cSCC pair and used as a template for cDNA synthesis (see chapter 
2.2.7 and 2.4.1 for methodology).  Two primer sets from Sato et al. (2005) were 
used to amplify fragments of the PTPRD cDNA corresponding to exons 2-5 and 
exons 35-36, at the beginning and end of the coding sequence.  Both primer sets 
revealed PTPRD expression in all 8 normal skin samples as well as the primary 
and metastatic cSCC (Figure 4.1).  Products were confirmed to be the correct 
PTPRD transcript by sequencing.  Although a non-quantitative method was used, 
the expression appeared considerably weaker than RNA from brain tissue, where 
PTPRD is known to be expressed at high levels.  No antibodies are currently 
available for use in immunohistochemistry or immunofluorescence, so it was not 
possible to continue these observations at the protein level.  For more detail on 
the antibodies currently available for PTPRD, see chapter 5. 
 
4.2.2 Optimisation of methods for screening formalin fixed paraffin 
embedded (FFPE) tissue for microdeletions of PTPRD 
Having established that PTPRD was expressed in skin, the proposed association 
of PTPRD microdeletions with more aggressive cSCC was investigated in further 
detail using primary-metastatic tumour pairs.  Fresh frozen (FF) tumour biopsies 
were available from very few patients with metastatic cSCC, so archival FFPE 
tumours from the Royal London and St Bartholomew‟s Hospital Pathology Trust 
were collected for analysis.  In total, 54 tumours from 19 patients who had been 
treated within the last ten years for metastatic cSCC were collected.  This 
included primary cSCC and subsequent recurrent and metastatic tumours, all of 
which were crudely microdissected to enrich for 85-100% tumour DNA (see 
chapter 2.2.2 for methodology). 
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Figure 4.1 2% agarose gels showing expression of PTPRD in normal skin and cSCC.  
Amplification of a) PTPRD using the primer set X2-X5, b) PTPRD using the primer set X35-36 
and C) the housekeeping gene Beta-actin.  RT = reverse transcriptase.  + indicates reactions 
containing RT and – indicates control reactions for which cDNA synthesis was carried out in the 
absence of RT.  cSCC indicates the primary tumour and met indicates the metastatic tumour.  
PCR neg = control PCR reaction without template DNA.  One normal skin sample is shown as 
representative of the 8 samples, all of which showed similar levels of PTPRD expression. 
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DNA isolated from FFPE tissue is usually highly degraded due to the fixation 
and embedding process (Goelz et al., 1985).  PCR based techniques with such 
material are therefore restricted to amplicons of small size (typically between 
100-200 bp) and other techniques such as microarrays tend to be unsuitable 
because they require high-quality, intact DNA.  Furthermore, the yield of DNA 
obtained from FFPE tissue is typically low and does not make a good template 
for whole genome amplification methods due to its degradation.  The 
optimisation of methods required for screening PTPRD for deletions in the FFPE 
primary-metastatic series of tumours are detailed below. 
 
 4.2.2.1 Semi-quantitative analysis of PCR amplicons is not consistent for FFPE 
DNA 
Multiplex PCR (mPCR) coupled with semi-quantitative analysis using the 
Agilent 2100 Bioanalyser is a useful tool for the analysis of large genes such as 
PTPRD, as different amplicons are combined in the same reaction to reduce the 
quantity of DNA and reagents that are required.  This technique has been used 
previously to demonstrate heterozygous loss of whole exons in disease associated 
genes when compared to normal controls (Thomas et al., 2006).  To assess the 
sensitivity of this technique, 3 primer sets that amplified different exons of 
PTPRD were multiplexed for use with DNA extracted from SCC 3, a cell line 
with a known homozygous deletion of exons B5-X1 as detected by SNP 
microarray analysis (primer sets are listed in Appendix F).  A primer set 
amplifying exon B9 that was within the region of deletion was multiplexed with 
primer sets for exon 4 and exon 27, both of which were outside the deleted 
region.  The largest amplicon included in the mPCR was a 268 bp fragment of 
the Beta-globin gene, to control for amplification of large PCR products (which 
would be important for subsequent analyses with FFPE DNA samples).  The cell 
line DNA was spiked with increasing amounts of placental DNA (10% to 50%) 
and run alongside 100% placental DNA as a normal control (see chapter 2.2.10 
and 2.3.4 for full details of methodology).   
 
Agilent Bioanalyser profiles showed a distinct reduction in the level of 
fluorescence for the amplicon that was homozygously deleted in the cell line 
(exon B9), when compared to the profile from placental DNA (Figure 4.2).  The 
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other PTPRD amplicons (exons 4 and 27) were unaffected.  Furthermore, the 
reduction was still evident when the tumour DNA was spiked with 50% of 
normal DNA (Figure 4.2), suggesting a low level contamination of DNA from 
normal cells post microdissection would not adversely affect the detection of 
deletions.  It was also noted that the Beta-globin amplicon showed a reduction in 
fluorescence in the tumour DNA sample compared to the placental control and a 
review of the SNP data revealed LOH on chromosome 11p15.5 where Beta-
globin resides.  A new size control fragment of the nucleolar protein 10 (Nol 10) 
gene was designed.  Nol 10 was selected because it has no disease associations 
and is on chromosome 2p25.1 which is the most genetically stable part of the 
genome in cSCC (affected by copy number changes in 10% (6/60) cSCC, Purdie 
et al., 2009). 
 
Primer sets for exons B1-B9 and exons 1-6 which encompass all previously 
identified deletions in cSCC were multiplexed in 6 PCRs, each containing 2-3 
PTPRD primer sets with a 269 bp amplicon of Nol 10 (the largest amplicon).  
DNA was extracted from 6 FFPE fibroepithelial polyps (FEPs) to use as a panel 
of normal controls.  FEPs, or skin tags as they are more commonly known, are 
small papules formed of skin that are presumed unlikely to contain high levels of 
genomic instability due to their benign nature.  Initially, DNA from 6 FEP 
samples and two FFPE tumour samples with previously identified deletions of 
PTPRD (SCC 12 and SCC 26) were used to assess the suitability of the technique 
with FFPE tissue.  SCC 12 has a heterozygous deletion of exons B9-X4, whilst 
SCC 26 has a homozygous deletion of exons B3-B9. 
 
The Bioanalyser profiles were not consistent across the panel of FEP DNA 
samples and did not reliably detect the deletions from the two tumour samples 
(Figure 4.3).  Whilst it is possible, although unlikely, that the FEP samples may 
also contain deletions within PTPRD, closer examination of the Bioanalyser 
profiles revealed 4/6 FEP samples showed preferential amplification of the 
smaller amplicons within the mPCR.  This is most likely an artefact of the poor 
quality of DNA obtained from FFPE tissue and this technique was consequently 
deemed unsuitable for detecting copy number changes in DNA from FFPE 
tissue.
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Figure 4.2 Agilent Bioanalyser electropherograms showing detection of a 
homozygously deleted amplicon of PTPRD within a mPCR.  A) control placental DNA, B-F) 
tumour DNA spiked with 10%, 20%, 30%, 40% and 50% of placental DNA respectively.  Time 
in seconds is shown on the x axis of each trace – smaller products move faster through the gel 
and are detected earlier.  The y axis shows the level of fluorescence for each amplicon, which is a 
semi-quantitative measure of PCR amplification.  The asterisk marks the amplicon that is deleted 
in the cSCC cell line and shows a clear loss of signal when compared to the same peak in the 
normal control. 
 
M = the marker, which is an internal quality control for the sizing of fragments 
and should always appear before the smallest amplicon of the mPCR is detected.  Peak one after 
the marker is exon B9, peak two is exon 4, peak three is exon 27 and peak four is an amplicon of 
the Beta-globin gene. 
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Figure 4.3 Agilent Bioanalyser electropherograms showing inconsistent amplification 
of mPCR 1 with FFPE DNA.  A) electropherogram of FFPE DNA from SCC 26, which has a 
homozygous deletion of exon B8, the first amplicon in the mPCR (indicated by *), B) FFPE 
DNA from SCC 12, which has a heterozygous deletion of exon 4, the second amplicon in the 
mPCR (indicated by **) and C) profiles of the mPCR from 3 FEPs, showing increasing degrees 
of bias towards amplification of the smaller amplicons in the mPCR.  M = marker, an internal 
size control.  Peak one after the marker is exon B8, peak two is exon 4, peak three is exon B1 and 
peak four is an amplicon of the Nol10 gene. 
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4.2.2.2 Affymetrix 250K SNP microarray profiling is not well suited to FFPE 
DNA 
The use of SNP microarrays has been used to produce reliable genotype and 
copy number changes in FFPE samples.  In particular, the Affymetrix 250K SNP 
microarrays that were used in the analysis of FF cSCC, have been used to 
investigate copy number changes in FFPE ovarian, breast and colorectal tumours 
and shown to produce similar patterns of copy number to corresponding FF 
samples from the same tumour (Jacobs et al., 2007).  An advantage of this 
method for the analysis of the FFPE primary-metastatic cSCC series is that the 
arrays contain ~250,000 SNPs spread across the whole genome, which would 
allow the investigation of genomewide copy number changes as well as those at 
the PTPRD locus.  In brief, DNA samples are digested to enable the ligation of 
adaptors, amplified using a primer pair specific to the adaptor, fragmented and 
labelled before hybridisation to the array (see chapter 2.3.11 for full details of 
methodology).  During the pre-hybridisation steps of the protocol, it is possible 
to follow the success of the process at the post-PCR stage, by running an agarose 
gel of the amplified products.   
 
Four FFPE cSCC from a total of 3 patients were analysed using the Affymetrix 
250K NSP protocol, with matched blood as a control for normal copy number 
variation.  Two of the four tumours had a known heterozygous deletion of 
PTPRD (SCC 12, primary and corresponding metastasis), whilst the remaining 
two had homozygous deletions (SCC 9 and SCC 26) as identified by microarray 
analysis of corresponding FF tissue or short term passage cultured cells (Purdie 
et al., 2009).  At the post-PCR stage, it was evident that 3 of the 4 FFPE DNA 
samples had not successfully amplified and could not be continued for 
hybridisation to the array (Figure 4.4).  The remaining sample amplified 
successfully but showed a reduction in the maximum size of PCR product in 
comparison to the blood DNA samples, which reflects the fragmented quality of 
DNA from the FFPE tumour.  This sample was hybridised to the microarray chip 
along with the matched blood DNA. 
 
The data from the FFPE equivalent of SCC 26 that was hybridised to the array 
was considerably more noisy than the corresponding DNA from short term 
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cultured cells, but showed a high level of concordance in the detection of copy 
number changes, including the identification of the homozygous deletion within 
PTPRD (Figure 4.5).  Given the small number of tumours in this primary-
metastatic series however, a drop-out rate of 3/4 FFPE tumours was not 
considered acceptable.  Previous studies have included stringent cut-offs for 
assessing the quality of FFPE DNA prior to analysis on the microarray, in order 
to improve successful hybridisations (Jacobs et al., 2007).  This strategy is useful 
if a large number of tumours are available for analysis allowing for such drop-out 
rates, but not with limited sample numbers.  Therefore, this approach was also 
deemed unsuitable for the analysis of this series of tumours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4 Failure of three FFPE DNA samples in Affymetrix SNP microarray pre-
processing steps.  2% agarose gel showing four FFPE cSCC samples and three matched blood 
samples after the PCR stage of Affymetrix 250K SNP profiling.  Sample IDs are based on those 
assigned in Purdie et al. (2009), met = metastatic tumour.  cSCC 12, 12_met and cSCC 9 have all 
failed the process, as evidenced by a faint smear of DNA in the first three lanes.  cSCC 26 has 
amplified successfully, although there is a reduction in the maximum size of PCR product in 
comparison to the three blood samples (indicated by the white lines and corresponding sizes 
shown on the right of the picture). 
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Figure 4.5 Whole genome copy number data to compare Affymetrix SNP microarray profiling from FFPE tissue with short-term passage cultured 
cells from the same tumour.  The top data set shows copy number data from the FFPE tumour DNA, the sample beneath that is the short-term cultured cells (kindly 
provided by Dr K. Purdie).  Data was analysed by the GOLF software.  The signal intensity of tumour vs. blood is plotted on a log2 scale, with SNPs that cluster 
around the central axis indicating a consensus of copy number between the tumour and blood.  The upper line for each plot indicates log2(2) and is indicative of 
amplification, whilst the lower line for each plot is log2(0.5) and indicates loss of genetic material in the tumour sample.  Data is arranged by chromosome, shown 
along the top axis.   The arrow indicates the microdeletion of PTPRD.  The FFPE DNA in the top panel is noisier than the cell line DNA, as indicated by a greater 
deviation of the signal intensity of SNPs, which can make assigning copy number changes more difficult. 
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4.2.2.3 Illumina’s GoldenGate assay is well suited to FFPE DNA 
Unlike the Affymetrix microarrays, Illumina‟s GoldenGate assay does not 
contain a restriction digest step prior to hybridisation and is therefore more 
tolerant of degraded DNA.  GoldenGate microarray analysis has been validated 
by several studies, both in comparison to established platforms such as array 
comparative genomic hybridisation (aCGH) and the Affymetrix SNP 
microarrays, as well as for consistent profiling between FF and FFPE DNA (Lips 
et al., 2005, Oosting et al., 2007).  Illumina have two established SNP microarray 
panels for use with the GoldenGate assay: the GoldenGate Linkage V and the 
Cancer SNP Panel, which have 12 or 0 SNPs respectively within PTPRD.  Thus, 
neither panel covered the locus with high enough resolution to reliably detect 
LOH and deletions, so a custom SNP panel was designed to cover the PTPRD 
gene at a high resolution. 
 
Design of the SNP microarray 
A 384 SNP Oligo Pool All (OPA) was designed using the Illumina Assay Design 
Tool (ADT), to give approximately 6 Kb spacing across the PTPRD locus.  In 
total, 10848 SNPs were identified by the ADT in the specified 2 Mb region of 
PTPRD.  384 SNPs were chosen from this list based on the following criteria, in 
descending order of importance: no design failure code (which indicate SNPs 
that are likely to impair the performance of the assay); approximate 6 Kb spacing 
between SNPs; GoldenGate validated or two-hit validated SNPs with a design 
score above 0.60 and a minor allele frequency (MAF) of 10% in the Caucasian 
population (see chapter 2.3.12 for further details on the design of the array and 
Appendix G for the full OPA list). 
 
Additional FFPE tumours were added to the list of 54 primary-metastatic DNA 
samples to make up a run of 96 samples.  This included PD primary cSCC 
unrelated to metastatic disease from 6 of the primary-metastatic patients and 14 
PD or aggressively recurrent primary cSCC from an additional 13 patients with a 
five year follow-up and no metastatic disease.  Venous blood samples were 
obtained from 22 of the patients with corresponding cSCC and included for 
comparative analysis of copy number.  Samples were prepared with the custom 
OPA according to the GoldenGate assay and hybridised to the Universal Array 
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Matrix by the Genome Centre, at Barts and the London.  Gene calls and signal 
intensities were analysed using the Illumina BeadStudio V3 software (for further 
details see chapter 2.3.12). 
 
In total, copy number data were obtained for 73/74 tumour samples, indicating 
this assay is well-suited to FFPE tissue (Figure 4.6).  Of the 384 SNPs, 5 failed to 
reach a standard GenCall cut-off score of 0.25 (which is a measure of the 
reliability of the SNP performance) and were excluded from further analysis.  
The presence or absence of deletions was assessed using the logR ratio and B 
allele frequency (BAF).  The logR ratio is a log transformed ratio of the 
measured SNP signal intensity by the expected intensity if two copies of DNA 
are present.  The presence of two copies generates a logR of 0, whilst loss of 
copy number deviates below this value.  The BAF is a normalised measure of the 
proportion of B-alleles in each SNP eg: 0 for AA homozygous SNPs, 0.5 for AB 
heterozygous SNPs and 1.0 for BB homozygous SNPs.  Deletions were only 
considered genuine events if there was a reduction in the logR ratio that was 
concomitant with an altered pattern of the BAF.  The coordinates for deletion 
were taken as the first and last SNP in a run of at least 5 consecutive SNPs that 
met the criteria of a low logR ratio and altered BAF plot. 
 
Validation of the custom microarray 
Four control FFPE tumours with FF or short-term passage cultured cell 
equivalents that had been SNP profiled using the Affymetrix 250K SNP 
microarrays were included amongst the samples to confirm the ability of the 
custom array to detect copy number changes.  The primary tumour from primary-
metastatic patient (PM) 12 (SCC 23) had LOH, PM1 (primary, SCC12) had a 
heterozygous deletion and PM13 (SCC9) and SCC 26 both had a homozygous 
deletion.  In all 4 cases, an identical pattern and location of the deletions were 
detected by the Illumina microarray, suggesting a high level of reliability (two 
examples of which are shown in Figures 4.7a and b).  To confirm the genotypes 
were being called correctly by the software, DNA was extracted by laser capture 
microdissection (LCM) from two previously unscreened primary cSCC – 
patients PM5 and PM6 – for which FF tissue and blood DNA were also available 
for analysis.  Four heterozygous SNPs identified from the array data were chosen 
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Figure 4.6 SNP genoplots of the normalised signal intensity and genotype calls from 3 
samples analysed by the custom Illumina SNP microarray.  The y axis shows the normalised 
signal intensity and the x axis shows the normalised theta value (deviation from a pure A 
genotype, whereby 0 represents pure A signal and 1.0 represents pure B signal).  Each dot in the 
graph represents an individual SNP.  A) blood DNA with 3 distinct genotype clusters at 0 (AA), 
0.5 (AB) and 1.0 (BB), B) FFPE tumour sample with LOH as evidenced by the loss of 
heterozygote SNPs, C) FFPE tumour sample that failed, seen by the lower signal intensity of a 
large subset of SNPs. 
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Figure 4.7a Heterozygous deletion of PTPRD in PM1 as detected by the custom 
Illumina SNP microarray.  The top panel shows the log 2 signal intensity of the tumour sample 
paired to its matched blood, 0.0 indicates a consensus of copy number between tumour and 
blood, SNPs below 0.0 indicate a loss of DNA in the tumour sample.  The lower panel shows the 
BAF.  Each dot in both panels represents an individual SNP.  The region of heterozygous 
deletion is shown by dotted lines and is indicated by the decrease in signal intensity and 
concomitant loss of heterozygote SNPs.  
 
A) 
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Figure 4.7b   Homozygous deletion of PTPRD on a background of LOH in SCC 26.  The 
region of deletion is again indicated by dotted lines.  Either side of the deleted region, LOH is 
evident by the loss of heterozygote SNPs in the BAF plot, whilst inside the deleted area there is a 
clear decrease in the signal intensity and an effect termed „waterfall‟ in the BAF, where the 
genotypes are called on background noise in the absence of signal. 
 
 
 
 
 
 
B) 
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at random throughout the gene and sequenced in both the FF tumour DNA and 
blood DNA.  These were confirmed to be heterozygous in both blood samples 
and the primary cSCC from PM6, whilst the primary cSCC from PM5, which 
showed LOH on the array, was confirmed to have lost heterozygosity at these 
SNPs (Figure 4.8). 
 
4.2.3 Deletions of PTPRD are significantly associated with metastatic 
tumours 
In total, microdeletions of PTPRD were found in primary and/or metastatic 
tumours from 37% (7/19) of patients with metastatic disease (Table 4.1).  Five of 
the deletions were homozygous occurring on a background of LOH, whilst the 
remaining two were heterozygous deletions with a normal copy number across 
the rest of the locus.  A further 7 patients showed LOH at the locus, which is 
consistent with the high level of 9p LOH seen by SNP microarray analysis of 
cSCC in the study by Purdie et al. (2009).  Of the PD cSCC included on the 
array, 22% (4/18) showed a microdeletion of PTPRD, of which two were 
homozygous on a background of LOH and two were heterozygous deletions with 
no LOH (Table 4.1).  Three PD cSCC also showed LOH without a microdeletion 
across the whole locus.  Eleven tumours that were analysed showed a broad 
scattering of the BAF, meaning it was not possible to determine whether LOH 
was present or not.  These samples included 8 tumours from the primary-
metastatic series of tumours and 3 PD tumours and are most likely to represent 
the most degraded DNAs. 
 
For statistical analysis, SNP microarray data of the PTPRD locus from the 60 
cSCC analysed by Purdie et al. (2009) were included with the series of tumours 
analysed by the custom microarray to give a total of 96 primary tumours from 80 
patients
1
.  This included one additional patient with metastatic disease.  A two-
tailed Fisher‟s Exact test was used to test the three following null hypotheses: 
deletions of PTPRD are not associated with metastasis, deletions of PTPRD are 
not associated with the differentiation status of tumours and deletions of PTPRD 
are not associated with metastatic and poorly differentiated tumours combined.  
In all cases, the null hypothesis was rejected, with a 2-tailed p value of 0.007, 
0.01 and 0.0002 respectively (Table 4.2), showing that deletions of PTPRD are 
1 Only one tumour derived from each metastatic series was included in the analysis, to avoid bias from unequal sample 
numbers per series.  In most cases this was the primary tumour, however where the genetic status differed from 
metastatic tumours or a primary tumour was unavailable, recurrent or metastatic tumours were used instead.  
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Figure 4.8 Sequencing electropherograms confirm genotype calls from the Illumina 
microarray.  SNP Rs10756030 was sequenced in A) PM6 blood DNA, B) PM6 primary cSCC 
DNA, C) PM5 blood DNA and D) PM5 primary cSCC DNA.  All SNPs were correctly called 
heterozygous by the BeadStudio software, with the exception of  PM5 primary cSCC which had 
LOH across the whole locus.  Arrows mark the position of the SNP. 
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Table 4.1   Clinicopathological details of the FFPE tumours analysed by custom Illumina microarray.   
 
Patient no 
Primary/metastatic/P
D cSCC 
Differentiation 
status Site 
Age at 
diagnosis 
Immune 
status 
Deletion at PTPRD 
locus LOH 
PM1* Primary (SCC12) MD Right temple 77 IC Het: 8528919-9380450 N 
 Metastasis Not reported Parotid 77  Het: 8528919-9380450 N 
 Metastasis MD Lymph node 78  Het: 8714264-9338102 N 
PM2 Primary MD Cheek 70 RTR N Y 
 Metastasis MD Lymph node 71  Sample failed Sample failed 
 Metastasis MD Lymph node 71  N Y 
PM3* Primary WD  Dorsum right hand 61 RTR N BAF uncertain 
 Primary MD Right hand 61  N Y 
 
Metastasis PD Right axilla Lymph 
node 
62  N Y 
  Primary PD Right jawline 67   N Y 
PM4* Primary   Left cheek 57 RTR     
 Recurrence PD Left cheek 59  N BAF uncertain 
 Recurrence M-PD Left cheek 60  N Y 
 Metastasis PD Superficial parotid 60  N Y 
PM5* Primary MD Right forehead 66 RTR N Y 
 Recurrence WD Right forehead 66  N Y 
 Recurrence  Right temple 67  N Y 
 Metastasis   Lymph node 68       
 Primary PD Right anterior shin   N N 
PM6* Primary M-PD Left scalp 65 RTR N N 
 
Primary lung cancer or 
metastatic cSCC 
 Lung 65  N BAF uncertain 
 
Metastasis  Left upper cervical 
lymph node 
65  N N 
  Primary PD Preauricular area 66   N BAF uncertain 
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Patient no 
Primary/metastatic/P
D cSCC 
Differentiation 
status Site 
Age at 
diagnosis 
Immune 
status 
Deletion at PTPRD 
locus LOH 
PM7* Primary M-PD Right forehead 60 RTR N N 
 Metastasis WD Superficial parotid 61  N N 
  Primary PD    60   N Y 
PM8* Primary PD Right wrist 64 RTR Het: 9063311-9807514 N 
 Skin metastasis  Right forearm 64  Het: 9109229-9807514 N 
 Dermal metastasis PD Right forearm 64  Het: 9199719-9807514 N 
  Metastasis PD Lymph node 64       
  Primary PD Right ear 63   N N 
PM9 Primary WD Left preauricular 74 RTR N N 
 Recurrence WD Left preauricular 74  N N 
 Recurrence WD Left preauricular 74  N N 
 Re-excision WD Left preauricular 74  N N 
PM10* Primary (SCC23) MD Left cheek 69 IC N Y 
 Primary/recurrence?  Left temple/cheek 70  N N 
 Recurrence MD Left cheek 71  Homo: 9435004-9559081 Y 
 Recurrence  Left mandible 71  N N 
 Recurrence WD Left cheek 71  N N 
  Metastasis   Parotid 71       
PM11 
Primary (SCC9) PD Scalp 81 IC Homo: 8927116-
10035049 
Y 
 
Skin metastasis MD Right preauricular 82  Homo: 8927116-
10021987 
Y 
PM12* Primary MD Right temple 77 IC N N 
 Metastasis  Parotid 78  N N 
PM13* 
Primary M-PD Right knee 54 IC Homo: 8899574-
10057853 
Y 
 
Metastasis  Lymph node (groin) 55  Homo: 8853644-
10013288 
Y 
Table 4.1 continued 
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Patient no 
Primary/metastatic/P
D cSCC 
Differentiation 
status Site 
Age at 
diagnosis 
Immune 
status 
Deletion at PTPRD 
locus LOH 
PM14 Primary PD Pinna right ear 65 IC Homo: 10160958-
10381984 
Y 
 
Recurrence MD Right ear 66  Homo: 10151681-
10389727 
Y 
 
Metastasis MD Parotid 66  High noise ratio for 
signal intensity 
Y 
 
Recurrence MD Right ear 67  Homo: 10147409-
10351438 
Y 
PM15 Primary   Left lower eyelid   IC      
 Metastasis MD Parotid 74  N Y 
 Metastasis MD Phrenic nerve 74  N BAF uncertain 
 
Recurrence /skin 
metastasis 
MD Left neck 75  N BAF uncertain 
 
Recurrence/skin 
metastasis 
MD Left neck 75  N BAF uncertain 
PM16 Primary W-MD Left lip 64  IC     
 Recurrence MD  64  N Y 
 Metastasis MD Lymph node 64  N BAF uncertain 
PM17* Primary WD Left outer canthus eye 91 IC N N 
 Metastasis PD Parotid 92  Homo: 9290973-9735530 Y 
PM18* Primary MD Right lower back 74 PUVA N Y 
 Metastasis MD Left axilla 74  N Y 
PM19* Skin metastasis PD Vertex scalp 63 RTR N N 
 Skin metastasis MD Vertex scalp 63  N N 
P1* Primary SCC MD Right temple 71 RTR N N 
 Recurrence? MD Right temple 71  N N 
P2* Recurrence PD spindle cell Scalp 60 RTR N BAF uncertain 
 Primary PD Left ear 58  Homo: 9092409-9884322 Y 
Table 4.1 continued 
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Patient no 
Primary/metastatic/P
D cSCC 
Differentiation 
status Site 
Age at 
diagnosis 
Immune 
status 
Deletion at PTPRD 
locus LOH 
P3* Primary PD Right cheek 86 IC Het: 9044621-9206908 
Het: 10113193-10344770 
N 
P4* Primary PD Left temple 64 RTR N N 
P5* Primary PD Vertex scalp 54 RTR N BAF uncertain 
P6* Primary PD Nose 63 RTR N Y 
P7* Primary PD Right cheek 76 IC N N 
P8* Primary PD Left pinna 70 IC N N 
P9 Primary PD Right thumb 64 RTR Het: 9589450-9771039 N 
P10 Primary PD Left pinna 80 IC N Y 
P11 Primary PD Right ear 81 IC N Y 
P12* Primary MD Right buttock 51 IC N BAF uncertain 
 
Primary (SCC26) PD Right buttock 51  Homo: 9135908-
10093302 
Y 
 
* Indicates patients for whom blood DNA was available for comparison of normal copy number.  Grey shading indicates tumours in the primary-metastatic series that were 
not available for analysis.  Yellow shading indicates aggressive tumours unconnected to the primary-metastatic series that were also analysed for deletion.  For patient codes, 
PM = primary-metastatic to indicate those patients with metastatic cSCC, whilst P indicates primary (no metastasis).  SCC ID in brackets are those assigned in Purdie et al. 
(2009).  RTR = renal transplant recipient and indicates patients on immunosuppression; PUVA = treatment with psoralen and UVA for psoriasis which results in 
immunosuppression; IC = immunocompetent, N = no, Y = yes. 
 
 
Table 4.1 continued 
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 Primary cSCC that 
metastasised  
Primary cSCC that did not 
metastasise  
Deletion of PTPRD 8 9 
No deletion of PTPRD 12 67 
P = 0.007 
 
 PD primary cSCC WD and MD primary 
cSCC 
Deletion of PTPRD 11 6 
No deletion of PTPRD 24 55 
P = 0.01 
 
 Metastatic or PD primary 
cSCC 
WD and MD primary 
cSCC with no metastatic 
potential 
Deletion of PTPRD 14 3 
No deletion of PTPRD 24 55 
P = 0.0002 
 
 
Table 4.2   Contingency Tables for Fishers Exact statistical analysis. 
 
 
 
 
 
 
 
 185 
significantly associated with the more aggressive tumours.  To exclude the 
possibility that patient effect may be skewing the data for the 13 patients from 
whom multiple tumours were analysed, the test was repeated with these patients 
excluded.  There was still a significant association between deletion and 
metastasis (p = 0.002), but the association with poorly differentiated cSCC 
dropped to below significance (p = 0.06).  This is unsurprising, given that 11 of 
the 13 patients with multiple tumours had PD cSCC and therefore the power of 
this sample group was reduced. 
 
4.2.4 Metastatic cSCC display clonal deletions in PTPRD 
In 6/8 cases of patients with metastatic disease and deletion of PTPRD, the 
deletion was identical throughout the individual tumour series, occurring in the 
primary tumour and subsequent recurrent and metastatic tumours, indicating a 
clonal origin of the metastases from the original primary tumour.  In the 
remaining 2 primary-metastatic series, deletion of PTPRD was detected in the 
metastatic tumours only and not the corresponding primary tumour (an example 
of which is shown in Figure 4.9).  Whilst these tumour series could point to the 
continued disruption of PTPRD during the metastatic process, it is also possible 
the primary tumour that was analysed was not the actual primary tumour that 
went on to metastasise.  It is not always possible to clinically determine which 
primary tumour has gone on to metastasise, particularly in high-risk patients who 
have multiple tumours in the same area.  
 
4.2.5 PTPRD deletions frequently target the 5’ UTR 
As previously discussed, PTPRD deletions have been reported in a wide range of 
different cancers.  Figure 4.10 shows the location of deletions from the primary-
metastatic cSCC series reported here, as well as those cited in the literature from 
5 studies on lung cancer, neuroblastoma, melanoma and cSCC (Zhao et al., 2005, 
Sato et al., 2005, Stallings et al., 2006, Stark and Hayward, 2007, Purdie et al., 
2009).  In total, 15% (6/39) of deletions extend into the protein coding region, 
with the remaining located exclusively in the 5‟ UTR.  Furthermore, 69% (27/39) 
of the deletions include exon B7 of the 5‟ UTR, suggesting this exon is a 
common target for deletion. 
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Figure 4.9   Primary and metastatic tumours from PM17, showing the presence of a 
novel deletion in the metastatic tumour.  A) primary tumour from PM17, B) metastatic tumour 
presumed to derive from the primary tumour in (A), showing a novel deletion of PTPRD that was 
not present in the primary tumour analysed.  The deleted region is indicated by dotted lines.  
A) 
B) 
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Figure 4.10   Map of deletions of PTPRD in multiple cancer types.  The two main 5‟ UTR isoforms – S and L – are shown in the upper part of the 
diagram, in a 3‟ to 5‟ orientation.  Each coloured line beneath the isoform structure belongs to a different tumour and shows the location of its PTPRD deletion, 
categorised by colour into tumour type.  The boxed exon indicates the most commonly deleted region, encompassing exon B7. 
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4.2.6 PTPRD is frequently mutated in cSCC 
To investigate if PTPRD is mutated in cSCC, primer sets were designed for all 
35 coding exons and used to amplify and sequence DNA from 7 short-term 
passage cSCC cultures and 12 fresh frozen (FF) microdissected cSCC tissue 
samples (see Appendix F for primer sequences and PCR conditions).  This 
included 4 tumour samples from the primary-metastatic series of tumours 
(Appendix H).  Due to the size of PTPRD and limitations of FFPE DNA with 
PCR, it was not possible to use the primary-metastatic series of FFPE tumours 
for this analysis.  DNA from short term cultures was used directly in PCR, 
whereas DNA from the FF cSCC were subject to whole genome amplification 
using RepliG (Qiagen, UK), to generate enough DNA for sequencing the whole 
gene (see chapter 2.3.2).  Any mutations were confirmed in both the forward and 
reverse direction of two independent PCR products, of which, the second product 
from the FF tumour samples was from DNA that had not been subject to whole 
genome amplification prior to use in PCR.  Of the 19 tumour samples, 18 had no 
deletion of PTPRD as detected by SNP microarray analysis, whilst the remaining 
one sample (PM1) had a heterozygous deletion that extended into the first three 
coding exons, thereby deleting the start site for translation.   
 
In total, 37% (7/19) of tumours had a novel coding region mutation, all of which 
were found to be somatic upon sequencing matched blood DNA (Figure 4.11, 
Appendix H).  This is the highest mutation frequency reported for PTPRD, with 
other cancers showing mutation rates of between 6-13% of tumours (Veeriah et 
al., 2009).  The majority of mutations (7/10) were missense changes spread 
throughout the PTPRD protein, including one in the first phosphatase subunit of 
the catalytic domain, which is considered the active phosphatase subunit.  One 
further change was a nonsense mutation – W775X – predicted to truncate the 
protein in a fibronectin subunit upstream of the catalytic domain of the protein.  
The remaining two changes included one synonymous mutation and a mutation 
in part of the 3‟ UTR.  W775X appeared to be present in a small population of 
cells rather than the whole tumour, as evidenced by a smaller peak for the mutant 
allele in the sequencing electropherograms (Figure 4.12).  Because of this, the 
mutation was confirmed using two different primer sets (Appendix F).  Of the 10 
mutations, only two were predicted to be deleterious to the protein function by
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mutation modelling programmes PolyPhen and SIFT.  These were W775X and 
T931I from a MD cSCC (SCC 10) and a metastatic cSCC (PM6) respectively 
(Figure 4.12).   
 
Of the 7 tumours that showed a mutation in PTPRD, 4 were from PD cSCC or 
primary tumours that had metastasised, which is consistent with the association 
observed between deletions at the locus and the more aggressive tumours.  The 
remaining were WD (2/7) or MD (1/7) cSCC that had not metastasised.  
Furthermore, the mutations in 4 of these 7 tumours revealed potential biallelic 
disruption of PTPRD, including PM1 and PM6, which had a heterozygous 
deletion coupled with a mutation and two missense mutations respectively.  The 
remaining two samples were SCC10 (MD cSCC) and SCC33 (WD cSCC) both 
of which have LOH across the locus as well as missense mutations and in the 
case of SCC 10, also a nonsense mutation. 
 
4.2.7 Promoter methylation is not a common mechanism of inactivation of 
PTPRD in cSCC  
As discussed in the background to this chapter, PTPRD has two 5‟ UTR isoforms 
called the S (short) and L (long) isoforms.  The transcription start site for each 
isoform are separated by approximately 1.5 Mb, suggesting they are associated 
with different promoter regions.  The L isoform has a canonical CpG island of 
698 bp (designated CpG59) at the promoter region and has been analysed for the 
presence of methylation in breast tumours, colorectal tumours and glioblastoma 
multiforme (GBM) (Chan et al., 2008, Veeriah et al., 2009).  There is a predicted 
promoter region approximately 160 kb downstream of the first exon of the S 
isoform for which expressed sequence tag (EST) evidence suggests PTPRD 
transcripts are generated by this promoter.  It is associated with the presence of 
an 1,223 bp CpG island (designated CpG87) and has not been previously 
analysed for methylation.  In the absence of a CpG island at the start site of the S 
isoform, both islands were investigated for methylation to identify if this 
represents another mechanism by which PTPRD is disrupted in cSCC.   
 1
9
0
 
 
Figure 4.11 Map of somatic cancer mutations reported to date in PTPRD.  Every mutation reported is unique. 
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Figure 4.12 Sequencing electropherograms showing mutation of PTPRD in cSCC.  A) 
W775stop from SCC 10, showing corresponding blood DNA in the top panel and sequencing of 
tumour DNA by two different primer sets in the lower two panels and B) T931I from PM6 
showing corresponding blood DNA in the top panel and tumour DNA in the lower panel.  
Mutation sites are marked by arrows.  In the case of all three tumour electropherograms, there is a 
mix of wildtype (WT) and mutant alleles at the mutation site, which is consistent with a decrease 
in peak height of the WT allele compared to the blood DNA. 
 
 
 
A) B) 
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MSP and bisulphite sequencing were optimised for each promoter region.  Both 
techniques require the bisulphite modification of template DNA, which 
deaminates any unmethylated cytosines to convert them into uracil, whilst those 
with an attached methyl group are protected.  Bisulphite modification results in 
DNA degradation and therefore requires starting DNA of high quality.  FFPE 
DNA can be used, however 1 μg or more is required to compensate for the 
degradation and this was not available for the FFPE primary-metastatic samples.  
For this reason, methylation was investigated in FF cSCC samples rather than the 
FFPE primary-metastatic series.  MSP relies on two distinct primer sets that will 
distinguish between methylated and unmethylated DNA respectively, by utilising 
multiple CpG sites towards the 3‟ end of the primers.  Conversely, bisulphite 
sequencing uses a primer pair that will amplify methylated and unmethylated 
DNA equally, followed by pyrosequencing of the amplicon to quantitatively 
analyse the incorporation of either cytosine (for methylated sites) or thymine (for 
unmethylated sites) at CpG dinucleotides.   
 
4.2.7.1 Methylation specific PCR can generate false positive results   
MSP primer sets for methylated and unmethylated DNA were designed to 
amplify part of each CpG island using MethPrimer software.  PCRs were 
optimised on commercially available methylated DNA (which is chemically 
modified so all CpG dinucleotides have a methyl group attached) and blood 
DNA, which is typically unmethylated.  Specificity of the MSP reaction is 
crucial for its ability to distinguish between methylated and unmethylated DNA 
and extensive PCR optimisation was therefore required.  This included the design 
of multiple primer sets, optimisation of PCR cycling conditions and PCR 
reagents (Figure 4.13). 
 
When primer sets for both the L and S CpG islands were shown to specifically 
amplify methylated and unmethylated controls as appropriate, bisulphite 
modification and PCR amplification of 24 microdissected FF cSCC was 
performed.  This included 14 WD cSCC, 8 MD cSCC and 2 PD cSCC (Table 
4.3).  MSP analysis of the CpG59 promoter region of the L isoform showed no 
positive bands for the methylated PCR, whilst the unmethylated PCR showed 
strong amplification of all samples (Figure 4.14).  Three cSCC samples had
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Figure 4.13 Optimisation of CpG59 MSP primer sets.  A) CpG59 methylated and 
unmethylated primer sets with a 55 
o
C annealing temperature and standard HotStart Taq, B) 
CpG59 primers sets with a 60 
o
C annealing temperature and standard HotStart Taq and C) CpG59 
primer sets using EpiTect Bisulphite PCR master mix at 60 
o
C.  M = methylated DNA and U = 
unmethylated DNA.  In panel A, there is a high level of non-specific amplification, evidenced by 
the presence of multiple bands in the unmethylated DNA with the methylated primer set and vice 
versa.  In panel B, there is non-specific amplification of the methylated primer set only, as seen 
by a band in the unmethylated DNA, whilst in panel C there is specific amplification of both 
primer sets. 
 
 
 
 
C) 
Methylated PCR    Unmethylated PCR 
  M       U        -         M       U       - 
Methylated PCR  Unmethylated PCR 
  M       U       -        M       U      - 
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positive bands with the methylated primer set for CpG87 (cSCC 14, 17 and 22, 
Figure 4.15).  However the unmethylated primer set for this CpG island showed 
weak amplification in some samples and no concurrent amplification with the 
methylated primer set (which would indicate a methylated sample) (Figure 4.15).  
Subsequent direct sequencing using three primer sets throughout the CpG87 
promoter region could not confirm the positive MSP results in these 3 cSCC, 
indicating the MSPs were not working reliably with tumour DNA samples. 
 
4.2.7.2 Bisulphite sequencing reveals methylation is not common in cSCC. 
Bisulphite sequencing is a more robust technique for investigating methylation 
than MSP as it directly quantifies the level of cytosine/thymine at each CpG 
dinucleotide in the PCR amplicon.  To confirm the MSP results, a primer set was 
designed for each island using Biotage primer design software (Biotage, 
Sweden).  The L isoform primer set amplified a fragment of the CpG island 
between -872 and -727 bp, relative to the transcription start site, which included 
part of the amplicon that showed positive methylation in breast and colorectal 
cancer in the publication by Chan et al. (2008).  The primer set for CpG87 
amplified the genomic region 8848098-8847923.  The 24 FF cSCC were 
analysed along with bisulphite modified DNA extracted from 8 normal skin 
biopsies, 12 short-term passage cSCC cultured cells and 3 cell lines (Table 4.3).  
These included 16 WD cSCC, 12 MD cSCC and 6 PD cSCC.   For both primer 
sets, the HeLa cell line was the only sample to show hemi-methylation at both 
CpG islands, all other cell lines and tissue samples were negative for methylation 
(Figure 4.16).  This result was confirmed by a second bisulphite modification of 
all the cell line DNAs and a repeat of the bisulphite sequencing.  This indicates 
neither promoter region is commonly methylated in cSCC tissue samples, normal 
skin or cultured cSCC cells. 
 
4.2.8 PTPRD is expressed at a lower level in MD and PD cSCC 
To investigate the expression level of PTPRD in tumours, relative quantitation to 
normal skin was performed using real-time PCR (qRT-PCR).  Briefly, a Taqman 
primer and probe set mapping to the 3‟ end of the transcript was used to measure 
PTPRD levels in normal skin and cSCC, along with a separate Taqman assay for 
a housekeeping gene (the choice of housekeeping gene is discussed in further
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SCC ID
†
 
 
Differentiation 
status 
PTPRD deletion LOH at 
locus 
Mutation Methylation 
SCC1* PD N N N N 
SCC2* WD N Y N N 
SCC3* primary MD Y – homozygous Y N/A N 
SCC3* 
metastasis 
Metastatic Y – homozygous Y N/A N 
SCC5* WD N Y N N 
SCC10 MD N Y Y (x3) N 
SCC11 WD N Y N/A N 
SCC12* 
primary 
MD Y – heterozygous N Y (x1) N 
SCC12* 
metastasis 
Metastatic Y – heterozygous N Y (x1) N 
SCC14 MD N Y N/A N 
SCC15 MD N Y N/A N 
SCC 16 MD N Y N N/A 
SCC20* MD N N N N 
SCC24* MD N Y N N 
SCC26* PD Y – homozygous Y N/A N 
SCC28 WD N N Y (x1) N 
SCC29 MD N Y N N 
SCC31 PD N N Y (x1) N 
SCC33 WD N Y Y (x1) N 
SCC35 MD N Y N/A N 
SCC36 WD N Y N/A N 
SCC37 MD N N N N 
SCC39 MD Y – homozygous Y N/A N 
SCC40* M-PD Y – homozygous N N/A N 
SCC46 WD N N N/A N 
SCC47 WD N N N/A N 
SCC48 MD N Y N/A N 
SCC49 WD N N N/A N 
SCC50 WD N Y N/A N 
SCC51 WD N N N/A N 
SCC52 WD Y - heterozygous N N/A N 
SCC53 WD N Y N/A N 
SCC54 WD N Y N N 
SCC55 WD N Y N/A N 
SCC57 M-PD N N N N 
SCC58 WD N N N/A N 
SCC59* PD N N Y (x1) N 
DT-16* 
HPV16 
immortalised normal 
keratinocytes 
N/A N/A N/A N/A N 
LSDM pool* 
Pre-malignant skin 
N/A N   N 
HeLa* N/A N N  Hemi-
methylation of 
CpG59 and 
CpG87 
 
Table 4.3   Details of FF cSCC and cell lines analysed for methylation.  
† 
SCC IDs, 
PTPRD deletion and LOH data are from Purdie et al. (2009).  
*
Indicates cultured cells were used 
for the methylation analysis.  N/A = not analysed.  Deletion, LOH and sequencing results are 
shown for reference. 
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Figure 4.14 Agarose gel showing MSP results for CpG59.  A) methylated primer set and 
b) unmethylated primer set showing strong amplification of all samples.  M = methylated DNA, 
U = unmethylated DNA, PCR neg = PCR control of no template DNA. 
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Figure 4.15 MSP results for CpG87.  A) methylated primer set reveals positive bands in 
SCC 36, 47 and 11 (indicated by *), B) unmethylated primer set shows weak amplification, even 
in the unmethylated control DNA.  M = methylated DNA, U = methylated DNA, PCR neg = no 
DNA PCR control.  C) sequencing electropherogram of part of CpG87 in SCC 17 showing no 
methylation at CpG dinucleotides, contrary to the MSP result.  * CpG associated cytosine, ^ non 
CpG associated cytosine.  From the non-CpG associated cytosines it is clear bisulphite 
modification is complete as there is no residual cytosine at these bases. 
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Figure 4.16   Pyrograms for CpG87.  A) pyrogram for a normal skin sample, b) pyrogram 
for SCC 10 and c) pyrogram for the HeLa cell line showing hemi-methylation.  Each peak in the 
pyrogram is directly proportional to the amount of nucleotide incorporated at that position 
according to the sequence along the x axis.  Incorporated nucleotides are measured in relative 
light units (shown on the Y axis) – nucleotide incorporation releases ATP which is used by 
luciferase to convert its substrate luciferin to oxyluciferin and light.  The shaded sites represent 
CpG dinucleotides.  C = cytosine, the percentages underneath indicate the quantification of 
cytosine incorporation as measured by the pyrosequencer software.   
  
 
A) B) C) 
C    C    C    C       C    
0% 0%  0% 0%     0% 
C     C    C      C     C    
0%  0%  9.5% 0%  0% 
C      C       C     C       C    
71%  82%  77% 48%  82% 
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detail below).  Measurements for qRT-PCR are taken during the exponential 
phase of the PCR, when the number of target DNA molecules doubles with each 
cycle (assuming 100% PCR efficiency) and is directly proportional to the starting 
quantity of target cDNA.  When the fluorescence passes a threshold level 
indicating the PCR is in the exponential phase, the cycle number, known as the 
cycle threshold (Ct), is measured and can be compared between different 
samples.  The expression level of PTPRD in each sample was first normalised to 
the housekeeping gene as an internal control to correct for errors in sample 
quantification (ΔCt = Ct PTPRD – Ct housekeeping gene).  Fold change 
differences in the cSCC were then determined relative to the average level of 
expression across a panel of 6 normal skin samples according to the following 
equation: ΔΔCt = 2ΔCt normal skin -Δct test sample.   
 
Twenty cSCC were laser capture microdissected for RNA extraction, to obtain a 
pure population of tumour cells for expression analysis.  The integrity of all RNA 
samples was assessed prior to qRT-PCR using the Agilent Bioanalyser, which 
uses various parameters to assign an RNA integrity number (RIN) to each 
sample, reflecting the quality of the RNA.  A RIN of 10 indicates intact, good 
quality RNA, whilst a RIN of 1 indicates RNA that is completely degraded.  
Only samples with a RIN of 7 or above were included in the analysis.  In total, 
16 laser capture microdissected cSCC were analysed, including 7 WD tumours, 7 
MD or PD tumours and two lymph node metastases. 
 
The yield of RNA obtained from the LCM tumour samples was low, ranging 
between 49 ng – 320 ng total.  Optimising the quantity of RNA used for cDNA 
synthesis was essential to provide reliable and reproducible data, whilst including 
as many samples as possible.  The quantity of RNA used for cDNA synthesis 
was initially optimised in 3 normal skin samples, with 10, 50 and 100 ng of RNA 
used as the input for cDNA synthesis.  At the lowest input of 10 ng, the cycle 
threshold (Ct) level of PTPRD expression was nearing 35 cycles, which is 
considered a general cut-off for reliable and reproducible data (Figure 4.17a).  
There was an average difference of one cycle between an RNA input of 50 and 
100 ng, so to include as many samples as possible, 50 ng was chosen for the 
input level of RNA.   
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4.2.8.1 HPRT and GUS are good housekeeping genes for expression studies in 
skin 
It was also apparent after testing the various input concentrations that the 
housekeeping gene 18S was detecting transcripts approximately 20 cycles before 
the PTPRD primer set.  The choice of housekeeping gene is critical for qRT-PCR 
as it is used as an internal control to normalise each individual sample and is 
designed to reflect discrepancies in the input of RNA or cDNA synthesis.  Using 
a high-abundance housekeeping gene with a target gene that has a low expression 
can lead to inaccuracies in the normalisation of data due to inadequate sensitivity 
of the housekeeping gene.  The hypoxanthine phosphoribosyltransferase (HPRT) 
and beta-glucuronidase (GUS) which are both medium abundance housekeeping 
genes were tested for their expression levels across a panel of RNA from 4 
normal skin samples and 6 cSCC, from which RNA had been extracted by 
pulverising the biopsy under liquid nitrogen.  Both genes showed a stable 
expression level across the samples that was within 5-10 cycles of the PTPRD 
primer set and showed no difference between the two target populations (normal 
skin and cSCC) (Figure 4.17b).  HPRT was used for all subsequent 
normalisation. 
 
4.2.8.2  PTPRD expression levels are lower in MD and PD cSCC 
The expression level of PTPRD in normal skin was consistent across the panel, 
with an average Ct value of 31.1.  Using the ΔΔCt method, there was an average 
2 fold increase in expression of PTPRD in WD cSCC compared to normal skin 
(excluding the two WD cSCC with a deletion of PTPRD), whereas MD and PD 
showed a 1.9 fold decrease in the levels of expression (Figure 4.18).  Indeed, in 2 
MD cSCC and 2 PD cSCC, the level of PTPRD expression was so low, 
transcripts were undetectable within the limits of the assay (Figure 4.18).  The 
difference in expression between WD cSCC (excluding those with a deletion) 
and MD/PD cSCC to normal skin was statistically significant using a two-tailed 
Mann-Whitney U test at a P-value of 0.05.  Intriguingly, tumours with a deletion 
in the 5‟ UTR region of the gene showed an increase in expression of PTPRD 
when compared to tumours of the same grade without a deletion (Figure 4.18).   
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Figure 4.17 Graphs showing the optimisation of qRT-PCR.  A) level of expression of 3 
genes – PTPRD, HPRT and 18S RNA – dependant on the initial RNA input, shown on the x axis.  
The y axis shows the level of expression as measured by the cycle threshold (Ct) value.  B) levels 
of the housekeeping genes HPRT and GUS are stable in cSCC and normal skin.  Each data point 
is an average of three triplicate measurements with standard error bars shown. 
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Fold change in cSCC compared to normal skin
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Figure 4.18 Fold changes in the expression levels of PTPRD in cSCC when compared 
to normal skin.  Triplicate measurements of PTPRD expression levels were averaged for each 
tumour, normalised to HPRT and fold change differences calculated to the average expression 
level of a panel of 6 normal skin samples.  
†
 Expression levels in these tumours were so low they 
were not reliably detected by the assay.  * Indicates a primary-metastatic pair from the same 
patient.  Hatched bars indicate samples with a deletion of PTPRD.   
† † † † 
* * 
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4.3 DISCUSSION AND SUGGESTIONS FOR FUTURE WORK 
The aim of the work presented in this chapter was to characterise the status of the 
PTPRD gene in cSCC and to investigate the hypothesis that deletion at the locus 
is associated with metastatic disease.  Prior to this work, there was limited 
knowledge on the disruption and expression of PTPRD in skin and cSCC.  
Microdeletions had been identified in 15% (9/60) of cSCC by our group and it 
was observed that the deletions appeared to be more common in aggressive 
tumours (Purdie et al., 2009).  No information on the methylation, mutation or 
expression of PTPRD in skin and corresponding tumours had been established.  
To summarise the findings, the analysis of a series of FFPE primary and 
metastatic tumours revealed a positive association between the frequency of 
PTPRD deletion and metastasis, when compared to non-metastatic tumours 
(p=0.007).  Furthermore, mutation analysis revealed a high proportion of 
tumours without deletion had a mutation in the gene, indicating this may also be 
an important mechanism of disruption in cSCC.  Conversely, methylation was 
not a common mechanism of inactivation in these tumours.  Expression levels of 
PTPRD were highest in WD tumours in comparison to MD and PD tumours, 
which is consistent with the finding that disruption of the gene is significantly 
more common in aggressive tumours. 
 
PTPRD deletion is associated with metastasis in cSCC 
This is the first study to specifically associate deletions at the PTPRD locus with 
metastatic tumours.  Previous studies on neuroblastoma, glioblastoma multiforme 
(GBM) and melanoma have not analysed the frequency of PTPRD aberrations in 
the context of clinical parameters such as metastasis, although one study provides 
anecdotal evidence through the identification of a focal deletion in a metastatic 
tumour that was not present in the corresponding primary neuroblastoma 
(Stallings et al., 2006).  In lung cancer, the study by Sato and colleagues (2005) 
provides information on the histological subgroups of the tumours, but does not 
include information on metastasis.  This showed no difference between the 
frequency of PTPRD deletions in the more aggressive small cell lung carcinomas 
and less aggressive non-small cell lung carcinomas, which had deletion rates of 
8% and 11% respectively.  The findings in cSCC are consistent with a meta-
analysis of expression studies in breast and colorectal cancer, that demonstrated a 
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positive association between the loss of PTPRD expression and poor prognosis, 
including a highly significant association with metastasis (p=0.009 for both 
cancer types) (Chan et al., 2008).  Furthermore, no deletions of PTPRD have 
been reported by SNP microarray analysis of BCCs, which, despite being more 
prevalent than cSCC, rarely metastasise (Teh et al., 2005). 
 
The finding that deletions of PTPRD tend to be clonal in the metastatic tumours 
when compared to their corresponding primary tumour strongly suggests deletion 
of PTPRD occurs in primary cSCC before metastasis.  The deletions are unlikely 
to occur in a premalignant stage of skin cancer, as 250K SNP microarray analysis 
across a sequential series of premalignant lesions from 30 patients found no 
deletions of PTPRD (personal communication, Dr Abha Gulati).  This included 
non-sun exposed normal skin, sun exposed normal skin and AK biopsies.  The 
deletions that were identified in cSCC by the custom Illumina microarray were 
also typically associated with a significant decrease in the signal intensity, which 
suggests they occur in an early or dominant clone of the tumour.  Whether the 
deletions contribute directly to the metastatic process is yet to be determined. 
 
PTPRD deletions target the 5’ UTR 
A current limitation of both this study and other published studies on PTPRD in 
cancer is that the actual effect of the deletions in the 5‟ UTR is not addressed.  
Only 15% of all deletions currently reported in the literature extend into the 
protein coding region, with the remaining 85% of deletions restricted exclusively 
to the 5‟ UTR.  The study by Sato et al. (2005) showed the levels of PTPRD 
expression in cell lines with a homozygous deletion was not significantly 
different to the expression levels of cell lines without a deletion.  This is in 
contrast to the findings presented here, which show a higher level of expression 
in tumour samples with a deletion of PTPRD when compared to tumour samples 
of the same differentiation state without a deletion.  This discrepancy could 
reflect differences between the two tumour types, or, more likely, a difference 
between the expression of PTPRD in culture compared to tissue samples. 
 
For human genes, 5‟ UTRs are typically around 200 bp in length.  They are 
important regulators of protein expression affecting the localisation, efficiency of 
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translation and stability of mRNA.  Features of UTRs that are responsible for 
mediating these effects include secondary structure of the mRNA, upstream 
initiation codons and open reading frames (uORF), internal ribosome entry sites 
(IRES) and protein binding sites.  Longer 5‟ UTRs usually have a higher level of 
secondary structure and uORFs that impede translation by inhibiting binding of 
the ribosome or stalling its scanning across the mRNA.  They are frequently 
reported for proteins that require highly controlled regulation such as growth 
factors, transcription factors, TS and proto-oncogenes (Pesole et al., 2001).  
Between 10-18% of genes express alternative 5‟ UTRs that can result in tissue 
specific expression of a gene, deregulation of gene expression or the expression 
of alternative protein isoforms (Hughes, 2006).  One such example is the TS 
gene BRCA1, which is associated with inactivation in breast cancer by inherited 
mutations or in somatic cases, by LOH and epigenetic inactivation (Esteller et 
al., 2000).  However, Sobczak and Krzyzosiak (2002) identified a transcript of 
BRCA1 in breast cancer tissue that expressed a longer 5‟ UTR to that found in 
normal breast tissue.  The translational efficiency of the longer 5‟ UTR was 10 
times lower than the short 5‟ UTR in vitro, suggesting that even in patients 
without mutation, LOH or epigenetic alteration of BRCA1, the protein level of 
the gene can still be affected.   
 
The long 5‟ UTR of PTPRD has a considerably higher degree of predicted 
secondary structure when compared to the short 5‟ UTR, with an estimated fold 
energy of -250.84 kcal/mol compared to -35.40 kcal/mol respectively (UCSC 
Genome Browser, Vienna RNA package).  The fold energy of a RNA transcript 
is a quantification of the amount of free energy released or used during base 
pairing in secondary structure formation.  A higher degree of secondary structure 
is represented by a more negative value.  Deletions within the long 5‟ UTR 
would be predicted to decrease the complexity of RNA and subsequently 
increase the fold energy of the transcript.  Furthermore, the increase in mRNA 
levels of PTPRD in tumours with a microdeletion suggests deleting some of the 
5‟ UTR exons may stabilise the mRNA, resulting in higher levels of transcript.  
This explanation seems contrary to the role of PTPRD as a TS, as it suggests the 
protein levels of PTPRD may actually be increased in tumours with a deletion.  
This seems unlikely, given the finding that in cSCC and other types of cancer, 
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the expression levels of PTPRD are lowest in tumours of a high histological 
grade, which typically carry an increased propensity for metastasis.  An 
alternative possibility may be that the 5‟ UTR contains a feature such as a protein 
binding site or IRES, which enhances the efficiency of translation.  Deleting the 
motif would therefore result in decreased levels of protein, even though there 
may be an apparent increase in mRNA levels.   
 
Future work to address these questions would include the analysis of the levels of 
PTPRD protein in tumours with and without deletion.  This would identify if the 
deletions have an in vivo effect on the level of protein production.  This work is 
currently hampered by a lack of reliable antibodies and is discussed in further 
detail in chapter 5.  Constructs could also be generated fusing the two 5‟ UTR 
sequences to the coding sequence of the luciferase gene for subsequent 
transfection into mammalian cells.  This would discern differences the two 5‟ 
UTR sequences may have on translational efficiency, as well as presenting an 
opportunity to create tumour specific mutant constructs to examine the effect of 
commonly deleted exons on translation in vitro. 
 
Two further possibilities are that deletions within the 5‟ UTR are not targeting 
the PTPRD gene at all, but are either the result of an inherent susceptibility of the 
region to genomic rearrangements or that other elements within the region are the 
target for deletion in cancers.  The first theory is supported by a study of 
lymphocytes in BRCA2 mutation carriers, which show non-random large-scale 
inversions and duplications in the 9p23-24 region encompassing PTPRD 
(Savelyeva et al., 2001).  However, the large-scale changes reported in the study 
cited above are quite different to the focal somatic deletions detected in cancer 
and are therefore unlikely to arise by the same mechanism.  The second 
suggestion that other elements in the region may be targeted for deletion was 
initially unsupported by bioinformatic analysis using the genome browsers 
UCSC and Ensembl, which revealed no other potential genes or regulatory 
elements within the region.  However, annotation since the recent advances in the 
study of non-coding RNAs (ncRNA) has revealed two potential ncRNAs within 
the region of hotspot deletion.  The first is a ncRNA that forms part of the signal 
recognition particle (SRP) (gene number: ENSG00000222476), which is 
 207 
involved in the co-translational targeting of proteins to the endoplasmic 
reticulum (ER), whilst the second is a novel microRNA (miRNA) (gene number: 
ENSG00000221708) with unknown function.  Both are predicted ncRNAs based 
on algorithms from the RFAM and miRBase databases, which use sequence 
similarities and transcript evidence to identify new ncRNAs.  Whilst it is possible 
these predicted ncRNAs are being targeted for deletion in cancer, the 
identification of multiple mechanisms of PTPRD disruption - including mutation 
and methylation - suggest it is likely the deletions at 9p23-24 are targeting the 
PTPRD gene.  As future work however, it would be interesting to investigate the 
two ncRNAs, by developing RT-PCR based assays for each element to see if 
there is expression of these two RNA molecules in normal skin and cSCC and if 
so, what effect removing them may have in an in vitro system. 
 
PTPRD is frequently mutated in cSCC 
The number of cSCC identified with a mutation was considerably higher at 37% 
than reported for other types of cancer.  Mutation rates from previous studies are 
6% of GBM analysed, 6-11% of lung carcinomas, 0-9% of colorectal 
carcinomas, 13% of head and neck SCC (HNSCC), 12% of melanoma and 0% of 
prostate and thyroid tumours (Veeriah et al., 2009, Solomon et al., 2008, Sjoblom 
et al., 2006, Kohno et al., 2010).  The mutations identified in these studies were 
predominantly missense changes, along with a smaller proportion of truncating 
nonsense mutations, spread throughout the PTPRD protein, which is consistent 
with findings from the cSCC.  Furthermore, all the mutations identified in 
melanomas were C/G>T/A mutations, which is consistent with UV damage 
(Solomon et al., 2008).  This was also seen for the missense and nonsense 
mutations identified in cSCC, suggesting mutation of PTPRD in skin tumours 
may be a result of UV induced DNA damage. 
 
A limitation of this study is that although a high number of missense changes 
were identified, it is unclear what effect these changes may have functionally.  
The majority of the mutations are missense changes in the extracellular domains 
of the protein and only one was predicted to be deleterious by PolyPhen and 
SIFT (although such software programmes are only based on model algorithms 
and are no substitute for the functional assessment of mutations).  Eight missense 
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changes identified from GBM, melanoma and HNSCC have been demonstrated 
to functionally affect the activity of the PTPRD protein in vitro (Solomon et al., 
2008, Veeriah et al., 2009).  These mutations were spread throughout the gene 
and suggest that the tumour derived mutations identified in the cSCC may also 
have functional consequences on the protein.  Given the high number of 
mutations identified in cSCC, it would be interesting for future work to study the 
effect of these different mutations.  This could be done by cloning the mutant 
PTPRD sequence into vectors for transfection into HEK293T cells, which 
express PTPRD at very low levels.  Transfecting the mutant vectors alongside 
WT protein would allow a comparison between the effect of WT and mutant 
proteins on the growth, apoptosis, migration and invasion of the cells.  
 
PTPRD is not frequently methylated in cSCC 
Methylation analysis revealed this was not a common mechanism of inactivation 
of PTPRD in cSCC.  This is in contrast to other cancer types such as colon 
carcinomas, breast cancer and GBM, which have methylation frequencies of 
50%, 20% and 37% respectively at the promoter region of the L isoform of 
PTPRD (Chan et al., 2008, Veeriah et al., 2009).  However, it is also clear that, 
like other TS genes, different mechanisms of disruption may be important in 
different types of cancer.  Colon cancer, for example, has the highest frequency 
of disruption at the locus, with methylation, deletion and mutation reported at 
frequencies of 50%, 0-15% and 0-9% respectively, whereas breast cancer has a 
lower rate of methylation (20%) and no reported mutations or focal deletions.  
Therefore, it is likely that in cSCC, deletion and mutation are the more common 
mechanisms of PTPRD aberration.   
 
It is also possible that methylation may occur in cSCC at CpG dinucleotides 
different to those included in the assays used in this study.  However, this is 
unlikely, as the bisulphite sequencing assays were designed to encompass 
multiple CpG dinucleotides and the L isoform primer set overlaps with the MSP 
primer set from Chan et al. (2008) which has been shown to positively detect 
methylation at this promoter.  The design, optimisation and sequencing of 
multiple primer sets across the entire promoter regions would be the only way to 
definitively rule out methylation at these promoter regions in cSCC.   
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The methylation studies of PTPRD showed bisulphite sequencing was a superior 
technique for investigating methylation in comparison to MSP.  The bisulphite 
sequencing results showed consistent profiles across samples that had been 
bisulphite modified in two separate reactions and produced quantitative analysis 
of multiple CpG dinucleotides.  Conversely, MSP can only analyse one CpG 
dinucleotide and generated false positive results in some samples, suggesting low 
level contamination of samples can contribute to the outcome of data with this 
technique.  This would obviously lead to an overestimation of the number of 
methylated samples, which is undesirable when screening promoter regions for 
methylation.   
 
Expression levels are lowest in MD and PD cSCC 
As mentioned earlier, the lowest levels of expression of PTPRD were seen in 
MD and PD tumours, which is consistent with the expression profile from breast 
and colorectal cancer (Veeriah et al., 2009).  The expression level of PTPRD in 5 
WD cSCC was ~2 fold higher than the expression levels in normal skin.  At a 
genetic level, WD cSCC are significantly associated with fewer genetic 
aberrations than MD and PD tumours, suggesting they are a distinct subgroup of 
cSCC (Purdie et al., 2009).  It is possible the differences in expression levels of 
PTPRD reflect this inherent difference between the two groups of tumours. 
 
The expression of PTPRD was readily detected at consistent levels in all 6 
normal skin biopsies that were tested.  The expression levels in MD and PD 
tumours were considerably lower and the assay did not show the necessary 
degree of sensitivity to accurately quantify the levels of expression in 4 of these 
tumours.  The isolation of greater quantities of RNA from the laser captured 
tumour samples may have improved the performance of the assay, by allowing a 
greater input of RNA into the cDNA synthesis.  Gene specific primers could also 
be used for the cDNA synthesis, as they generally improve the yield of low 
abundance targets, although do also restrict the analysis to one gene only and 
therefore also require higher quantities of starting RNA for appropriate 
housekeeping gene analysis.  It is also necessary to extend the number of 
tumours analysed, to see if the pattern of expression remains consistent across 
the different histological grades. 
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Summary 
This study represents the first comprehensive analysis of PTPRD in cSCC and 
identifies this gene as an important and potentially clinically relevant gene in 
cSCC pathogenesis and progression.  In summary, microdeletions at the PTPRD 
locus were found to be significantly associated with metastatic tumours, there 
was a high UV-signature mutation frequency of PTPRD in cSCC and tumours 
with a poorer differentiation status had lower levels of PTPRD mRNA.  Further 
work is clearly necessary to elucidate the function of PTPRD in skin and tumour 
development and it would be interesting to investigate the association between 
PTPRD and metastasis in other cancer types such as lung, colorectal and brain 
cancers, in which PTPRD is also known to be disrupted.  From the data presented 
in this study, PTPRD could potentially be used as a genetic marker for aggressive 
cSCC that may go on to metastasise, although the analysis of a larger cohort of 
metastatic tumours would clearly be essential to corroborate the association.  
Screening the entire gene for deletions would not be a time and cost effective 
approach in a clinical setting and as the expression data shows a general decrease 
of PTPRD mRNA in MD and PD tumours, an antibody based screening 
technique may be unable to discriminate between tumours with a deletion and 
those of a high histological grade.  Cytogenetic based techniques using a probe 
that targets the hotspot region of deletion would detect ~70% of cases with 
deletion at the locus and may prove the most useful tool for clinical analysis.   
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CHAPTER FIVE: RESULTS THREE 
CHARACTERISATION OF THE PTPRD PROTEIN 
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5.2.2 Expression of PTPRD in culture is different to tissue 
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5.2.5 Titre determination of terminal bleeds by ELISA 
5.2.6 Optimisation of PTPRD anti-sera for immunostaining 
5.2.7 Optimisation of PTPRD anti-sera for western blotting 
5.2.8 Immunohistochemistry of Stat3 and MTSS1 
5.3 DISCUSSION AND SUGGESTIONS FOR FUTURE WORK 
 
 
5.1 BACKGROUND  
As discussed in the previous chapter, PTPRD is a candidate gene in cSCC 
pathogenesis that is frequently disrupted in aggressive and metastatic cSCC.  The 
function of PTPRD is not fully characterised and it has not been investigated in 
skin or skin cancer biology.  A role for PTPRD in tumourigenesis was implicated 
by a siRNA screen of kinases and phosphatases by Mackeigan and colleagues 
(2005), which found PTPRD was associated with cell death.  Downregulation of 
PTPRD in HeLa cells resulted in increased cell survival and protection from 
cisplatin induced apoptosis.  Alternative splicing generates multiple variants of 
the extracellular domain (ECD) of the protein that are expressed in a tissue 
specific pattern (Pulido et al., 1995a).  It is strongly expressed in the brain and to 
a lesser extent in skin, heart, placenta and kidney tissue (chapter 4.2.1, Pulido et 
al., 1995b).  The predominant isoform in brain is a shorter version of the protein 
lacking the 4
th
-7
th
 fibronectin domains, whilst in kidney tissue, the full length 
protein is expressed (Pulido et al., 1995a).  PTPRD belongs to a family of highly 
homologous transmembrane phosphatase receptors.  The two most closely 
related proteins are PTPRS and leukocyte common antigen-related protein 
(LAR), with which PTPRD shares 73% and 71% sequence homology 
respectively (Pulido et al., 1995b).   
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The PTPRD protein has two main domains: the ECD consists of fibronectin and 
immunoglobulin subunits, whilst the catalytic domain contains two phosphatase 
subunits (Figure 5.1).  The protein is synthesised as a full length proprotein and 
is cleaved intracellularly at the membrane, resulting in shedding of the ECD 
(Pulido et al., 1995a).  Shedding of the ECD is a common feature of receptor 
phosphatases (including LAR) and is thought to control the responsiveness of the 
cell to ligand activated signal transduction  (Streuli et al., 1992).  No ligand has 
been identified for PTPRD and its role in signal transduction is unknown.  In the 
developing brain of chick embryos, the ECD of PTPRD has been demonstrated 
to promote neurite outgrowth, as well as homophilic binding between cells in 
vitro, resulting in enhanced cell adhesion (Wang and Bixby, 1999, Gonzalez-
Brito and Bixby, 2006).   
 
Recently, PTPRD has been shown to dephosphorylate the signal transducer and 
activator of transcription 3 (Stat3) protein in vitro (Veeriah et al., 2009).  This 
was supported by the up- or downregulation of phospho-Stat3 (Tyr705, p-Stat3) 
in cells transfected with PTPRD siRNA or WT protein respectively.  
Furthermore, a yeast two-hybrid screen to identify binding partners of the 
metastasis suppressor 1 (MTSS1) protein – also commonly known as the 
missing-in-metastasis (MIM) protein – identified an interaction with PTPRD 
(Woodings et al., 2003).  This was independent of the phosphatase activity of 
PTPRD and resulted in relocalisation of the MTSS1-PTPRD complex to the 
membrane, where MTSS1 facilitated actin bundling (Gonzalez-Quevedo et al., 
2005).  Another interaction demonstrated for the catalytic domain of PTPRD is 
heterophilic binding with PTPRS in vitro, whereby the distal catalytic domain of 
PTPRD bound to and partially inhibited the proximal catalytic domain of PTPRS 
(Wallace et al., 1998).  All of these interactions have only been demonstrated in 
vitro, but suggest PTPRD may reside in a complex network of different 
functions. 
  
Functional studies of PTPRD in vivo have been limited by the availability of 
commercial antibodies, which are either inadequate for the purposes of 
immunostaining and western blotting, or cross-react with the closest family 
member, PTPRS.  Whilst Stat3 and MTSS1 have both been associated with 
 2
1
3
 
 
Figure 5.1   Schematic representation of PTPRD protein isoforms.  Molecular weight of the protein is shown beneath the isoform variant, aa = amino acid.  Amino acids that are 
alternatively spliced are written immediately below each isoform, with the corresponding mRNA exons in bold underneath.  Annotation for the amino acids and mRNA exons is relative to 
isoform 1. 
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tumour development, in vivo data to corroborate their interaction with PTPRD is 
lacking.  Understanding PTPRD at a functional level is pivotal to elucidating its 
role in the development of tumours and its link with metastasis in cSCC.  This 
chapter describes the design of an in-house PTPRD antibody raised through the 
Cancer Research UK (CRUK) antibody facility.  The aim of the work presented 
here was to identify which protein isoform is expressed in skin, to characterise 
the anti-sera from immunised animals and to investigate the MTSS1 and Stat3 
proteins by immunohistochemistry (IHC) of cSCC with and without 
microdeletions of PTPRD. 
 
5.2 RESULTS 
5.2.1 Multiple splice variants of PTPRD are expressed in normal skin and 
cSCC 
To investigate which protein isoform(s) is expressed in skin, cDNA from 6 
normal skin samples, 11 laser capture microdissected (LCM) primary cSCC and 
one metastatic LCM cSCC was amplified using the primer sets listed in Table 5.1 
(see chapter 2.2.6, 2.4.1 and 2.4.2 for methodology).  All primer sets were 
checked for having no homology to the PTPRD pseudogene on chromosome 5 
using NCBI‟s BLAST.  Sequencing of the PCR products generated by primer 
sets cDNA 2 and cDNA 4 revealed the presence of one isoform in all samples 
analysed, which was consistent with isoform 2 (Figure 5.2, Table 5.2).  This is a 
large isoform lacking exons 6, 7 and 9 and is the same isoform that is expressed 
in kidney tissue.  The primer set for cDNA 3 however showed mixed 
amplification across the samples, with multiple aberrantly sized bands in 1/6 
normal skin samples and 6/12 cSCC/metastatic samples (Figure 5.2).  
Sequencing of the band at ~1.5 kb from the normal skin samples revealed the 
presence of two PTPRD transcripts in 5/6 samples, which differed by 27 bp.  
These were consistent with isoforms 1 and 2, which are a full length isoform and 
an isoform lacking exon 16 respectively.  The sixth normal skin sample showed 
isoform 2 only. 
 
Sequencing of the cDNA3 PCR products that were ~1.5 kb in the cSCC revealed 
that 4/12 cSCC/metastatic samples showed a mix of products that were also 
consistent with isoforms 1 and 2.  A further 1/12 tumour samples showed 
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isoform 1 only and 4/12 showed isoform 2 only.  This suggests isoforms 1 and 2 
are the predominant PTPRD isoforms in skin.  The remaining three cSCC failed 
to generate sequence data.  Four of the cSCC had a second PCR product that 
corresponded to ~220 bp, which is consistent with the smaller PTPRD isoforms.  
These bands were gel purified and sequenced.  They were confirmed to encode a 
PTPRD isoform that splices exon 13 to exon 19, resulting in a protein lacking 4 
central fibronectin domains.  There were also multiple bands of aberrant size that 
did not match to known isoforms of PTPRD in 6 of the cSCC and 1 normal skin 
sample.  The aberrant band of ~300 bp in normal skin 2 and SCC6 was shown by 
sequencing to represent a non-specific PCR product.  It is likely the other 
aberrant bands also represent non-specific PCR products or perhaps, unknown 
splice variants.   
 
 
 
 
Primer 
name 
Primer sequence (5’-3’) Exons 
 
Product size (bp) 
Isoform 
1 
Isoform 
2 
Isoform 
3 
Isoform 
4 
Isoform 
5 
Isoform 
6 
cDNA 1_F AGGGTTTCCAAGGAGGACTG B1-  
Ex 2 
728 728 728 728 728 728 
cDNA 1_R TCAACGGGTGTTCGTGTAAA 
cDNA 2_F TTTGCGGGAAGATCAAATTC Ex4-
Ex11 
644 605 626 644 635 614 
cDNA 2_R CAGGAGTTCCTGGAGGTTTG 
cDNA 3_F CATGGAGAGGAGCAACGAAT Ex12-
Ex18 
1457 1430 224 224 224 224 
cDNA 3_R GGAATCTCCCAAGACAGCAA 
cDNA 4_F GATGTATGCAACCAGCCCTTA Ex23-
Ex25 
278 278 278 293 290 278 
cDNA 4_R CCATACCCGGTGTTTGAAAG 
 
Table 5.1 Primer sets and expected product sizes for isoform detection of PTPRD.  
Four primer sets were designed to encompass isoforms 1-5.   B denotes exons that are unique to 
the long 5‟ UTR isoform, whilst common exons shared between the short and long isoforms are 
denoted by Ex. 
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Sample cDNA1 cDNA2 cDNA3 cDNA4 
Normal skin 1 L absent Isoform 2 T1: isoform 1 ?* 
T2: isoform 2 ?* 
Consistent with isoform 2 
Normal skin 2 L present Isoform 2 T1: isoform 1 
T2: isoform 2 
Consistent with isoform 2 
Normal skin 3 L absent Isoform 2 T1: isoform 1 
T2: isoform 2 
Consistent with isoform 2 
Normal skin 4 L absent Isoform 2 T1: isoform 1 
T2: isoform 2 
Consistent with isoform 2 
Normal skin 5 L present Isoform 2 T1: isoform 1 ?* 
T2: isoform 2 ?* 
Consistent with isoform 2 
Normal skin 6 L present Isoform 2 Isoform 2 N/A 
cSCC 1 (WD) L present Isoform 2 Isoform 2* Consistent with isoform 2 
cSCC 2 (WD) L present Isoform 2 Isoform 2* Consistent with isoform 2 
cSCC 3 (PD) L absent Isoform 2 Isoform 1 Consistent with isoform 2 
cSCC 4 (MD) L present Isoform 2 T1: isoform 1 
T2: isoform 2 
Consistent with isoform 2 
cSCC 5 (WD) L absent Isoform 2 T1: isoform 2 
T2: isoform 3*  
 
cSCC 6 (MD) L present Isoform 2 No PTPRD transcript 
detected 
Consistent with isoform 2 
cSCC 7 (WD) L present Isoform 2 T1: undetermined 
T2: Isoform 3 
T3: isoform 3* 
 
cSCC 8 (MD) L present Isoform 2 T1: undetermined 
T2: Isoform 3* 
Consistent with isoform 2 
cSCC 9 (MD) L present* N/A T1: isoform 1 ?* 
T2: isoform 2 ?* 
Consistent with isoform 2 
cSCC 9_met L present* N/A T1: isoform 1 ?* 
T2: isoform 2 ?* 
Consistent with isoform 2 
cSCC 10 (WD) L present Isoform 2 Isoform 2* N/A 
cSCC 11 (PD) L present Isoform 2 T1: isoform 1* 
T2: isoform 2* 
T3: isoform 3 
Consistent with isoform 2 
 
Table 5.2 Summary of PTPRD isoform sequencing in normal skin and cSCC.  * 
Indicates transcripts with an extra CAG, ?* indicates the presence of two transcripts, one of 
which contained an extra CAG, but it was not possible from the sequencing to identify which 
transcript it belonged to.  L = long isoform and indicates exons corresponding to the longer 5‟ 
UTR.  T1, T2 and T3 indicate transcript 1, 2 and 3 and denotes the presence of multiple 
transcripts from the same sample.  Undetermined = no sequence data generated.              
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Figure 5.2   Agarose gels showing RT-PCR of PTPRD isoforms in normal skin and cSCC.  
The primer set used is indicated in bold above each gel picture, with appropriate band sizes indicated.  
Beta-actin was used to verify cDNA synthesis, whilst no RT-control indicates duplicate control cDNA 
synthesis reactions that were carried out without the addition of RT.  The PCR for cDNA 1 and cDNA 
2 was not performed in the primary and metastatic cSCC pair because a known deletion in these 
samples encompassed the forward or reverse primer.  Products highlighted in white were gel purified 
and sequenced, whilst those in red were sequenced and found to be non-specific products.  Products 
that are not circled were sequenced directly without prior gel purification. 
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Transcripts from 2/6 normal skin and 9/12 cSCC/metastatic tumours had an extra 
CAG spliced in frame at the front of exon 19 (Table 5.2).  This corresponds to 
the genomic sequence immediately prior to exon 19 and suggests a third 
alternative splicing event may occur in this region.  The 3 bp insertion would 
incorporate an extra alanine into the protein sequence, Q1018insA (annotation is 
described for isoform 1, the longest PTPRD transcript).  This variant has not 
been previously reported by Ensembl or NCBI resources.  Amplification using 
primer set cDNA1 that amplifies exons specific to the long 5‟ UTR of PTPRD 
detected L isoform exons (denoted B exons) in 3/6 normal skin samples and 8/10 
cSCC.  Sequencing of clean bands confirmed the products were PTPRD 
transcripts, however there were again multiple bands of aberrant size in some 
samples.  These could represent splicing variations of the B exons in the 5‟ UTR, 
or non-specific products.  There was no apparent correlation between the 
expression of L isoform exons and the protein variant encoded. 
 
5.2.2 Expression of PTPRD in culture is different to tissue 
To identify an appropriate cell line for the optimisation of antibodies and for 
subsequent functional studies such as siRNA or lentiviral knockdown of PTPRD, 
a variety of cell lines were screened by RT-PCR to assess their expression of 
PTPRD.  A total of 57 primary cultures and cell lines were screened, including 
10 cultures of primary normal or premalignant keratinocytes, 10 cSCC short-
term passage cells or cell lines, 32 melanoma cell lines and 4 other lines not 
derived from skin, including the HeLa cell line and human embryonic kidney 
(Hek) 293T cell line (Table 5.3).  All cultures were grown to 70% confluency 
prior to collection into RLT lysis buffer (Qiagen).  RNA was extracted using the 
Qiagen RNeasy Mini Kit and 1 μg of extracted RNA was used as a template for 
cDNA synthesis (see chapter 2.2.8 and 2.4.1 for full methodology).  cDNA from 
the 32 melanoma cell lines was kindly provided by Dr Rubeta Matin and had 
been prepared to the same protocol.  RT-PCR was performed using the primer set 
published by Sato and colleagues (2005) that had been used in the previous 
chapter to screen RNA extracted from normal skin and cSCC FF biopsies 
(section 4.2.1).  This primer set amplifies exons 2-5 and detects all known 
isoforms of PTPRD. 
 219 
The screening results for each culture are shown in Table 5.3.  The 10 primary 
keratinocyte and premalignant skin cultures were found to express PTPRD at 
either very low or undectable levels.  Similarly, PTPRD expression was absent or 
at low levels in 8/10 cSCC cell lines (Figure 5.3).  Two of the cSCC cell lines 
showed a stronger level of expression.  These were SCC26 and SCC40, both of 
which have a homozygous deletion within the 5‟ UTR of PTPRD, as determined 
by SNP microarray analysis (Purdie et al., 2009).  Four other cell lines that had 
similar deletions within the 5‟ UTR did not show higher levels of expression, 
suggesting there is no link between deletion at the locus and expression of 
PTPRD in culture.  The melanoma cell lines showed a varied pattern of 
expression, with 5/14 primary melanoma lines and 6/18 metastatic lines positive 
for expression.  Five of these showed strong levels of expression (Figure 5.3).  
Of the 4 non-skin cell lines that were tested for expression, all were negative 
except for the Hek 293T cells which showed low level expression.   
 
Although the cell line data presented here is non-quantitative, the expression of 
PTPRD in normal, premalignant and cSCC skin cultures appeared to be quite 
different to FF skin biopsies (see chapter 4.2.1 and 4.2.8).  PTPRD expression in 
culture was predominantly low or absent, whereas all FF biopsies showed 
detectable levels of PTPRD (albeit at low levels in most MD and PD cSCC).  
Furthermore, the culture of PM1 (SCC 12) and its corresponding metastatic cell 
line did not show expression of PTPRD in culture, whereas RT-PCR analysis of 
FF biopsies from the same primary and metastatic tumours did show expression 
of PTPRD using the same primer set and PCR conditions (chapter 4.2.1).  The 
expression of PTPRD in culture did not appear to be linked to any known 
histological or technical attributes, including disease stage (normal, premalignant 
or tumour), tumour differentiation status, media in which the cells were grown or 
passage number.  Taken together, these data suggest PTPRD is differentially 
regulated in culture in comparison to an in vivo setting.     
 
 
 220 
Table 5.3 Summary of PTPRD expression screen in cultured cells.   
 
Cell line Source of cell line Passage 
number 
Media Expression of 
PTPRD 
Genetic 
status 
PK_1 Primary keratinocytes 2 DMEM/F12 / N/A 
PK_2 Primary keratinocytes 4 DMEM/F12 / N/A 
PK_3 Primary keratinocytes 3 DMEM/F12 + N/A 
F6-16 Normal keratinocytes, 
immortalised by HPV16 
10 DMEM/F12 / N/A 
DT-16 Normal keratinocytes, 
immortalised by HPV16 
35 DMEM/F12 / N/A 
LSDM 2 Premalignant skin 15 DMEM/F12 + LOH 
LSDM 3 Premalignant skin 20 DMEM/F12 + N/A 
LH3-1 Premalignant skin 18 DMEM/F12 / N/A 
LH3-3 Premalignant skin 15 DMEM/F12 / N/A 
LSDM pool Premalignant skin 5 DMEM/F12 + N/A 
T2 (SCC 2) Short-term passage cSCC 14 DMEM/F12 + WT 
T1  (SCC 5) Short-term passage cSCC 21 DMEM/F12 + WT 
SCC 20 Short-term passage cSCC 12 DMEM/F12 / WT 
SCC 26 Short-term passage cSCC 14 DMEM/F12 ++ HD 
SCC40 Short-term passage cSCC 4 DMEM/F12 +++ HD 
SCC 1 (3-1-b) cSCC cell line 23 DMEM/F12 / WT 
PM1 (SCC 12) cSCC cell line 12 DMEM/F12 / Het 
PM1_met 
(SCC 12_ met) 
cSCC cell line 26 DMEM/F12 / Het 
SCC 3 (Met 1) cSCC cell line 21 DMEM/F12 + HD 
SCC 3_met 
(Met 4) 
cSCC cell line 31 DMEM/F12 + HD 
5810P Primary melanoma 15 RPMI / N/A 
1402P Primary melanoma 11 RPMI / N/A 
10538P Primary melanoma 5 RPMI / N/A 
ME10538 Primary melanoma 5 RPMI + N/A 
WM35 Primary melanoma 12 RPMI / N/A 
WM1575 Primary melanoma 6 TU 2% (80% MCDB 153, 
20% Leibovitz‟s L15, 2% 
FCS, 5µg/ml insulin,  1.68mM 
CaCl2).  No glutamine 
/ N/A 
WM1552C Primary melanoma 4 TU 2%, no FCS or 
glutamine 
+++ N/A 
SBCL2 Primary melanoma 65 RPMI / N/A 
WM793 Primary melanoma 9 RPMI ++ N/A 
WM115 Primary melanoma 11 RPMI / N/A 
WM278 Primary melanoma 7 RPMI ++ LOH 
VMM39 Primary melanoma 21 DMEM ++ HD 
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Cell line Source of cell line Passage 
number 
Media Expression of 
PTPRD 
Genetic 
status 
MEL 224 Primary melanoma 6 RPMI,  0.5% non-essential 
amino acids 
/ N/A 
MEL505 Primary melanoma 6 RPMI, 0.5% non-essential 
amino acids 
/ N/A 
26258M Metastatic melanoma 18 RPMI / N/A 
3988M Metastatic melanoma 15 RPMI / N/A 
21768M Metastatic melanoma 16 RPMI / N/A 
MEL501 Metastatic melanoma 14 HAMS-F10 + N/A 
SK-MEL5 Metastatic melanoma 5 MEM / N/A 
DX3 Metastatic melanoma 11 RPMI / N/A 
LT51 Metastatic melanoma 12 RPMI / N/A 
WM1158 Metastatic melanoma 13 RPMI + WT 
WM9 Metastatic melanoma 9 RPMI + N/A 
WM852 Metastatic melanoma 12 RPMI ++ N/A 
WM983B Metastatic melanoma 12 RPMI / N/A 
A375M Metastatic melanoma 12 RPMI / N/A 
A375P Metastatic melanoma 10 RPMI / N/A 
C81-61 Metastatic melanoma 32 RPMI,  20mM Hepes, 
0.1% gentamicin sulphate 
/ N/A 
C8161 Metastatic melanoma 28 RPMI,  20mM Hepes, 
0.1% gentamicin sulphate 
/ N/A 
SK-MEL-24 Metastatic melanoma 5 MEM + N/A 
WM239A Metastatic melanoma 18 RPMI +++ LOH 
MM-AN Metastatic melanoma 32 DMEM / N/A 
HeLa Cervical carcinoma 
epithelia 
N/A DMEM  / LOH 
H357 Oral SCC N/A DMEM/F12 / LOH 
SW620 Colorectal carcinoma N/A DMEM  / LOH 
Hek293 T Human embryonic kidney 
cells 
N/A DMEM + N/A 
 
+ = weak PTPRD expression, ++ = moderate expression and +++ = strong expression, as 
observed by RT-PCR.  LOH and deletion data for the SCC cell lines are from Purdie et al. 
(2009).  N/A = non-applicable and is used to indicate situations where information is unknown.  
All culture media contained 10% FCS and 1% L-glutamine unless otherwise stated. 
 
Table 5.3 continued 
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Figure 5.3   RT-PCR screen of PTPRD expression in cell lines.  RT-PCR of A) 10 cSCC 
cell lines and 1 premalignant cell line, B) Beta-actin for the same samples as (A) and C) 
melanoma cell lines, the top panel shows metastatic lines, whilst the lower panel represents 
primary melanoma lines.  * PM1_pri and PM1_met have a heterozygous deletion that includes 
the location of the forward primer - these tumours were also analysed by a second primer set 
outside of the deleted region, which was negative for expression.  RT = reverse transcriptase and 
is used to indicate negative control reactions.  PCR neg = negative control reaction in which 
water was substituted for template DNA.  The positive control in the melanoma screen is cDNA 
from SCC 40. 
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To optimise the antibodies and for future functional work, a cell line that strongly 
expressed PTPRD and was genetically wildtype (WT) was ideally required.  The 
2 cSCC cell lines that showed the highest level of PTPRD expression both had 
microdeletions in the 5‟ UTR.  As discussed in the previous chapter, the effect of 
these microdeletions is unknown, but as they could potentially affect mRNA 
stability,  localisation or translation, these samples were considered inappropriate 
for initial antibody optimisation and functional studies.  Of the remaining cSCC 
cell lines that were positive for PTPRD expression, SCC 2 and SCC 5 were the 
only two lines that had no deletions or coding sequence mutations within PTPRD  
(Purdie et al., 2007, chapter 4.2.6).  Both cell lines had LOH of 9p, although as 
this is one of the most common genetic aberrations in cSCC, this was considered 
unavoidable.  Both of these lines showed relatively low expression levels of 
PTPRD, so a selection of melanoma cell lines that showed stronger expression 
were screened for microdeletions within PTPRD using the Affymetrix 250K SNP 
microarrays.  Four cell lines were analysed: WM278, VMM39, WM239a and 
WM1158.  The SNP microarray analysis detected LOH across 9p in WM278, 
VMM39 and WM239a and revealed a homozygous microdeletion within the 5‟ 
UTR of PTPRD in VMM39 (Figure 5.4).  WM1158 had a normal copy number 
across 9p.  WM239a and WM1158, were selected for antibody optimisation.  
Both had been successfully characterised for transfection, which would be a 
useful attribute for future functional studies (personal communication, Dr R. 
Matin).  
 
5.2.3 Commercial PTPRD antibodies 
There are 4 commercial PTPRD antibodies currently available, which recognise 
all known isoforms of PTPRD (listed in Table 5.4).  The C-20 antibody from 
Santa Cruz has been published for use in immunohistochemistry (IHC) (Wu et 
al., 2006), but is raised against an epitope that shows a high level of homology to 
PTPRS and detects both proteins.  As the two proteins have a similar size (215 
kDa for full length PTPRD and 217 kDa for PTPRS) and proposed localisation, it 
is not possible to distinguish between them in either western blotting (WB) or 
immunostaining.  To investigate if PTPRS was also expressed in skin, a primer 
set designed to a region of PTPRS that showed no homology to PTPRD or other 
close family members was used for RT-PCR.  This showed strong expression of 
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Figure 5.4 Copy number data of chromosome 9p for 4 melanoma cell lines that 
showed moderate or strong expression of PTPRD.  A) shows the log ratio of signal intensity, 
whilst b) indicates the individual SNP calls.  In panel A, each dot represents an individual SNP.   
SNPs that fall along the central axis indicate a copy number of 2, whilst SNPs that deviate below 
the central axis (most clearly seen for the cell line WM239a) indicate LOH.  In panel B, the upper 
blue lines for each samples indicate BB homozygous SNPs, the lower blue lines indicate AA 
homozygous SNPs and red lines indicate AB heterozygous SNPs.  The PTPRD locus is between 
the two dotted lines.  VMM39 and WM239a both show loss of heterozygous SNPs in the lower 
panel, with a concomitant reduction in the signal intensity in the upper panel, indicating LOH.  
WM278 shows loss the AB fraction of SNPs but no reduction in signal intensity, indicating LOH 
as a result of UPD. 
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PTPRS in a sample of normal skin and a cSCC, rendering the C-20 antibody 
from Santa Cruz unsuitable for the analysis of PTPRD in skin.  Of the remaining 
3 antibodies, the K20 antibody from Santa Cruz and the antibody from Orbigen 
were tested by immunofluorescence of normal skin and WB analysis of cell line 
lysates.  The C-18 antibody from Santa Cruz was not tested, as it maps to the 
same region of the protein as the Orbigen antibody and may have been raised 
against the same epitope. 
 
 
 
 
 
Name and 
manufacturer 
Epitope Protein domain Comments 
K-20: sc-10868  
Santa Cruz 
Within αα 1100-1150 
 
Between Fibronectin type 
III_8 and transmembrane 
domains 
Goat polyclonal.    
C-18: sc-10867 
Santa Cruz 
Within αα 1275-
1325  
Transmembrane domain. Goat polyclonal. 
C-20: sc-1118 
Santa Cruz 
Within αα 1875-1912 Phosphatase catalytic 
domain, D1 
90% sequence 
homology to PTPRS.  
Goat polyclonal. 
Orbigen αα  1302 – 1316: 
SSIPNNKEIPSHHPT 
Transmembrane Rabbit polyclonal. 
 
Table 5.4   Commercial polyclonal antibodies against PTPRD.  αα = amino acid. 
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Immunofluorescence (IF) was performed using frozen sections of normal skin.  
Normal skin was chosen for analysis because it was presumed unlikely to contain 
either microdeletions or mutational events (the effects of which on translation 
and localisation are unknown).  Furthermore, unlike paraffin embedded samples 
that have been treated with formalin, frozen sections have not undergone a 
crosslinking procedure, which is beneficial for antigen presentation.  PTPRD has 
a transmembrane domain, separating the ECD of the protein from the catalytic 
intracellular domain and would therefore be predicted to reside with membrane 
localisation.  The K20 antibody recognises an extracellular epitope of PTPRD, 
whilst the Orbigen antibody recognises an epitope within the transmembrane 
domain.  For the visualisation of extracellular and transmembrane epitopes, 
permeabilisation with fixatives such as acetone or wash buffers containing strong 
detergents such as Triton can disrupt the detection of proteins, by solubilising the 
cell membrane and destroying membrane bound proteins.  Therefore, 4% PFA 
was initially used to fix the sections and 0.1% Tween (a mild detergent) was 
added to the wash buffers (for the standard IF protocol, see chapter 2.5.4).  
Primary antibody dilutions of 1/50 and 1/250 were used to stain the tissue 
overnight, neither of which showed positive staining (Figure 5.5).  Subsequent 
staining attempts using acetone fixation, the addition of 0.1% triton to wash 
buffers and an increased antibody concentration of 1/20 did not result in positive 
staining with either antibody. 
 
For WB analysis, lysates were prepared from the melanoma cell line WM1158 
and Hek293T cells.  Fifty micrograms of protein was loaded into an 8% 
acrylamide gel and the K20 antibody from Santa Cruz was used to probe the 
corresponding blot at a starting concentration of 1/250.  Ponceau stain was used 
post-transfer to ensure the proteins had transferred efficiently and that there was 
equal loading across all lanes.  The proproteins of isoforms 1 and 2 have a 
molecular weight of 215 kDa, whilst the smaller isoforms, 3-6, are 170 kDa.  
After cleavage at the membrane, the molecular weight of the catalytic domain is 
85 kDa for all isoforms.  For the larger isoforms, the ECD is predicted to be ~143 
kDa and, for the shorter forms, ~75 kDa.  WB analysis revealed the antibody did 
not detect any bands corresponding to the appropriate size for the PTPRD 
protein.  This is consistent with WB analysis using the antibody from Orbigen, 
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which also did not detect the PTPRD protein (personal communication, Professor 
Max Partridge). 
 
 
 
 
 
 
 
 
 
Figure 5.5  Immunofluorescent image of normal skin stained with the PTPRD K20 Santa 
Cruz antibody.  Acetone was used to fix the section and the primary antibody was used at a 
concentration of 1/20.  DAPI (in blue) was used to label the nuclei of cells, whilst an Alexa-Fluor 
anti-goat FITC conjugate was used for detection of the PTPRD antibody.  No positive staining of 
cells was seen with the PTPRD antibody.  Non-specific staining can be seen in the cornified layer 
and dermis. 
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5.2.4 Generation of anti-sera against PTPRD 
As discussed in the background to this chapter, PTPRD is translated as a 
proprotein that is subsequently cleaved to separate the extracellular and catalytic 
domains of the protein.  Due to the 92% amino acid sequence identity between 
the catalytic domains of PTPRD, PTPRS and LAR, it was not possible to design 
a unique epitope in this region for the production of a PTPRD specific antibody.  
Therefore, anti-sera were generated using epitopes corresponding to the ECD of 
the protein (see chapter 2.5.1).  Like the commercially available antibodies, these 
would detect the proprotein and cleaved extracellular subunit.  The two epitopes 
chosen for antibody production were NSEELYKEIDGVA (designated peptide 
A) and TQHVNNWM (designated peptide B), which are located in the first and 
second FN domains respectively.  Each peptide was used to inoculate two 
different rabbits: peptide A was used for rabbits JF1 and JF2 and peptide B was 
used for rabbits JF3 and JF4. 
 
5.2.5 Titre determination of terminal bleeds by ELISA 
To determine the titre of PTPRD antibody in the anti-sera from each rabbit, an 
ELISA was performed using the peptide against which the antibodies had been 
raised.  Briefly, the appropriate peptide was used to coat an ELISA plate, blocked 
with BSA and a dilution series of the anti-sera applied.  After thorough washing 
of the wells to remove any unbound proteins, an anti-rabbit AP conjugate was 
used to detect antibodies from the sera that had bound to the peptide coated 
wells.  p-NPP was added to each well and produces a water-soluble yellow 
coloured product upon hydrolysis by AP to p-nitrophenol.  The quantity of 
coloured product is directly proportional to the quantity of anti-rabbit AP 
conjugate bound in the well and was measured by absorbance at 405 nm (see 
chapter 2.5.7 for full methodology).  The ELISA showed a good titre of anti-
PTPRD had been generated by each rabbit, whilst corresponding pre-immune 
sera taken before the first inoculation demonstrated low reactivity (Figure 5.6).  
Furthermore, the two peptides performed with similar efficiencies, suggesting 
neither epitope had a preferential antigenic effect. 
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Figure 5.6  Anti-PTPRD titres from the sera of 4 rabbits, measured by ELISA.  The titre is 
measured by the reciprocal dilution factor when the absorbance is equivalent to 1 unit, indicating 
the lowest dilution that still produces maximum binding of the antibody in the ELISA.  The 
highest titre is seen in JF2, whilst the lowest is in JF3.  Pre-immune sera shows minimal levels of 
reactivity against the appropriate peptide in all 4 animals.  Dilutions of anti-sera up to a factor of 
800 show high variability, indicating the assay is not sensitive at these high-titre fractions.   
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5.2.6 Optimisation of antibody for immunostaining 
Anti-sera from all four rabbits was used in IF of fresh frozen normal skin to 
determine if it was suitable for visualisation of the PTPRD protein in tissue 
biopsies.  Initially, two dilutions were tested – 1/100 and 1/250 – using 10 
minutes of 4% PFA to fix the tissue sections.  JF1, JF3 and JF4 showed a nuclear 
staining pattern, although the staining with JF4 was barely detectable (Figure 
5.7).  JF2 did not show positive staining.  The pre-immune sera from one animal 
(JF1) was run as a negative control.  This also showed nuclear staining, 
suggesting the pattern was not epitope-specific but caused by background signal.  
Conversely, using no sera at all resulted in no background signal, indicating the 
sera itself was responsible for the background staining (Figure 5.7).  The staining 
was repeated with JF1 using a 1/50 dilution.  This revealed a cytoplasmic pattern 
of staining, suggesting the previous dilution of 1/100 was too low and may have 
contributed to the generation of background nuclear signal (Figure 5.8).  
However, the pre-immune sera also showed a similar pattern of staining at this 
dilution, again indicating contaminants in the sera were generating false-positive 
results.  Staining of the WM239a melanoma cell line on coverslips also showed 
overlap between the background signal of JF1 and the preimmune sera (Figure 
5.9).  Although the staining was predominantly cytoplasmic in the WM239a cells 
stained with JF1 anti-sera, there was some nuclear signal which was also present 
in cells stained with the pre-immune sera (Figure 5.9). 
 
To overcome this problem, anti-sera from JF1 was purified by affinity 
chromatography.  The protocol is described fully in detail in chapter 2.5.8.  
Briefly, peptide A was immobilised to thiopropylactivated sepharose beads and 
mixed with 10 mls of anti-sera at 4 
o
C overnight.  After washing to remove 
unbound proteins, the beads with immobilised peptide:antibody complexes were 
loaded into a BioRad affinity chromatography column and the peptide:antibody 
bonds broken using a low pH 0.2 M glycine solution.  Following elution of the 
fractions containing the antibody, the fractions were pooled and dialysed against 
PBS containing 0.05% sodium azide.  WB was performed by Dr Malgorzata 
Romanowska to confirm the eluted fractions contained the PTPRD antibody 
(Figure 5.10).    
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Figure 5.7 IF images of normal skin stained with anti-sera from JF1-4.  PTPRD is 
labelled with a FITC (green) conjugate, whilst DAPI (blue) indicates nuclear counterstain.  
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Figure 5.8 IF images of normal skin stained with JF1 anti-sera.  The left hand panel shows 
FITC labelling of PTPRD whilst the right hand panel shows the merged image with DAPI to 
stain the nuclei of cells. 
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Figure 5.9 IF images of WM239a melanoma cell line stained with JF1.  The left hand panel 
shows FITC labelling of PTPRD whilst the right hand panel shows the merged image with DAPI 
to stain the nuclei of cells. 
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Figure 5.10  Western blot analysis to confirm fractions from antibody purification 
contained PTPRD antibody.  A) 50 μg of protein lysate collected from the T2 cell line was 
loaded into each lane.  Ponceau stain was used to stain the membrane after transfer of the 
proteins, to indicate equal loading of the gel and efficient transfer.  B) The membrane was probed 
with either a 1/300 dilution of purified antibody (lane 1), or a 1/300 dilution of purified antibody 
that had been premixed for 30 minutes at room temperature with peptide A prior to incubation 
with the membrane.  There is a band at 220 kDa with the purified antibody, indicating the 
detection of full length PTPRD protein, whilst in the second lane, the signal has been blocked by 
prior incubation of the purified antibody with the peptide.  Western blotting was performed by Dr 
M. Romanowska. 
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The purified antibody was used in IHC of FFPE normal skin and cSCC by Dr M. 
Romanowska.  The results were inconsistent, showing prominent nuclear 
staining that was not always blocked if the purified antibody was incubated with 
the peptide prior to application to the tissue section.  This indicates non-specific 
background was still generating false positive staining results.  Optimisation of 
the anti-sera for immunostaining is ongoing.  
 
5.2.7 Optimisation of antibody for western blotting 
The anti-sera was initially used for WB analysis of whole cell lysates from two 
melanoma cell lines (WM239a and WM1158) that showed strong mRNA 
expression of PTPRD and did not have a microdeletion at the locus.  Alternate 
wells of an 8% SDS-Page gel were loaded with 60 μg of protein lysate from each 
cell line.  Following transfer, the membrane was stained with Ponceau stain to 
check for equal loading, split into four sections (each containing two lanes 
containing the two protein lysates) and probed with a 1/250 dilution of each anti-
sera.   Even with a short exposure time when developing the blot, there was 
heavy background staining that made it impossible to detect bands of the correct 
size with any of the anti-sera.   
 
A second WB was performed using protein lysates from the Hek293T cells, 
which showed a lower level of mRNA expression.  Alternate wells of the SDS-
Page gel were loaded with 20 μg and 40 μg of lysate and probed with either a 
1/1000 dilution of JF1 or JF2, or a 1/1000 dilution of JF1 or JF2 that had been 
preincubated with 50 μg of peptide A (against which the anti-sera was raised) for 
30 minutes at room temperature.  This also revealed high levels of background 
for the JF1 anti-sera and the presence of a non-specific band at ~60 kDa for JF2 
anti-sera.  It is unlikely the band in JF2 represents a splice variant of PTPRD, as 
the signal was not blocked upon pre-incubation of the anti-sera with the peptide.  
Pre-immune sera from the JF1 rabbit showed no non-specific bands, indicating 
the background noise was due to the inoculation procedure.  JF1 and JF2 anti-
sera had a dark smear at the top of the gel, which can indicate high molecular 
weight proteins that have degraded.  The Ponceau stain supported this, as no 
discrete bands were visible for high molecular weight proteins.  Furthermore, the 
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1/1000 dilution of anti-sera may have been too low and could have contributed to 
the background noise.   
 
Further optimisation of the JF1 antibody was performed by Dr M. Romanowska, 
who undertook WB analysis using 50 μg of whole cell lysate from the T2 cSCC 
cell line.  This identified a band corresponding to the full length PTPRD 
proprotein (215 kDa), that was confirmed by blocking the signal with prior 
incubation of the anti-sera with peptide A.  Titration of the anti-sera revealed 
good detection of the proprotein up to a 1/400 dilution factor (Figure 5.11). 
 
 
 
 
 
 
 
  
                              
 
 
Figure 5.11 Western blot characterisation of JF1 anti-sera.  A) Ponceau stain of the 
membrane post-transfer to indicate equal loading and efficient transfer, B)  detection of PTPRD 
protein after western blotting using a serial dilution of anti-sera.  In the second lane, the signal 
has clearly been blocked by preincubation of the highest anti-sera dilution with peptide A prior to 
incubation with the membrane.  Western blot performed by Dr M. Romanowska. 
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5.2.8 Stat3 and MTSS1 
Stat3 and MTSS1 have been reported to interact with PTPRD in vitro.  
Therefore, these two proteins were visualised in FFPE cSCC for which the 
genetic status of PTPRD was known, to investigate if there was any correlation 
between microdeletions at the PTPRD locus and intensity or localisation of 
pStat3 and MTSS1.  In total, 6 WD cSCC, 7 MD cSCC and 9 PD cSCC were 
collected together for analysis.  Four of these had a homozygous microdeletion 
of PTPRD and two had heterozygous microdeletions.   
 
The tissue sections that were used for analysis had been cut onto slides several 
months prior to staining and stored at room temperature, which can affect epitope 
presentation (Jacobs et al., 1996, Fergenbaum et al., 2004).  MTSS1 is a SHH 
responsive gene and should therefore show positive staining of the hair follicle, 
which has high expression of the SHH pathway.  To control for possible 
degradation of epitopes within individual tumour samples, those that did not 
show positive staining of the hair follicle with MTSS1 were excluded from the 
analysis.  This left 4 WD cSCC, 2 MD cSCC and 5 PD cSCC.  Unfortunately, 
this excluded most of the samples with microdeletions of PTPRD.  Those that 
were left included one MD cSCC with a heterozygous deletion (PM1), 1 PD 
cSCC with 2 heterozygous deletions (P3) and 1 PD cSCC with a homozygous 
deletion (SCC 40).  IHC was performed by Dr M. Ikram, using the automated 
Ventana system at St. Bart‟s Pathology Service.   
 
The antibody used for pStat3 immunostaining recognises the phosphorylated 
epitope of Tyr705, which is the residue proposed to be the target of PTPRD 
phosphatase action.  Most tumour samples showed weak and scattered staining of 
pStat3, with typically less than 10% of tumour cells positive for expression, 
irrespective of the tumour grade (Table, 5.5, Figure 5.12).  PM1, that had a 
heterozygous deletion of PTPRD showed a similar staining pattern to the rest of 
the cSCC analysed, with very weak tumour staining in <2% of cells.  P3 and 
SCC 40 however showed widespread expression of p-Stat3, with ~40% and 
~50% of tumour cells positive respectively (Figure 5.12).  This indicates that in 
tumour samples with potentially biallelic PTPRD microdeletion events, p-Stat3 
levels are increased.   
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MTSS1 showed a stronger pattern of staining than p-Stat3, with typically 60-
80% of tumour cells positive for expression (Figure 5.13).  The localisation of 
MTSS1 was consistently nucleolar, with no membrane-bound MTSS1 protein 
detected.  There was no apparent link between the expression of MTSS1 and 
tumour grade or the presence of microdeletions at the PTPRD locus. 
 
 
Sample Differentiation 
status 
Genetic status of 
PTPRD 
pStat3 
staining 
MTSS1 
staining 
SCC 1 WD LOH <10 % >80 % 
SCC 2 WD LOH <10 % 60-70 % 
SCC 3 WD WT <10 % >80 % 
SCC 4 WD LOH <10 % 60-70 % 
SCC 5 MD Heterozygous 5‟ UTR 
deletion 
<10 % 70-80 % 
SCC 6 MD LOH <10 % >80% 
SCC 7 PD Homozygous 5‟ UTR 
deletion 
~ 50-60 % >80 % 
SCC 8 PD 2 x heterozygous 5‟ 
UTR deletions 
~ 40-50 % >80 % 
SCC 9 PD LOH <10% >80 % 
SCC 10 PD WT Negative >80 % 
SCC 11 PD LOH <10% ~ 40 % 
 
Table 5.5 Summary of immunostaining for pStat3 and MTSS1.  Percentage positivity 
indicates the percentage of tumour cells that showed positive signal. 
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Figure 5.12 IHC of p-Stat3 in cSCC.  cSCC without PTPRD microdeletions: A) WD, B) MD and C) PD.  D) MD cSCC with a heterozygous 5‟ UTR deletion of PTPRD, E) PD cSCC 
with 2 x heterozygous deletions and F) PD cSCC with a homozygous deletion.  G) Breast carcinoma was used as a positive control and H) PD cSCC with no primary antibody.  Black arrows 
indicate positive cells.   A-E = x20 magnification, I = tumour shown in panel F, x40 oil magnification.  Brown staining indicates DAB labelled detection of the primary antibody, blue is the 
haematoxylin counterstain. 
A B C 
D E F 
G H I 
 2
4
0
 
                         
                         
                      
Figure 5.13 IHC of MTSS1 in cSCC.  x20 magnification A) WD cSCC, B) MD cSCC and C) PD cSCC.  x40 magnification D) WD cSCC, E) MD cSCC and F) PD 
cSCC.  G) hair follicle showing positive staining, H) negative control showing the same tumour as picture C, but with the primary antibody omitted.  Brown staining indicates 
DAB labelled detection of the primary antibody, blue is the haematoxylin counterstain. 
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5.3 DISCUSSION AND SUGGESTIONS FOR FUTURE WORK 
PTPRD is an attractive candidate gene in cSCC pathogenesis, with an association 
between microdeletions at the locus and metastatic disease.  Elucidating the role 
of PTPRD in skin biology is pivotal to understanding how this gene may 
contribute to the metastatic process of cSCC.  The data presented in this chapter 
has begun the investigation of this, through the optimisation of a custom 
antibody against the PTPRD protein and analysis of the MTSS1 and Stat3 
proteins in cSCC biopsies.  This has lead to the characterisation of a custom 
antibody for WB analysis of PTPRD and revealed an apparent correlation 
between biallelic genetic events at the PTPRD locus and an upregulation of p-
Stat3.  However, many questions remain unanswered, most notably, the 
expression and distribution of the PTPRD protein in normal skin and cSCC.  This 
work is ongoing and requires further optimisation of the custom anti-sera 
generated against PTPRD epitopes.  Furthermore, more samples with 
microdeletions of PTPRD are required for the analysis of p-Stat3 expression, to 
confirm the observed increase of p-Stat3 in tumours with biallelic deletion of 
PTPRD. 
  
Complex pattern of isoform splicing 
Analysis of the PTPRD isoforms expressed in skin and cSCC revealed a complex 
splicing pattern by RT-PCR analysis, particularly in the cSCC.  In normal skin, 
two distinct transcripts were detected, both of which encoded large protein 
isoforms.  Splicing events in the IG domain were consistent with isoform 2 
(which splices out exons 6, 7 and 9), whilst splicing in the FN domain showed 
exon 16 was present in one transcript and absent in the other.  These isoforms 
were also detected in the majority of cSCC.  However, in 4/12 tumours, there 
was an additional short isoform with the 4
th
-7
th
 FN subunits spliced out.  This 
suggests the expression of PTPRD is dysregulated in some cSCC compared to 
normal skin.  The extracellular domains of PTPRD and other PTPRs have been 
shown to promote cell adhesion through homophilic and heterophilic binding 
(Wang and Bixby, 1999).  The production of variants in the tumour cells that 
differ to the surrounding normal cells could potentially abrogate any cell 
adhesive properties of PTPRD and enhance cell detachment, a key process in 
metastasis.  Expressing a combination of the WT and variant proteins together in 
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vitro would allow the investigation of this hypothesis, using cell adhesion assays 
to test how well the different isoforms bind to each other. 
 
There were also multiple bands of aberrant size in the cSCC that were not present 
in the normal skin samples.  Their presence in the cSCC but not normal skin 
suggests these bands represent novel splice variants of PTPRD rather than non-
specific PCR amplification.  However, this cannot be confirmed without further 
gel purification and sequencing of these bands.  Sequencing also revealed the 
presence of an extra amino acid, Q1018insA, in 2/6 normal skin and 8/12 cSCC.  
The insertion is located in the 8
th
 FN subunit of the ECD and although its 
relevance is unknown, it is unlikely to affect the catalytic activity of the protein 
due to its location.  There was no apparent correlation between expression of the 
B exons (corresponding to the longer 5‟ UTR) and the variant encoded.  
Similarly, the isoforms expressed did not appear to be linked to the 
differentiation status of the tumour. 
 
Splicing events that determine which protein isoform of PTPRD is expressed 
have not been examined in any other cancer and it would be interesting to see if 
other cancers that display genetic aberration of PTPRD show similar complexity.  
In particular, the main isoform that is expressed in normal brain tissue is one of 
the shortened isoforms and it would be interesting to see if this is consistent with 
the transcript pattern in GBM, for which microdeletions and mutations of 
PTPRD have been reported (Veeriah et al., 2009).  
 
PTPRD expression in culture 
The expression of PTPRD in vitro was absent or low in most skin derived 
cultures, with the exception of two cSCC cell lines that both had microdeletions 
in the 5‟ UTR.  A similar situation was seen in the screen of melanoma cell lines, 
although a subset of these showed stronger levels of expression.  Although the 
level of expression was not quantitatively compared between tissue samples and 
cultured cells, the expression levels did appear to be reduced in the in vitro 
setting.  This was particularly evident for the cell lines corresponding to the PM1 
primary and metastatic tumours, as the tissue equivalents of these samples 
showed detectable levels of PTPRD, whereas the corresponding cultures were 
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negative.  Gene expression changes in cultured cells have been well documented 
and are a fundamental challenge to the extrapolation of data generated from in 
vitro models to human disease settings (Stein et al., 2004, Zaitseva et al., 2006).  
In a culture dish, cells typically form a monolayer through adhesion to plastic, 
which is dramatically different to the 3D structure of in vivo tissue.  Furthermore, 
they are grown in the absence of systemic, local and environmental cues, all of 
which would influence the expression profile of cells in vivo.  As a result, many 
differences in gene expression occur upon transfer of cells to culture, including 
overexpression of genes involved in protein synthesis and proliferation and 
dysregulation of genes involved in cell adhesion (Smiley et al., 2005, Stein et al., 
2004, Zaitseva et al., 2006).  This suggests PTRPD expression could be 
controlled by a signalling network or transcription factor that is differentially 
expressed in culture.  It is unknown what stimulates or represses PTPRD 
expression, as there was no apparent correlation between culture media 
constituents, growth conditions or passage number of the cells.  For future work, 
cultured cells that do not express PTPRD could be challenged with different 
growth factors (such as transforming growth factor alpha (TGFα)) or with drugs 
(such as cytotoxic agents), to investigate if these have any effect on its 
expression.  This might elucidate further functional evidence of the pathways in 
which PTPRD is involved.   
 
Generation of a custom PTPRD antibody 
The generation of a custom antibody revealed good detection of endogenous 
PTPRD protein by western blotting.  Only the full length proprotein was 
detected, suggesting that either PTPRD is not subject to proteolytic cleavage, or 
that cleavage at the membrane results in immediate shedding of the ECD.  It 
would be informative to correlate mRNA and protein levels in vitro, particularly 
in the 2 cSCC cultures that have a  microdeletion in the 5‟ UTR, but showed 
strong expression at the mRNA level.  This may elucidate if the microdeletions 
have an effect on mRNA stability or translation.  The characterisation of PTPRD 
expression by IHC/IF was not successful and requires further work to optimise 
the anti-sera.  This is being continued by Dr M. Romanowska, who is currently 
purifying the anti-sera from JF3 to investigate if the second epitope generates a 
more reliable and specific pattern of staining.  With hindsight, the generation of 
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an overexpression construct would have been a better approach for the 
optimisation of anti-sera by WB and IHC/IF analysis.  Endogenous expression of 
PTPRD appears to be largely reduced in culture and is variable between different 
cell lines, making it more difficult to optimise new antibodies.  Furthermore, the 
effect of the long 5‟ UTR and the role of microdeletions in this region is 
unknown.  As 5‟ UTRs affect mRNA stability and localisation, as well as 
translation, it is difficult to predict protein expression from the level of mRNA.  
Therefore, endogenous expression of the PTPRD protein in cultures and tissue 
could be markedly different to observations at the mRNA level.  Using an 
overexpression system would have avoided this problem, as the protein would 
have been produced at high levels for subsequent detection. 
 
Following the successful characterisation of the anti-sera against PTPRD in 
immunoblotting, it could be used to investigate the effect of PTPRD 
overexpression and knockdown in keratinocyte/cSCC cell lines.  Overexpression 
of PTPRD in three GBM cell lines, two melanoma cell lines and 2 colorectal 
carcinoma cell lines resulted in growth arrest and a decrease in cell viability 
(Solomon et al., 2008, Veeriah et al., 2009).  Similarly, knockdown of PTPRD in 
normal human astrocytes resulted in increased cell growth and enhanced tumour 
growth in a mouse zenograft model, whilst knockdown in the HeLa cell line 
resulted in an increased resistance to apoptosis (MacKeigan et al., 2005, Veeriah 
et al., 2009).  To follow on from these studies and to investigate the role of 
PTPRD in skin, a construct for PTPRD overexpression could be transfected into 
the two WT cSCC cell lines, T1 and T2, as well as the two cell lines with 
homozygous deletion of PTPRD, SCC26 and SCC40.  Similarly, siRNA 
knockdown could be performed in these lines to induce transient knockdown of 
PTPRD expression, for direct comparison to the overexpression data.  As cited 
above, previous reports suggest the effect of PTPRD knockdown may be cell line 
specific, with normal human astrocytes exhibiting increased proliferation and the 
HeLa cell line showing increased resistance to apoptosis.  To investigate the 
effect of PTPRD overexpression and knockdown in cSCC, numerous assays 
could be performed to assess the effect on common tumour attributes.  This 
would include using Annexin V and flow cytometry to assess the percentage of 
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apoptotic cells in each experiment, the MTT assay for cell proliferation, scratch 
assays for effects on migration and the use of matrigel transwells for invasion.   
 
p-Stat3 
The p-Stat3 staining identified a potential correlation between biallelic deletion 
within the PTPRD locus and increased levels of p-Stat3.  The number of samples 
analysed is too small to be conclusive, with only 3 cSCC with microdeletions at 
the locus available for analysis.  Further cSCC, particularly with heterozygous or 
homozygous microdeletions, should be analysed to confirm the findings.  This 
should also be extended to IHC of metastatic cSCC, to see if the pattern of p-
Stat3 is increased in comparison to primary tumours that have not metastasised.  
The expression of p-Stat3 has been investigated previously in 30 cSCC and a 
positive correlation was found between high levels of the phosphorylated protein 
and PD and metastatic tumours (Suiqing et al., 2005).  However, as the 
association with PTPRD was not established at the time of this study, no 
correlation between the genetic status of PTRPD and p-Stat3 was investigated.  
This should definitely be addressed in future studies and would represent the first 
report to correlate PTPRD status with p-Stat3 overexpression in vivo.   
 
Stat3 is an oncoprotein that is frequently activated in cancer by cytokines such as 
IL-6 and growth factors such as EGF and platelet derived growth factor (PDGF).  
Upon tyrosine phosphorylation, Stat3 dimerises, translocates to the nucleus and 
binds to the enhancer elements of target genes to upregulate their expression.  
Targets of p-Stat3 include the anti-apoptotic factors Bcl2 and Bclx and the pro-
survival factor Survivin.  The Stat3 knockout mouse model is unique amongst 
the Stat family of transcription factors because it is the only model to display an 
embryonic lethal phenotype (Takeda et al., 1997).  This suggests Stat3 is 
essential for normal development and plays a critical role during embryogenesis.  
Conditional knockdown of Stat3 in the epidermis of adult mice leads to 
compromised hair cycling and wound healing, indicating a role for Stat3 in the 
migration of keratinocytes (Sano et al., 1999).  Furthermore, in two-stage skin 
carcinogenesis models, depletion of Stat3 resulted in decreased epidermal 
proliferation (Chan et al., 2004).  Taken together, this suggests p-Stat3 has 
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proliferative and migratory effects on keratinocytes which are consistent with a 
role in cancer and the metastatic process.   
 
MTSS1 
MTSS1, otherwise known as missing-in-metastasis (MIM) and BCC enriched 
gene 4 (BEG4), was first associated with cancer by the identification of absent 
levels of mRNA in metastatic bladder cancer cell lines compared to low grade 
bladder carcinoma cell lines (Lee et al., 2002).  These observations were 
extended in the same study, to show the mRNA of MTSS1 was also missing in 
metastatic breast and prostate cancer cell lines, but was present in many normal 
tissues.  MIM is a SHH responsive gene that potentiates Gli transcriptional 
regulation and also binds to actin (Callahan et al., 2004).  Forced expression of 
MIM with either Gli1 or Gli2 in vitro mimics the hyperproliferative and invasive 
phenotype of SHH signalling.  IHC analysis of the MTSS1 protein revealed 
strong expression in most tumours analysed, with no apparent correlation to the 
genetic status of PTPRD.  Furthermore, the localisation of MTSS1 was 
exclusively restricted to the nucleolus.  The association of PTPRD with MTSS1 
has been reported to take place in the cytoplasm initially, prior to translocation to 
the cell membrane.  In this study, no cytoplasmic or membrane localisation of 
MTSS1 was observed, suggesting either that the reported association between 
MTSS1 and PTPRD is an in vitro artefact, or that in cSCC, it is not the principle 
role of MTSS1 expression.   
  
Summary 
Although the results presented in this chapter are preliminary, they represent the 
first investigation into the role of PTPRD in skin biology.  This has demonstrated 
that a complex splicing pattern occurs at the mRNA level, including novel 
splicing events that have not been previously documented.  It was also evident 
that the expression of PTPRD in culture is different to tissue samples, although 
the reason behind this remains unclear.  The optimisation of a custom antibody 
against the ECD of PTPRD in immunodetection will be a useful tool for future 
functional studies to further investigate the role of PTPRD.  Preliminary data on 
the levels of p-Stat3 expression suggest an association between homozygous 
deletion of PTPRD and increased p-Stat3, however this must be confirmed with 
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significantly more samples.  Future functional studies, combined with the 
optimisation of an antibody for IHC and IF, will provide information on the 
effect of microdeletions within the 5‟ UTR and the role of PTPRD in normal skin 
and cSCC biology.  
 
 248 
CHAPTER 6: CONCLUDING REMARKS 
 
6.1 Whole genome expression analysis of cSCC 
cSCC is the second most common skin cancer in fair-skinned individuals, yet the 
molecular events leading to its development remain largely uncharacterised.  In 
this study, whole genome expression microarray profiling was carried out on 30 
LCM cSCC, using AK samples from 9 matched patients as a baseline for 
comparison (chapter 3).  This identified the following: 
 
1) 318 probe sets (corresponding to 222 genes) were differentially expressed 
between AK and cSCC, of which, 31 represented a robust set of 
differentially expressed transcripts after multiple statistical comparisons. 
2) 21% of the 318 differentially expressed transcripts were concordant with 
changes in copy number. 
3) The Jun and Met oncogenes were both identified as differentially 
expressed between AK and cSCC. 
4) The MAPK pathway was identified as a central pathway that was 
dysregulated in cSCC. 
5) Amongst the remaining DEGs there were additional potentially 
interesting targets, including ANXA1, PTHLH, PTPN12 and PAK2 that 
will be investigated further with qRT-PCR and/or IHC. 
6) There was dysregulation of the MMP and mucin gene family members in 
the two metastatic samples, indicating these two families could be 
involved in the metastatic progression of cSCC. 
 
Gene expression microarray profiling has been performed in many cancer types 
and has proved a powerful technology for the study of changes in tumour cells.  
It has facilitated the classification of molecular subtypes of cancer, identified 
new targets for potential therapeutic agents, discovered biomarkers for disease 
progression or prognosis and advanced our basic understanding of how cancers 
develop (Golub et al., 1999, Rhodes and Chinnaiyan, 2005, Rickman et al., 
2008).  In cSCC, existing gene expression microarray studies have yielded little 
consensus on those genes that are differentially expressed between normal or 
precancerous skin and cSCC.  Subsequently, it has been difficult to interpret 
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which genes identified from each study represent cSCC as a whole, rather than 
simply reflecting individual study designs.  The gene expression profiling 
presented in this thesis is the most comprehensive analysis of cSCC to date.  
Furthermore, the transcripts that were identified as differentially regulated 
between AK and cSCC were shown to successfully cluster cSCC lesions from 
normal skin in two different datasets (Riker et al., 2008, Dr A. Gulati, 
unpublished data), indicating the findings are likely to be broadly applicable to 
cSCC, rather then restricted to this dataset alone.   
 
This study identified upregulation of the Jun and Met oncogenes, suggesting their 
potential involvement in cSCC development.  As discussed in chapter 1.5.3, the 
contribution of oncogenes to cSCC pathogenesis is unclear, with conflicting data 
published regarding the activation of common oncogenes such as Ras.  Both the 
Jun and Met oncogenes are upregulated in a wide variety of cancer types and are 
important in numerous aspects of tumour development, including cell survival, 
migration and invasion.  The association between Jun and cSCC is also 
supported by mouse models of skin carcinogenesis, in which inhibition of Jun 
resulted in decreased cSCC formation in nude mice (Bowden et al., 1994).  
Clearly these two oncogenes require further investigation in cSCC to confirm 
their involvement in cSCC pathogenesis and as potential future therapeutic 
targets.   
 
In addition, this is the first study in which SNP and expression microarray data 
have been integrated in cSCC and this identified 21% of gene expression changes 
were concordant with copy number changes.  This is important to capitalise on 
previous work from our group, which detailed copy number changes in cSCC 
using high resolution whole genome SNP microarrays (Purdie et al., 2009).  
Most of the copy number changes that were identified were gross chromosomal 
aberrations containing hundreds or thousands of potential target genes.  
Combining SNP and expression microarray data has facilitated the identification 
of genes that may be targeted for disruption by these common regions of genetic 
aberration. 
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Whilst this study represents the most comprehensive analysis of expression 
changes in cSCC to date, further work is necessary to validate the findings.  In 
particular, the confirmation of up- or downregulation of a subset of genes should 
be confirmed by qRT-PCR and/or IHC analysis in an independent set of samples.  
If findings such as the overexpression of the Jun and Met oncogenes are 
validated, this study will have significantly advanced our understanding of how 
cSCC develops and which key genes/pathways are involved in the progression of 
cSCC from AK lesions.  It is hoped this may lead to the generation of novel 
therapeutic targets for the treatment of cSCC, particularly in high-risk patients 
who develop multiple and often aggressive tumours. 
 
6.2 PTPRD in cSCC 
PTPRD has been recently identified as a potential tumour suppressor gene in 
multiple cancer types, including malignant melanoma, breast, colorectal, lung 
and brain cancers (Sato et al., 2005, Zhao et al., 2005, Stallings et al., 2006, Stark 
and Hayward, 2007, Chan et al., 2008).  Its role in tumourigenesis is unclear.  
However, functional studies have reported an association between PTPRD and 
two other proteins that are associated with tumour development: Stat3 and 
MTSS1.  In this thesis, the disruption of PTPRD in cSCC has been investigated 
for the first time (chapter 4 and 5), which has found the following: 
 
1) Microdeletions at the PTPRD locus are significantly associated with 
metastatic cSCC. 
2) The mutation rate of PTPRD in cSCC is the highest reported for any 
cancer and is consistent with UVB induced DNA damage. 
3) Methylation is not a mechanism of PTPRD disruption in cSCC. 
4) The expression of PTPRD mRNA is lowest in MD and PD tumours in 
comparison to normal skin and WD cSCC. 
5) Multiple splice variants of PTPRD are expressed in normal skin and 
cSCC, with additional shorter isoforms expressed in a proportion of 
tumours, but not in normal skin. 
6) PTPRD expression in keratinocyte and cSCC cultures is predominantly 
low or absent. 
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7) cSCC with potential biallelic deletion events at the PTPRD locus display 
higher levels of pStat3 than those with no microdeletion at the locus. 
 
PTPRD belongs to a family of 21 transmembrane protein tyrosine phosphatase 
receptors that are implicated in ligand-controlled protein dephosphorylation, cell-
cell adhesion and cell-matrix adhesion (Tonks, 2006).  Many different family 
members have been implicated as tumour suppressor genes in cancer, including 
PTPRG which is disrupted in nasopharyngeal carcinoma, PTPRK which 
dephosphorylates the epidermal growth factor receptor (EGFR) and is disrupted 
in lymphomas and PTPRJ which is downregulated in pancreatic cancer (Trapasso 
et al., 2004, Xu et al., 2005, Flavell et al., 2008, Cheung et al., 2008).  The role of 
PTPRD has not been fully characterised and determining its function in both 
normal skin and cSCC is essential to understand its role in cSCC progression.  A 
recent publication has shown that PTPRD dephosphorylates the Stat3 protein in 
vitro.  In chapter 5, the first in vivo data to support this association is presented in 
the form of IHC staining of Stat3 in cSCC with and without deletion of PTPRD.  
This showed an apparent increase in pStat3 levels in tumours with potentially 
biallelic deletions of PTPRD, suggesting pStat3 may play an important role in 
cSCC pathogenesis (Figure 6.1).   
 
pStat3 is also dephosphorylated by a second PTPR – PTPRT – which is the most 
frequently mutated gene in colorectal carcinomas (Wang et al., 2004, Zhang et 
al., 2007b).  Substrate redundancy amongst PTPR family members suggests the 
dephosphorylation of PTPR target proteins is tightly regulated and/or tissue 
specific  differences in PTPR expression may be responsible for regulating key 
cellular pathways.  In colorectal cancer where PTPRT is frequently mutated, 
multiple mechanisms of disruption have also been demonstrated for PTPRD 
(Cox et al., 2005, Chan et al., 2008), suggesting that in this particular cancer 
type, both PTPRs are disrupted.  Given the potential redundancy between 
PTPRD and PTPRT, it would be instructive to investigate the expression of 
PTPRT in skin and cSCC, to see if the levels of these two proteins correlate with 
each other in any way.  PTPRT has not been previously associated with cSCC 
development and was not identified as a differentially expressed gene from the 
microarray analysis presented in chapter 3.  Furthermore, it is located on 
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chromosome 20q13.11, which is not a common region for copy number change 
in cSCC. 
   
The association between microdeletions at the PTPRD locus and metastatic 
cSCC is of clinical relevance, as genes that are involved in the metastatic 
progression of cSCC have not been widely reported.  The EGF receptor has been 
proposed as a biomarker of cutaneous and HNSCC progression (Ch'ng et al., 
2008, Fogarty et al., 2007).  However, its overexpression in primary tumours that 
go on to metastasise is not maintained in metastatic tumours and the levels of 
active (phosphorylated) protein do not correlate with tumour grade or 
progression to metastasis (Ch'ng et al., 2008, Fogarty et al., 2007).  These data 
suggest EGFR is not consistently overexpressed or activated in cSCC that 
metastasise, making it an unattractive prognostic indicator for disease 
progression.  Currently, only clinicopathological criteria are available for 
assessing metastatic risk and include immunosuppression, size and thickness of 
the tumour, localisation of the tumour and histological grade (Brantsch et al., 
2008, Vartanian et al., 2004).  Metastatic cSCC is treated by surgical intervention 
and/or chemotherapy or radiotherapy and is associated with a poor outcome 
(Kraus et al., 1998).   
 
Fortunately, the metastatic rate of cSCC is relatively low, between 0.1% and 9.9 
% (Lund, 1965, Rowe et al., 1992, Tavin and Persky, 1996, Brantsch et al., 
2008).  However, it still represents the main cause of death for patients suffering 
from NMSC, despite cSCC accounting for only 20% of total cases.  Furthermore, 
high-risk patients such as those on immunosuppression are at an increased risk of 
developing multiple, aggressive cSCC and have a higher rate of metastasis 
(Euvrard et al., 2003).  For these patients in particular, a marker to discern which 
tumours are likely to metastasise would be a highly desirable clinical tool, 
enabling more efficient targeted management such as sentinel lymph node 
surveillance.  Based on the findings from this study, PTPRD could potentially be 
used as a genetic marker for disease progression in high-risk patients.  As 
discussed in section 4.3, a cytogenetic based approach to detect microdeletions at 
the locus may represent the most appropriate technique to use in a clinical 
setting.  Cytogenetic based methods are routinely used for diagnostic purposes in 
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haematological malignancies, where they represent an integral tool for the 
clinical management of these cancers. 
 
The PTPRD pathway could also potentially be used as a novel therapeutic target 
in cancer, which could have wider implications for other cancer types in which it 
is also disrupted.  A recent clinical trial involving 33 patients with advanced 
BCC used targeted therapy to the hedgehog (HH) signalling pathway, which is 
dysregulated in BCC (Rudin et al., 2009).  This resulted in a substantial 
improvement in 18 patients and arrested the spread of cancer in 11 others, for 
whom conventional treatments were ineffective.  These promising clinical results 
support the development of targeted cancer therapies and suggest a pathway 
involving PTPRD justifies investigation as a clinical target in the treatment of 
metastatic cSCC.  Although phosphatases themselves are typically viewed as 
difficult pharmacological targets, corroboration of the pathway in which PTPRD 
resides may reveal therapeutic targets for the treatment of metastatic cSCC.  In 
particular, confirmation of the association between pStat3 and PTPRD is highly 
relevant, as inhibitors of pStat3 are already in development (Scheper et al., 2007, 
Kong et al., 2008).  Sulindac, a non-steroidal anti-inflammatory drug that is 
currently licensed in the UK, modulates Stat3 activation in oral SCC via a COX2 
independent mechanism, suggesting this drug could represent a novel therapeutic 
agent in the treatment of cSCC (Scheper et al, 2007).  Further work is necessary 
to confirm the association between PTPRD, pStat3 and metastatic cSCC, as well 
as the role of potential pStat3 inhibitors as therapeutic agents. 
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Figure 6.1 Model of PTPRD in cSCC.  Panel A represents a normal cell with wildtype 
PTPRD, which has dimerised in response to an unknown ligand.  The dimerised form of PTPRD 
dephosphorylates Stat3, resulting in transcriptional silencing of p-Stat3 activated pathways.  In 
panel B, a tumour cell with decreased expression or mutation of PTPRD is unable to dimerise and 
dephosphorylate Stat3.  p-Stat3 dimerises, translocates to the nucleus and activates a variety of 
pro-tumourigenic factors, including the pro-survival factor Survivin and the anti-apoptotic factors 
Bcl2 and Bcl-X.  Collectively, these factors contribute to a favourable phenotype for metastatic 
spread of the tumour. 
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APPENDIX A: top 300 differentially expressed probe sets identifed between 
FF and RNAlater samples.  P-value and fold change are shown. 
 
Probe set ID Gene title 
Gene 
symbol P-Value Fold change Cytoband 
223811_s_at 
chromosome 7 open reading 
frame 20 C7orf20 3.67509E-08 1.737192386 7p22.3 
227588_s_at 
chromosome 7 open reading 
frame 20 C7orf20 4.25935E-08 1.622717917 7p22.3 
221512_at transmembrane protein 222 TMEM222 9.34037E-08 1.71900422 1p36.11 
221759_at 
glucose 6 phosphatase, 
catalytic, 3 G6PC3 1.13886E-07 1.752206296 17q21.31 
208336_s_at glycoprotein, synaptic 2 GPSN2 8.10815E-07 2.063374885 19p13.12 
224661_at 
phosphatidylinositol glycan 
anchor biosynthesis, class Y PIGY 1.03416E-06 1.427095607 4q22.1 
241344_at   1.62718E-06 -1.617547718  
52078_at transmembrane protein 222 TMEM222 1.77472E-06 1.610125766 1p36.11 
201119_s_at 
cytochrome c oxidase subunit 
8A (ubiquitous) COX8A 1.78438E-06 1.940979611 11q12-q13 
202025_x_at 
acetyl-Coenzyme A 
acyltransferase 1 ACAA1 1.82862E-06 1.601233221 3p23-p22 
204860_s_at 
NLR family, apoptosis 
inhibitory protein NAIP 1.93249E-06 -2.010530238 5q13.1 
224301_x_at 
H2A histone family, member 
J H2AFJ 2.53017E-06 1.833564449 12p12 
224886_at jumonji domain containing 8 JMJD8 2.97532E-06 1.532482488 16p13.3 
231681_x_at histone cluster 3, H2a HIST3H2A 3.05173E-06 1.618881823 1q42.13 
231059_x_at SCAN domain containing 1 SCAND1 3.28462E-06 1.421952989 
20q11.1-
q11.23 
213490_s_at 
mitogen-activated protein 
kinase kinase 2 MAP2K2 3.33612E-06 1.906842897 19p13.3 
210778_s_at MAX dimerization protein 4 MXD4 3.33766E-06 1.608721098 4p16.3 
65086_at 
Yip1 domain family, member 
2 YIPF2 3.38756E-06 1.54433725 19p13.2 
224466_s_at 
v-maf musculoaponeurotic 
fibrosarcoma oncogene 
homolog G (avian) MAFG 3.70674E-06 1.448083483 17q25.3 
217854_s_at 
polymerase (RNA) II (DNA 
directed) polypeptide E, 
25kDa POLR2E 3.93592E-06 1.417140576 19p13.3 
229471_s_at 
splicing factor, 
arginine/serine-rich 2B SFRS2B 3.97873E-06 1.919091064 11q22 
228622_s_at 
DnaJ (Hsp40) homolog, 
subfamily C, member 4 DNAJC4 3.98356E-06 1.58082414 11q13 
32837_at 
1-acylglycerol-3-phosphate 
O-acyltransferase 2 
(lysophosphatidic acid 
acyltransferase, beta) AGPAT2 4.01394E-06 1.360584163 9q34.3 
225245_x_at 
H2A histone family, member 
J H2AFJ 4.55248E-06 1.81893738 12p12 
204599_s_at 
mitochondrial ribosomal 
protein L28 MRPL28 4.6901E-06 1.515088676 16p13.3 
215649_s_at mevalonate kinase MVK 4.81083E-06 2.480703317 12q24 
227863_at cathepsin D CTSD 5.00107E-06 1.523177138 11p15.5 
241936_x_at   5.03813E-06 -2.419638372  
212632_at syntaxin 7 STX7 5.05668E-06 -1.480070334 6q23.1 
229524_at KIAA0494 KIAA0494 5.1335E-06 1.699665142 1pter-p22.1 
213041_s_at 
ATP synthase, H+ 
transporting, mitochondrial 
F1 complex, delta subunit ATP5D 5.14461E-06 1.727459956 19p13.3 
218563_at 
NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 3, 9kDa NDUFA3 5.17256E-06 1.818930518 19q13.42 
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Probe set ID Gene title 
Gene 
symbol P-Value Fold change Cytoband 
210678_s_at 
1-acylglycerol-3-phosphate 
O-acyltransferase 2 
(lysophosphatidic acid 
acyltransferase, beta) AGPAT2 5.32066E-06 1.34364345 9q34.3 
224011_at   5.77843E-06 1.409689462  
201395_at RNA binding motif protein 5 RBM5 6.46779E-06 -1.750899286 3p21.3 
214988_s_at SON DNA binding protein SON 6.62541E-06 -1.382247623 
21q22.1-
q22.2 
226616_s_at 
NADH dehydrogenase 
(ubiquinone) flavoprotein 3, 
10kDa NDUFV3 6.66861E-06 1.463588637 21q22.3 
221587_s_at 
chromosome 19 open reading 
frame 24 C19orf24 6.72025E-06 1.88732237 19p13.3 
225823_at 
chromosome 19 open reading 
frame 70 C19orf70 6.8948E-06 1.719968292 19p13.3 
243258_at KIAA0664 KIAA0664 6.89897E-06 1.502497897 17p13.3 
204480_s_at 
chromosome 9 open reading 
frame 16 C9orf16 6.98323E-06 2.406284509 9q34.1 
202799_at 
ClpP caseinolytic peptidase, 
ATP-dependent, proteolytic 
subunit homolog (E. coli) CLPP 7.14148E-06 1.710466736 19p13.3 
241804_at   7.15751E-06 -2.102562499  
1568666_at lipid storage droplet protein 5 LSDP5 7.33108E-06 1.501467591 19p13.3 
221936_x_at 
mitochondrial ribosomal 
protein L41 MRPL41 7.50304E-06 1.848010213 9q34.3 
203027_s_at 
mevalonate (diphospho) 
decarboxylase MVD 7.51124E-06 1.430868105 16q24.3 
209627_s_at 
oxysterol binding protein-like 
3 OSBPL3 8.09522E-06 -1.767569784 7p15 
228874_at 
pleckstrin homology-like 
domain, family B, member 3 PHLDB3 8.12321E-06 1.52782437 19q13.31 
237023_at   8.28759E-06 -2.436711862  
210694_s_at 
midline 1 (Opitz/BBB 
syndrome) MID1 8.33714E-06 -2.354794752 Xp22 
224706_at KIAA2013 KIAA2013 8.602E-06 1.393427846 1p36.22 
213487_at 
mitogen-activated protein 
kinase kinase 2 MAP2K2 8.62929E-06 1.710684664 19p13.3 
204056_s_at mevalonate kinase MVK 8.89237E-06 1.43599413 12q24 
213966_at high-mobility group 20B HMG20B 9.45776E-06 1.39663251 19p13.3 
203810_at 
DnaJ (Hsp40) homolog, 
subfamily B, member 4 DNAJB4 9.53729E-06 -1.742487862 1p31.1 
209665_at 
cytochrome b-561 domain 
containing 2 CYB561D2 9.79407E-06 1.493892955 3p21.3 
226645_at Kruppel-like factor 2 (lung) KLF2 9.89662E-06 1.356288953 
19p13.13-
p13.11 
220079_s_at 
ubiquitin specific peptidase 
48 USP48 1.00119E-05 -1.478773538 1p36.12 
203190_at 
NADH dehydrogenase 
(ubiquinone) Fe-S protein 8, 
23kDa (NADH-coenzyme Q 
reductase) NDUFS8 1.05063E-05 1.69132093 11q13 
235965_at   1.05745E-05 1.502885501  
211165_x_at EPH receptor B2 EPHB2 1.08799E-05 1.693141519 1p36.1-p35 
221967_at neurexophilin 4 NXPH4 1.09888E-05 1.67081378 12q13.3 
230726_at 
mitochondrial ribosomal 
protein L38 MRPL38 1.12014E-05 1.524383066 17q25.3 
212209_at 
mediator complex subunit 
13-like MED13L 1.12429E-05 -1.507606983 12q24.21 
228016_s_at 
metallothionein 1 
pseudogene 3 MT1P3 1.14084E-05 1.616373261 20q11.2 
235091_at phosphodiesterase 12 PDE12 1.23574E-05 1.570916983 3p14.3 
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Probe set ID Gene title 
Gene 
symbol P-Value Fold change Cytoband 
1555370_a_at 
calmodulin binding 
transcription activator 1 CAMTA1 1.26978E-05 -1.783220807 
1p36.31-
p36.23 
203719_at 
excision repair cross-
complementing rodent repair 
deficiency, complementation 
group 1 (includes 
overlapping antisense 
sequence) ERCC1 1.29568E-05 1.564461462 
19q13.2-
q13.3 
221544_s_at mediator complex subunit 16 MED16 1.32854E-05 1.332538653 19p13.3 
203931_s_at 
mitochondrial ribosomal 
protein L12 MRPL12 1.33613E-05 1.606513172 17q25 
217236_x_at 
immunoglobulin heavy 
constant gamma 1 (G1m 
marker) IGHG1 1.34344E-05 1.434601383 14q32.33 
201401_s_at 
adrenergic, beta, receptor 
kinase 1 ADRBK1 1.35576E-05 1.351983522 11q13.1 
208906_at 
Bernardinelli-Seip congenital 
lipodystrophy 2 (seipin) BSCL2 1.38458E-05 1.713286699 
11q12-
q13.5 
235625_at 
vacuolar protein sorting 41 
homolog  VPS41 1.47495E-05 -1.829207756 7p14-p13 
225147_at cytohesin 3 CYTH3 1.50664E-05 -1.384322303 7p22.1 
219606_at PHD finger protein 20-like 1 PHF20L1 1.54304E-05 -1.568304335 8q24.22 
1555783_x_at PQ loop repeat containing 2 PQLC2 1.55803E-05 1.731313407 1p36.13 
228078_at 
alkB, alkylation repair 
homolog 5 (E. coli) ALKBH5 1.55883E-05 1.432166358 17p11.2 
238607_at zinc finger protein 296 ZNF296 1.5614E-05 1.4538739 19q13.32 
224633_s_at G patch domain containing 4 GPATCH4 1.56237E-05 1.548994284 1q22 
217354_s_at 
Hermansky-Pudlak syndrome 
1 HPS1 1.60234E-05 1.48045076 
10q23.1-
q23.3 
202281_at cyclin G associated kinase GAK 1.6063E-05 1.384064261 4p16 
219075_at 
Yip1 domain family, member 
2 YIPF2 1.60771E-05 1.496373868 19p13.2 
236487_at 
sodium channel and clathrin 
linker 1 SCLT1 1.61886E-05 -1.559744876 4q28.2 
212995_x_at 
family with sequence 
similarity 128, member B FAM128B 1.68346E-05 1.618099901 2q21.1 
213542_at zinc finger protein 710 ZNF710 1.70625E-05 1.389355979 15q26.1 
225552_x_at cyclin L2 CCNL2 1.73014E-05 1.56172983 1p36.33 
223479_s_at 
coiled-coil-helix-coiled-coil-
helix domain containing 5 CHCHD5 1.75575E-05 1.963084506 2q13 
218388_at 6-phosphogluconolactonase PGLS 1.75697E-05 1.648797043 19p13.2 
217368_at 
ATP synthase, H+ 
transporting, mitochondrial 
F0 complex, subunit C2 
(subunit 9) ATP5G2 1.76066E-05 1.32129842 12q13.13 
218425_at ring finger protein 216 RNF216 1.79217E-05 1.430579152 7p22.1 
228670_at 
telomerase-associated protein 
1 TEP1 1.80626E-05 -1.663250619 14q11.2 
78047_s_at 
metallothionein 1 
pseudogene 3 MT1P3 1.80859E-05 1.592425714 20q11.2 
227186_s_at 
mitochondrial ribosomal 
protein L41 MRPL41 1.81551E-05 1.875907844 9q34.3 
243816_at zinc finger protein 70 ZNF70 1.82526E-05 -1.678254299 22q11.2 
212406_s_at 
protein-L-isoaspartate (D-
aspartate) O-
methyltransferase domain 
containing 2 PCMTD2 1.84482E-05 -1.629682036 20q13.33 
232946_s_at NAD synthetase 1 NADSYN1 1.85443E-05 1.510546543 11q13.4 
222138_s_at WD repeat domain 13 WDR13 1.86606E-05 1.493032548 Xp11.23 
203926_x_at 
ATP synthase, H+ 
transporting, mitochondrial ATP5D 1.91088E-05 1.546709397 19p13.3 
 258 
Probe set ID Gene title 
Gene 
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F1 complex, delta subunit 
229193_at   1.92702E-05 -2.242200072  
203686_at 
N-methylpurine-DNA 
glycosylase MPG 1.92768E-05 1.456584776 16p13.3 
221251_x_at INO80 complex subunit B INO80B 1.96326E-05 1.492225896 2p13.1 
202574_s_at casein kinase 1, gamma 2 CSNK1G2 1.9811E-05 1.444746351 19p13.3 
1558577_at actin pseudogene 
LOC14870
9 2.00131E-05 1.330217484 1q32.1 
230888_at WD repeat domain 91 WDR91 2.0059E-05 -1.464844589 7q33 
203391_at 
FK506 binding protein 2, 
13kDa FKBP2 2.05861E-05 1.475269481 
11q13.1-
q13.3 
228122_at 
coiled-coil domain 
containing 66 CCDC66 2.06034E-05 -1.732359947 3p14.3 
223482_at transmembrane protein 120A 
TMEM120
A 2.10405E-05 1.458549031 7q11.23 
202120_x_at 
adaptor-related protein 
complex 2, sigma 1 subunit AP2S1 2.12332E-05 2.052617001 
19q13.2-
q13.3 
218112_at 
mitochondrial ribosomal 
protein S34 MRPS34 2.13552E-05 1.534733705 16p13.3 
230034_x_at 
mitochondrial ribosomal 
protein L41 MRPL41 2.14263E-05 1.97240933 9q34.3 
244182_at   2.17382E-05 1.305842855  
208874_x_at 
protein phosphatase 2A 
activator, regulatory subunit 
4 PPP2R4 2.19028E-05 1.365805759 9q34 
239882_at   2.19129E-05 1.522817471  
224005_at   2.25071E-05 -1.718431696  
203720_s_at 
excision repair cross-
complementing rodent repair 
deficiency, complementation 
group 1 (includes 
overlapping antisense 
sequence) ERCC1 2.31891E-05 1.734589225 
19q13.2-
q13.3 
222501_s_at replication initiator 1 REPIN1 2.39695E-05 1.397676074 7q36.1 
223743_s_at 
mitochondrial ribosomal 
protein L4 MRPL4 2.40248E-05 2.214185398 19p13.2 
38710_at 
OTU domain, ubiquitin 
aldehyde binding 1 OTUB1 2.41347E-05 1.571068008 11q13.1 
229797_at mucolipin 3 MCOLN3 2.43795E-05 -2.29266112 1p22.3 
235078_at   2.44202E-05 -1.709193604  
212698_s_at septin 10 SEPT10 2.51115E-05 -1.54784027 2q13 
223186_at transmembrane protein 189 TMEM189 2.59363E-05 1.900792029 20q13.2 
226873_at   2.59709E-05 -1.610569272  
227879_at 
alkB, alkylation repair 
homolog 7 (E. coli) ALKBH7 2.60037E-05 1.882621068 19p13.3 
216868_s_at 
hypothetical protein 
LOC100129656 
LOC10012
9656 2.63691E-05 2.227638813 1q44 
211074_at folate receptor 1 (adult) FOLR1 2.66257E-05 1.422104861 
11q13.3-
q14.1 
230474_at 
UbiA prenyltransferase 
domain containing 1 UBIAD1 2.71046E-05 1.387943134 1p36-p34.1 
238132_at 
Williams-Beuren syndrome 
chromosome region 16 WBSCR16 2.71937E-05 1.410313256 7q11.23 
229113_s_at 
chromosome 1 open reading 
frame 86 C1orf86 2.81119E-05 1.75233895 1p36.33 
205788_s_at 
zinc finger CCCH-type 
containing 11A ZC3H11A 2.81628E-05 -1.503671481 1q32.1 
222245_s_at fer-1-like 4 (C. elegans) FER1L4 2.85634E-05 1.376322925 20q11.22 
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36994_at 
ATPase, H+ transporting, 
lysosomal 16kDa, V0 subunit 
c ATP6V0C 2.87271E-05 1.451953615 16p13.3 
209844_at homeobox B13 HOXB13 2.89306E-05 1.391622698 17q21.2 
220917_s_at WD repeat domain 19 WDR19 2.89535E-05 -1.737441529 4p14 
225425_s_at 
mitochondrial ribosomal 
protein L41 MRPL41 2.96669E-05 1.646913438 9q34.3 
227878_s_at 
alkB, alkylation repair 
homolog 7 (E. coli) ALKBH7 3.01722E-05 1.571949631 19p13.3 
231061_at   3.04679E-05 -1.568766829  
201050_at 
phospholipase D family, 
member 3 PLD3 3.06548E-05 1.486239497 19q13.2 
226983_at zinc finger protein 777 ZNF777 3.07192E-05 1.404698788 7q36.1 
229165_at 
mitochondrial ribosomal 
protein L12 MRPL12 3.0832E-05 1.53767799 17q25 
209577_at 
phosphate 
cytidylyltransferase 2, 
ethanolamine PCYT2 3.11635E-05 1.425438262 17q25.3 
226917_s_at 
anaphase promoting complex 
subunit 4 ANAPC4 3.12696E-05 -1.626447731 4p15.2 
229707_at zinc finger protein 606 ZNF606 3.13899E-05 -1.713136934 19q13.4 
201246_s_at 
OTU domain, ubiquitin 
aldehyde binding 1 OTUB1 3.15794E-05 1.715493202 11q13.1 
229354_at 
aryl-hydrocarbon receptor 
repressor AHRR 3.17677E-05 -1.625821449 5p15.3 
212628_at protein kinase N2 PKN2 3.1832E-05 -1.452884217 1p22.2 
36907_at mevalonate kinase MVK 3.24287E-05 1.267558446 12q24 
215952_s_at 
ornithine decarboxylase 
antizyme 1 OAZ1 3.25351E-05 1.899638922 19p13.3 
218969_at 
mitochondria-associated 
protein involved in 
granulocyte-macrophage 
colony-stimulating factor 
signal transduction Magmas 3.26292E-05 1.691706163 16p13.3 
213586_at 
cyclin-dependent kinase 
inhibitor 2D (p19, inhibits 
CDK4) CDKN2D 3.31224E-05 1.361997516 19p13 
209086_x_at 
melanoma cell adhesion 
molecule MCAM 3.31382E-05 1.522532219 11q23.3 
201374_x_at 
protein phosphatase 2 
(formerly 2A), catalytic 
subunit, beta isoform PPP2CB 3.3302E-05 1.491791367 8p12 
203607_at 
inositol polyphosphate-5-
phosphatase F INPP5F 3.36025E-05 -1.32021322 10q26.11 
211047_x_at 
adaptor-related protein 
complex 2, sigma 1 subunit AP2S1 3.38423E-05 1.986571951 
19q13.2-
q13.3 
241571_at   3.38868E-05 1.499128782  
219972_s_at 
chromosome 14 open reading 
frame 135 C14orf135 3.42834E-05 -1.724819907 14q23.1 
203009_at 
basal cell adhesion molecule 
(Lutheran blood group) BCAM 3.47494E-05 1.355810111 19q13.2 
218290_at 
pleckstrin homology domain 
containing, family J member 
1 PLEKHJ1 3.50132E-05 1.483564124 19p13.3 
204941_s_at 
aldehyde dehydrogenase 3 
family, member B2 ALDH3B2 3.55451E-05 2.652333067 11q13 
223318_s_at 
alkB, alkylation repair 
homolog 7 (E. coli) ALKBH7 3.63169E-05 2.030976838 19p13.3 
225555_x_at cyclin L2 CCNL2 3.65769E-05 1.638983171 1p36.33 
224676_at 
transmembrane emp24 
protein transport domain 
containing 4 TMED4 3.67288E-05 1.642416257 7p13 
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221466_at 
pyrimidinergic receptor P2Y, 
G-protein coupled, 4 P2RY4 3.6939E-05 1.385039349 Xq13 
228733_at 
pseudouridylate synthase-like 
1 PUSL1 3.69519E-05 1.665839874 1p36.33 
227105_at 
centrosome and spindle pole 
associated protein 1 CSPP1 3.69879E-05 -1.948090411 8q13.2 
238228_at 
component of oligomeric 
golgi complex 3 COG3 3.70205E-05 1.551277143 13q14.12 
211933_s_at 
heterogeneous nuclear 
ribonucleoprotein A3 HNRNPA3 3.72118E-05 -1.398150164 2q31.2 
226597_at receptor accessory protein 6 REEP6 3.72844E-05 1.615930049 19p13.3 
229371_at   3.81597E-05 -1.924501256  
218580_x_at 
aurora kinase A interacting 
protein 1 
AURKAIP
1 3.82196E-05 1.594447291 1p36.33 
220885_s_at centromere protein J CENPJ 3.83504E-05 -1.586834264 13q12.12 
201086_x_at SON DNA binding protein SON 3.85022E-05 -1.403475007 
21q22.1-
q22.2 
235775_at 
transmembrane and 
tetratricopeptide repeat 
containing 2 TMTC2 3.93541E-05 -1.682597503 12q21.31 
227994_x_at 
chromosome 20 open reading 
frame 149 C20orf149 3.97621E-05 1.722901512 20q13.33 
228925_at   3.98415E-05 -2.24900648  
203342_at 
translocase of inner 
mitochondrial membrane 17 
homolog B  TIMM17B 4.05958E-05 1.377198586 Xp11.23 
213751_at 
leucine rich repeat containing 
68 LRRC68 4.06194E-05 1.499475512 19q13.32 
203513_at 
spastic paraplegia 11 
(autosomal recessive) SPG11 4.0674E-05 -1.448597076 15q14 
200852_x_at 
guanine nucleotide binding 
protein (G protein), beta 
polypeptide 2 GNB2 4.14943E-05 1.378339033 
7q21.3-
q22.1 
211974_x_at 
recombination signal binding 
protein for immunoglobulin 
kappa J region RBPJ 4.19152E-05 -1.406627605 4p15.2 
65133_i_at INO80 complex subunit B INO80B 4.27642E-05 1.500638333 2p13.1 
202586_at 
polymerase (RNA) II (DNA 
directed) polypeptide L, 
7.6kDa POLR2L 4.30568E-05 1.411912572 11p15 
218010_x_at 
chromosome 20 open reading 
frame 149 C20orf149 4.39166E-05 1.828297217 20q13.33 
219130_at 
coiled-coil domain 
containing 76 CCDC76 4.40569E-05 -1.842297929 1pter-q31.3 
41386_i_at 
jumonji domain containing 3, 
histone lysine demethylase JMJD3 4.46282E-05 1.484064309 17p13.1 
232652_x_at SCAN domain containing 1 SCAND1 4.52918E-05 1.364224987 
20q11.1-
q11.23 
213480_at 
vesicle-associated membrane 
protein 4 VAMP4 4.59719E-05 -1.664953925 1q24-q25 
230514_s_at lysozyme-like 2 LYZL2 4.644E-05 1.270409718 10p11.23 
217912_at 
dihydrouridine synthase 1-
like  DUS1L 4.66176E-05 1.413215361 17q25.3 
202736_s_at 
LSM4 homolog, U6 small 
nuclear RNA associated  LSM4 4.67348E-05 1.468472161 19p13.11 
230099_at   4.6751E-05 -2.33274571  
225423_x_at 
mitochondrial ribosomal 
protein L41 MRPL41 4.71246E-05 1.953976256 9q34.3 
212682_s_at lipase maturation factor 2 LMF2 4.80929E-05 1.32927482 22q13.33 
220641_at 
NADPH oxidase, EF-hand 
calcium binding domain 5 NOX5 4.83067E-05 1.436339251 15q23 
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64486_at 
coronin, actin binding 
protein, 1B CORO1B 4.85144E-05 1.525749838 11q13.1 
213141_at protein serine kinase H1 PSKH1 4.87419E-05 1.484037956 16q22.1 
206452_x_at 
protein phosphatase 2A 
activator, regulatory subunit 
4 PPP2R4 4.88902E-05 1.298372351 9q34 
218649_x_at 
serologically defined colon 
cancer antigen 1 SDCCAG1 4.90791E-05 -1.451442409 14q22 
213166_x_at 
family with sequence 
similarity 128, member A FAM128A 4.91688E-05 1.580272547 2q21.1 
218280_x_at histone cluster 2, H2aa3 
HIST2H2A
A3 4.92583E-05 1.882110785 1q21.2 
226290_at 
B double prime 1, subunit of 
RNA polymerase III 
transcription initiation factor 
IIIB BDP1 4.94594E-05 -1.455767629 5q13 
209077_at thioredoxin 2 TXN2 4.96225E-05 1.383813908 22q13.1 
217871_s_at 
macrophage migration 
inhibitory factor 
(glycosylation-inhibiting 
factor) MIF 5.0086E-05 2.682155567 22q11.23 
212782_x_at 
polymerase (RNA) II (DNA 
directed) polypeptide J, 
13.3kDa POLR2J 5.0129E-05 1.484487598 7q22.1 
229020_x_at EPS8-like 2 EPS8L2 5.01428E-05 1.397017061 11p15.5 
208677_s_at basigin (Ok blood group) BSG 5.08255E-05 1.772122319 19p13.3 
1554006_a_at 
lethal giant larvae homolog 2 
(Drosophila) LLGL2 5.11968E-05 1.501164419 17q24-q25 
219665_at 
nudix (nucleoside 
diphosphate linked moiety 
X)-type motif 18 NUDT18 5.15555E-05 1.467790902 8p21.3 
225870_s_at 
trafficking protein particle 
complex 5 TRAPPC5 5.45187E-05 1.638518073 19p13.2 
228267_at tripartite motif-containing 11 TRIM11 5.4544E-05 1.354111865 1q42.13 
203198_at cyclin-dependent kinase 9 CDK9 5.4647E-05 1.52288578 9q34.1 
226205_at 
ankyrin repeat domain 13 
family, member D 
ANKRD13
D 5.47111E-05 1.320539447 11q13.1 
234316_x_at 
kallikrein-related peptidase 
12 KLK12 5.47947E-05 1.884623958 
19q13.3-
q13.4 
201895_at 
v-raf murine sarcoma 3611 
viral oncogene homolog ARAF 5.48758E-05 1.366079806 
Xp11.4-
p11.2 
229604_at 
cytidine monophosphate-N-
acetylneuraminic acid 
hydroxylase (CMP-N-
acetylneuraminate 
monooxygenase) pseudogene CMAH 5.56089E-05 -1.872917668 6p21.32 
203271_s_at 
unc-119 homolog (C. 
elegans) UNC119 5.64264E-05 1.430077134 17q11.2 
237636_at 
protein phosphatase 2 
(formerly 2A), regulatory 
subunit B, alpha isoform PPP2R2A 5.709E-05 -1.681642177 8p21.2 
220757_s_at UBX domain protein 6 UBXN6 5.78855E-05 1.460442124 19p13 
216855_s_at 
heterogeneous nuclear 
ribonucleoprotein U (scaffold 
attachment factor A) HNRNPU 5.82208E-05 1.479925532 1q44 
233695_s_at 
cat eye syndrome 
chromosome region, 
candidate 2 CECR2 5.93642E-05 1.382580183 22q11.2 
214643_x_at bridging integrator 1 BIN1 5.94353E-05 1.372802285 2q14 
225271_at transmembrane protein 63B TMEM63B 6.04874E-05 1.376612911 6p21.1 
213895_at 
epithelial membrane protein 
1 EMP1 6.10205E-05 -1.618715207 12p12.3 
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225683_x_at 
phosphohistidine 
phosphatase 1 PHPT1 6.17771E-05 1.38410126 9q34.3 
228843_at   6.17771E-05 -1.819486593  
225454_at 
coiled-coil domain 
containing 124 CCDC124 6.20717E-05 1.531018945 19p13.11 
233586_s_at 
kallikrein-related peptidase 
12 KLK12 6.32402E-05 1.826438742 
19q13.3-
q13.4 
220001_at 
peptidyl arginine deiminase, 
type IV PADI4 6.3576E-05 1.527367388 1p36.13 
225304_s_at 
NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 11, 14.7kDa NDUFA11 6.42704E-05 2.143544356 19p13.3 
204928_s_at 
solute carrier family 10 
(sodium/bile acid 
cotransporter family), 
member 3 SLC10A3 6.4488E-05 1.557958356 Xq28 
1557797_a_at   6.47542E-05 -2.821093545  
209284_s_at 
chromosome 3 open reading 
frame 63 C3orf63 6.54699E-05 -1.511110217 3p14.3 
203306_s_at 
solute carrier family 35 
(CMP-sialic acid 
transporter), member A1 SLC35A1 6.56135E-05 -1.4582939 6q15 
213897_s_at 
mitochondrial ribosomal 
protein L23 MRPL23 6.56941E-05 1.814279996 
11p15.5-
p15.4 
213218_at zinc finger protein 187 ZNF187 6.59663E-05 -1.52709892 6p21.31 
217753_s_at ribosomal protein S26 RPS26 6.61515E-05 1.644465503 12q13 
224464_s_at 
nudix (nucleoside 
diphosphate linked moiety 
X)-type motif 22 NUDT22 6.62014E-05 1.487490707 11q13.1 
238019_at lipid storage droplet protein 5 LSDP5 6.63238E-05 1.544365851 19p13.3 
204331_s_at 
mitochondrial ribosomal 
protein S12 MRPS12 6.6806E-05 1.381481331 
19q13.1-
q13.2 
222266_at 
chromosome 19 open reading 
frame 2 C19orf2 6.69904E-05 -1.797730625 19q12 
203255_at F-box protein 11 FBXO11 6.72457E-05 -1.448980045 2p16.3 
1555896_a_at 
ADAM metallopeptidase 
domain 15 ADAM15 6.75508E-05 1.411477487 1q21.3 
238317_x_at   6.80931E-05 -2.4399524  
208751_at 
N-ethylmaleimide-sensitive 
factor attachment protein, 
alpha NAPA 6.87451E-05 2.107879821 19q13.32 
211752_s_at 
NADH dehydrogenase 
(ubiquinone) Fe-S protein 7, 
20kDa (NADH-coenzyme Q 
reductase) NDUFS7 6.90296E-05 1.857128398 19p13.3 
208861_s_at 
alpha thalassemia/mental 
retardation syndrome X-
linked (RAD54 homolog, S. 
cerevisiae) ATRX 6.99745E-05 -1.595450243 
Xq13.1-
q21.1 
200789_at 
enoyl Coenzyme A hydratase 
1, peroxisomal ECH1 7.00609E-05 1.541758711 19q13.1 
230155_x_at 
male-specific lethal 1 
homolog (Drosophila) MSL1 7.0228E-05 1.304254789 17q21.1 
1556316_s_at 
hypothetical protein 
LOC284889 
LOC28488
9 7.03556E-05 2.228446497 22q11.23 
241969_at 
AT rich interactive domain 
5B (MRF1-like) ARID5B 7.03832E-05 -1.838969925 10q21.2 
211987_at 
topoisomerase (DNA) II beta 
180kDa TOP2B 7.0561E-05 -1.423589178 3p24 
209113_s_at high-mobility group 20B HMG20B 7.06827E-05 1.721355059 19p13.3 
242941_x_at T-box 1 TBX1 7.08671E-05 1.322908462 22q11.21 
219241_x_at 
slingshot homolog 3 
(Drosophila) SSH3 7.11143E-05 1.397050368 11q13.1 
 263 
Probe set ID Gene title 
Gene 
symbol P-Value Fold change Cytoband 
224591_at 
heterochromatin protein 1, 
binding protein 3 HP1BP3 7.15292E-05 -1.404146697 1p36.12 
222478_at 
vacuolar protein sorting 36 
homolog  VPS36 7.18842E-05 -1.658923316 13q14.3 
228251_at UBX domain protein 6 UBXN6 7.30153E-05 1.579580908 19p13 
209943_at 
F-box and leucine-rich repeat 
protein 4 FBXL4 7.30975E-05 -1.808077951 
6q16.1-
q16.3 
217756_x_at small EDRK-rich factor 2 SERF2 7.33257E-05 1.662519486 15q15.3 
203467_at phosphomannomutase 1 PMM1 7.34059E-05 1.424677896 22q13.2 
227917_at 
family with sequence 
similarity 85, member A FAM85A 7.42076E-05 -1.943061721 8p23.1 
236496_at 
degenerative spermatocyte 
homolog 2, lipid desaturase 
(Drosophila) DEGS2 7.42527E-05 1.690155156 14q32.2 
205667_at Werner syndrome WRN 7.4313E-05 -1.728698192 8p12-p11.2 
200948_at myeloid leukemia factor 2 MLF2 7.4883E-05 1.372646723 12p13 
1570255_s_at 
ankyrin repeat domain 20 
family, member A 
pseudogene 
LOC37501
0 7.51874E-05 -1.915152479 1q12 
231271_x_at 
NmrA-like family domain 
containing 1 NMRAL1 7.545E-05 1.414425634 16p13.3 
218743_at 
chromatin modifying protein 
6 CHMP6 7.56213E-05 1.424963038 17q25.3 
1562762_at 
chromosome 3 open reading 
frame 56 C3orf56 7.5981E-05 1.368551532 3q21.3 
203310_at syntaxin binding protein 3 STXBP3 7.60534E-05 -1.677254106 1p13.3 
239136_at hCG1818231 
hCG_1818
231 7.69267E-05 2.126355616 10q22.1 
223312_at 
chromosome 2 open reading 
frame 7 C2orf7 7.73347E-05 1.5636213 2p13.2 
217729_s_at 
amino-terminal enhancer of 
split AES 7.76311E-05 1.987999025 19p13.3 
225022_at 
golgi associated PDZ and 
coiled-coil motif containing GOPC 7.77664E-05 -1.536875674 6q21 
212574_x_at 
chromosome 19 open reading 
frame 6 C19orf6 7.92467E-05 1.567026544 19p13.3 
204165_at 
WAS protein family, member 
1 WASF1 8.07107E-05 -1.533883397 6q21-q22 
231166_at 
G protein-coupled receptor 
155 GPR155 8.11117E-05 -1.661146269 2q31.1 
203774_at 
5-methyltetrahydrofolate-
homocysteine 
methyltransferase MTR 8.11754E-05 -1.708434188 1q43 
219171_s_at zinc finger protein 236 ZNF236 8.13229E-05 -1.59022103 18q22-q23 
41047_at 
chromosome 9 open reading 
frame 16 C9orf16 8.23979E-05 1.785732645 9q34.1 
218634_at 
pleckstrin homology-like 
domain, family A, member 3 PHLDA3 8.36331E-05 1.377881234 1q31 
209705_at 
metal response element 
binding transcription factor 2 MTF2 8.38979E-05 -1.740623178 1p22.1 
203049_s_at 
tetratricopeptide repeat 
domain 37 TTC37 8.43686E-05 -1.472240731 5q15 
203193_at 
estrogen-related receptor 
alpha ESRRA 8.44555E-05 1.266341286 11q13 
217083_at 
immunoglobulin heavy 
constant gamma 1 (G1m 
marker) IGHG1 8.50348E-05 1.325092379 14q32.33 
219214_s_at 
RB-associated KRAB zinc 
finger RBAK 8.55336E-05 1.401263253 7p22.1 
205314_x_at 
syntrophin, beta 2 
(dystrophin-associated 
protein A1, 59kDa, basic SNTB2 8.5747E-05 1.423865259 16q22-q23 
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component 2) 
200954_at 
ATPase, H+ transporting, 
lysosomal 16kDa, V0 subunit 
c ATP6V0C 8.64443E-05 1.527694932 16p13.3 
217782_s_at 
G protein pathway 
suppressor 1 GPS1 8.68781E-05 1.517177934 17q25.3 
218105_s_at 
mitochondrial ribosomal 
protein L4 MRPL4 8.7032E-05 1.679245378 19p13.2 
203189_s_at 
NADH dehydrogenase 
(ubiquinone) Fe-S protein 8, 
23kDa (NADH-coenzyme Q 
reductase) NDUFS8 8.73655E-05 2.014528133 11q13 
208603_s_at 
mitogen-activated protein 
kinase 8 interacting protein 2 MAPK8IP2 8.76429E-05 1.309576969 22q13.33 
210350_x_at 
inhibitor of growth family, 
member 1 ING1 8.78081E-05 1.306323029 13q34 
213789_at 
emopamil binding protein 
(sterol isomerase) EBP 8.78664E-05 2.050895811 
Xp11.23-
p11.22 
217006_x_at fatty acid synthase FASN 8.86278E-05 1.616463446 17q25 
221693_s_at 
mitochondrial ribosomal 
protein S18A MRPS18A 8.98702E-05 1.621615121 6p21.3 
202473_x_at 
host cell factor C1 (VP16-
accessory protein) HCFC1 9.00122E-05 1.308345581 Xq28 
237228_at 
zinc finger, DHHC-type 
containing 1 ZDHHC1 9.04202E-05 1.297956414 16q22.1 
222604_at 
general transcription factor 
IIIC, polypeptide 3, 102kDa GTF3C3 9.05107E-05 -1.345543339 2q33.1 
227281_at 
solute carrier family 29 
(nucleoside transporters), 
member 4 SLC29A4 9.05316E-05 1.32903678 7p22.1 
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Probeset ID Gene Title Gene Symbol p-value Fold-
Change 
229780_at --- --- 2.42E-06 1.53632 
218802_at coiled-coil domain containing 109B CCDC109B 2.23E-06 1.69093 
213807_x_at met proto-oncogene (hepatocyte growth factor 
receptor) 
MET 2.96E-06 2.80179 
209493_at PDZ domain containing 2 PDZD2 3.09E-06 -3.14394 
200872_at S100 calcium binding protein A10 S100A10 3.55E-06 2.05505 
205327_s_at activin A receptor, type IIA ACVR2A 3.63E-06 -2.05176 
1556409_a_at hypothetical protein LOC100129932 LOC1001299
32 
4.49E-06 7.81602 
230973_at SH2 domain containing 5 SH2D5 4.54E-06 4.85248 
210841_s_at neuropilin 2 NRP2 2.00E-05 1.90916 
205676_at cytochrome P450, family 27, subfamily B, 
polypeptide 1 
CYP27B1 5.41E-06 4.58211 
211811_s_at protocadherin alpha 6 PCDHA6 0.000503 1.09282 
226682_at RAR-related orphan receptor A RORA 6.86E-06 -3.71951 
1552264_a_at mitogen-activated protein kinase 1 MAPK1 7.44E-06 1.5263 
222108_at adhesion molecule with Ig-like domain 2 AMIGO2 7.62E-06 5.57191 
222646_s_at ERO1-like  ERO1L 8.32E-06 3.43587 
225824_at cyclin K CCNK 9.27E-06 1.4076 
242197_x_at CD36 molecule (thrombospondin receptor) CD36 9.34E-06 -4.58633 
215300_s_at flavin containing monooxygenase 5 FMO5 1.01E-05 -3.62491 
240602_at HBS1-like  HBS1L 7.42E-05 -1.57954 
241633_x_at --- --- 2.88E-05 -1.74248 
1554016_a_at chromosome 16 open reading frame 57 C16orf57 1.59E-05 2.2748 
230621_at isoamyl acetate-hydrolyzing esterase 1 homolog  IAH1 1.80E-05 1.42922 
200625_s_at CAP, adenylate cyclase-associated protein 1  CAP1 1.75E-05 1.50643 
1554432_x_at family with sequence similarity 165, member B FAM165B 5.50E-05 1.40019 
205680_at matrix metallopeptidase 10 (stromelysin 2) MMP10 1.97E-05 19.3414 
235975_at --- --- 9.97E-05 -1.2992 
229135_at FAST kinase domains 2 FASTKD2 9.42E-05 -1.28937 
218060_s_at chromosome 16 open reading frame 57 C16orf57 2.18E-05 1.70954 
242515_x_at chromosome 11 open reading frame 17 C11orf17 2.89E-05 1.49073 
206300_s_at parathyroid hormone-like hormone PTHLH 2.50E-05 6.32889 
231094_s_at methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1-like 
MTHFD1L 2.43E-05 2.76837 
202591_s_at single-stranded DNA binding protein 1 SSBP1 3.28E-05 1.23288 
233011_at Annexin A1 ANXA1 2.47E-05 5.95756 
213798_s_at CAP, adenylate cyclase-associated protein 1  CAP1 2.54E-05 1.50484 
213816_s_at met proto-oncogene (hepatocyte growth factor 
receptor) 
MET 2.79E-05 3.72034 
243626_at --- --- 3.02E-05 -2.01484 
203233_at interleukin 4 receptor IL4R 2.84E-05 2.37028 
202006_at protein tyrosine phosphatase, non-receptor type 
12 
PTPN12 2.92E-05 1.89658 
235798_at transmembrane protein 170B TMEM170B 3.09E-05 -3.15968 
219190_s_at eukaryotic translation initiation factor 2C, 4 EIF2C4 3.22E-05 -1.83623 
210486_at ankyrin repeat and MYND domain containing 1 ANKMY1 6.11E-05 -1.42345 
1569269_s_at SLIT-ROBO Rho GTPase activating protein 1 SRGAP1 3.75E-05 2.17369 
225349_at zinc finger protein 496 ZNF496 0.000392 1.42188 
207342_at cyclic nucleotide gated channel beta 1 CNGB1 4.16E-05 5.57959 
222704_at polymerase (RNA) I polypeptide A, 194kDa POLR1A 9.75E-05 1.2764 
219750_at transmembrane protein 144 TMEM144 0.000132 -1.80169 
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242379_at --- --- 4.23E-05 -3.94757 
226609_at discoidin, CUB and LCCL domain containing 1 DCBLD1 4.18E-05 2.7221 
224747_at ubiquitin-conjugating enzyme E2Q family 
member 2 
UBE2Q2 4.21E-05 2.1095 
235971_at --- --- 0.000147 -2.2957 
1557342_a_at hypothetical LOC400931 LOC400931 5.52E-05 1.54781 
211599_x_at met proto-oncogene (hepatocyte growth factor 
receptor) 
MET 5.30E-05 2.75304 
218498_s_at ERO1-like  ERO1L 4.86E-05 2.54495 
203256_at cadherin 3, type 1, P-cadherin (placental) CDH3 4.71E-05 3.33239 
235914_at synaptopodin SYNPO 5.17E-05 2.27042 
222339_x_at --- --- 9.27E-05 -2.13736 
205745_x_at ADAM metallopeptidase domain 17 ADAM17 5.74E-05 1.37447 
208622_s_at ezrin EZR 8.09E-05 1.41628 
204494_s_at chromosome 15 open reading frame 39 C15orf39 6.64E-05 1.24764 
238482_at Kruppel-like factor 7 (ubiquitous) KLF7 6.04E-05 3.64464 
201087_at paxillin PXN 6.54E-05 1.93387 
201393_s_at insulin-like growth factor 2 receptor IGF2R 0.000415 1.28926 
240015_at --- --- 0.000151 1.91345 
217867_x_at beta-site APP-cleaving enzyme 2 BACE2 8.64E-05 1.82256 
211426_x_at guanine nucleotide binding protein (G protein), q 
polypeptide 
GNAQ 7.14E-05 1.75944 
237701_at chromosome 12 open reading frame 54 C12orf54 8.00E-05 1.65768 
1559052_s_at p21 protein (Cdc42/Rac)-activated kinase 2 PAK2 8.95E-05 1.74901 
1556773_at --- --- 8.12E-05 12.3023 
202728_s_at latent transforming growth factor beta binding 
protein 1 
LTBP1 7.28E-05 3.00104 
226214_at glycerophosphodiester phosphodiesterase 1 GDE1 7.59E-05 -1.78374 
235236_at Uncharacterized protein LOC100131897 LOC1001318
97 
8.69E-05 -1.62846 
225464_at FERM domain containing 6 FRMD6 8.89E-05 1.53394 
1569878_at cyclin Y-like 2 CCNYL2 0.000205 1.24885 
41220_at septin 9 Sep-09 8.76E-05 1.59908 
225750_at --- --- 8.38E-05 2.75938 
226038_at LON peptidase N-terminal domain and ring 
finger 1 
LONRF1 8.19E-05 -3.07316 
241811_x_at solute carrier family 6 (neurotransmitter 
transporter, serotonin), member 4 
SLC6A4 8.51E-05 -1.41113 
1559949_at --- --- 9.33E-05 -2.10212 
204207_s_at RNA guanylyltransferase and 5'-phosphatase RNGTT 9.71E-05 1.65204 
225756_at casein kinase 1, epsilon CSNK1E 8.59E-05 1.50522 
239543_s_at --- --- 9.11E-05 -1.24391 
229865_at fibronectin type III domain containing 3B FNDC3B 0.000101 3.04804 
203142_s_at adaptor-related protein complex 3, beta 1 subunit AP3B1 0.000244 1.41198 
209162_s_at PRP4 pre-mRNA processing factor 4 homolog  PRPF4 0.000147 1.61844 
230360_at gliomedin GLDN 8.95E-05 -3.49393 
203510_at met proto-oncogene (hepatocyte growth factor 
receptor) 
MET 9.20E-05 3.10666 
225520_at methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1-like 
MTHFD1L 9.22E-05 3.7706 
208188_at keratin 9 KRT9 9.48E-05 -39.196 
225589_at SH3 domain containing ring finger 1 SH3RF1 0.000151 1.52718 
226797_at mbt domain containing 1 MBTD1 0.000116 -1.56071 
209535_s_at --- --- 0.000106 -2.3754 
211546_x_at synuclein, alpha (non A4 component of amyloid 
precursor) 
SNCA 0.000278 -1.352 
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212364_at myosin IB MYO1B 0.000127 2.06592 
227629_at prolactin receptor PRLR 0.000133 -3.86993 
1554835_a_at UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 5 
B3GNT5 0.00012 2.22531 
217733_s_at thymosin beta 10 TMSB10 0.000116 1.66637 
235881_at Formin-like 2 FMNL2 0.000124 2.03375 
240951_at RAR-related orphan receptor A RORA 0.000124 -2.80465 
221962_s_at ubiquitin-conjugating enzyme E2H (UBC8 
homolog, yeast) 
UBE2H 0.00014 1.63875 
209453_at solute carrier family 9 (sodium/hydrogen 
exchanger), member 1 
SLC9A1 0.000153 1.64827 
220750_s_at leucine proline-enriched proteoglycan (leprecan) 
1 
LEPRE1 0.000335 1.18465 
201990_s_at cAMP responsive element binding protein-like 2 CREBL2 0.000335 -1.78935 
1562682_at RAR-related orphan receptor A RORA 0.000137 -2.50265 
AFFX-
HSAC07/X0035
1_M_at 
actin, beta ACTB 0.000132 1.42301 
201397_at phosphoglycerate dehydrogenase PHGDH 0.000127 -2.05541 
228710_at --- --- 0.000128 -1.33834 
208901_s_at topoisomerase (DNA) I TOP1 0.000184 1.24945 
242665_at formin-like 2 FMNL2 0.00013 2.38695 
207531_at crystallin, gamma C CRYGC 0.000237 1.20957 
1560001_at hypothetical LOC100131581 LOC1001315
81 
0.000155 -2.20269 
235567_at RAR-related orphan receptor A RORA 0.000132 -2.98321 
212365_at myosin IB MYO1B 0.000142 2.4953 
217789_at sorting nexin 6 SNX6 0.000133 1.41191 
200079_s_at lysyl-tRNA synthetase KARS 0.000159 1.37345 
1563728_at non-protein coding RNA 32 NCRNA0003
2 
0.000146 1.41163 
208740_at Sin3A-associated protein, 18kDa SAP18 0.0002 -1.43278 
1552716_at sperm flagellar 2 SPEF2 0.000144 -1.8938 
226153_s_at CCR4-NOT transcription complex, subunit 6-
like 
CNOT6L 0.000175 -1.37733 
210779_x_at survival of motor neuron protein interacting 
protein 1 
SIP1 0.000145 1.62958 
239380_at chromosome 5 open reading frame 27 C5orf27 0.000149 -5.65543 
1566268_at --- --- 0.000147 3.88214 
227806_at chromosome 16 open reading frame 74 C16orf74 0.000191 1.51851 
231060_at Heterogeneous nuclear ribonucleoprotein A/B HNRNPAB 0.000539 1.15992 
56256_at SID1 transmembrane family, member 2 SIDT2 0.000159 -1.95267 
213214_x_at actin, gamma 1 ACTG1 0.000158 1.21985 
203484_at Sec61 gamma subunit SEC61G 0.000158 1.36189 
221691_x_at nucleophosmin (nucleolar phosphoprotein B23, 
numatrin) 
NPM1 0.000182 1.21563 
226303_at phosphoglucomutase 5 PGM5 0.000173 -1.78319 
216297_at --- --- 0.00017 -2.59228 
216235_s_at endothelin receptor type A EDNRA 0.000177 1.58481 
206571_s_at mitogen-activated protein kinase kinase kinase 
kinase 4 
MAP4K4 0.000175 1.70297 
210479_s_at RAR-related orphan receptor A RORA 0.000169 -3.31144 
235921_at --- --- 0.000319 1.72817 
206445_s_at protein arginine methyltransferase 1 PRMT1 0.000178 1.54856 
203324_s_at caveolin 2 CAV2 0.000171 2.03479 
203736_s_at PTPRF interacting protein, binding protein 1 
(liprin beta 1) 
PPFIBP1 0.000191 1.70213 
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213283_s_at sal-like 2 (Drosophila) SALL2 0.000178 -1.64097 
225893_at ring finger and CCCH-type zinc finger domains 
1 
RC3H1 0.000261 -1.29057 
229933_at chromosome 1 open reading frame 74 C1orf74 0.00018 2.6003 
202990_at phosphorylase, glycogen, liver PYGL 0.000181 2.41028 
207761_s_at methyltransferase like 7A METTL7A 0.000195 -4.06615 
1566830_at hypothetical gene supported by BC040853 LOC440028 0.000276 1.27376 
204989_s_at integrin, beta 4 ITGB4 0.000181 1.50695 
202192_s_at growth arrest-specific 7 GAS7 0.000254 -2.67155 
217904_s_at beta-site APP-cleaving enzyme 1 BACE1 0.000182 -1.8068 
210627_s_at mannosyl-oligosaccharide glucosidase MOGS 0.000307 1.50038 
219953_s_at chromosome 11 open reading frame 17 C11orf17 0.000188 1.90815 
203607_at inositol polyphosphate-5-phosphatase F INPP5F 0.000191 1.2477 
211926_s_at myosin, heavy chain 9, non-muscle MYH9 0.000344 1.75241 
203695_s_at deafness, autosomal dominant 5 DFNA5 0.000186 4.57299 
202085_at tight junction protein 2 (zona occludens 2) TJP2 0.000234 1.81425 
201231_s_at enolase 1, (alpha) ENO1 0.000199 1.47025 
200650_s_at lactate dehydrogenase A LDHA 0.000193 1.32291 
222583_s_at nucleoporin 50kDa NUP50 0.00019 1.57447 
233903_s_at Src homology 3 domain-containing guanine 
nucleotide exchange factor 
SGEF 0.000198 -3.69115 
207798_s_at ataxin 2-like ATXN2L 0.000196 1.63942 
210355_at parathyroid hormone-like hormone PTHLH 0.000225 11.9142 
202720_at testis derived transcript (3 LIM domains) TES 0.000223 1.68248 
210493_s_at microfibrillar-associated protein 3-like MFAP3L 0.000203 -2.05447 
204268_at S100 calcium binding protein A2 S100A2 0.000207 1.29623 
1552477_a_at interferon regulatory factor 6 IRF6 0.000353 2.32054 
212871_at mitogen-activated protein kinase-activated 
protein kinase 5 
MAPKAPK5 0.000398 1.27048 
230380_at THAP domain containing, apoptosis associated 
protein 2 
THAP2 0.000345 2.04029 
209344_at tropomyosin 4 TPM4 0.000212 1.72218 
210426_x_at RAR-related orphan receptor A RORA 0.000211 -3.16527 
209190_s_at diaphanous homolog 1 (Drosophila) DIAPH1 0.000234 1.46642 
1559240_at --- --- 0.000352 1.85358 
215744_at fusion (involved in t(12;16) in malignant 
liposarcoma) 
FUS 0.000288 1.32056 
229331_at spermatogenesis associated 18 homolog (rat) SPATA18 0.00024 -2.74211 
227140_at --- --- 0.000223 4.8803 
226190_at --- --- 0.000242 2.05277 
227197_at Src homology 3 domain-containing guanine 
nucleotide exchange factor 
SGEF 0.000251 -3.25162 
204926_at inhibin, beta A INHBA 0.000223 6.10956 
205786_s_at integrin, alpha M (complement component 3 
receptor 3 subunit) 
ITGAM 0.000478 -2.61529 
241147_at --- --- 0.000244 -2.51995 
238867_at transmembrane protein 182 TMEM182 0.000255 1.91138 
209302_at polymerase (RNA) II (DNA directed) 
polypeptide H 
POLR2H 0.000294 1.36332 
225545_at eukaryotic elongation factor-2 kinase EEF2K 0.00023 -1.71607 
218982_s_at mitochondrial ribosomal protein S17 /// zinc 
finger protein 713 
MRPS17 /// 
ZNF713 
0.000235 1.67682 
211241_at annexin A2 pseudogene 3 ANXA2P3 0.000248 1.30391 
233924_s_at exocyst complex component 6 EXOC6 0.000341 -1.69732 
221641_s_at acyl-CoA thioesterase 9 ACOT9 0.000241 2.16669 
219313_at GRAM domain containing 1C GRAMD1C 0.000251 -4.25361 
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201251_at pyruvate kinase, muscle PKM2 0.000248 1.68619 
1553083_at --- --- 0.000317 -1.30593 
201196_s_at adenosylmethionine decarboxylase 1 AMD1 0.000303 1.38815 
225990_at Boc homolog (mouse) BOC 0.000256 -2.55229 
239453_at --- --- 0.00033 -1.83834 
212548_s_at FRY-like FRYL 0.000254 1.34956 
243244_at calcium channel, voltage-dependent, beta 4 
subunit 
CACNB4 0.000256 -4.08476 
1560683_at B-cell CLL/lymphoma 8 BCL8 0.000464 -1.15467 
214433_s_at selenium binding protein 1 SELENBP1 0.00027 -1.8987 
206581_at basonuclin 1 BNC1 0.00028 1.48407 
1568574_x_at Secreted phosphoprotein 1 SPP1 0.000327 10.8626 
222799_at WD repeat domain 91 WDR91 0.000282 1.84593 
224862_at Guanine nucleotide binding protein (G protein), 
q polypeptide 
GNAQ 0.000272 1.71912 
212224_at aldehyde dehydrogenase 1 family, member A1 ALDH1A1 0.000282 -6.31864 
227280_s_at cyclin Y-like 1 CCNYL1 0.000398 1.81355 
204334_at Kruppel-like factor 7 (ubiquitous) KLF7 0.000277 2.46142 
202603_at --- --- 0.00028 1.45967 
201950_x_at capping protein (actin filament) muscle Z-line, 
beta 
CAPZB 0.000405 1.21881 
204731_at transforming growth factor, beta receptor III TGFBR3 0.0003 -4.70196 
231984_at methylthioadenosine phosphorylase MTAP 0.000296 1.8099 
231041_at polymerase (RNA) I polypeptide E, 53kDa POLR1E 0.000347 1.63073 
206662_at glutaredoxin (thioltransferase) GLRX 0.000287 -3.0689 
210511_s_at inhibin, beta A INHBA 0.000294 6.97435 
202824_s_at transcription elongation factor B (SIII), 
polypeptide 1 (15kDa, elongin C) 
TCEB1 0.0004 1.33214 
208613_s_at filamin B, beta (actin binding protein 278) FLNB 0.000501 1.82915 
221891_x_at heat shock 70kDa protein 8 HSPA8 0.000299 1.23602 
244395_at hypothetical gene supported by AK123449; 
BX641014 
FLJ41455 0.000308 -1.74541 
226625_at transforming growth factor, beta receptor III TGFBR3 0.000309 -3.8052 
201516_at spermidine synthase SRM 0.000333 1.42134 
227391_x_at leucine rich repeat (in FLII) interacting protein 1 LRRFIP1 0.000336 1.48843 
211756_at parathyroid hormone-like hormone PTHLH 0.000327 16.6142 
201170_s_at basic helix-loop-helix family, member e40 BHLHE40 0.000319 2.0829 
202780_at 3-oxoacid CoA transferase 1 OXCT1 0.000315 -1.95223 
207988_s_at actin related protein 2/3 complex, subunit 2, 
34kDa 
ARPC2 0.000363 1.26092 
232746_at Chemokine (C-X-C motif) receptor 7 CXCR7 0.000443 2.31508 
232840_at --- --- 0.000468 1.62886 
32699_s_at poliovirus receptor PVR 0.000408 1.39631 
203263_s_at Cdc42 guanine nucleotide exchange factor 
(GEF) 9 
ARHGEF9 0.000325 -1.61066 
220765_s_at LIM and senescent cell antigen-like domains 2 LIMS2 0.000355 -1.24366 
204315_s_at G-2 and S-phase expressed 1 GTSE1 0.000328 1.79314 
216884_at protein tyrosine phosphatase, non-receptor type 
12 
PTPN12 0.000342 1.82271 
204344_s_at Sec23 homolog A  SEC23A 0.000375 1.52361 
227513_s_at Leucine rich repeat (in FLII) interacting protein 
1 
LRRFIP1 0.000333 1.51272 
228376_at glycoprotein, alpha-galactosyltransferase 1 GGTA1 0.000387 -2.33678 
207390_s_at smoothelin SMTN 0.000339 1.8882 
235563_at --- --- 0.000346 7.5843 
225688_s_at pleckstrin homology-like domain, family B, PHLDB2 0.000348 3.25654 
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member 2 
211924_s_at plasminogen activator, urokinase receptor PLAUR 0.000435 3.29669 
210554_s_at C-terminal binding protein 2 CTBP2 0.000482 1.57007 
232030_at KIAA1632 KIAA1632 0.000379 -2.37945 
212563_at block of proliferation 1 BOP1 0.000373 1.67015 
231773_at angiopoietin-like 1 ANGPTL1 0.000504 -2.34584 
211947_s_at BAT2 domain containing 1 BAT2D1 0.000368 1.45674 
201052_s_at proteasome (prosome, macropain) inhibitor 
subunit 1 (PI31) 
PSMF1 0.000366 1.2456 
41660_at cadherin, EGF LAG seven-pass G-type receptor 
1 (flamingo homolog, Drosophila) 
CELSR1 0.000451 1.78107 
210845_s_at plasminogen activator, urokinase receptor PLAUR 0.000397 4.37906 
201888_s_at interleukin 13 receptor, alpha 1 IL13RA1 0.000443 1.67993 
231063_at --- --- 0.000363 -1.56295 
201466_s_at jun oncogene JUN 0.000542 2.42646 
212056_at KIAA0182 KIAA0182 0.000369 -1.69278 
231016_s_at --- --- 0.000459 1.22162 
201590_x_at annexin A2 ANXA2 0.000385 1.27343 
212104_s_at RNA binding motif protein 9 RBM9 0.000377 1.30734 
200830_at proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 2 
PSMD2 0.000377 1.33128 
222976_s_at tropomyosin 3 TPM3 0.000403 1.43347 
222396_at hematological and neurological expressed 1 HN1 0.00038 1.68386 
202440_s_at suppression of tumorigenicity 5 ST5 0.000389 2.092 
227461_at stonin 2 STON2 0.000408 1.69335 
211621_at androgen receptor AR 0.00042 -1.54911 
208816_x_at annexin A2 pseudogene 2 ANXA2P2 0.000414 1.31903 
218368_s_at tumor necrosis factor receptor superfamily, 
member 12A 
TNFRSF12A 0.000534 1.97176 
210843_s_at microfibrillar-associated protein 3-like MFAP3L 0.000466 -5.77982 
228835_at --- --- 0.000431 -1.7084 
217807_s_at glioma tumor suppressor candidate region gene 2 GLTSCR2 0.000513 -1.71327 
227917_at family with sequence similarity 85, member A FAM85A 0.000434 -2.21545 
212201_at ankyrin repeat and LEM domain containing 2 ANKLE2 0.000442 1.56306 
211048_s_at protein disulfide isomerase family A, member 4 PDIA4 0.000506 1.52113 
213387_at ATPase family, AAA domain containing 2B ATAD2B 0.000478 -1.36004 
1558489_at --- --- 0.00047 -1.35187 
207945_s_at casein kinase 1, delta CSNK1D 0.0005 1.638 
213503_x_at annexin A2 ANXA2 0.000434 1.26797 
1562529_s_at --- --- 0.000434 -2.4999 
231449_at --- --- 0.000441 -2.49737 
202615_at Guanine nucleotide binding protein (G protein), 
q polypeptide 
GNAQ 0.000448 1.60767 
1559048_at --- --- 0.000473 1.38646 
210023_s_at polycomb group ring finger 1 PCGF1 0.000445 1.50738 
211160_x_at actinin, alpha 1 ACTN1 0.000441 2.71319 
224187_x_at heat shock 70kDa protein 8 HSPA8 0.000511 1.24773 
227519_at placenta-specific 4 PLAC4 0.000452 1.94776 
212133_at Cytoplasmic FMR1 interacting protein 1 CYFIP1 0.000452 1.37851 
215707_s_at prion protein PRNP 0.000562 1.66007 
203857_s_at protein disulfide isomerase family A, member 5 PDIA5 0.000455 1.98868 
202949_s_at four and a half LIM domains 2 FHL2 0.00046 1.94775 
1569044_at CDC42 binding protein kinase gamma (DMPK-
like) 
CDC42BPG 0.000461 -2.20035 
1564208_x_at hypothetical LOC255031 FLJ35390 0.000473 -1.40198 
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231064_s_at --- --- 0.000472 1.4564 
227484_at SLIT-ROBO Rho GTPase activating protein 1 SRGAP1 0.000472 2.48497 
208824_x_at PCTAIRE protein kinase 1 PCTK1 0.000564 1.37206 
1552390_a_at chromosome 8 open reading frame 47 C8orf47 0.000475 -2.05693 
229208_at HAUS augmin-like complex, subunit 2 HAUS2 0.00048 1.74977 
204475_at matrix metallopeptidase 1 (interstitial 
collagenase) 
MMP1 0.000508 22.8693 
32091_at solute carrier family 25, member 44 SLC25A44 0.000506 -1.14295 
232547_at SNAP25-interacting protein SNIP 0.000517 -2.70783 
226377_at --- --- 0.000542 -2.00079 
219246_s_at 2-oxoglutarate and iron-dependent oxygenase 
domain containing 2 
OGFOD2 0.00057 -1.57057 
202604_x_at ADAM metallopeptidase domain 10 ADAM10 0.000495 1.60142 
219350_s_at diablo homolog (Drosophila) DIABLO 0.000523 1.2135 
219489_s_at nucleoredoxin NXN 0.000494 1.8431 
242228_at --- --- 0.000536 2.37938 
214451_at transcription factor AP-2 beta (activating 
enhancer binding protein 2 beta) 
TFAP2B 0.0005 -3.41372 
219693_at 1-acylglycerol-3-phosphate O-acyltransferase 4 
(lysophosphatidic acid acyltransf 
AGPAT4 0.000546 2.17749 
1554778_at pleckstrin homology-like domain, family B, 
member 2 
PHLDB2 0.000514 1.7124 
213337_s_at suppressor of cytokine signaling 1 SOCS1 0.000507 1.48022 
213514_s_at diaphanous homolog 1 (Drosophila) DIAPH1 0.000571 1.43084 
244572_at kyphoscoliosis peptidase KY 0.000507 -3.45999 
209465_x_at pleiotrophin PTN 0.00055 -4.5912 
221915_s_at RAN binding protein 1 RANBP1 0.000519 1.82766 
224184_s_at Boc homolog (mouse) BOC 0.000575 -1.84533 
238431_at --- --- 0.000521 -1.67145 
34689_at three prime repair exonuclease 1 TREX1 0.000578 -1.42624 
1554314_at chromosome 6 open reading frame 141 C6orf141 0.00055 3.19033 
236266_at RAR-related orphan receptor A RORA 0.000541 -2.95675 
237737_at similar to ankyrin repeat domain 20 family, 
member A1 
LOC727770 0.000568 -2.2394 
226621_at --- --- 0.000546 2.62483 
204178_s_at RNA binding motif protein 14 RBM14 0.000579 1.31102 
212012_at peroxidasin homolog (Drosophila) PXDN 0.00056 3.21308 
226347_at --- --- 0.000561 1.56434 
238419_at pleckstrin homology-like domain, family B, 
member 2 
PHLDB2 0.000575 3.01183 
201751_at Josephin domain containing 1 JOSD1 0.000564 1.81602 
210352_at bromodomain containing 8 BRD8 0.000566 -1.27596 
1559753_at --- --- 0.000564 1.25479 
212363_x_at actin, gamma 1 ACTG1 0.000564 1.43291 
201550_x_at actin, gamma 1 ACTG1 0.000576 1.28519 
236511_at --- --- 0.000578 -2.02281 
205729_at oncostatin M receptor OSMR 0.000581 2.41762 
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APPENDIX C: Heatmaps showing clustering of normal and precancerous skin samples (Dr A. Gulati, unpublished data). 
1) Samples clustered using the 65 differentially expressed probe sets from ANOVA 2. 
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2) Samples clustered using the 47 differentially expressed probe sets from ANOVA 3. 
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3) Samples clustered using the 31 differentially expressed probe sets common to all three ANOVA analyses. 
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APPENDIX D: Heatmap showing clustering of normal skin and BCC from the Riker (2008) dataset. 
1) Samples clustered using the 65 differentially expressed probe sets identified by ANOVA 2. 
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2) Samples clustered using the 47 differentially expressed probe sets identified by ANOVA 3. 
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APPENDIX E: 396 differentially expresesed probe sets from the metastatic 
vs. AK analysis.  P-value and fold change are shown. 
 
Probeset ID Gene Title Gene Symbol p-value 
Fold-
Change 
214676_x_at mucin 3A, cell surface associated MUC3A 1.66E-08 8.39213 
218537_at host cell factor C1 regulator 1 (XPO1 dependent) HCFC1R1 6.76E-08 4.28399 
231504_at coiled-coil domain containing 148 CCDC148 7.73E-08 2.08829 
203877_at matrix metallopeptidase 11 (stromelysin 3) MMP11 7.83E-08 8.27272 
214898_x_at mucin 3B, cell surface associated MUC3B 1.59E-07 4.22645 
1569659_at --- --- 5.20E-07 6.20182 
201465_s_at jun oncogene JUN 6.95E-07 5.91626 
227925_at Hypothetical gene supported by AK096370 FLJ39051 7.26E-07 6.24976 
205278_at glutamate decarboxylase 1 (brain, 67kDa) GAD1 8.81E-07 2.55818 
1554706_at 
olfactory receptor, family 2, subfamily L, 
member 13 OR2L13 9.89E-07 2.99635 
45714_at host cell factor C1 regulator 1 (XPO1 dependent) HCFC1R1 1.33E-06 5.37559 
213602_s_at Matrix metallopeptidase 11 (stromelysin 3) MMP11 1.35E-06 7.80853 
209324_s_at regulator of G-protein signaling 16 RGS16 2.81E-06 3.30966 
236984_at chromosome 4 open reading frame 26 C4orf26 3.84E-06 6.36432 
229902_at fms-related tyrosine kinase 4 FLT4 4.26E-06 1.96422 
213307_at SH3 and multiple ankyrin repeat domains 2 SHANK2 4.29E-06 4.33835 
204955_at sushi-repeat-containing protein, X-linked SRPX 5.16E-06 20.0842 
213281_at Jun oncogene JUN 5.44E-06 5.33384 
1554862_at 
cytidine monophosphate-N-acetylneuraminic 
acid hydroxylase (CMP-N-acetylneuramin CMAH 5.63E-06 1.88746 
1561140_at --- --- 5.73E-06 8.42344 
206527_at 4-aminobutyrate aminotransferase ABAT 5.79E-06 4.86341 
226839_at nuclear receptor 2C2-associated protein NR2C2AP 6.08E-06 2.2087 
233030_at patatin-like phospholipase domain containing 3 PNPLA3 6.72E-06 -37.6766 
228259_s_at erythrocyte membrane protein band 4.1 like 4A EPB41L4A 6.87E-06 -4.04601 
208124_s_at 
sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short cyt SEMA4F 7.39E-06 2.03837 
228996_at 
ring finger and CCCH-type zinc finger domains 
1 RC3H1 7.41E-06 -1.97677 
208231_at neuregulin 1 NRG1 7.74E-06 18.7803 
1565849_a_at hypothetical protein LOC100170229 
LOC1001702
29 8.13E-06 3.60924 
204338_s_at regulator of G-protein signaling 4 RGS4 8.19E-06 2.78307 
1555738_at 
CKLF-like MARVEL transmembrane domain 
containing 1 CMTM1 8.60E-06 3.28988 
220203_at bone morphogenetic protein 8a BMP8A 9.12E-06 1.9316 
228172_at --- --- 9.43E-06 7.01591 
217297_s_at myosin IXB MYO9B 1.09E-05 2.57666 
208706_s_at eukaryotic translation initiation factor 5 EIF5 1.14E-05 -2.01198 
217117_x_at mucin 3A, cell surface associated MUC3A 1.20E-05 2.0706 
1562940_at --- --- 1.29E-05 2.19892 
216471_x_at 
similar to Protein SSX2 (Synovial sarcoma, X 
breakpoint 2) (Cancer/testis antige 
LOC1001306
48 /// SSX2 /// 
SSX2B 1.32E-05 -1.7725 
236245_at outer dense fiber of sperm tails 3-like 1 ODF3L1 1.33E-05 3.20364 
218368_s_at 
tumor necrosis factor receptor superfamily, 
member 12A TNFRSF12A 1.38E-05 5.67127 
226413_at hypothetical protein LOC400027 LOC400027 1.45E-05 -3.84581 
239342_at diacylglycerol kinase, zeta 104kDa DGKZ 1.46E-05 3.17224 
203389_at kinesin family member 3C KIF3C 1.54E-05 2.69025 
1553155_x_at 
ATPase, H+ transporting, lysosomal 38kDa, V0 
subunit d2 ATP6V0D2 1.55E-05 4.58802 
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204753_s_at hepatic leukemia factor HLF 1.57E-05 -14.9967 
210841_s_at neuropilin 2 NRP2 1.59E-05 4.39425 
1554982_a_at chromosome 9 open reading frame 11 C9orf11 1.75E-05 1.96453 
205510_s_at hypothetical protein FLJ10038 FLJ10038 1.83E-05 -2.99251 
217949_s_at vitamin K epoxide reductase complex, subunit 1 VKORC1 1.88E-05 3.9296 
203876_s_at matrix metallopeptidase 11 (stromelysin 3) MMP11 1.88E-05 1.79891 
227711_at gametocyte specific factor 1 GTSF1 1.89E-05 7.06256 
218282_at 
ER degradation enhancer, mannosidase alpha-
like 2 EDEM2 2.08E-05 2.617 
201466_s_at jun oncogene JUN 2.17E-05 5.8609 
219020_at HCLS1 binding protein 3 HS1BP3 2.20E-05 2.12855 
205545_x_at DnaJ (Hsp40) homolog, subfamily C, member 8 DNAJC8 2.24E-05 1.90563 
1564049_at hypothetical LOC339593 LOC339593 2.42E-05 6.22715 
206701_x_at endothelin receptor type B EDNRB 2.54E-05 -10.3336 
244018_at --- --- 2.60E-05 3.0409 
212647_at related RAS viral (r-ras) oncogene homolog RRAS 2.63E-05 3.73789 
228528_at --- --- 2.78E-05 -10.4555 
1561324_at --- --- 2.92E-05 1.70523 
203507_at 
CD68 molecule /// eukaryotic translation 
initiation factor 4A, isoform 1 
CD68 /// 
EIF4A1 3.02E-05 3.28982 
243837_x_at hypothetical protein LOC100128500 
LOC1001285
00 3.12E-05 2.98652 
218084_x_at 
FXYD domain containing ion transport regulator 
5 FXYD5 3.14E-05 6.34151 
220043_s_at 
antigen p97 (melanoma associated) identified by 
monoclonal antibodies 133.2 and  MFI2 3.19E-05 2.31395 
236422_at --- --- 3.45E-05 -8.27516 
219410_at transmembrane protein 45A TMEM45A 3.52E-05 -11.094 
226916_x_at dipeptidyl-peptidase 9 DPP9 3.56E-05 2.04121 
219275_at programmed cell death 5 PDCD5 3.66E-05 2.18244 
205117_at fibroblast growth factor 1 (acidic) FGF1 3.69E-05 5.07818 
204093_at cyclin H CCNH 3.71E-05 -2.19286 
212703_at talin 2 TLN2 3.89E-05 3.33603 
244780_at sphingosine-1-phosphate phosphotase 2 SGPP2 3.93E-05 -10.5964 
1559072_a_at 
extracellular leucine-rich repeat and fibronectin 
type III domain containing 2 ELFN2 3.94E-05 1.78103 
201704_at 
ectonucleoside triphosphate diphosphohydrolase 
6 (putative function) ENTPD6 4.36E-05 3.03379 
229189_s_at --- --- 4.42E-05 4.48062 
238180_at --- --- 4.50E-05 2.12651 
236176_at hypothetical LOC645757 LOC645757 4.51E-05 2.17958 
219953_s_at chromosome 11 open reading frame 17 C11orf17 4.57E-05 4.83273 
32699_s_at poliovirus receptor PVR 4.64E-05 2.10905 
208168_s_at chitinase 1 (chitotriosidase) CHIT1 4.92E-05 2.53913 
224252_s_at 
FXYD domain containing ion transport regulator 
5 FXYD5 5.04E-05 6.46148 
217733_s_at thymosin beta 10 TMSB10 5.15E-05 2.30801 
228272_at DNL-type zinc finger DNLZ 5.39E-05 2.87551 
1553153_at 
ATPase, H+ transporting, lysosomal 38kDa, V0 
subunit d2 ATP6V0D2 5.39E-05 4.68947 
230686_s_at 
solute carrier family 13 (sodium-dependent 
dicarboxylate transporter), member 3 SLC13A3 5.60E-05 2.1069 
208448_x_at interferon, alpha 16 IFNA16 5.64E-05 1.44078 
226684_at ATG2 autophagy related 2 homolog B  ATG2B 5.92E-05 -2.63386 
221021_s_at catenin, beta like 1 CTNNBL1 5.95E-05 2.06418 
211502_s_at PFTAIRE protein kinase 1 PFTK1 6.01E-05 4.96715 
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203368_at cysteine-rich with EGF-like domains 1 CRELD1 6.33E-05 2.50872 
200827_at 
procollagen-lysine 1, 2-oxoglutarate 5-
dioxygenase 1 PLOD1 6.69E-05 3.66618 
241356_at --- --- 6.91E-05 -6.73871 
205244_s_at 
solute carrier family 13 (sodium-dependent 
dicarboxylate transporter), member 3 SLC13A3 7.06E-05 1.84388 
223864_at ankyrin repeat domain 30A ANKRD30A 7.17E-05 -1.4417 
244312_at --- --- 7.18E-05 -2.12066 
220120_s_at erythrocyte membrane protein band 4.1 like 4A EPB41L4A 7.41E-05 -7.75931 
201464_x_at jun oncogene JUN 7.47E-05 2.70704 
214866_at plasminogen activator, urokinase receptor PLAUR 7.48E-05 5.6284 
228256_s_at erythrocyte membrane protein band 4.1 like 4A EPB41L4A 7.50E-05 -4.40204 
220133_at odontogenic, ameloblast asssociated ODAM 7.58E-05 3.23619 
230995_at 
carboxymethylenebutenolidase homolog 
(Pseudomonas) CMBL 7.67E-05 1.78098 
230660_at SERTA domain containing 4 SERTAD4 7.76E-05 -6.88835 
238226_at family with sequence similarity 70, member B FAM70B 7.84E-05 2.88639 
208230_s_at neuregulin 1 NRG1 8.07E-05 12.7967 
209453_at 
solute carrier family 9 (sodium/hydrogen 
exchanger), member 1 SLC9A1 8.51E-05 2.92217 
223130_s_at myosin regulatory light chain interacting protein MYLIP 8.72E-05 -5.94527 
1558682_at high mobility group AT-hook 2 HMGA2 8.75E-05 1.95999 
224797_at arrestin domain containing 3 ARRDC3 9.00E-05 -3.35504 
1559970_at Hypothetical LOC730034 LOC730034 9.06E-05 3.29407 
237120_at keratin 77 KRT77 9.19E-05 -80.7387 
220936_s_at H2A histone family, member J H2AFJ 9.21E-05 -5.72794 
204271_s_at endothelin receptor type B EDNRB 9.42E-05 -8.69035 
214564_s_at protocadherin gamma subfamily C, 3 PCDHGC3 9.42E-05 3.06147 
1558890_at --- --- 9.51E-05 2.79939 
219041_s_at replication initiator 1 REPIN1 9.67E-05 -4.60366 
220945_x_at MANSC domain containing 1 MANSC1 9.92E-05 -11.3381 
209451_at 
TRAF family member-associated NFKB 
activator TANK 0.000104 -2.62416 
218681_s_at stromal cell-derived factor 2-like 1 SDF2L1 0.000104 1.94536 
228804_at 
DiGeorge syndrome critical region gene 5 (non-
protein coding) DGCR5 0.000107 1.99717 
1558930_at hypothetical protein LOC728192 LOC728192 0.000107 16.5663 
203270_at deoxythymidylate kinase (thymidylate kinase) DTYMK 0.000107 2.59227 
214770_at macrophage scavenger receptor 1 MSR1 0.00011 3.46713 
227381_at Cerebral endothelial cell adhesion molecule CERCAM 0.000111 2.12509 
229479_at --- --- 0.000111 4.82208 
1562415_a_at SPOC domain containing 1 SPOCD1 0.000113 7.83521 
210479_s_at RAR-related orphan receptor A RORA 0.000113 -13.6509 
202719_s_at testis derived transcript (3 LIM domains) TES 0.000115 3.7271 
201042_at 
transglutaminase 2 (C polypeptide, protein-
glutamine-gamma-glutamyltransferase) TGM2 0.000117 4.38029 
207821_s_at PTK2 protein tyrosine kinase 2 PTK2 0.000117 3.28881 
201210_at 
DEAD (Asp-Glu-Ala-Asp) box polypeptide 3, 
X-linked DDX3X 0.000118 -1.80571 
220119_at erythrocyte membrane protein band 4.1 like 4A EPB41L4A 0.000119 -5.3343 
210845_s_at plasminogen activator, urokinase receptor PLAUR 0.00012 10.462 
205114_s_at 
chemokine (C-C motif) ligand 3 /// chemokine 
(C-C motif) ligand 3-like 1 /// che 
CCL3 /// 
CCL3L1 /// 
CCL3L3 /// 
LOC728830 0.000121 7.35394 
211099_s_at cyclic nucleotide gated channel beta 1 CNGB1 0.000124 3.81005 
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217855_x_at stromal cell derived factor 4 SDF4 0.000124 2.41361 
229190_at --- --- 0.000126 4.0665 
1559689_a_at GRB2-related adaptor protein-like LOC400581 0.000129 2.03003 
201028_s_at CD99 molecule CD99 0.00013 3.61634 
242445_at FYVE, RhoGEF and PH domain containing 4 FGD4 0.000131 -3.63926 
243318_at WD repeat domain 42A WDR42A 0.000131 -3.58272 
227945_at 
TBC1 (tre-2/USP6, BUB2, cdc16) domain 
family, member 1 TBC1D1 0.000134 4.0083 
222396_at hematological and neurological expressed 1 HN1 0.000135 2.94795 
227233_at tetraspanin 2 TSPAN2 0.000141 4.13406 
230999_at Hypothetical gene supported by AK096370 FLJ39051 0.000142 3.69226 
202267_at laminin, gamma 2 LAMC2 0.000142 15.6594 
226417_at Ras homolog gene family, member B RHOB 0.000143 2.42369 
210805_x_at runt-related transcription factor 1 RUNX1 0.000145 5.84619 
227238_at mucin 15, cell surface associated MUC15 0.000146 -52.9361 
237166_at --- --- 0.000147 2.22123 
222581_at xenotropic and polytropic retrovirus receptor XPR1 0.000148 4.05373 
209962_at erythropoietin receptor EPOR 0.000148 2.07928 
219313_at GRAM domain containing 1C GRAMD1C 0.000149 -16.6084 
226937_at Cardiolipin synthase 1 CRLS1 0.000149 1.92925 
204358_s_at fibronectin leucine rich transmembrane protein 2 FLRT2 0.00015 7.68189 
218529_at CD320 molecule CD320 0.000155 2.43377 
216554_s_at --- --- 0.000157 4.06408 
1568574_x_at Secreted phosphoprotein 1 SPP1 0.000158 116.124 
238567_at sphingosine-1-phosphate phosphotase 2 SGPP2 0.000159 -26.6805 
201231_s_at enolase 1, (alpha) ENO1 0.000159 2.944 
1559949_at --- --- 0.00016 -7.45188 
227705_at transcription elongation factor A (SII)-like 7 TCEAL7 0.00016 2.61196 
244089_at --- --- 0.000161 1.79161 
232730_at chromosome 19 open reading frame 44 C19orf44 0.000161 1.92118 
207038_at 
solute carrier family 16, member 6 
(monocarboxylic acid transporter 7) SLC16A6 0.000162 -7.51337 
210426_x_at RAR-related orphan receptor A RORA 0.000166 -13.2584 
230491_at --- --- 0.000171 -4.30839 
230410_at Neuropilin 2 NRP2 0.000171 9.15602 
235785_at --- --- 0.000177 2.66725 
206359_at suppressor of cytokine signaling 3 SOCS3 0.000177 2.78094 
231489_x_at --- --- 0.000178 2.88959 
1552289_a_at cartilage intermediate layer protein 2 CILP2 0.000179 2.33354 
228567_at --- --- 0.000182 -5.66993 
209731_at nth endonuclease III-like 1 (E. coli) NTHL1 0.000185 1.88183 
1555736_a_at angiotensin II receptor-associated protein AGTRAP 0.000185 2.16643 
201105_at lectin, galactoside-binding, soluble, 1 LGALS1 0.000188 15.3302 
204862_s_at non-metastatic cells 3, protein expressed in NME3 0.000188 1.7769 
1558540_s_at 
solute carrier family 2 (facilitated glucose 
transporter), member 11 SLC2A11 0.000188 2.79888 
201373_at 
plectin 1, intermediate filament binding protein 
500kDa PLEC1 0.00019 2.93844 
209507_at replication protein A3, 14kDa RPA3 0.000193 2.54289 
209287_s_at CDC42 effector protein (Rho GTPase binding) 3 CDC42EP3 0.000195 4.51909 
231060_at Heterogeneous nuclear ribonucleoprotein A/B HNRNPAB 0.000195 1.37251 
201855_s_at ATM interactor ATMIN 0.000196 -2.49786 
217755_at hematological and neurological expressed 1 HN1 0.000197 3.32211 
228298_at family with sequence similarity 113, member B FAM113B 0.000201 2.80202 
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211160_x_at actinin, alpha 1 ACTN1 0.000201 7.0276 
215305_at 
platelet-derived growth factor receptor, alpha 
polypeptide PDGFRA 0.000207 2.79888 
1556629_a_at Synaptosomal-associated protein, 25kDa SNAP25 0.000207 1.40857 
204337_at regulator of G-protein signaling 4 RGS4 0.000208 6.99388 
213352_at transmembrane and coiled-coil domain family 1 TMCC1 0.000208 4.69573 
208659_at chloride intracellular channel 1 CLIC1 0.000208 2.18099 
211844_s_at neuropilin 2 NRP2 0.000209 5.17244 
229762_at Chromosome 7 open reading frame 38 C7orf38 0.00021 -4.59741 
1559901_s_at chromosome 21 open reading frame 34 C21orf34 0.000217 -13.2918 
203878_s_at matrix metallopeptidase 11 (stromelysin 3) MMP11 0.000221 6.65552 
203228_at 
platelet-activating factor acetylhydrolase, 
isoform Ib, subunit 3 (29kDa) PAFAH1B3 0.000222 2.28541 
212014_x_at CD44 molecule (Indian blood group) CD44 0.000226 3.48182 
210916_s_at CD44 molecule (Indian blood group) CD44 0.000229 4.00863 
216039_at 
postmeiotic segregation increased 2-like 5-like /// 
PMS2 postmeiotic segregation 
LOC1001328
32  0.000229 1.52483 
209493_at PDZ domain containing 2 PDZD2 0.000231 -7.34378 
218788_s_at SET and MYND domain containing 3 SMYD3 0.000231 3.6686 
243987_at --- --- 0.000237 3.61958 
205199_at carbonic anhydrase IX CA9 0.00024 10.1701 
227241_at mucin 15, cell surface associated MUC15 0.000243 -97.5336 
238726_at --- --- 0.000248 -3.83709 
204443_at arylsulfatase A ARSA 0.000251 2.12511 
216310_at TAO kinase 1 TAOK1 0.000251 -1.5773 
234946_at 
ectonucleoside triphosphate diphosphohydrolase 
6 (putative function) ENTPD6 0.000255 3.01284 
205153_s_at 
CD40 molecule, TNF receptor superfamily 
member 5 CD40 0.000255 3.54885 
227380_x_at Chromosome 16 open reading frame 13 C16orf13 0.000255 2.72808 
214632_at neuropilin 2 NRP2 0.00026 5.25586 
225802_at topoisomerase (DNA) I, mitochondrial TOP1MT 0.000265 3.22877 
213308_at SH3 and multiple ankyrin repeat domains 2 SHANK2 0.000268 4.61364 
212491_s_at DnaJ (Hsp40) homolog, subfamily C, member 8 DNAJC8 0.00027 1.77721 
201818_at lysophosphatidylcholine acyltransferase 1 LPCAT1 0.000271 3.78723 
204051_s_at secreted frizzled-related protein 4 SFRP4 0.000273 2.11248 
224020_at hypothetical LOC79100 MGC4473 0.000273 1.60746 
225327_at KIAA1370 KIAA1370 0.000275 -4.3374 
53991_at DENN/MADD domain containing 2A DENND2A 0.000276 5.1575 
229023_at SFT2 domain containing 3 SFT2D3 0.000276 -2.2866 
237415_at --- --- 0.000277 2.91331 
209114_at tetraspanin 1 TSPAN1 0.000278 3.81358 
228737_at TOX high mobility group box family member 2 TOX2 0.000285 5.80085 
235911_at --- --- 0.000288 5.08832 
221421_s_at 
ADAM metallopeptidase with thrombospondin 
type 1 motif, 12 ADAMTS12 0.000288 4.09453 
210813_s_at 
X-ray repair complementing defective repair in 
Chinese hamster cells 4 XRCC4 0.000293 2.9136 
1553333_at chromosome 1 open reading frame 161 C1orf161 0.000294 -19.2187 
219655_at chromosome 7 open reading frame 10 C7orf10 0.000296 4.71703 
1554499_s_at pyrophosphatase (inorganic) 2 PPA2 0.000297 -2.12895 
1561509_at --- --- 0.000306 -1.51465 
1563420_at Xg pseudogene, Y-linked 2 XGPY2 0.000306 -5.33546 
244119_at hypothetical protein LOC283483 LOC283483 0.000309 2.90926 
225893_at 
ring finger and CCCH-type zinc finger domains 
1 RC3H1 0.000311 -1.7422 
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1567240_x_at 
olfactory receptor, family 2, subfamily L, 
member 2 OR2L2 0.000311 2.70376 
213873_at discoidin, CUB and LCCL domain containing 2 DCBLD2 0.000312 6.88244 
214814_at YTH domain containing 1 YTHDC1 0.000315 -2.3552 
202943_s_at N-acetylgalactosaminidase, alpha- NAGA 0.00032 2.41388 
211924_s_at plasminogen activator, urokinase receptor PLAUR 0.00032 9.43377 
206084_at protein tyrosine phosphatase, receptor type, R PTPRR 0.000321 3.82447 
226560_at --- --- 0.000324 -20.7066 
1562326_at hypothetical gene supported by AL832565 FLJ30838 0.000326 -1.57488 
205574_x_at bone morphogenetic protein 1 BMP1 0.000328 6.76969 
229958_at 
ceroid-lipofuscinosis, neuronal 8 (epilepsy, 
progressive with mental retardation CLN8 0.000329 -5.06509 
1554864_a_at syndecan 3 SDC3 0.000331 2.57724 
209364_at BCL2-associated agonist of cell death BAD 0.000331 2.56991 
207595_s_at bone morphogenetic protein 1 BMP1 0.000335 3.20269 
214102_at 
ArfGAP with RhoGAP domain, ankyrin repeat 
and PH domain 2 ARAP2 0.000337 -3.50249 
205959_at matrix metallopeptidase 13 (collagenase 3) MMP13 0.000339 45.7205 
235065_at --- --- 0.000344 -6.55482 
228716_at 
thyroid hormone receptor, beta (erythroblastic 
leukemia viral (v-erb-a) oncogene THRB 0.000345 -8.24672 
205071_x_at 
X-ray repair complementing defective repair in 
Chinese hamster cells 4 XRCC4 0.000349 2.83183 
1560089_at hypothetical LOC286208 LOC286208 0.000354 -3.34216 
201781_s_at aryl hydrocarbon receptor interacting protein AIP 0.000357 3.07179 
209344_at tropomyosin 4 TPM4 0.000359 2.84408 
201804_x_at tubulin folding cofactor B TBCB 0.000364 2.50824 
228662_at Suppressor of cytokine signaling 7 SOCS7 0.000367 -2.30213 
214876_s_at tubulin, gamma complex associated protein 5 TUBGCP5 0.000374 2.7104 
228115_at --- --- 0.000375 -7.05282 
205341_at EH-domain containing 2 EHD2 0.000375 3.4664 
226682_at RAR-related orphan receptor A RORA 0.000376 -11.7867 
229256_at phosphoglucomutase 2-like 1 PGM2L1 0.000377 8.14692 
205259_at nuclear receptor subfamily 3, group C, member 2 NR3C2 0.000378 -3.34731 
219051_x_at meteorin, glial cell differentiation regulator METRN 0.000381 1.78915 
242285_at --- --- 0.000381 1.98589 
227411_at Wilms tumor 1 interacting protein WTIP 0.000383 2.29454 
218081_at chromosome 20 open reading frame 27 C20orf27 0.000384 1.78244 
1560573_at hypothetical gene supported by BC040060 LOC387895 0.000386 2.82436 
232032_x_at stromal cell derived factor 4 SDF4 0.000394 2.51585 
228366_at --- --- 0.000395 -3.29256 
229991_s_at Synaptotagmin-like 4 SYTL4 0.000396 4.25285 
209017_s_at lon peptidase 1, mitochondrial LONP1 0.000396 2.50386 
216483_s_at chromosome 19 open reading frame 10 C19orf10 0.000397 3.54987 
1555728_a_at 
membrane-spanning 4-domains, subfamily A, 
member 4 MS4A4A 0.000398 6.96543 
210511_s_at inhibin, beta A INHBA 0.000403 23.3929 
235921_at --- --- 0.000408 4.42508 
202856_s_at 
solute carrier family 16, member 3 
(monocarboxylic acid transporter 4) SLC16A3 0.000409 12.1652 
227938_s_at delta-like 1 (Drosophila) DLL1 0.000409 1.95072 
207866_at bone morphogenetic protein 8a BMP8A 0.000412 2.51431 
33304_at interferon stimulated exonuclease gene 20kDa ISG20 0.000412 8.4676 
209906_at complement component 3a receptor 1 C3AR1 0.000415 2.78018 
204755_x_at hepatic leukemia factor HLF 0.000417 -13.8507 
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205132_at actin, alpha, cardiac muscle 1 ACTC1 0.000422 3.02721 
226625_at transforming growth factor, beta receptor III TGFBR3 0.000424 -8.9064 
216095_x_at myotubularin related protein 1 MTMR1 0.000426 -2.07045 
219378_at NMDA receptor regulated 1-like NARG1L 0.000426 -2.89491 
212788_x_at ferritin, light polypeptide FTL 0.000429 3.42878 
205635_at kalirin, RhoGEF kinase KALRN 0.000429 1.97922 
203592_s_at follistatin-like 3 (secreted glycoprotein) FSTL3 0.000433 4.83528 
61734_at 
reticulocalbin 3, EF-hand calcium binding 
domain RCN3 0.000437 2.71846 
213430_at RUN and FYVE domain containing 3 RUFY3 0.000438 -3.40583 
231957_s_at dipeptidyl-peptidase 9 DPP9 0.000441 2.47438 
203314_at GTP binding protein 6 (putative) GTPBP6 0.000447 3.44003 
206605_at 26 serine protease P11 0.000448 -26.0435 
212680_x_at 
protein phosphatase 1, regulatory (inhibitor) 
subunit 14B PPP1R14B 0.00045 2.82401 
242523_at --- --- 0.000451 -3.95674 
206106_at mitogen-activated protein kinase 12 MAPK12 0.000453 1.78753 
40472_at lysophosphatidylcholine acyltransferase 4 LPCAT4 0.000457 1.83544 
217294_s_at enolase 1, (alpha) ENO1 0.000461 2.87823 
209835_x_at CD44 molecule (Indian blood group) CD44 0.000464 2.99478 
1553417_at chromosome 11 open reading frame 44 C11orf44 0.000464 1.81523 
241280_at Aldolase B, fructose-bisphosphate ALDOB 0.000466 1.47293 
208637_x_at actinin, alpha 1 ACTN1 0.000468 6.77358 
34406_at phosphofurin acidic cluster sorting protein 2 PACS2 0.000471 2.28915 
1557055_s_at hypothetical LOC643837 LOC643837 0.000471 2.82427 
1560743_a_at --- --- 0.000476 -2.25956 
234258_at --- --- 0.000477 -3.39445 
203857_s_at protein disulfide isomerase family A, member 5 PDIA5 0.000478 3.69575 
227806_at chromosome 16 open reading frame 74 C16orf74 0.000479 2.11999 
223626_x_at interferon, alpha-inducible protein 27-like 2 IFI27L2 0.00048 1.96744 
1552972_at --- --- 0.000482 3.09844 
227802_at RUN and FYVE domain containing 3 RUFY3 0.000482 -3.35649 
243940_at teashirt zinc finger homeobox 2 TSHZ2 0.000483 3.21281 
219523_s_at odz, odd Oz/ten-m homolog 3 (Drosophila) ODZ3 0.000485 4.4475 
224346_at --- --- 0.000487 3.75172 
202483_s_at RAN binding protein 1 RANBP1 0.000487 2.74154 
211881_x_at immunoglobulin lambda joining 3 IGLJ3 0.000488 2.22262 
235567_at RAR-related orphan receptor A RORA 0.000489 -7.99633 
1569191_at zinc finger protein 826 ZNF826 0.000496 4.41969 
218848_at THO complex 6 homolog (Drosophila) THOC6 0.000499 2.16306 
1568765_at 
serpin peptidase inhibitor, clade E (nexin, 
plasminogen activator inhibitor type SERPINE1 0.000504 2.80858 
1557905_s_at CD44 molecule (Indian blood group) CD44 0.000505 1.97648 
229924_s_at --- --- 0.000508 2.7446 
242989_at --- --- 0.000508 -2.85017 
232492_at chromosome 6 open reading frame 112 C6orf112 0.000511 2.50706 
210486_at ankyrin repeat and MYND domain containing 1 ANKMY1 0.000514 -2.03545 
205680_at matrix metallopeptidase 10 (stromelysin 2) MMP10 0.000515 77.301 
227291_s_at bolA homolog 3 (E. coli) BOLA3 0.000518 2.77167 
214780_s_at myosin IXB MYO9B 0.000518 1.65118 
200755_s_at calumenin CALU 0.00052 3.39207 
228500_at THAP domain containing 8 THAP8 0.00052 2.40438 
207157_s_at 
guanine nucleotide binding protein (G protein), 
gamma 5 GNG5 0.000523 2.21744 
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209875_s_at secreted phosphoprotein 1 SPP1 0.000523 89.5773 
205374_at sarcolipin SLN 0.000524 2.36518 
238137_at --- --- 0.000527 -2.80982 
217731_s_at integral membrane protein 2B ITM2B 0.00053 -2.1663 
204490_s_at CD44 molecule (Indian blood group) CD44 0.000531 2.38153 
211003_x_at 
transglutaminase 2 (C polypeptide, protein-
glutamine-gamma-glutamyltransferase) TGM2 0.000537 3.56745 
202148_s_at pyrroline-5-carboxylate reductase 1 PYCR1 0.000538 1.73717 
203336_s_at integrin beta 1 binding protein 1 ITGB1BP1 0.000544 2.4929 
236616_at --- --- 0.000546 -5.74344 
214841_at cornichon homolog 3 (Drosophila) CNIH3 0.000547 5.25886 
200862_at 24-dehydrocholesterol reductase DHCR24 0.000548 -6.26502 
211599_x_at 
met proto-oncogene (hepatocyte growth factor 
receptor) MET 0.000552 4.99878 
225384_at dedicator of cytokinesis 7 DOCK7 0.000552 2.75367 
213624_at sphingomyelin phosphodiesterase, acid-like 3A SMPDL3A 0.000553 -5.73952 
239605_x_at --- --- 0.000553 1.90241 
216965_x_at spastic paraplegia 20 (Troyer syndrome) SPG20 0.000554 -1.90521 
224510_s_at ClpB caseinolytic peptidase B homolog (E. coli) CLPB 0.000554 1.95264 
228766_at CD36 molecule (thrombospondin receptor) CD36 0.000556 -87.6889 
202071_at syndecan 4 SDC4 0.00056 4.10341 
1553984_s_at deoxythymidylate kinase (thymidylate kinase) DTYMK 0.000563 2.34615 
1567238_at 
olfactory receptor, family 2, subfamily L, 
member 2 OR2L2 0.000569 3.0614 
235422_at --- --- 0.00057 -2.94605 
204103_at chemokine (C-C motif) ligand 4 CCL4 0.000571 2.85054 
206343_s_at neuregulin 1 NRG1 0.000572 19.2461 
242647_at ubiquitin specific peptidase 34 USP34 0.000574 -1.98651 
204617_s_at adrenocortical dysplasia homolog (mouse) ACD 0.000574 3.03433 
1555363_s_at hypothetical LOC284440 LOC284440 0.000576 3.42138 
234721_s_at 
cytochrome P450, family 26, subfamily B, 
polypeptide 1 CYP26B1 0.000577 2.25576 
200668_s_at 
ubiquitin-conjugating enzyme E2D 3 (UBC4/5 
homolog, yeast) UBE2D3 0.000578 -1.5961 
230706_s_at 
calcium/calmodulin-dependent protein kinase II 
inhibitor 2 CAMK2N2 0.000584 5.33914 
216971_s_at 
plectin 1, intermediate filament binding protein 
500kDa PLEC1 0.000588 3.46723 
231735_s_at 
metastasis associated lung adenocarcinoma 
transcript 1 (non-protein coding) MALAT1 0.000597 -1.44836 
243072_at --- --- 0.000598 -2.83334 
204413_at TNF receptor-associated factor 2 TRAF2 0.000608 1.58233 
201782_s_at aryl hydrocarbon receptor interacting protein AIP 0.000608 3.28715 
215717_s_at fibrillin 2 FBN2 0.000612 4.34026 
205743_at SH3 and cysteine rich domain STAC 0.000615 2.20325 
204890_s_at lymphocyte-specific protein tyrosine kinase LCK 0.000616 2.06114 
241545_x_at --- --- 0.000624 -2.66066 
219497_s_at B-cell CLL/lymphoma 11A (zinc finger protein) BCL11A 0.000624 -7.98922 
202431_s_at 
v-myc myelocytomatosis viral oncogene 
homolog (avian) MYC 0.000625 2.48726 
226038_at 
LON peptidase N-terminal domain and ring 
finger 1 LONRF1 0.000627 -5.58484 
AFFX-
HSAC07/X00
351_M_at actin, beta ACTB 0.00063 2.23352 
211354_s_at leptin receptor LEPR 0.000632 5.70108 
1565677_at --- --- 0.000634 4.10919 
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201666_at TIMP metallopeptidase inhibitor 1 TIMP1 0.000635 6.38219 
202035_s_at secreted frizzled-related protein 1 SFRP1 0.000638 3.02056 
1555827_at Cyclin L1 CCNL1 0.00064 -3.57264 
1552496_a_at cordon-bleu homolog (mouse) COBL 0.000646 -5.35661 
221126_at dickkopf homolog 3 (Xenopus laevis) DKK3 0.000652 2.07934 
214365_at tropomyosin 3 TPM3 0.000654 1.88328 
226639_at SFT2 domain containing 3 SFT2D3 0.000655 -2.39791 
209309_at alpha-2-glycoprotein 1, zinc-binding AZGP1 0.000655 -111.199 
214277_at 
COX11 homolog, cytochrome c oxidase 
assembly protein  COX11 0.000657 -3.63056 
215150_at YOD1 OTU deubiquinating enzyme 1 homolog  YOD1 0.000659 -8.28551 
236266_at RAR-related orphan receptor A RORA 0.000662 -9.44189 
222862_s_at adenylate kinase 5 AK5 0.000665 2.2655 
1562512_at Sphingomyelin phosphodiesterase, acid-like 3A SMPDL3A 0.000675 -4.57395 
221739_at chromosome 19 open reading frame 10 C19orf10 0.000699 2.4933 
205228_at 
RNA binding motif, single stranded interacting 
protein 2 RBMS2 0.0007 4.27625 
244856_at --- --- 0.000706 -3.62782 
1562743_at Zinc finger protein 33B ZNF33B 0.000707 3.01516 
201346_at adiponectin receptor 2 ADIPOR2 0.000712 -1.97969 
229252_at ATG9 autophagy related 9 homolog B  ATG9B 0.000712 -4.30389 
232222_at chromosome 18 open reading frame 49 C18orf49 0.000718 2.11372 
229643_at Integrin, alpha 6 ITGA6 0.000721 4.24794 
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APPENDIX F: PTPRD Primers 
1) Exonic primers for all exons.  PCR and sequencing conditions shown. 
 
Exon Primer (5’ – 3’) Product 
size 
(bp) 
Annealing 
temp (
o
C) 
Sequencing 
primer 
B1 ACCAAAGCCAAACCCTGAC 
ATTGGGCATTGAAAAGCATC 
231 61 N/A 
B2 GATCTAGCCCAATGTCCTCA 
CCAGGTGGCACACCATTAGT 
246 59 N/A 
B3 GGCAGTTTTTCCTGTTTTCCT 
CAGCCAAGCCAAAGACTGTAT 
245 61 N/A 
B4 GGAACATGAAGAAATGACTGACAC 
GCGTAAAAGGGTTGATGGAG 
250 61 N/A 
B5 CACAATATGAGCAATGATGGAG 
ATTTCCAAGCATGCAACAGT 
256 60 N/A 
B6 AAAGTGTTTATTCAGCCAGCAG 
AGAAGACTGAGAGTCCCAAAGAA 
203 60 N/A 
B7 TGATGTAAGATGAGTAACTGGTAATGC 
AAAAGCGGTAATGAAAATAACTCTA 
293 58 N/A 
B8 TGTTTGAAGACAATTTGAAAGGTT 
TGCCTAATGAACTGCCAGAA 
239 58 N/A 
B9 CTCTGCCTCAATCCCCACTA 
AGGACCCAGAGAAGGGAAAG 
213 61 N/A 
1 TTTCACTTCTTGTTGGAATTTGAC 
CAGGCACACAACCCAGTATG 
200 56 N/A 
2 GGGGAAAGAGTAAGAAATCTAAGCA 
AAACAAAACCACTCATTATGGTCA 
293 61 F 
3 GGTGTGGTTGAGGATGGTG 
CCAAAGACAGAGCAGATACATTC 
298 60 F 
4 ATTGAGAGCTTTAGCTGAGAGG 
AAGCACCATCACAATGCTAGTC 
307 59 F 
5 CTCTTGAATTTGGAGCATCTGA 
TGGACCACCCATTAAGTAACAG 
399 60 F  
6 TGCCTCTTTTGCTTGTTGTC 
GAAATTAGTGGGGTTGAAGTGC 
245 61 F 
7 AATTCTTCTCCCCAGCCCTA 
TGACGCTGAAAACAGGACAA 
194 60 F 
8 TGAATCGACGTTGAGTGGAC 
CCCCTGAGCCTGAATGAAG 
282 60 F 
9 TCCTCATTTCATTGTGTTCTGC 
CCACCATGCACCACAGTTAG 
243 60 R only 
10 TTCCCTTGTGTTTTGTTCCA 
TTGGCTTGAGTGTACCCAGA 
339 57 F and R 
11 GGGATGATGGGTAGTCATTGT 
CTTCCCTCCTGCCCTATTTC 
664 60 R and int F 
12 CGCTAATGGAAGAACTTTGTG 
TCTGACCAAGAATGTGGATAAATAC 
293 58 F 
13 CCTTAGTATAGCCCTGGATACTCAC 
AGCAGGTTTGCTTATTGGTG 
391 58 F 
14 CAACCACTCCTGTCCTTTCA 
ACGTAGCGGAGGCAACATAC 
380 60 F 
15 GCTCTGATAGGGTGGGACAA 
GAGCAATTTCAGGATATGAACTAAGA 
324 60 F 
16 TTGTTTTCCTCCCAACCTTC 
CATGCATCCAAGCAAACTGT 
168 50 R 
17 AGCATGTTTTGAATCAGTGACA 
TGGACAAATTATGCACTTGGAC 
358 62 F and int R 
18 TGGCAATGACTGAAATGTGAA 675 60 F 
 287 
Exon Primer (5’ – 3’) Product 
size 
(bp) 
Annealing 
temp (
o
C) 
Sequencing 
primer 
GCCGTAAGCAGACAAATCCT 
19 GGTGGAAAGGACAGGTCATC 
TCTGCTTGCTGTGCAAATAAC 
249 62 F 
20 AAAGCTAGTGCACATTGGTTTAGA 
CAGCCCTAAGCCTTCAATCA 
368 60 R and int F 
21 CCACGTTTTCCTCCTTTCAA 
AGCCAGCACCCAGATTAGAT 
249 60 F 
22 TCAATAAGCTGGGTTATTATTTACAG 
AGGAAACAGATGCCATCATAA 
298 60 F 
23 CCTCCCCTCTGTTTTGCTAAT 
AAGGCAGCCTCCAAAATTAC 
348 60 F 
24 TCAGCTGGGTTGAAAAGTTGTA 
GGGAAAGACTGTGTGTGGATTA 
283 60 F 
25 GAGCATGTCCTGCTTTGAGTAA 
GGGAAAAGCACTGATGAAGTTA 
368 60 F 
26 GTGGTTTTCAGTATTGATTTTGTGTA 
CACCATGCACAGCCATCTTA 
295 60 F 
27 GAACAGTAAGATAGCACTGCCATTAG 
TTTTAGCAACCACACACATCATAAC 
495 60 F 
28 AGCATTTGCCCTGAATGTGT 
GAGAAGGGAAAGGGAGGAGA 
194 60 F and R 
29 CCTGAGGCTTGGAAAACAGA 
TTGCAGAAACATCCAATGAGA 
273 58 F and R 
30 ATTTGAGTAGAAGTAATGGATGTAAGG 
TCAAAGACAAACCCAGAATGAC 
462 62 F 
31 CATTCAAACTGTAGGTGAAAATGAT 
AGGGCACATGTAAATATCAAGG 
299 58 R 
32 TGTGAGCTTTTGCATGTTCTC 
TCATTTCTCCACAGAGTAAATGTCTT 
245 58 F 
33 TTTGAAATTTTATTAATGGGATAAGGA 
AGACTACTTTTCAGCTAATGGTTAAGA 
290 55 F 
34 CCTGGCGTCTTCCTTTGC 
GAAGAAACACCACCACTTATCACT 
250 58 F and Int R 
35 AATGTGGCCAAGACTGTGAA 
CCAGGCTAGCAAAACGTAGG 
250 58 F 
36 TCATGGTCCCTTCTTTTGCT 
TGCCTCATCAGTCAGGATTC 
345 55 F and R 
37 TATGTGCTGGTGTGGCTTCT 
TACTTTGCGCCTCCCTGTT 
500 60 N/A 
 
Exon Internal sequencing 
primer direction 
Primer (5’ – 3’) 
10 F AACCTCAGAGCAAGCACCAT 
16 R TCAAGGCACATACATGCACA 
19 F GCTGACAAATCGTGGAAACA 
33 R CCATCTTGGCCAAACTGTTC 
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2) PTPRD multiplex PCR primer sets 
 
Primer name Primer sequence (5’-3’) Product 
size 
mPCR 
grouping 
B1 See Appendix E, table 1 231 1 
B2 mPCR F  GCCCAATGTCCTCATTTTTG 152 2 
R TGAGAAGCTATTATTATGCAATGGA 
B3 mPCR F CAACTGCCAGAGAATGTGAA 158 6 
R GCATTAAAAAGAAAAATTAGAATGAGT 
B4 mPCR F GCTTCAAGGAACATGAAGAAA 193 5 
R TTGTGTCATGGGAAACTAGCA 
B5 mPCR F TGATGGAGTTTTAAAATTTGTTCTTA 240 2 
R TTCCAAGCATGCAACAGTAA 
B6 See Appendix E, table 1 203 6 
B7 mPCR F TTGTGTTATACTTTTCTAGGTCTCAGG 133 5 
R GGACATGATCAAAAAGCGGTA 
B8 mPCR F TGTTTGAAGACAATTTGAAAGGTT 140 1 
R CGTGCAGACATAAGATGAGCA 
B9 See Appendix E, table 1 213 4 
X1 mPCR F TCTCTTCCTCCCCGCTTT 200 3 
R TATGGTCACAGCCCCCTAGA 
X2 mPCR F TTTATTTCAGCACCTCCAAGG 227 5 
R CAGAGAAACAGAACAATGGACCTA 
X3 mPCR F CCTGTGACAGCTATTGTTTCCTC 184 4 
R CGACAACCTTCACTTGAGCA 
X4 mPCR F TCACCTTTTGTCTTGCAGAA 196 1 
R GGAGTTAGTAGAAACAGTAACAAGACC 
X5 mPCR F TTTTATGCTGTCTTTCTTCTCTCCGTA 238 6 
R TGGATATGGAAATTAGTGGGGTTG 
X6 mPCR  F CTCGTACTAATGCTTCTTCTTTCTAA 100 3 
R CTGTGAACGTTAGTTCAGCACTC 
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APPENDIX G: 384 SNPs used for PTPRD custom Illumina SNP 
microarray. 
 
SNP_Name Coordinate SNP_ Score Validation 
MAF_ 
Caucasian Location 
rs6474564 10606168 1.1 goldengate validated 0.183 flanking_5UTR 
rs10114665 10602178 1.1 goldengate validated 0.367 flanking_5UTR 
rs1358919 10597960 1.1 goldengate validated 0.033 flanking_5UTR 
rs1018556 10591597 1.1 goldengate validated 0.492 flanking_5UTR 
rs10756066 10585208 1.1 goldengate validated 0.292 flanking_5UTR 
rs10120070 10577205 1.1 goldengate validated 0.133 flanking_5UTR 
rs1322282 10572586 1.1 goldengate validated 0.283 flanking_5UTR 
rs1980670 10567293 1.1 goldengate validated 0.2708 flanking_5UTR 
rs10959172 10559790 1.1 goldengate validated 0.25 flanking_5UTR 
rs1475111 10554866 1.1 goldengate validated 0.35 flanking_5UTR 
rs833416 10548102 1.1 goldengate validated 0.125 flanking_5UTR 
rs2784611 10541203 1.1 goldengate validated 0.408 flanking_5UTR 
rs2181158 10536257 1.1 goldengate validated 0.425 flanking_5UTR 
rs2784610 10531042 1.1 goldengate validated 0.142 flanking_5UTR 
rs833435 10524642 1.1 goldengate validated 0.15 flanking_5UTR 
rs1336000 10517419 1.1 goldengate validated 0.075 flanking_5UTR 
rs10756055 10511629 1.1 goldengate validated 0.167 flanking_5UTR 
rs2757859 10505720 1.1 goldengate validated -99 flanking_5UTR 
rs2784592 10500683 1.1 goldengate validated 0.133 flanking_5UTR 
rs833417 10495161 1.1 goldengate validated 0.283 flanking_5UTR 
rs833442 10489212 1.1 goldengate validated 0.22 flanking_5UTR 
rs1323479 10481210 1.1 goldengate validated 0.225 flanking_5UTR 
rs2757851 10477710 1.1 goldengate validated -99 flanking_5UTR 
rs1853232 10471205 0.961 two-hit or HapMap validated 0.127 flanking_5UTR 
rs1999742 10463073 1.1 goldengate validated 0.025 flanking_5UTR 
rs1335997 10457074 1.1 goldengate validated 0.2 flanking_5UTR 
rs2382216 10453098 1.1 goldengate validated 0.167 flanking_5UTR 
rs13287491 10447788 1.1 goldengate validated 0.117 flanking_5UTR 
rs12682854 10440981 1.1 goldengate validated 0 flanking_5UTR 
rs16926034 10435439 0.961 two-hit or HapMap validated 0.05 flanking_5UTR 
rs620558 10426921 1.1 goldengate validated 0.042 flanking_5UTR 
rs669484 10423023 1.1 goldengate validated 0.117 flanking_5UTR 
rs585875 10417780 1.1 goldengate validated 0 flanking_5UTR 
rs10809092 10411687 1.1 goldengate validated 0.051 flanking_5UTR 
rs6474548 10406736 1.1 goldengate validated 0.158 flanking_5UTR 
rs1359101 10396755 1.1 goldengate validated 0.1 flanking_5UTR 
rs10809086 10389727 1.1 goldengate validated 0.1 flanking_5UTR 
rs10733206 10381984 1.1 goldengate validated 0.1 flanking_5UTR 
rs10738163 10375811 1.1 goldengate validated 0.1 flanking_5UTR 
rs1407923 10369349 1.1 goldengate validated 0 flanking_5UTR 
rs1359088 10363423 1.1 goldengate validated -99 flanking_5UTR 
rs1323489 10359009 1.1 goldengate validated 0 flanking_5UTR 
rs10756030 10351438 1.1 goldengate validated 0.275 flanking_5UTR 
rs16925863 10344770 0.92 two-hit or HapMap validated 0.033 flanking_5UTR 
rs1323493 10338246 1.1 goldengate validated 0.4583 flanking_5UTR 
rs12551193 10331449 0.847 two-hit or HapMap validated 0.117 flanking_5UTR 
rs10756027 10328320 1.1 goldengate validated 0.225 flanking_5UTR 
rs10959051 10320850 1.1 goldengate validated 0.292 flanking_5UTR 
rs9657580 10312721 1.1 goldengate validated 0.242 flanking_5UTR 
 290 
SNP_Name Coordinate SNP_ Score Validation 
MAF_ 
Caucasian Location 
rs10511544 10309881 1.1 goldengate validated 0.237 flanking_5UTR 
rs679856 10304738 1.1 goldengate validated 0.217 flanking_5UTR 
rs7860593 10296728 0.925 two-hit or HapMap validated 0 flanking_5UTR 
rs661198 10289084 1.1 goldengate validated 0.092 flanking_5UTR 
rs7022343 10285527 0.833 two-hit or HapMap validated 0 flanking_5UTR 
rs942159 10278680 1.1 goldengate validated 0.183 flanking_5UTR 
rs16925695 10274150 0.948 two-hit or HapMap validated 0 flanking_5UTR 
rs1359095 10266100 1.1 goldengate validated 0.483 flanking_5UTR 
rs1322155 10260636 1.1 goldengate validated 0.333 flanking_5UTR 
rs2025152 10255725 1.1 goldengate validated 0.3 flanking_5UTR 
rs2475335 10250263 1.1 goldengate validated 0.175 flanking_5UTR 
rs2498610 10244545 1.1 goldengate validated 0.325 flanking_5UTR 
rs4741021 10237653 1.1 goldengate validated 0.305 flanking_5UTR 
rs1570267 10230428 1.1 goldengate validated 0.192 flanking_5UTR 
rs7866028 10225458 1.1 goldengate validated 0.45 flanking_5UTR 
rs1407913 10218955 1.1 goldengate validated 0.233 flanking_5UTR 
rs2065070 10212790 1.1 goldengate validated 0.325 flanking_5UTR 
rs2498600 10206903 1.1 goldengate validated 0.108 flanking_5UTR 
rs2498596 10201759 1.1 goldengate validated 0.142 flanking_5UTR 
rs1322133 10195835 1.1 goldengate validated 0.35 flanking_5UTR 
rs294820 10190272 1.1 goldengate validated 0.292 flanking_5UTR 
rs294857 10182858 1.1 goldengate validated 0.275 flanking_5UTR 
rs1322163 10177598 1.1 goldengate validated 0.167 flanking_5UTR 
rs10511535 10171673 1.1 goldengate validated 0.017 flanking_5UTR 
rs1358889 10164668 1.1 goldengate validated 0.217 flanking_5UTR 
rs10958933 10160958 1.1 goldengate validated 0.292 flanking_5UTR 
rs1590348 10151681 1.1 goldengate validated 0.067 flanking_5UTR 
rs10958922 10147409 1.1 goldengate validated 0 flanking_5UTR 
rs291289 10138779 1.1 goldengate validated 0.317 flanking_5UTR 
rs12551163 10134409 1.1 goldengate validated 0 flanking_5UTR 
rs2382193 10130101 1.1 goldengate validated 0.1667 flanking_5UTR 
rs10958908 10122437 0.937 two-hit or HapMap validated 0.058 flanking_5UTR 
rs291303 10118814 1.1 goldengate validated 0.242 flanking_5UTR 
rs1567404 10113193 0.935 two-hit or HapMap validated 0.127 flanking_5UTR 
rs725261 10104943 1.1 goldengate validated 0.183 flanking_5UTR 
rs12237912 10100346 0.973 two-hit or HapMap validated 0 flanking_5UTR 
rs860563 10093302 1.1 goldengate validated 0.275 flanking_5UTR 
rs424305 10088776 1.1 goldengate validated 0.408 flanking_5UTR 
rs435384 10082319 1.1 goldengate validated 0.4792 flanking_5UTR 
rs291324 10076390 1.1 goldengate validated 0.4 flanking_5UTR 
rs10958874 10067477 1.1 goldengate validated 0.267 flanking_5UTR 
rs443224 10064880 1.1 goldengate validated 0 flanking_5UTR 
rs291316 10057853 1.1 goldengate validated 0.083 flanking_5UTR 
rs449090 10053345 1.1 goldengate validated 0.033 flanking_5UTR 
rs1396906 10046880 1.1 goldengate validated 0.133 flanking_5UTR 
rs291255 10038401 1.1 goldengate validated 0 flanking_5UTR 
rs291265 10035049 1.1 goldengate validated 0.033 flanking_5UTR 
rs1441410 10028322 1.1 goldengate validated 0.108 flanking_5UTR 
rs4237124 10021987 1.1 goldengate validated 0.442 flanking_5UTR 
rs727756 10015975 1.1 goldengate validated 0.392 flanking_5UTR 
rs16930832 10013288 0.958 two-hit or HapMap validated 0 flanking_5UTR 
rs1343534 10004813 1.1 goldengate validated 0.35 flanking_5UTR 
rs2382104 9998726 1.1 goldengate validated 0.117 flanking_5UTR 
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rs10978160 9994157 0.852 two-hit or HapMap validated 0 flanking_5UTR 
rs9774772 9989345 0.712 two-hit or HapMap validated 0 flanking_5UTR 
rs1936366 9977043 0.842 two-hit or HapMap validated 0.325 flanking_5UTR 
rs9299106 9969990 1.1 goldengate validated 0.2 flanking_5UTR 
rs2890897 9963935 1.1 goldengate validated 0.175 flanking_5UTR 
rs10739206 9958038 1.1 goldengate validated 0.5 flanking_5UTR 
rs7860014 9952204 1.1 goldengate validated 0.067 flanking_5UTR 
rs10816263 9943127 1.1 goldengate validated 0.375 flanking_5UTR 
rs10978127 9938303 1.1 goldengate validated 0.033 flanking_5UTR 
rs10491910 9933196 1.1 goldengate validated 0.042 flanking_5UTR 
rs2382083 9927960 1.1 goldengate validated 0.292 flanking_5UTR 
rs10759107 9920866 1.1 goldengate validated 0.342 flanking_5UTR 
rs2890894 9916143 1.1 goldengate validated 0.008 flanking_5UTR 
rs10120380 9908787 0.937 two-hit or HapMap validated 0 flanking_5UTR 
rs10759103 9901656 1.1 goldengate validated 0.155 flanking_5UTR 
rs10978077 9898296 1.1 goldengate validated 0.142 flanking_5UTR 
rs16930519 9891170 0.935 two-hit or HapMap validated 0 flanking_5UTR 
rs10122065 9884322 1.1 goldengate validated 0 flanking_5UTR 
rs7853562 9880747 1.1 goldengate validated 0 flanking_5UTR 
rs7871503 9872625 0.909 two-hit or HapMap validated 0 flanking_5UTR 
rs7857912 9866992 1.1 goldengate validated 0 flanking_5UTR 
rs12000306 9860233 1.1 goldengate validated 0 flanking_5UTR 
rs6477424 9856363 1.1 goldengate validated 0 flanking_5UTR 
rs1951850 9848194 1.1 goldengate validated 0.325 flanking_5UTR 
rs1323793 9845158 1.1 goldengate validated 0.492 flanking_5UTR 
rs9408796 9838848 1.1 goldengate validated 0.133 flanking_5UTR 
rs10759094 9830822 0.947 two-hit or HapMap validated 0.15 flanking_5UTR 
rs1408134 9822914 1.1 goldengate validated 0.441 flanking_5UTR 
rs10125401 9819018 1.1 goldengate validated 0.05 flanking_5UTR 
rs2476593 9814156 1.1 goldengate validated 0.383 flanking_5UTR 
rs2761748 9807514 1.1 goldengate validated 0.475 flanking_5UTR 
rs1768872 9799590 1.1 goldengate validated 0.475 flanking_5UTR 
rs10816186 9795954 1.1 goldengate validated 0.042 flanking_5UTR 
rs2296171 9789476 1.1 goldengate validated 0.042 flanking_5UTR 
rs1174592 9782811 1.1 goldengate validated 0.092 flanking_5UTR 
rs1768878 9776586 1.1 goldengate validated 0.308 flanking_5UTR 
rs9695314 9771039 0.807 two-hit or HapMap validated 0 flanking_5UTR 
rs10977970 9764194 0.872 two-hit or HapMap validated 0 flanking_5UTR 
rs768224 9760495 1.1 goldengate validated 0.35 flanking_5UTR 
rs2821513 9753186 1.1 goldengate validated 0.05 flanking_5UTR 
rs1408119 9746587 0.85 two-hit or HapMap validated 0 flanking_5UTR 
rs1323797 9740514 1.1 goldengate validated 0.4 flanking_5UTR 
rs2761701 9735530 1.1 goldengate validated 0.233 flanking_5UTR 
rs1746803 9730825 1.1 goldengate validated 0.367 flanking_5UTR 
rs2821461 9723713 1.1 goldengate validated 0.483 flanking_5UTR 
rs4382526 9716395 1.1 goldengate validated 0.15 flanking_5UTR 
rs6477405 9710279 1.1 goldengate validated 0.39 flanking_5UTR 
rs16930096 9704838 0.856 two-hit or HapMap validated 0.075 flanking_5UTR 
rs4628308 9698107 1.1 goldengate validated -99 flanking_5UTR 
rs9657638 9691354 1.1 goldengate validated 0.45 flanking_5UTR 
rs10759089 9688642 1.1 goldengate validated 0.358 flanking_5UTR 
rs2803366 9677742 0.879 two-hit or HapMap validated 0.075 flanking_5UTR 
rs7872414 9675661 0.775 two-hit or HapMap validated 0.271 flanking_5UTR 
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rs10816162 9668908 1.1 goldengate validated 0.325 flanking_5UTR 
rs2821477 9663320 1.1 goldengate validated 0.425 flanking_5UTR 
rs16930006 9654440 0.756 two-hit or HapMap validated 0 flanking_5UTR 
rs1326767 9651951 1.1 goldengate validated 0.4583 flanking_5UTR 
rs10977914 9644161 1.1 goldengate validated 0.125 flanking_5UTR 
rs12351554 9639179 0.908 two-hit or HapMap validated 0.158 flanking_5UTR 
rs1326766 9633444 1.1 goldengate validated 0 flanking_5UTR 
rs10977905 9627189 0.992 two-hit or HapMap validated 0.283 flanking_5UTR 
rs10977894 9620643 1.1 goldengate validated 0.117 flanking_5UTR 
rs1409618 9614219 1.1 goldengate validated 0.342 flanking_5UTR 
rs1926665 9609210 1.1 goldengate validated 0.225 flanking_5UTR 
rs10977874 9599283 1.1 goldengate validated 0.225 flanking_5UTR 
rs7029761 9595832 1.1 goldengate validated 0.408 flanking_5UTR 
rs651116 9589450 1.1 goldengate validated 0.4 flanking_5UTR 
rs659206 9584010 1.1 goldengate validated 0.358 flanking_5UTR 
rs598356 9578824 1.1 goldengate validated 0.308 flanking_5UTR 
rs681437 9572128 1.1 goldengate validated 0.275 flanking_5UTR 
rs649649 9564336 1.1 goldengate validated 0.267 flanking_5UTR 
rs660717 9559081 1.1 goldengate validated 0.292 flanking_5UTR 
rs10491609 9554203 1.1 goldengate validated 0 flanking_5UTR 
rs653896 9548791 1.1 goldengate validated 0.292 flanking_5UTR 
rs1359698 9542739 1.1 goldengate validated 0.292 flanking_5UTR 
rs616850 9537370 1.1 goldengate validated 0.283 flanking_5UTR 
rs639168 9529574 1.1 goldengate validated 0.133 flanking_5UTR 
rs2182548 9523788 1.1 goldengate validated 0.158 flanking_5UTR 
rs10739194 9518291 1.1 goldengate validated 0.458 flanking_5UTR 
rs1555919 9510937 1.1 goldengate validated 0.258 flanking_5UTR 
rs672211 9507393 1.1 goldengate validated 0.267 flanking_5UTR 
rs6477400 9500358 1.1 goldengate validated 0.275 flanking_5UTR 
rs1332202 9495249 1.1 goldengate validated 0.425 flanking_5UTR 
rs10759079 9488412 1.1 goldengate validated 0.392 flanking_5UTR 
rs10816143 9480689 0.672 two-hit or HapMap validated 0 flanking_5UTR 
rs4237177 9477771 1.1 goldengate validated 0.433 flanking_5UTR 
rs13299296 9470284 0.859 two-hit or HapMap validated 0.029 flanking_5UTR 
rs16929560 9464970 0.94 two-hit or HapMap validated 0.35 flanking_5UTR 
rs2382013 9460243 1.1 goldengate validated 0.292 flanking_5UTR 
rs10977781 9452880 0.988 two-hit or HapMap validated 0 flanking_5UTR 
rs1332808 9444411 1.1 goldengate validated 0.158 flanking_5UTR 
rs12378742 9442307 1.1 goldengate validated 0.158 flanking_5UTR 
rs1467790 9435004 1.1 goldengate validated 0.4792 flanking_5UTR 
rs1412873 9427674 1.1 goldengate validated 0.092 flanking_5UTR 
rs10977743 9422824 0.822 two-hit or HapMap validated 0 flanking_5UTR 
rs2890867 9416169 1.1 goldengate validated 0 flanking_5UTR 
rs1889104 9411495 1.1 goldengate validated 0.175 flanking_5UTR 
rs1412869 9404162 0.952 two-hit or HapMap validated 0.02 flanking_5UTR 
rs869869 9398460 1.1 goldengate validated 0.3 flanking_5UTR 
rs1333110 9392044 1.1 goldengate validated 0.125 flanking_5UTR 
rs10977726 9386576 1.1 goldengate validated 0.367 flanking_5UTR 
rs1007727 9380450 1.1 goldengate validated 0.15 flanking_5UTR 
rs10977701 9374488 0.924 two-hit or HapMap validated 0.28 flanking_5UTR 
rs2780078 9367679 1.1 goldengate validated 0.483 flanking_5UTR 
rs1023218 9364091 1.1 goldengate validated 0.283 flanking_5UTR 
rs10115809 9355138 0.924 two-hit or HapMap validated 0 flanking_5UTR 
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rs1889108 9350547 1.1 goldengate validated 0.483 flanking_5UTR 
rs1547287 9344303 1.1 goldengate validated 0.15 flanking_5UTR 
rs1332802 9338102 1.1 goldengate validated 0.333 flanking_5UTR 
rs7019201 9332490 1.1 goldengate validated 0.5 flanking_5UTR 
rs1332800 9327454 1.1 goldengate validated 0.175 flanking_5UTR 
rs2802285 9318355 1.1 goldengate validated 0.25 flanking_5UTR 
rs1556520 9313563 1.1 goldengate validated 0.25 flanking_5UTR 
rs953632 9307368 1.1 goldengate validated 0.0208 flanking_5UTR 
rs10120509 9303816 1.1 goldengate validated 0.025 flanking_5UTR 
rs1333105 9295655 1.1 goldengate validated 0.167 flanking_5UTR 
rs4742582 9290973 1.1 goldengate validated 0.125 flanking_5UTR 
rs1412884 9284171 1.1 goldengate validated 0.15 flanking_5UTR 
rs4097905 9279760 1.1 goldengate validated 0.242 flanking_5UTR 
rs4492438 9272982 1.1 goldengate validated 0.308 flanking_5UTR 
rs4563945 9267320 1.1 goldengate validated 0.417 flanking_5UTR 
rs10816082 9260642 0.781 two-hit or HapMap validated 0.271 flanking_5UTR 
rs7863177 9253980 1.1 goldengate validated 0.5 flanking_5UTR 
rs6477383 9248963 1.1 goldengate validated 0.225 flanking_5UTR 
rs7872553 9243587 1.1 goldengate validated 0.117 flanking_5UTR 
rs4568657 9236647 1.1 goldengate validated 0.5 flanking_5UTR 
rs4073524 9230851 0.939 two-hit or HapMap validated 0.033 flanking_5UTR 
rs4568656 9226327 0.763 two-hit or HapMap validated 0 flanking_5UTR 
rs17667848 9218867 0.92 two-hit or HapMap validated 0.183 flanking_5UTR 
rs13294494 9212258 0.956 two-hit or HapMap validated 0.275 flanking_5UTR 
rs10816064 9206980 0.989 two-hit or HapMap validated 0.1 flanking_5UTR 
rs10977579 9199799 1.1 goldengate validated 0.192 flanking_5UTR 
rs1982319 9194531 1.1 goldengate validated 0.242 flanking_5UTR 
rs2890856 9190590 1.1 goldengate validated 0.15 flanking_5UTR 
rs1445210 9182961 1.1 goldengate validated 0.358 flanking_5UTR 
rs945464 9176346 1.1 goldengate validated 0.433 flanking_5UTR 
rs1889820 9171361 1.1 goldengate validated 0.225 flanking_5UTR 
rs2120924 9166176 1.1 goldengate validated 0.425 flanking_5UTR 
rs7027972 9159043 0.755 two-hit or HapMap validated 0 flanking_5UTR 
rs10816054 9152042 0.964 two-hit or HapMap validated 0.5 flanking_5UTR 
rs722636 9147088 1.1 goldengate validated 0.433 flanking_5UTR 
rs2381968 9140790 1.1 goldengate validated 0.175 flanking_5UTR 
rs1992672 9135908 0.988 two-hit or HapMap validated 0.447 flanking_5UTR 
rs7043302 9129951 0.886 two-hit or HapMap validated 0.042 flanking_5UTR 
rs10977509 9121375 1.1 goldengate validated 0 flanking_5UTR 
rs10117009 9118101 1.1 goldengate validated 0 flanking_5UTR 
rs1373806 9112954 1.1 goldengate validated -99 flanking_5UTR 
rs17589981 9109229 0.762 two-hit or HapMap validated 0.45 flanking_5UTR 
rs324544 9098336 1.1 goldengate validated 0.275 flanking_5UTR 
rs324542 9092409 1.1 goldengate validated 0.208 flanking_5UTR 
rs10977486 9086813 1.1 goldengate validated 0.108 flanking_5UTR 
rs10977479 9082345 0.828 two-hit or HapMap validated 0.1 flanking_5UTR 
rs484454 9075530 1.1 goldengate validated 0.175 flanking_5UTR 
rs324478 9069698 1.1 goldengate validated 0.325 flanking_5UTR 
rs324483 9063311 1.1 goldengate validated 0.144 flanking_5UTR 
rs324508 9057510 1.1 goldengate validated 0.325 flanking_5UTR 
rs324498 9049545 1.1 goldengate validated 0.15 flanking_5UTR 
rs324457 9044621 1.1 goldengate validated 0.467 flanking_5UTR 
rs7035296 9039813 1.1 goldengate validated 0.025 flanking_5UTR 
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rs324529 9032840 1.1 goldengate validated 0.367 flanking_5UTR 
rs324517 9027625 1.1 goldengate validated 0.425 flanking_5UTR 
rs895173 9022560 1.1 goldengate validated 0.292 flanking_5UTR 
rs540259 9016157 1.1 goldengate validated 0.424 flanking_5UTR 
rs17587734 9008296 0.867 two-hit or HapMap validated 0.38 intron 
rs424051 9004740 1.1 goldengate validated 0.373 intron 
rs7851907 8996519 1.1 goldengate validated 0.142 intron 
rs973117 8990033 1.1 goldengate validated 0.45 intron 
rs2150767 8985016 1.1 goldengate validated 0.4 intron 
rs2039331 8978375 1.1 goldengate validated 0.233 intron 
rs10816027 8972620 1.1 goldengate validated 0.212 intron 
rs12339776 8967031 0.974 two-hit or HapMap validated 0 intron 
rs1433553 8961282 1.1 goldengate validated 0.333 intron 
rs4314697 8954637 1.1 goldengate validated 0.333 intron 
rs1433546 8949811 1.1 goldengate validated 0 intron 
rs7852703 8945010 1.1 goldengate validated -99 intron 
rs919859 8939661 0.885 two-hit or HapMap validated 0 intron 
rs12378208 8931067 0.901 two-hit or HapMap validated 0 intron 
rs1433548 8927116 1.1 goldengate validated 0.342 intron 
rs1897674 8917101 1.1 goldengate validated 0.425 intron 
rs4740969 8912286 1.1 goldengate validated 0.325 intron 
rs10046838 8906449 1.1 goldengate validated 0.492 intron 
rs12337183 8899574 0.9 two-hit or HapMap validated 0 intron 
rs1019955 8893857 1.1 goldengate validated 0.083 intron 
rs16928589 8889516 0.932 two-hit or HapMap validated 0 intron 
rs7850165 8883834 0.901 two-hit or HapMap validated 0.144 intron 
rs10815988 8877610 1.1 goldengate validated 0.467 intron 
rs10815983 8871741 1.1 goldengate validated 0.475 intron 
rs4621865 8866936 1.1 goldengate validated -99 intron 
rs1368686 8858684 1.1 goldengate validated 0.242 intron 
rs1991863 8853644 1.1 goldengate validated -99 intron 
rs751372 8846908 1.1 goldengate validated 0.083 intron 
rs10759003 8841012 0.934 two-hit or HapMap validated 0.083 intron 
rs2814723 8836151 1.1 goldengate validated 0.333 intron 
rs1865207 8825056 1.1 goldengate validated 0.408 intron 
rs10121203 8823227 0.876 two-hit or HapMap validated 0.425 intron 
rs2099406 8819043 1.1 goldengate validated 0.308 intron 
rs1434253 8812069 1.1 goldengate validated 0.4 intron 
rs1434273 8807060 1.1 goldengate validated 0.4 intron 
rs3802395 8800447 1.1 goldengate validated 0.267 intron 
rs4562389 8795462 1.1 goldengate validated 0.333 intron 
rs9644892 8790078 1.1 goldengate validated 0.5 intron 
rs10977301 8782628 1.1 goldengate validated 0 intron 
rs3802396 8777733 1.1 goldengate validated 0.058 intron 
rs17660536 8770604 0.958 two-hit or HapMap validated 0.133 intron 
rs1036331 8764381 1.1 goldengate validated 0.275 intron 
rs12346008 8756570 1.1 goldengate validated 0.017 intron 
rs1368983 8751408 1.1 goldengate validated 0.425 intron 
rs956154 8746140 1.1 goldengate validated 0.292 intron 
rs7039134 8739552 1.1 goldengate validated 0.067 intron 
rs7021929 8735095 1.1 goldengate validated 0 intron 
rs6477333 8727316 0.807 two-hit or HapMap validated 0.328 intron 
rs1004489 8723398 1.1 goldengate validated 0.008 intron 
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rs2117325 8714264 0.806 two-hit or HapMap validated 0 intron 
rs10815926 8710582 0.912 two-hit or HapMap validated 0.375 intron 
rs3802397 8703734 1.1 goldengate validated 0.008 intron 
rs16924694 8698188 0.776 two-hit or HapMap validated 0.317 intron 
rs1543083 8693025 1.1 goldengate validated 0.392 intron 
rs1877448 8686410 1.1 goldengate validated 0.025 intron 
rs7030931 8680155 1.1 goldengate validated 0.15 intron 
rs12341997 8673334 1.1 goldengate validated 0.025 intron 
rs16928255 8668991 0.977 two-hit or HapMap validated 0 intron 
rs7859995 8660834 1.1 goldengate validated 0 intron 
rs12686188 8656150 1.1 goldengate validated 0.058 intron 
rs4742528 8650447 1.1 goldengate validated 0 intron 
rs7032242 8645013 1.1 goldengate validated 0 intron 
rs1033125 8637808 1.1 goldengate validated 0.058 intron 
rs12348522 8633259 1.1 goldengate validated 0.483 intron 
rs17652574 8623872 0.901 two-hit or HapMap validated 0.108 intron 
rs1337805 8620084 1.1 goldengate validated 0.167 intron 
rs12686827 8612613 0.965 two-hit or HapMap validated 0.058 intron 
rs1361117 8605045 1.1 goldengate validated 0.092 intron 
rs10977233 8601414 1.1 goldengate validated 0 intron 
rs9697029 8595589 0.917 two-hit or HapMap validated 0.092 intron 
rs10815921 8590627 1.1 goldengate validated 0.183 intron 
rs1999850 8583035 1.1 goldengate validated 0.217 intron 
rs12000186 8580026 1.1 goldengate validated 0 intron 
rs7026040 8574223 0.87 two-hit or HapMap validated 0.008 intron 
rs10977210 8568261 1.1 goldengate validated 0.325 intron 
rs10511502 8563166 1.1 goldengate validated 0 intron 
rs10511500 8555802 0.832 two-hit or HapMap validated 0.319 intron 
rs7870438 8550363 1.1 goldengate validated 0.008 intron 
rs7864527 8543569 1.1 goldengate validated 0.092 intron 
rs7856850 8536095 1.1 goldengate validated 0.208 intron 
rs2184978 8528919 1.1 goldengate validated 0.183 intron 
rs7046918 8524385 1.1 goldengate validated 0.15 intron 
rs13283094 8519177 0.957 two-hit or HapMap validated 0 intron 
rs3818346 8511244 1.1 goldengate validated 0.108 intron 
rs3763653 8508395 1.1 goldengate validated 0.133 coding 
rs10119236 8506194 1.1 goldengate validated 0.292 intron 
rs1535678 8499378 1.1 goldengate validated 0.158 intron 
rs10758977 8494101 0.966 two-hit or HapMap validated 0.35 intron 
rs10116020 8489960 0.895 two-hit or HapMap validated 0.1 intron 
rs17650289 8483161 0.954 two-hit or HapMap validated 0.125 intron 
rs3824417 8475928 1.1 goldengate validated 0 coding 
rs10815885 8470428 1.1 goldengate validated 0.35 intron 
rs10977146 8465677 1.1 goldengate validated 0.233 intron 
rs10977132 8459337 1.1 goldengate validated 0.067 intron 
rs1407973 8452030 1.1 goldengate validated 0 intron 
rs10121643 8447047 0.935 two-hit or HapMap validated 0 intron 
rs2296096 8439502 1.1 goldengate validated 0.058 intron 
rs10977110 8435066 1.1 goldengate validated 0.317 intron 
rs1323585 8428004 1.1 goldengate validated 0.283 intron 
rs10815872 8422878 0.949 two-hit or HapMap validated 0.1 intron 
rs1535677 8415998 1.1 goldengate validated 0.158 intron 
rs2296094 8410673 1.1 goldengate validated 0.133 intron 
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rs3896024 8406068 1.1 goldengate validated 0.492 intron 
rs12345027 8399633 0.893 two-hit or HapMap validated 0.018 intron 
rs2133790 8392162 1.1 goldengate validated 0.1 intron 
rs7873894 8387579 0.956 two-hit or HapMap validated 0 intron 
rs1500331 8382759 1.1 goldengate validated 0.224 intron 
rs989815 8376418 1.1 goldengate validated 0.475 intron 
rs1156793 8368662 1.1 goldengate validated 0.258 intron 
rs1909752 8361974 1.1 goldengate validated 0.075 intron 
rs10125894 8356757 1.1 goldengate validated 0.092 intron 
rs20513 8352155 1.1 goldengate validated 0.4 intron 
rs1500315 8344942 1.1 goldengate validated -99 intron 
rs4740941 8337472 1.1 goldengate validated 0.392 intron 
rs3817027 8331545 1.1 goldengate validated 0 intron 
rs7032880 8327939 1.1 goldengate validated 0.4 intron 
rs10739155 8320652 1.1 goldengate validated 0.342 intron 
rs7848626 8312288 1.1 goldengate validated 0.258 intron 
rs7027735 8305133 0.916 two-hit or HapMap validated 0 flanking_3UTR 
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Sample ID 
DNA source 
Differentiation 
status 
LOH at 
locus Mutation Mutation effect 
Heterozygous or 
homozygous Domain 
SCC 1 Cultured cells PD N N / / / 
SCC 2 Cultured cells WD Y N / / / 
SCC 5 Cultured cells WD Y - UPD N / / / 
SCC 10 
 
 
Tissue 
 
 
MD 
 
 
Y 
 
 
G/A  
G/A  
C/T 
G450E  
W775Stop  
3' UTR 
Het 
Het 
Het 
Fibronectin, type III  
Fibronectin, type III  
Non-coding 
SCC 16 Tissue MD Y N / / / 
SCC 20 Cultured cells MD Amp N / / / 
SCC 24 Cultured cells MD Y N / / / 
SCC 28 FF tissue WD N G/A   E1078K Het None 
SCC 29 FF tissue MD Y - UPD N / / / 
SCC 31 FF tissue PD N G/A S1471N 
Het Protein tyrosine phosphatase 
C1 
SCC 33  FF tissue WD Y C/T T13I Het Signal peptide 
SCC 37 FF tissue MD N N / / / 
SCC 54 FF tissue WD Y N / / / 
SCC 57 FF tissue M-PD Amp N / / / 
SCC 59 Cultured cells PD N T/C V340 Synon Homo Fibronectin, type III 
Pri-met 1 (SCC 12) Cultured cells MD N G/A G554A Het Fibronectin, type III 
Pri-met 3 FF tissue MD Y N / / / 
Pri-met 5 FF tissue MD Y N / / / 
Pri-met 6 
 
FF tissue 
 
PD 
 
N 
 
C/T  
C/T 
T849I  
T931I 
Het 
Het 
Fibronectin, type III 
Fibronectin, type III 
 
SCC sample IDs are based on those given in Purdie et al. (2009).  Tumours with a homozygous deletion of PTPRD were excluded from mutation analysis.  UPD = 
uniparental disomy, Amp – amplification, Synon = synonymous.  Annotation of mutations is according to the longest transcript of PTPRD, NM_002839. 
Appendix H: Summary of properties and mutations of PTPRD in cSCC that were analysed by sequencing.   
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